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.   
Part I. The first enantiospecific, stereospecific total synthesis of ervincidine 89 has been 
accomplished from commercially available D-(+)-tryptophan 37 which has served both as 
the chiral auxiliary and the starting material. Moreover, this is the first synthesis which 
unequivocally sets the stereochemistry of the hydroxyl group at C-6 in sterospecific 
fashion, as well as the C-16 hydroxy methyl group. The stereospecific conversion of D-
(+)-tryptophan 37 into the key template (−)-Na-H, Nb-benzyl tetracyclic ketone 49 via the 
asymmetric Pictet-Spengler reaction (600 gram scale) and Dieckmann cyclization on 
multi-hundred gram scale was reduced to only two reaction vessels. The optically active 
tetracyclic ketone 49 was converted into the core pentacyclic framework 56 using the 
intramolecular palladium-mediated enolate cross coupling reaction which was developed 
ii 
 
here in Milwaukee to afford the core pentacylic framework 56. This robust reaction could 
be scaled up to multigram scale in this series. Important to success here were the 
sequence of chemical reactions which included a Wittig reaction, a regioselective 
hydroboration and protection/deprotection steps in order to provide regiospecific 
oxidation at C-6. The IBX mediated oxidation and the Luche reduction using CeCl3. 
7H20 in the presence of NaBH4 afforded the first enantiospecific, stereospecific total 
synthesis of ervincidine 89. The indole alkaloid ervincidine 89 could be prepared from D-
(+)-tryptophan 37 in 13 reaction vessels in 19.2% overall yield. Another important 
experiment was the epimerization of the C-6 alcohol with 0.2N HCl which indicated that 
care must be employed in isolation of these alkaloids which contain a benzylic hydroxyl 
group. This research process developed here also provides a general entry to the C-6 
hydroxy substituted indole alkaloids of either alpha or beta stereochemistry. Two other 
diasteromers were made to rule them out as potential structures. This research corrects 
the errors in Glasby’s book and Lousnamma’s review and clarifies the work of Yunusov 
et al. as well as providing the correct absolute configuration of the C-6 hydroxyl function 
in ervincidine 89.  
Part.II..GABAA/BzR chloride ion channels comprise the major inhibitory 
neurotransmitter system in the CNS. This central role carries with it a direct influence on 
many diseases of the CNS. Inverse agonists acting at α5 subunits containing GABAA 
receptors are thought to act as cognitive enhancers while eliminating unwanted side 
effects associated with non-selective compounds. From the recent work of Rowlett, Cook 
et.al. it was demonstrated that novel α5 selective inverse agonist PWZ-029 was evaluated 
as a cognitive enhancer in rhesus monkeys in the CANTAB paradigm. This ligand had 
iii 
 
the ability to reverse cholinergic deficits in performance induced by the antimuscarinic 
scopolamine under mixed trial conditions. In the ORD task, PWZ-029 showed only a 
modest trend for enhancement of performance, but when task difficulty was increased by 
testing with difficult trials only, PWZ-029 robustly increased performance.  This 
enhancement was reversed by administration of the α5 GABA (A) subtype selective 
antagonist XLi-093 and this antagonism in turn was reversed by increasing the dose of 
PWZ-029. In addition, PWZ-029 enhanced performance in the DNMS task using the 10 
minute delay with distracters. This ligand also exhibited anxiolytic activity in some 
primates and was an orally active anticonvulsant in rats. These findings are consistent 
with a key role for α5 GABAA receptors in the treatment of age-associated memory 
impairment and Alzheimer’s disease. 
 
 
 
 
 
 
 
   
 
 
iv 
 
  
 
 
 
To 
My Parents Sugunavathi and Satyanarayana Rallapalli 
and 
My Husband Srihari Vedartham 
and  
My Son Anirudh Vedartham and Daughter Amulya Vedartham 
 
 
 
 
 
 
v 
 
TABLE OF CONTENTS 
 
PART I. The First Enantiospecific, Stereospecific Total Synthesis of the Indole 
Alkaloid Ervincidine 
 
1. Introduction…………………………………………………………………………….2 
1.1. Classification and biological activity of the sarpagine/macroline related indole 
alkaloids………………………………………………………………………………2 
1.2. Previous approaches to the tetracyclic azabicyclo [3.3.1] nonane core framework 
5 of the sarpagine/macroline related indole alkaloids ............................................... 34 
1.2.1. A racemic synthesis by Rassat et al. ................................................................ 34 
1.2.2. Approach to the core tetracyclic structure via the aza-Diels Alder/intra-
molecular Heck cyclization by Kuethe et al. ………………………………………36  
1.2.3. Approach to the core structure 36 via a ring-closing olefin metathesis by 
Martin et al………………………………………………………………………….37 
1.2.4. Synthesis of the tetracyclic core 42 via the cis-selective Pictet-Spengler reac-
tion by Bailey et al. …………………………………………………………………38 
1.2.5. Synthesis of the tetracyclic core 48 by Magnus et al. ……………………….40 
         1.3 Previous syntheses of sarpagine/macroline related indole alkaloids……………41 
1.3.1. Synthesis of sarpagine/macroline related indole alkaloids in Milwaukee .. .... 41 
1.3.1.1. The enantiospecific total synthesis of (+)-vellosimine by Wang ................. 42 
1.3.1.2. Total synthesis of the enantiomer of macroline, the Na-H analog of macroline 
and trinervine via a regiospecific hydroboration process by Liu et al. ...................... 44 
1.3.1.3. Improved total synthesis of macroline by Liao et al. ................................... 48 
1.3.2. A biomimetic total synthesis of (+)-Na-methyl vellosimine 74 by Martin et al.
 ................................................................................................................................... 50 
2. Objectives and synthetic approach…………………………………………………….54 
3.  Results and Discussion ...…..………………………………………………….….….58 
vi 
 
3.1. The First enantiospecific, stereospecific total synthesis of the sarpagine alkaloids 
related to structures of the proposed ervincidine (88 and 89) including ervindicine..
 ................................................................................................................................... 58 
3.1.1.  Synthesis of the (-)-Na-H, Nb-H tetracyclic ketone 50 on large scale ……...58 
3.1.2.  Synthesis of the -Na-H pentacyclic ketone 56 ................................................ 64 
3.1.3.  Completion of the regiospecific, stereospecific total synthesis of ervincidine 
proposed by Glasby and Lousnamaa ......................................................................... 72 
3.1.4.  Completion of the regiospecific, stereospecific total synthesis of ervincidine 
proposed by  Yunusov ............................................................................................... 74 
3.1.5. Completion of the regiospecific, stereospecific total synthesis of the 
diasteromer (118) of Ervincidine ………………………………………………….90  
4.  Conclusion……………………………………………………………………………91 
5.  Experimental Details………………………………………………………………….92 
6.  References:…………………………………………………………………………..125 
 
Part II. The Synthesis of Alpha 5 Subtype Selective Ligands for GABA(A) 
/Benzodiazepine Receptors 
 
1. Introduction ..................................................................................................................138 
2. Objective of this research.............................................................................................146 
3. Results and Discussion ................................................................................................148 
4. Synthesis of α5 selective BzR bivalent ligands ...........................................................166 
5. Synthesis of Bivalent Ligands with Oxygen Linkers ..................................................182 
6. Synthesis of α5 subtype selective inverse agonist PWZ-029 ......................................199 
7.  Conclusions .................................................................................................................219 
8. General Experimental Details ......................................................................................221 
9. Computer Modeling .....................................................................................................243 
vii 
 
10. Electrophysiological Experiments (with Sieghart et al.) ...........................................244 
11. Experiments of GABA signaling in neuroblastoma (Weiss and Cook et al.) ............254 
12. Behavioral experiments (with Savic et al.) ................................................................258 
13. Two-Way Active Avoidance (AA) Paradigm (with Savic et al.) ..............................259 
14. Measurement of Locomotor Activity (with Savic et al.) ...........................................260 
15. Behavior on the Elevated Plus Maze (EPM) (with Savic et al.) ................................260 
16. Grip Strength Test (with Savic et al.) ........................................................................261 
17. In vivo studies on XLi-093 on mice (Rowlett and Cook et al) ..................................262 
18. CANTAB work (Rowlett and Cook et al.) ................................................................264 
18.5. CANTAB Tasks in Monkeys. .................................................................................266 
19.  Object Retrieval with Detours (ORD) Task..............................................................272 
20.  Assessment of Motor Coordination and Behavioral Effects in Monkeys.................273 
21. References ..................................................................................................................276 
III. Appendix I: Crystal Data for 110 and 111……......................…………………...293 
 IV. Appendix II: Data on QH-II-066 (Lelas et al.).............………………………….310 
V. Appendix III: Data on QH-II-066 (Weiss et al.).....……………………………….344 
VI. Appendix IV: Anticonvulsant screening data on PWZ-029 ( Stables)..….............383 
VII. Appendix V: Data on QH-II-066 (Platt et al.).....………………….....................385 
VIII. Appendix VI: Crystal Data for XLi-093 (33).................................….…………419 
IX. Appendix VII: SBIR grant ……………….............................…………………...427 
X. Curriculum Vitae ......................................................................………………..….476 
 
 
 
viii 
 
LIST OF FIGURES 
 
Part 1 
Figure 1. Bisindoles .......................................................................................................... 3 
Figure 2. Dimeric Indole Alkaloids accedinisine and N′-demethylaccedinisine .............. 8 
Figure 3. Macroline, Sarpagine and Ajmaline .................................................................. 8 
Figure 4. Biosynthetic Relationship Between Macroline and Sarpagine.......................... 9 
Figure 5. Biosynthetic Relationship Between Sarpagine and Ajmaline Type Alkaloids 10 
Figure 6. Sarpagine Type Indole Alkaloids .................................................................... 54 
Figure 7. The Indole Alkaloid Ervincidine ..................................................................... 56 
Figure 8.  ORTEP View of the Crystal Structure of the Monol 110............................... 72 
Figure 9.  ORTEP View of the Crystal Structure of the Diol 88 which shows the Alpha 
Hydrogen at C-6 with C-5................................................................................................ 74 
Figure 10: Proton Spectrum of Natural Product Ervincidine 89 ..................................... 78 
Figure 11. Carbon Spectrum of Natural Product Ervincidine 89 .................................... 79 
Figure 12. Selected NOEs of Ervincidine 89 .................................................................. 80 
Figure 13. 1D NOEs Observed after Irradiation of Protons at H-3 ................................ 81 
Figure 14. 1D NOEs Observed after Irradiation of Protons at H-15 .............................. 81 
Figure 15. 1D NOEs Observed after Irradiation of Protons at H-17 .............................. 82 
Figure 16. 1D NOEs Observed after Irradiation of Protons at H-6 ................................ 82 
Figure 17. 1D NOE data H-15 irradiated ........................................................................ 84 
Figure 18. 2D NOESY of Ervincidine 89 ....................................................................... 89 
 
ix 
 
Part II. 
Figure 1.  Absolute subunit arrangement of the α1β2γ2GABAA receptor .....................140 
Figure 2.  The schematic diagram of subunits and ligands of the benzodiazepine-GABA 
receptor-chloride channel complex ..................................................................................141 
Figure 3.  GABA, diazepam, triazolam and midazolam. ................................................143 
Figure 4.   Mode of action of benzodiazepines ...............................................................144 
Figure 5.   Diazepam in the Pharmacophore/Receptor Model for the BzR Site. ............145 
Figure 6.   Distribution of α5 in Hippocampus ...............................................................147 
Figure 7.  Diazepam (2) aligned in the pharmacophore model. ......................................150 
Figure 8. The ligand QH-II-66, (11, a 7-acetylenyl-1,4-benzodiazepine, in black), was 
designed to offer better occupation of this region and exhibit α5 selectivity ..................151 
Figure 9. The ligand, QH-II-66 11, aligned in the included volume of the 
pharmacophore/receptor model for the α2β3γ2 subtype. ................................................152 
Figure10. The ligand, QH-II-66 11, aligned in the included volume of the 
pharmacophore/receptor model for the α5β3γ2 subtype. ................................................152 
Figure 11. GABA activation decreases viability and induces apoptosis in neuroblastoma 
cells   . ..............................................................................................................................156 
Figure 12. The Oocyte Efficacy Data on PS-1-37(18)....................................................159 
Figure 13. Ro 15-4513 (19), RY-023 (20), RY-024 (21), RY-079 (22), RY-80 (23) and 
the Merck compound (24). ...............................................................................................161 
Figure 14. Subtype efficacy of RY-24 (21), ...................................................................162 
Figure 15. Crystal Structure of Bivalent Ligand XLI093 (33). ......................................169 
Figure 16. XLi093 (33) Aligned in the Included Volume of the Pharmacophore/Receptor 
Model for the α5β3γ2 Subtype. .......................................................................................169 
Figure 17. Effects of XLi093 (33) on GABAA receptors were tested by two-electrode 
voltage clamp experiments in cRNA injected Xenopus oocytes .....................................172 
Figure 18. In vivo binding of Xli-093. ............................................................................174 
Figure 19. XLi-093 (3.0 mg/kg) blocked the DZ-induced suppression of performance 
ratio on the holeboard task.   ............................................................................................175 
Figure 20. Subtype efficacy of XLi356 (34)   .................................................................178 
Figure 21. Visual and audio que data for XLi356   .........................................................179 
x 
 
Figure 22. Subtype efficacy of XLi210 (35) ...................................................................180 
Figure 23. Crystal structures of XLi-093, DMH-D-053, and DM-III-96. ......................186 
Figure 24.  Aromatic region of 1HNMR spectra of XLi-093 (33) in CD2Cl2 at variable 
temperatures. ....................................................................................................................188 
Figure 25.  Aromatic region of 1HNMR spectra of SR-II-35 (42) in CD2Cl2 at variable 
temperatures. ....................................................................................................................189 
Figure 26.  Aliphatic region of 1HNMR spectra of SR-II-35 (42) in CD2Cl2 at variable 
temperatures. ....................................................................................................................190 
Figure 27. Aromatic region of 1HNMR spectra of XLi-093 (33)  in MeOH-d4 at different 
temperatures .....................................................................................................................193 
Figure 28. Bivalent ligand  XLi093 (33) aligned in the included volume of the 
pharmacophore/receptor model for the α5β3γ2 subtype. .................................................194 
Figure 29. The linkers of the bivalent ligands. ...............................................................195 
Figure 30. The conformations for dimethoxymethane....................................................196 
Figure 31. Newman projection for linkers B, C and D. ..................................................197 
Figure 32. Oocyte data for PWZ-029 by Sieghart et al. .................................................204 
Figure 33. Fear conditioned contextual memory ............................................................205 
Figure 34. Passive avoidance task ...................................................................................206 
Figure 35. Preliminary profile of cognitive enhancing and anxiolytic like effects of 
PWZ-029 in monkeys. .....................................................................................................208 
Figure 36. Cognitive-enhancing effects of PWZ-029 in the rhesus monkey ..................209 
Figure 37. Binding affinity data of PWZ-029 (47) and Roche compound 49 ................211 
Figure 38. Oocyte data of SR-II-097 ..............................................................................213 
Figure 39. Oocyte data of SR-III-38 ...............................................................................215 
Figure 40. Oocyte data of SR-III-61 ...............................................................................217 
Figure 41. Movement Assessment Panel for rhesus monkeys. .......................................274 
 
 
 
xi 
 
LIST OF TABLES 
 
Part I. 
Table 1. Antiamoebic and Antimalarial Activity of Selected Alstonia Alkaloids24 ........ 5 
Table 2. IC50 Values of Alkaloids Tested Against Plasmodia falciparum (K1 and T9-96 
strains) ................................................................................................................................ 6 
Table 3. IC50 Values of Alkaloids Tested Against Plasmodia falciparum (K1 strain)47 .. 7 
Table 4. Sarpagine Indole Alkaloids ............................................................................... 11 
Table 5. Macroline Related Indole Alkaloids ................................................................. 21 
Table 6. Bisindole Alkaloids ........................................................................................... 24 
Table 7. Degradation Products of Alstonia Alkaloids ..................................................... 33 
 
Part II. 
Table 1.  In Vitro Receptor Binding Data on Diazepam (2) and QH-II-066 (11). Binding 
Affinity at αxβ3γ2 GABAA/BzR Receptor Subtypes (Values are Reported in nM) .... 155 
 
Table 2. In Vitro Receptor Binding Data on Diazepam (2) and PS-1-37 (18). Binding 
Affinity at αxβ3γ2 GABAA/BzR Receptor Subtypes (Values are Reported in nM)...... 158 
 
Table 3. EC50 and Hill Slope for Modulation of Control GABA EC3 by PS-1-37 (18) in 
Xenopus Oocytes Expressing Different GABAA Receptor Subtypes. Results Represent 
EC50 (95% Confidence Interval for EC50) and Hill Slope (Nh) ± SD from at Least Four 
Cells from Two Batches................................................................................................. 159 
 
Table 4. Modulation of Control GABA EC3 by Diazepam and HZ166 (7) on Xenopus 
Oocytes Expressing Different GABAA Receptor Subtypes. Values are Presented as Mean 
± SEM of at Least Four Oocytes from at Least Two Batches ....................................... 160 
 
Table 5. In Vitro Receptor Binding Data of α5 ligands. Binding Affinity at αxβ3γ2 
GABAA/BzR Receptor Subtypes (Values are Reported in nM) .................................... 163 
xii 
 
 Table 6. In Vitro Binding Affinities at  GABAA/BzR Subtypes. aValues Reported are in 
nM. ................................................................................................................................. 170 
 
Table 7. Percent of α5GABAA binding sites occupied by XLi-093 and DZ at doses used 
in the behavioral studies................................................................................................. 176 
 
Table 8. In Vitro Binding Affinities of bivalent ligands at GABAA/BzR subtypes.. .... 178 
 
Table 9. EC50 and Hill Slope for Modulation of Control GABA EC3 by XLi 210 (35) in 
Xenopus Oocytes ........................................................................................................... 181 
 
Table 10. Modulation of Control GABA EC3 by XLi 210 (35) on Xenopus Oocytes 
Expressing Different GABAA Receptor Subtypes. ........................................................ 181 
 
Table 11. In Vitro Binding Affinities of bivalent ligands at GABAA/BzR subtypes. 
aValues Reported are in nM. .......................................................................................... 185 
 
Table 12. The Molecular Composition and Stable Conformation of Various Bz BS 
Bivalent Ligands.   ......................................................................................................... 187 
 
Table 13. In Vitro Binding Affinities of bivalent ligands at GABAA/BzR subtypes. ... 203 
 
Table 14. EC50 and Hill Slope for Modulation of Control GABA EC3 by SR-II-097 (57) 
in Xenopus Oocytes Expressing Different GABAA Receptor Subtypes.  ..................... 214 
 
Table 15. Modulation of Control GABA EC3 by SR-II-097 (57) on Xenopus Oocytes 
Expressing Different GABAA Receptor Subtypes. ........................................................ 214 
 
Table 16. EC50 and Hill Slope for Modulation of Control GABA EC3 by SR-III-38 (58) 
in Xenopus Oocytes Expressing Different GABAA Receptor Subtypes. ..................... 216 
 
Table 17. Modulation of Control GABA EC3 by SR-III-38 (58) on Xenopus Oocytes 
Expressing Different GABAA Receptor Subtypes. ........................................................ 216 
 
xiii 
 
Table 18. EC50 and Hill Slope for Modulation of Control GABA EC3 by SR-III-61 (49) 
in Xenopus Oocytes Expressing Different GABAA Receptor Subtypes. ..................... 218 
 
Table 19. Modulation of Control GABA EC3 by SR-III-61 (49) on Xenopus Oocytes 
Expressing Different GABAA Receptor Subtypes. ........................................................ 218 
 
Table 20. Schedule of CANTAB tests for a single dose of compound plus vehicle 271 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv 
 
ACKNOWLEDGMENTS 
This PhD degree would not have been possible without the help and support of many 
people. I would like to thank my advisor Professor James M. Cook, for his enthusiastic 
supervision and patience during this work. I am grateful for his advice and guidance 
throughout my work at UW-Milwaukee. He has and will always be an inspiration and 
motivation to me.  
I would like to thank the members of my doctoral committee, Professor’s Hossain, 
Schwabacher, Pacheco and Dietz, for their suggestions and instructive discussions during 
my graduate studies at UW-Milwaukee. I am also very grateful to Dr. Föersterling for his 
instruction and guidance for the NMR studies. I thank Mr. Neal Korfhage for his 
expertise in glassblowing which enabled me to set up equipment that may have otherwise 
been impossible. I would also like to acknowledge Mr. Frank Laib for mass spectral 
analysis and CHN analysis. I greatly appreciate Dr. Jeffery R. Deschamps for his 
outstanding help in X-ray analysis of the key compounds during my research. Thanks to 
Elise Nicks, Mary Eckert and Wendy Grober for all their help during my graduate studies 
at UW-Milwaukee. 
I would like to thank my in-laws Krishnamacharyulu and Satyavathi Vedartham who 
helped me in the last semester of my PhD degree. It would have been difficult to write 
and defend my thesis without their help. I would like to thank my brother Krishna 
Rallapalli and my sister in-law Chandra Rallapalli who have always been of great 
support. Thanks to my brother for always being around whenever I needed him. My life 
is indebted to my parents who have always been my pillar of strength. Without their 
support and guidance, this achievement would not have been accomplished. This PhD 
xv 
 
degree is dedicated to my dad who longed to see me with a doctorate degree. I would like 
to thank my husband Srihari Vedartham who has always encouraged and supported me 
during this endeavor. All these six years he never complained about the long drive to 
Chicago for his work.  I would like to thank him for all his help at home and also for his 
professional advice. Without his patience, vision and guidance it would have been 
impossible to continue and finish my education. Srihari has always been by my side 
through thick or thin. Special thanks to my son Anirudh Vedartham who went through a 
lot of hardship during the initial stages of my PhD program. He never showed tantrums as 
a toddler and without his support it would have been impossible for me to reach this 
milestone. 
It was a pleasure to share doctoral studies with past and current members of the Cook 
group. I would like to thank Dr. Srirama Sarma Pullela, Dr. Ranjit Verma, Dr. Ojas 
Namjoshi and Dr. Michael Lorenz, and for all their help and guidance during the years of 
my PhD program. It was a pleasure to share and eat lunch every day with Dr. Ojas 
Namjoshi and Ms. Poonam Biawat. I would like to thank Ms. Poonam Biawat and Mr. 
Toufiqur Rahman for all the help with my thesis corrections and printing. I would also 
like to thank my colleagues Dr. Michael VanLinn, Dr. M. Shahjahan Kabir, Dr. Wenyuan 
Yin, Dr. Terry Clayton, Dr. Rahul Edwankar, Dr. Chitra Edwankar, Mr. German 
Fonseca, Mr. Christopher Witzigman, Mr. Michael Poe, Mr. Phanibabu Tiruveedula and 
Mr. Toufiqur Rahman for providing amicable atmosphere to work.  I would also like to 
acknowledge the financial, academic and technical support of the Department of 
Chemistry at UW-Milwaukee, the Graduate School at UW-Milwaukee, and the NIMH.  
 
 
xvi 
 
1 
 
 
 
 
 
 
 
 
 
 
 
I. THE FIRST ENANTIOSPECIFIC, STEREOSPECIFIC TOTAL 
SYNTHESIS OF THE INDOLE ALKALOID ERVINCIDINE 
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1. Introduction 
1.1. Classification and biological activity of the sarpagine/macroline related indole 
alkaloids 
Alkaloids are of importance due to their biological activity. They are distributed diversely 
and have been isolated from plant and animal sources worldwide.1-5 Indole alkaloids are 
of prominence because of the similarity with tryptophan which is an essential amino acid. 
The medicinal properties6 of these indole alkaloids remain of great interest as well as the 
nature of their structure and stereochemistry. From the synthetic point of view, these 
complex molecules remain of paramount significance. The enantiospecific and 
regiospecific synthesis of alkaloids or their enantiomers has always been a challenge to 
the synthetic chemist.7-9 Synthetic routes are designed and revised continually in order to 
provide material for testing and for commercial uses. For all of these reasons, indole 
alkaloids play an important role in organic chemistry. This chapter includes the various 
classes of ajmaline and sarpagine-related indole alkaloids and also provides the previous 
synthetic methods to construct these molecules.10 
Biological activity of sarpagine/macroline related indole alkaloids 
Indole alkaloids of the sarpagine/macroline/ajmaline type comprise one of the largest 
groups of structurally related indole natural products.10 These indole alkaloids are 
primarily isolated from three plant families: Apocynaceae, Rubiaceae and 
Loganiaceae.11-13 Interest in the macroline/sarpagine alkaloids originated as a result of 
folk tales that described the medicinal properties of the plants from which these alkaloids 
were isolated.9,14 Various species of Rauwolfia which are broadly distributed among Asia 
3 
 
and Africa 15-20are widely used in traditional Chinese medicine for the treatment of 
neuralgia, migraine21 and hypertension.18,20,22 
As early as 1958,23 and later in 196724 the bisindole macralstonine 1a (Figure 1), which 
had been isolated from Alstonia macrophylla Wall and Alstonia muelleriana Domin, was 
shown to exhibit potent hypotensive activity. 
Nine alkaloids from Alstonia angustifolia were tested by Wright et al.25 for antiprotozoal 
activity against Entamoeba histolytica and Plasmodium falciparum in vitro (Table 1). 
Three dimeric alkaloids, macralstonine O-acetate 1b,26 (-)-macrocarpamine 2a,27 and (+)-
villalstonine 3a28, 29 (Figure 1) were found to possess significant activity against both 
protozoa. Macrocarpamine 2a was found to be the most active antiamoebic compound 
with an antiamoebic activity one fourth that of the standard drug emetine. Villalstonine 
3a was found to be the most potent alkaloid against P. falciparum, and was about fifteen 
Figure 1. Bisindoles 
 
N
N
H
H
H
H3C
O
R
Me
N
N
H
H
H
H3C
MeO
O
Me
O
1a R = OH, macralstonine
1b R = OCOCH3,O-acetyl macralstonine
H
Me
H
Me
 
4 
 
                  
N
N
N
H
H
MeO2C
H
H
H
O
N
MeH
H
HH
R
Me
2a R=H, macrocarpamine
2b R=OMe,10-methoxy macrocarpamine
H
             
N
N
H
H
MeO2C
H
O
N
Me
H
H
HH
N
R
Me
O
H
Me
3a R = H, villalstonine
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times less active than the antimalarial drug chloroquine. The acetate of macralstonine 1b 
was much more active against both protozoa when compared with the parent 
macralstonine 1a. The monomeric alkaloids were found to be considerably less active 
than the bisindoles. These results were in agreement with the studies carried out later by 
Houghton et al. (Tables 2 and 3).30 The results of these in vitro studies provide some 
basis for the traditional use of the plant extract from Alstonia angustifolia for the 
treatment of amoebic dysentery and malaria by the people of the Malay peninsula.31,32 
 
 
 
 
 
5 
 
Table 1. Antiamoebic and Antimalarial Activity of Selected Alstonia Alkaloids25 
 ED50: Effective dose at 50% inhibition. See Table 2 for source of P.falciparum 
The bisindole alkaloid  accedinisine 4a was first reported to be isolated from the root of 
epithelium T. accedens in 1976.33  Later in 1994,  accedinisine 4a and N′-
demethylaccedinisine 4b were isolated from Peschiera van heurkii. These two bisindole 
alkaloids exhibited potent antileishmanial and antibacterial activities.34 Dimeric alkaloids 
are often more potent in vivo than their monomeric progenitors. Much of the early 
isolation and structural work on the Alstonia alkaloids was performed in the laboratories 
of Elderfield35 and Schmid36,37 and was followed by the biomimetic interconversions of 
LeQuesne et al.26,28,29,38-40  
 
 
Alkaloids E. histolytica        
ED50(95% C. I.) µM 
P. falciparum        
ED50(95% C. I.) µM 
             alstonerine 75.3(65.0-85.6)             46.3(27.7-77.3) 
alstophylline 67.7(57.2-78.2)              82.3(65.9-102) 
macralstonine inactive at 70 inactive at 178 
O-acetyl macralstonine 15.51(14.78-16.24) 3.43(1.86-6.34) 
villalstonine 11.8(11.7-12.0) 2.92(1.11-3.14) 
pleiocarpamine 47.4(46.8-52.90) 20.5(12.6-33.17) 
macrocarpamine 8.21(7.76-8.48) 9.36(7.20-12.1) 
11-methoxyakuammicine 70.5(65.3-75.6) 41.3(26.5-64.3) 
norfurocurarine 84.1(82.9-89.6) 129(70.2-239) 
vincamajine inactive at 70 138(79.3-238) 
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Table 2. IC50 Values of Alkaloids Tested Against Plasmodia falciparum (K1 and T9-96 
strains)30  
Alkaloids K1 (μM, n = 3) T9-96 (μM, n = 3) K1/T9-96 ratio 
O-acetyl macralstonine 0.53 ± 0.09 12.4 ± 1.6 0.04 
villalstonine 0.27 ± 0.06 0.94 ± 0.07 0.29 
alstomacroline 1.12 ± 0.35 10.2 ± 0.4 0.11 
macrocarpamine 0.36 ± 0.06 >39* <0.009 
chloroquine diphosphate 0.20 ± 0.07 0.019 ± 0.002 10.53 
K1: the multi-drug resistant strain, which is highly resistant to chloroquine; T9-96: the chloroquine 
sensitive strain; n: number of independent experiments; *: % inhibition at 39 µM (7.5 µg/mL), the highest 
concentration tested was 32.6 ± 4.1 µM. The experiment was done with infected human red blood cells.  
During the structure determination of Alstonia bisindole alkaloids by Schmid et al.36,37 
macroline 6 (Figure 3) was obtained as a degradation product from villalstonine 3a. To 
date, macroline 6 has not been isolated as a natural product but it is believed to be a 
biomimetic precursor to many Alstonia alkaloids.26,28,29,38,39  
Studies on individual sarpagine/ajmaline indole alkaloids have shown normacusine B 
exhibited sedative and ganglion blocking activity,41 lochnerine elicited hypoglycemic 
activity,42 pericyclivine has been shown to exhibit weak cytotoxic activity against P-388 
leukemia,43 while gardnutine, gardnerine, and hydroxygardnutine have been shown to 
elicit ganglion blocking effects as well as anticancer activity.44-46 The mixture of 
constituents (normacusine B, affinisine, Na-methylpericyclivine, and voachalotine) 
present in Peschiera van Heurckii from the tropical rain forest in Bolivia is known for its 
alleged leishmanicidal and bactericidal activity.34 Like many quaternary alklaoids, the 
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major quaternary sarpagine alkaloid from Strychnos angolensis, 11-methylmacusine A, 
demonstrated muscle relaxant 
Table 3. IC50 Values of Alkaloids Tested Against Plasmodia falciparum (K1 strain)47  
K1 strain: multidrug resistant strain; n: number of independent experiments. The test was done with 
infected human red blood cells. 
activity.48 The crude mixture of nine alkaloids present in Ervatamia yunnanesis is used in 
Chinese folk medicine for the treatment of hypertension.22 Scientists have begun to 
ALKALOID n         IC50 (µg/mL) 
            talcarpine 3            40.3 ± 2.9 
pleiocarpamine 2              6.44 ± 0.98 
alstoumerine 2 13.1 ± 2.7 
20-epi-antirhine 3 7.51 ± 1.17 
alstonerine 2 9.67 ± 3.57 
alstophylline 2 12.7 ± 1.7 
macralstonine 3 8.92 ± 2.95 
O-methylmacralstonine 2 0.85 ± 0.20 
O-acetylmacralstonine 3 0.53 ± 0.09 
alstomacrophylline 2 1.10 ± 0.30 
villalstonine 3 0.27 ± 0.06 
villalstonine Nb-oxide 2 10.7 ± 1.9 
alstomacroline 3 1.12 ± 0.35 
macrocarpamine 3 0.36 ± 0.06 
chloroquine diphosphate 3 0.20 ± 0.07 
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evaluate these alkaloids for activity against cancer49,50 and HIV,51,52 however, the paucity 
of isolable material from these plants has retarded in depth evaluation. 
Figure 2. Dimeric Indole Alkaloids accedinisine and N′-demethylaccedinisine  
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Figure 3. Macroline, Sarpagine and Ajmaline 
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The number of macroline-related alkaloids which have been isolated has increased 
rapidly. At this time, the group contains more than 150 alkaloids, of which over a 100 are 
monomeric indoles. The remainder belongs to the bisindole class of alkaloids.40,53-55 The 
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sarpagine group of alkaloids (represented by 7, Figure 3) is the largest class of natural 
products related to the macroline bases and both series originate from common biogenetic 
intermediates. Illustrated in Figure 3 are the basic macroline and sarpagine skeletons. The 
biogenetic numbering of LeMen and Taylor56 is used throughout this chapter. Note the 
four stereocenters at C-3, C-5, C-15 and C-16 in macroline. The β-hydrogen atom at C-15 
of this group, as well as the chiral centers at C-3, C-5 and C-16 are the same for the 
sarpagine series. The two classes can be related in a synthetic sense by a Michael addition 
of the nitrogen atom of N-4 of macroline 6 to the α, β-unsaturated carbonyl system at C-
21, or by direct 1, 2 addition of N-4 to the ketone at C-19, as illustrated in Figure 4.54,55 
Conversely, sarpagine can be converted into macroline 6 by a retro-Michael reaction or 
Hoffmann elimination of the Nb-methyl intermediate, as demonstrated earlier by 
LeQuesne et al.38 (see Figure 4).  
Figure 4. Biosynthetic Relationship Between Macroline and Sarpagine 
1, 4- addition
1, 2-
 add
ition
12, R' = (=CH2)
13, R'' = OH, CH3
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N
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O
 retro Michael reaction or
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The macroline/sarpagine alkaloids bear important structural similarities to the ajmaline 
alkaloids, the latter of which are well known for their biological activity.57 Ajmaline 8, is 
a clinically important indole alkaloid with historical significance.58,59 Both these bases are 
structurally related by the presence of the quinuclidine ring and the C-5―C-16 bond 
linkage. The absolute configurations of the stereogenic centers at C-3, C-5 and C-15 of 
both series are identical, except at C-16 which is antipodal to the sarpagine series. The 
biogenetic connection between the sarpagine and ajmaline alkaloids proposed earlier60-62 
was confirmed by Stöckigt et al.63-66 by conversion of 16-epi-vellosimine 14 into 
deacetylvinorine 16 in the presence of the enzyme, acetyl-CoA dependent vinorine 
synthase (see Figure 5). 
Figure 5. Biosynthetic Relationship Between Sarpagine and Ajmaline Type Alkaloids 
                       
14 R = H, 16-epi-vellosimine
15 R = CO2CH3,
     polyneuridine aldehyde
16 R = H, deacetylvinorine 
17 R = CO2CH3, quebrachidine 
            (α-hydrogen at C-2)
HCl, HOAc/Ac2O
-or- acetyl CoA/vinorine 
synthaseNH
N
H H
R
N N
HO
H
H
H
R
O
H
2
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Table 4. Sarpagine Indole Alkaloids (1)40 
R=H, R'=H,  normacusine B
R=H, R'=Ac, O-acetylnormacusine B
R=H, R'=COPh, O-benzoyl
normacusine B
R=H, R'=Me, O-methylnormacusine B
R=Me, R'=H,  affinisine
R=R1=R2=H,  sarpagine
R=H, R1=Me, R2=H,  lochnerine
R=R1=H, R2=Ac, O-acetylsarpagine
R=Me, R1=R2=H, Na-methylsarpagine
R=H, R'=H,  vellosimine
R=Me, R'=H, Na-methylvellosimine
R=H, R'=OMe, 10-methoxyvellosimine
R=Me , R'=OMe,  majvinine
(40)
(40)
(40)
(40)
        AlkaloidStructure        Refs.
(40)
(40)
(40)
(40)
(40)
(40)
(40)
(40)
(40)
R1=R2=H, pericyclivine
R1=CH3, R2=H, 
Na-methylpericyclivine
R1=H, R2=OH, 10-hydroxy
pericyclivine
R1=H, R2=OMe, 10-methoxy
pericyclivine
R1=Me, R2=OH, 10-hydroxy-
Na-methylpericyclivine
R1=Me, R2=OMe, 10-methoxy-
Na-methylpericyclivine
(40)
(40)
(40)
(40)
(40)
(40)
N N
R H
H
H
CHO
H
R'
N N
R H
H
H
H
OR'
N N
R H
H
H
H
OR2
R1O
N N
R1 H
H
H
H
R2
CO2CH3
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Table 4. Sarpagine Indole Alkaloids (2) 67-69 
        AlkaloidStructure        Refs.
R1=R3=H, R2=OH,  16-episarpagine
R1=R3=H, R2=OMe,  lochvinerine
R1=R2=H, R3=OCH3, gardnerine
(40)
(40)
(40)
R'=OMe, R= H, 18-hydroxy
lochnerine
R'=H, R=Me, 18-hydroxy
affinisine
(40)
(40)
18-hydroxygardnerine (40)
11-methoxy-Na-methyldihydro-
pericyclivine
(68)
R=H, R'=CH=CHCOCH3, difforine
R=CH3, R'=CO2CH3
Na-methyl-16-epipericyclivine
(40, 69)
(40, 70)
N N
R1 H
H
H
H
R2
R3
OH
N N
R H
H
H
H
OH
R'
OH
N N
H H
H
H
HH3CO
OH
OH
N N
Me H
H
H
HH3CO
N N
R H
H
H
R'
H
CO2CH3
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Table 4. Sarpagine Indole Alkaloids (3)  
macrosalhine bromide
O-acetylpreperakine
R1=OH, R2=CH3
verticillatine (Cl salt)
R1=H, peraksine         
 (vomifoline)
(40)
(40)
        AlkaloidStructure        Refs.
(40)
R=R"=H, R'=CH2OH, 
16-epinormacusine B
R=Me, R'=CH2OH, R"=H, 
16-epiaffinisine
R=Me, R'=CH2OAc, R"=H, 
O-acetyl-16-epiaffinisine
(40)
(40)
(40)
R1=H, R2=CH2OH, 
19(S),20(R)-dihydroperaksine
R1=OH, R2=CH2OH, 
10-hydroxy-19(S),20(R)-
dihydroperaksine
R1=H, R2=CHO, 
19(S),20(R)-dihydroperaksine-17-
al
N N
H H
H
H
CH2OH
H
H
R2
R1
N N
H H
H
H
H
CH2OAc
N N
R H
H
H
R"
R'
N N
H H
H
H
H
O
H
OH
H
R1
R2
N N
Me H
H
H
O
H
OH
H
H
Br
CHO
(40)
(40)
(40)
(40)
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Table 4. Sarpagine Indole Alkaloids (4) 
trinervine
(40)
        AlkaloidsStructure        Refs.
(40)
(40)
(40)
N N
H H
H
H
O
Me
OH
H
H
N N
Me H
H
H
O
Me
OH
H
CO2CH3
voacoline
R=H, R'=Me, talpinine
R=OMe, R'=H, 21-hydroxy
cyclolochnerine
N N
R' H
H
H
O
H
H
R
OH
N N
H H
H
H
O
Me
OH
H
H
venecurine (40)
N N
H H
H
H
OH
CO2CH3
O eburnaphylline (40)
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Table 4.  Sarpagine Indole Alkaloids (5)70-73 
R=H, 
Na-demethylaccedine
     (amerovolfine)
R=OH, 3-hydroxysarpagine
        AlkaloidStructure        Refs.
neo-sarpagine (71)
R1=CH3, R2=H, R3=CH3,
dehydro-16-epiaffinisine
R1=H, R2=OCH3, R3=CH3,
gardnutine
R1=H, R2=OCH3, R3=CH2OH,
18-hydroxygardnutine
(40)
(40)
(40, 74)
R=H, dehydrovoachalotine
R=OH, 17-hydroxy-
dehydrovoachalotine
(40)
(40)
N N
H HO
H
H
H
OH
R
N N
H H
H
H
H
OH
HO
H
N N
R1 H
H
H
H
R3
H
O
R2
N N
Me H
H
H
CO2Me
H
O
R
N N
H H
H
H
H
OH
OH
ervincidine (40, 138,139)
(72)
(73)
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Table 4. Sarpagine Indole Alkaloids (6)  
alstoumerine (40)
        AlkaloidStructure        Refs.
koumidine (40)
R1=H, R2=CHO,
polyneuridine aldehyde
R1=H, R2=CH2OH, polyneuridine
R1=CH3, R2=CHO, voachalotinal
R1=CH3, R2=CH2OH, voachalotine
(40)
(40)
(40)
(40)
R1=R2=H, R3=CH2OH, 
E-akuammidine 
R1=R2=H, R3=CH2OAc, 
acetylakuammidine
R1=CH3, R2=OCH3, R3=CH2OH,
10-methoxy-Na-methylakuammidine
(40)
(40)
(40)
N N
H H
H
H
H
OH
N N
Me H
H
H
H
OH
OH
H
N N
R1 H
H
H
CO2CH3
R2
N N
R1 H
H
H
R3
R2
CO2CH3
 
17 
 
Table 4. Sarpgine Indole Alkaloids (7)  
panarine
        AlkaloidStructure        Refs.
(40)
R1=CH2OH, R2=H, macusine B
R1=CH2OCH3, R2=H,
O-methylmacusine B
R1=CO2CH3, R2=H, alkaloid Q3
R1=H, R2=CH2OCH3,
O-methyl-16-epimacusine B
R1=H, R2=CO2-, 16-epipanarine
R1=CO2CH3, R2=CH2OH
macusine A
R1=CH2OH, R2=CO2CH3,
Nb-methylakuammidine
(40)
(40)
(40)
(40)
(40)
(40)
(40)
R=H, R'=H, spegatrine
R=H, R'=Me, lochneram
R=Me, R'=H, 
Na-methylsarpagine metho salt
(40)
(40)
(40)
R1=CH3, R2=H,
Na-methyl-11-hydroxymacusine A
R1=H, R2=CH3,
11-methoxymacusine A
(40)
(40)
N N
H H
H
H
CO2
H
N N
H H
H
H
R1
R2
Cl
N N
R H
H
H
H
OH
R'O
Cl
N N
R1 H
H
H
CO2CH3
R2O
OH
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Table 4. Sarpgine Indole Alkaloids (8) 
R1=H, R2=CO2Et, fuchsiaefoline
R1=CH2OH, R2=CO2Me,
12-methoxy-Nb-methylvoachalotine
R1=CH2OH, R2=CO2Et
12-methoxy-Nb-methylvoachalotine
ethyl ester
        AlkaloidsStructure        Refs.
R1=H, R2=CO2CH3, R3=CH2OH,
19,20-dihydroakuammidine
R1=H, R2=CH2OH, R3=CO2CH3,
19,20-dihydropolyneuridine
R1=CH3, R2=CH2OAc, R3=CO2CH3,
17-O-acetyl-19,20-dihydrovoachalotine
(40)
(40)
(40)
R1=CH3, R2=H, affinisine Nb-oxide
R1=H, R2=CH3,
O-methylnormacusine B Nb-oxide
N N
Me H
H
H
R2
R1
N N
H H
H
H
H
N N
R1 H
H
H
H
H3CO
OMe
H
19,20-dihydro-O-methylmacusine B
N N
R1 H
H
H
R3
R2
H
OR2
O
N N
Me H
H
H
CO2CH3
OH
OH
21-hydroxyvoachalotine (40)
(40)
(40)
(40)
(40)
(40)
(40)
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Table 4. Sarpagine Indole Alkaloids (9)74-78 
R =R1=H, 16-epiaffinine
R =Me, R1 =H, hystrixnine
R =H, R1 =OMe, pelirine
(75)
(76)
(77)
        AlkaloidStructure        Refs.
affinine (78)
R=H, 19E, gelsempervine-A 
R=Ac, 19E, gelsempervine-B
 
R=H, 19Z, gelsempervine-C
R=Ac, 19Z, gelsempervine-D
(79)
(79)
(79)
(79)
19Z, 19Z-16-epivoacarpine
19ZE, 19E-16-epivoacarpine
N N
H
H
H
H
O
OH
N N
H
H
H
H
O
OR
R1
N N
H
H
H
CO2CH3
O
OR
19
N N
H
H
H
CO2CH3
OH
HO
19
(79)
(79)
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Table 4. Sarpagine Indole Alkaloids (10)71,79-82 
(80)
        AlkaloidStructure        Refs.
pagicerine (81)
R =H, amerovolficine
R =OMe, 
10-methoxy-16-de(methoxycarbonyl)
pagicerine
erichsonine
pagisulfine
N N
H
H
HO
O
CO2CH3
N N
H
H
HO OH
H
H
OH
N N
H
H
H
H
S
NH2
CO2CH3
N N
H
H
HO
O
H
R
(72)
(82)
(83)
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Table 5. Macroline Related Indole Alkaloids (1) 83-87 
        AlkaloidStructure        Refs.
R1= R2=H2, alstonerine
R1=OMe, R2=H2, alstophylline
R1=OMe, R2=O, 6-oxoalstophylline
(84)
(85)
(85)
R1=OMe, R2=H, R3=H2,
19,20-dehydro,10-methoxytalcarpine
R1=H, R2=OMe, R3=H2, alstophyllal
R1=H, R2=OMe, R3=O, 6-oxo-alstophyllal
R1=H, R2=H, R3=H2, alstonerinal
(27)
(85)
(85)
R1=H, R2=CHO, talcarpine 
R1=H, R2=CH2OH, macrocarpine A 
R1=OH, R2=CH2OH, alstohentine
(85, 86)
(85, 86)
       (85)
R=CHO, secotalcarpine 
R=CH2OH, macrocarpine B
R=CH2OAc, macrocarpine C
N N
H
H
HMe
R1
O
Me O
H
R2
N N
H
H
HMe
R2
O
CHO
H
R1
Me
R3
N N
H
H
HMe
O
H
R2
Me
R1
N N
H
H
HMe
O
H
R
N N
H
H
HMe
O
H
OH
H
alstomacroine (87)
       (86)
 (85, 86)
       (86)
(85, 88)
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Table 5. Macroline Related Indole Alkaloids (2)88 
N
Me
R=H, alstonisine
R=OCH3, Nb-demethylalstophylline 
oxindole
(89)
        AlkaloidStructure        Refs.
R1=H, alstonal
R1=OCH3, Nb-demethylalstophyllal 
                 oxindole
(89)
(89)
(89)
(89)
(89)
R
O
O
NH
H
H
H
H
H3C
O
N
Me
R
O
O
NH
H
H
H
H
OHC Me
N
Me
R
O
O
NH
OH
H
H
H
H3C
O
R=H, 16-hydroxyalstonisine
R=OCH3, 16-hydroxy-Nb-demethyl 
               alstophylline oxindole
N
Me
R
O
O
NH
OH
H
H
H
OHC Me
R1=H, 16-hydroxyalstonal
R1=OCH3, 16-hydroxy-Nb-demethyl 
alstophyllal oxindole
N
Me
R
O
N
H
H
H
OH
H
O
H
macroxine (89)
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Table 5. Macroline Related Indole Alkaloids (3) 89 
(86, 90)
        AlkaloidsStructure        Refs.
macrodasine A
macrodasine B
N N
H
H
HMe
H
N N
H
H
Me
O
H
O
O
O
Me
HH
CH2OH
N N
H
H
Me
O
H
O
O
Me
HH
CH2OH
OH
(86)
OH
O alstomicine (85)
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Table 6. Bisindole Alkaloids (1) 
(40)
(40)
        AlkaloidStructure        Refs.
R =H, desformoundulatine
R =CH2OH, undulatine
(40)
(40)
(40)
R =H, N'-demethylaccedinisine
R =CH3, accedinisine
N
N
MeH
H
MeO
CO2CH3
macralstonidine
N N
H
H
H
H
R
N N
Me H
H
H
CH2OH
H
CO2CH3
2Cl
N
N
O
Me
H
N
Me
N
H
H
H
H OH
O
H H
Me
H
H Me
N N
Me H
H
H
R
CO2CH3H
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Table 6. Bisindole alkaloids (2)90,91 
(91)
        AlkaloidStructure        Refs.
(91)
(92)macrospegatrine
vobatracine
vobasonidine
N N
H
H
H
H
CO2CH3
N
H
N
HCHO
H Me
N N
H
H
H
CO2CH3
H Me
OH
N
N
H
H
CO2CH3
HMe
HO
OH
N
N
O
Me
H
N
H
N
H
H
H
H OH
O
H
H
H
H
H
H H
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Table 6. Bisindole Alkaloids (3)92-94 
(93)
        AlkaloidStructure        Refs.
geissolosimine (40, 94)
(95)
divaricine
alstolactazine
N N
H H H
N
N
H
O
H
O
H H
H
N N
H H H
N
N
H
O
H
H
HH
H
N N
H
H
HMe
O
H
OH
Me
N N
OH
H
H3CO
O
OH
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Table 6. Bisindole Alkaloids (4) 
N
N
H (14)
        AlkaloidStructure        Refs.
(51)
(23,24)
(26)
R=H, macralstonine
R=Ac, O-acetate macralstonine
alstonisidine
HO CO2CH3
O
N
N Me
HH
Me
H
H
H3C
H
H H
N
N
H
HO CO2CH3
O
N
N Me
HH
Me
H
H
H3C
H
H HOH
alstomacroline
N
N
H
H
H
H3C
O
OR
Me
N
N
H
H
H
H3C
MeO
O
Me
O
H
Me
H
Me
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Table 6. Bisindole Alkaloids (5)95 
(96)
        AlkaloidStructure        Refs.
(51)
(86)
anhydromacralstonine
alstomacrophylline
(proposed structure by Lazar)
perhentinineN
N
H
H
H
H3C
N
N
H
H
H
Me
MeO
O
Me
O
H
Me
H
Me
O
OH
N
N
H
H
H
O
OMe
N
N
H
H
H
H3C
MeO
O
Me
O
H
Me
H
Me
Me
N
N
H
H
H
CH3
O
N
N
H
H
H
CH3
MeO
O
Me
O
H
Me
H
Me Me
H3C
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Table 6. Bisindole Alkaloids (6) 
        AlkaloidStructure        Refs.
(25)
(25)
(25)
N
N
O
H
H
Me
Me
R
H H
N N
O
H
Me
HH
MeO2C
R =H, villalstonine
R =H, Nb-O, villalstonine Nb-oxide
R =OMe, 10-methoxy villalstonine
R =OMe, Nb-O, 10-methoxy 
villalstonine Nb-oxide
N
N
O
H
H
Me
Me
R
H H
N N
H
MeO2C
H H
R =H, macrocarpamine
R =OMe, 10-methoxy macrocarpamine
R =OMe, Nb-O, 10-methoxy 
macrocarpamine Nb-oxide
b
b
(26, 27)
      (28)
(26, 27)
(26, 27)
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Table 6. Bisindole Alkaloids (7)  
(27)
        AlkaloidStructure        Refs.
(27)
(27)
foliacraline
N
N
Me
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H
H
H
H
N
N
Me
Me
H
H
H
H
N
N
Me
MeO
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O
MeO
H
Me
H
N
N HH
MeO2C
N
N
Me
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H
H
H
H
O
MeO
H
Me
H
N
N HH
MeO2C
Me
H
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MeO
H
OH
Me
H H CO2Me
H
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Table 6. Bisindole Alkaloids (8)96,97 
(97)
        AlkaloidStructure        Refs.
(98)
(98)
(98)
flexicorine
R =H, 
11-methoxy-10-(11'-vincorinyl)-vincamajine
R =Ac, 
11-methoxy-10-(11'-vincorinyl)-vincamedine
N
N
Me
N
N
CO2MeO
H
N
N
CO2MeMeO
HMe
HH
O
MeO
N
N
Me
HH
MeO
RO CO2CH3
N
N
CO2MeMeO
HMe
N
N
Me
HH
MeO
CO2CH3
OH
11-methoxy-10-(11'-vincorinyl)
-17-epivincamajine
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Table 6. Bisindole Alkaloids (9)98,99 
( 99)
        AlkaloidStructure        Refs.
(100)
(40)
11-methoxy-10-[11'(10'-methoxy
-cathafolinyl)]vincamajine
N
N
CO2MeMeO
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N
N
Me
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MeO
HO CO2CH3
H
N
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H
H
H
H
N
N
H
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O
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H
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H
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H
H
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Table 7. Degradation Products of Alstonia Alkaloids100 
(36, 37)
(36, 37)
        AlkaloidStructure        Refs.
(36, 37)
(36, 37)
N
N
H
H
Me
Me
H H
N N
O
H
HH
MeO2C
R =H, villamine
R =Ac, O-acetylvillamine
R =H, macroline
R =Ac, O-acetylmacroline
anhydromacrosalhine-methine
Na-desmethylalstophylline
N N
H
H
HMe
O
H
N N
H
H
HMe
OR
H
O
OR
Me
(101)
N N
H
H
HH
O
H
O
MeO
(101)
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1.2. Previous approaches to the tetracyclic azabicyclo [3.3.1] nonane core framework 
5 of the sarpagine/macroline related indole alkaloids 
As illustrated in Figure 3, as well as Tables 4, 5, and 7, a core tetracyclic system (rings A, 
B, C and D) appears to be a common structural feature of the macroline related sarpagine 
and ajmaline alkaloids. A general approach to the synthesis of these macroline–related 
alkaloids should involve enantiospecific synthesis of this core structure with the correct 
configurations at stereocenters C-3, and C-5 and the appropriate functional groups at C-
15/C-16 for further transformations. The racemic azabicyclo [3.3.1] nonane has been 
prepared in the late 1970’s by Yoneda,101 Mashimo,102 Kluge103 and Hobson,104 and was 
later improved by Soerens105 on a kilogram scale. In 1988, Zhang et al.106 achieved the 
synthesis of the optically active tetracyclic ketone 25 in a stereospecific fashion by 
employing the asymmetric Pictet-Spengler reaction. Many improvements have been 
made to prepare both the Na-H and the Na-CH3 tetracyclic ketones. Other recent routes 
toward the formation of the tetracyclic core, which deserve mention, include the racemic 
synthesis by Rassat,107,108 the aza Diels-Alder approach by Kuethe,109 the olefin 
metathesis process of Martin110 and the cis-Pictet-Spengler approach by Bailey111 and 
Magnus.112 
1.2.1. A racemic synthesis by Rassat et al. 59, 60 
In 2000, Rassat et al.107, 108designed the synthesis of 2,6-dihyroxy-9-azabicyclo[3.31]-
nonane 25 from the bis epoxide 18 (Scheme 1),  which could be carried out on large 
scale. The bis epoxide 18 was easily converted into a 1:1 mixture of regioisomeric diols 
19 and 20 via transannular cyclization with benzylamine in refluxing water. The 
undesired diol 20 was then converted into 19 by reacting it with trifluroacetic anhydride 
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in refluxing dichloromethane, followed by hydrolysis with sodium hydroxide to furnish 
19 in 95% yield (from 18). This bicyclic nonane 19, was then converted into 25, as 
illustrated in Scheme 1. 
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Monoprotection of the diol 19 with tert-butyldimethylsilyl chloride, followed by 
replacement of the N-benzyl group with the N-benzoyl group gave the desired monol 22. 
Swern oxidation of the alcohol 22, followed by removed of the silyl group gave 23 in 
95% yield (2 steps). Fischer indole cyclization of 23 with N-methyl, N-phenylhydrazine 
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in refluxing methanolic HCl led to the indole, which on reduction with LiAlH4 provided 
the Nb-benzyl derivative 24. The racemic tetracyclic ketone 25 could then be obtained by 
Swern oxidation of 24 in 73% yield. 
1.2.2. Approach to the core tetracyclic structure via the aza-Diels Alder/intra-
molecular Heck cyclization by Kuethe et al.61 
Scheme 2 
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Keuthe and co-workers adopted a [4+2] annulation strategy for construction of the 
tetracyclic cores 30a,b. As illustrated in Scheme 2, indoles 26a,b on treatment with n-
BuLi or LDA in refluxing MTBE, followed by addition of iodine furnished the iodo 
compounds 27a,b individually. Dess-Martin oxidation of the primary alcohol provided 
the aldehydes 28a,b. The aza-Diels Alder reaction of 28a,b with the Danishefsky diene 
provided 29a,b, which was subjected to an intramolecular Heck cyclization to furnish the 
desired cyclized indole scaffolds in both series 30a,b. Although this route requires 
stoichiometric amounts of palladium in the Heck coupling reaction, it does provide the 
tetracyclic framework in five steps, albeit the carbonyl group is not in an ideal position 
for regiospecific transformations. 
1.2.3. Approach to the core structure 36 via a ring-closing olefin metathesis by 
Martin et al.110  
During their extensive study on the use of olefin metathesis reactions for the synthesis of 
various azabicyclo structures with the nitrogen in the one-atom bridge, Martin et al.110 
were able to construct the tetracyclic core (ABCD rings), necessary for the synthesis of 
the macroline/sarpagine alkaloids. As illustrated in Scheme 3, the dihydro-β-carboline 31 
(obtained from L-tryptophan) was N-protected with Cbz-Cl, followed by esterification to 
provide a diastereomeric mixture of aminals 32. This diastereomeric mixture of aminals 
32 was then treated with allyltrimethylsilane and boron-trifluoride etherate to afford the 
cis-tetrahydro-β-carboline 33 as a mixture of two compounds in a 5.5:1 diastereomeric 
ratio which must be separated. Selective reduction of the ester, followed by a Wittig 
reaction yielded the alkyne 34 in a one-pot procedure. Treatment of the alkyne 34 with 
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Grubb’s first generation catalyst promoted the enyne metathesis to furnish the tetracyclic 
diene 35 in essentially quantitative yield. Selective oxidation of the exocylic olefin 
provided the aldehyde 36 in 54% yield (two steps). 
1.2.4. Synthesis of the tetracyclic core 42 via the cis-selective Pictet-Spengler reac-
tion by Bailey et al.111 
Bailey employed the cis-selective Pictet-Spengler reaction to synthesize the tetracyclic 
intermediate 42. As Illustrated in Scheme 4, the synthesis began with L-(-)-tryptophan 
37' which was converted into the homologated nitrile 38 via the reduction/ 
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activation/replacement sequence in 50% overall yield. The homologated nitrile 38 was 
then treated with methyl propynoate in refluxing chloroform for 100 hours to afford the 
enamines 39a and 39b, after which the mixture was directly added to excess 
trifluoroacetic acid at 0 °C to provide a mixture of cis and trans diastereomers (40a and 
40b) in the ratio of 77:23. The diastereomeric mixture was then converted into the Nb-
benzyl compound, which was further methylated to provide 41 in 39% yield (2 steps). 
The ring closure was mediated by the action of lithium diethylamide at -78 °C on ester 41 
to afford the tetracyclic core in 42 in 90% yield. Although the tetracyclic ketone 42 can 
be synthesized by this method, this route suffers due to the number of steps involved in 
comparison to other routes and also from the poor diastereoselectivity obtained in the 
Pictet-Spengler reaction. 
Scheme 4 
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1.2.5. Synthesis of the tetracyclic core 48 by Magnus et al.64 
In 1989, Magnus et al.64 reported the synthesis of the Na-H tetracyclic ketone 49 from L-
(-)-tryptophan 37' which he employed for the total synthesis of (+)-koumine, (+)-
taberpsychine and (+)-koumidine. Illustrated in Scheme 5 is the cis-selective Pictet-
Spengler reaction, which began with L-(-)-tryptophan37'. 
Scheme 5 
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The L-(-)-tryptophan 37' was converted into the Na-benzyl, tryptophan methyl ester 43 by 
first benzylation with sodium amide/PhCH2Cl in 92% yield, followed by Fischer 
esterification of the alkylated L-(+)-tryptophan in 68% yield. This ester 43 was then 
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reacted with benzaldehyde at 22 °C and the imine which resulted was reduced with 
sodium borohydride in methanol to provide Na-benzyl, Nb-benzyl tryptophan methyl ester 
44 in 95% yield. This intermediate was then converted into a mixture of diastereomeric 
acids 45a/45b, by employing the conditions of the Pictet-Spengler reaction as developed 
by Zhang et al.106 Esterification of this mixture with MeOH/ClSiMe3 provided the esters 
46a/46b (2:1) in 80% yield. The major cis-diastereomer 46a was isolated in 58% yield by 
crystallization from methanol and carried through to the tetracyclic ketone 48 via a 
Dieckmann cyclization and acid-mediated decarboxylation, as illustrated in Scheme 5 
following the route developed in Milwaukee and reported in the racemic series by 
Yoneda et al.101 
1.3. Previous syntheses of sarpagine/macroline related indole alkaloids  
1.3.1. Synthesis of sarpagine/macroline related indole alkaloids in Milwaukee113  
Vellosimine 14a and normacusine B are the simplest representatives of the family of 
sarpagine indole alkaloids. Until 2000, no enantiospecific total synthesis of members of 
the sarpagine series was reported. The partial total synthesis of (-)-koumidine [which is 
similar in structure to 14a, except it has a more stable Z-ethylidene double bond and the S 
configuration at C-16], was first reported by Sakai.114 Magnus later synthesized the 
enantiomer of (-)-koumidine via a Pictet- Spengler reaction. However, establishment of 
the double bond (Z:E=1:5.7) was not stereospecific112 and the reaction was hampered by 
poor diasteroselectivity in the Pictet-Spengler reaction. Entry into the pentacyclic 
sarpagine skeleton in Milwaukee for the total synthesis of ajmaline previously, was 
through a macroline framework which did not have the potential for incorporation of the 
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E-ethylidene double bond sterospecifically and also involved a large number of steps. 
Martin reported the total synthesis of geissoschizine with stereoselective establishment of 
the E-ethylidene double bond by an elimination process.115 Furthermore Rawal116 and 
Bosch117 reported the total synthesis of Strychnos alkaloids with stereocontrolled 
establishment of the double bond by a Heck coupling reaction. 
1.3.1.1. The enantiospecific total synthesis of (+)-vellosimine by Wang10,118,119  
In 2000 Wang reported an efficient, enantiospecific total synthesis of (+)-vellosimine 14a 
with the first stereospecific establishment of the ethylidene double bond by a key 
palladium (enolate-mediated) carbon-carbon bond forming process. This key reaction 
provided a very efficient approach and allowed a direct entry to the basic pentacylic 
skeleton of the sarpagine alkaloid system, and permitted introduction of the C-19—C-20 
olefinic bond with the E configuration, stereospecifically. The synthesis began with the 
tetracyclic ketone 49, which was subjected to the conditions of catalytic hydrogenation to 
provide the Na-H, Nb-H tetracyclic ketone 50 in 95% yield. Alkylation of the secondary 
amine in 50 with Z-1-bromo-2-iodo-2-butene 51, a unit prepared by Ensley et al.120 and 
employed by Rawal,116 Bosch117 and Kuehne121 provided the Nb-Z-2'-iodo-2'-butenyl 
tetracyclic ketone 52 in 87% yield. This Z-olefin 51 can now be prepared on a 500 gram 
scale in a regiospecific fashion in three steps from crotonaldehyde.122 Ketone 52 was then 
converted into the α, β-unsaturated aldehyde 53 in high yield (see Scheme 6).  
Numerous attempts to effect the intramolecular Michael addition in α,β-unsaturated 
aldehyde 53 by generating a vinyl anion, followed by cyclization failed to give the 
desired product.10,119 Radical-mediated cyclization121 was then attempted on 53 by  
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treating it with Bu3SnH/AIBN in refluxing benzene. A mixture of (+)-vellosimine 14a, 
accompanied by the undesired Z-olefinic isomer 54 in a 1:3 (E/Z) ratio was obtained in 
40% overall yield. The olefinic bond had isomerized under the radical conditions to 
provide the thermodynamically more stable olefin as the major isomer.10 Attempts to 
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carry out the Heck reaction under the conditions developed by Rawal,123 as well as under 
modified conditions did not provide the desired E-olefin.  
Muratake and Natsume124 had reported a direct palladium-mediated arylation at the γ-
position of a simple α, β-unsaturated aldehyde under basic conditions in high yield. When 
the α, β-unsaturated aldehyde 53 was stirred under similar conditions, the C-14 insertion 
product (aldehyde 55) was isolated in 71% yield. With the formation of this product it 
was felt a similar mechanism could be envisaged to occur with iodo olefin 52. The 
relative acidity inherent at the α-position of the ketone in 52 would facilitate the enolate 
mediated Pd(0)-cyclization into the desired sarpagine system in 14a. When iodo olefin 52 
was subjected to the optimized conditions of the intramolecular palladium-mediated cross 
coupling reaction (3 mol% Pd(OAc)2, 30 mol% PPh3),10 it furnished the cyclized product 
56 stereospecifically in 80% yield. Wittig reaction of this ketone was followed by 
hydrolysis to provide the thermodynamically more stable α-aldehyde in 14a. 
Consequently, the first total synthesis of the Na-H substituted sarpagine indole alkaloid 
(+)-vellosimine 14a was accomplished from commercially available D-(+)-tryptophan 
methyl ester 107 (Scheme 16) in seven reaction vessels in 27% overall yield. With the 
success achieved in stereospecific construction of the sarpagine skeleton via the enolate 
mediated palladium cross coupling reaction, a similar strategy was employed for the 
synthesis of the related sarpagine alkaloids in the Na-H as well as Na-methyl series.113 
1.3.1.2. Total synthesis of the enantiomer of macroline, the Na-H analog of macroline 
and trinervine via a regiospecific hydroboration process by Liu et al.125-127 
From the earlier work of LeQuesne et al.,38 the biogenetic origin of macroline 6 could be 
envisaged to arise from affinisine (enantiomer of 57', see Scheme 7) via a retro Michael 
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reaction (Figure 4). Consequently, the total synthesis of the enantiomer of macroline 6' 
was designed based on this approach. Shortly after the synthesis of (+)-vellosimine 14a, 
Liu125-127 followed the same strategy (from L-tryptophan 37') to provide the enantiomer 
of affinisine 57'. 
Scheme 7 
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The hydroxyl group of the enantiomer of affinisine 57' was protected as the t-
butyldimethylsilyl ether to afford olefin 58' (Scheme 7). Hydroboration of olefin 58' with 
1 equivalent of BH3·THF at 0 °C resulted in the formation of the Nb-BH3 complex 59'. 
Further addition of 5 equivalents of BH3·THF at 0 °C afforded a mixture of the secondary 
alcohols 60a',b' and undesired tertiary alcohol 61' in a ratio of 7:3.125 The poor yield 
(49% of the desired secondary alcohols 60a',b'), as well as the formation of the undesired 
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tertiary alcohol 61' prompted a more detailed study of this process (see Scheme 8). After 
executing various reaction conditions,127 which involved the use of hindered boranes and  
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a change of the reaction temperature as well as the use of a bulkier TIPS protecting 
group, the desired secondary alcohols could be prepared (the TIPS group was employed 
because it was found to be more stable and bulkier than the TBDMS). As illustrated in 
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Scheme 8, the TIPS group was used to protect the alcohol 57' to provide the ether 62' in 
90% yield. Hydroboration of olefin 62' under the modified conditions with 9 equivalents 
of BH3/DMS at room temperature provided the desired secondary alcohols 63a' and 63b' 
in 80% yield after oxidative workup.126,127 
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Swern oxidation of this mixture of secondary alcohols furnished the ketones 64a',b' in  
85% yield. This mixture of ketones was heated in THF in the presence of 1.5 equivalents 
of HCl (1N aqueous) for 3 hours, after which ketone 65', which was devoid of the boron 
species, was obtained in 90% yield. The methylation of 65' with methyl iodide gave the 
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Nb-methiodide salt which was subjected to the modified conditions for ring cleavage (t-
BuOK in refluxing THF/EtOH [6:1]) to provide the enantiomer 66' of the macroline 
equivalent. Deprotection of the TIPS group in 66' with TBAF in THF afforded the 
enantiomer 6' of macroline in 86% yield (see Scheme 8). 
Normacusine B 67 was converted into the Na-H analog of macroline 71 (Scheme 9) 
following the same sequence of steps as outlined for 6' in Scheme 8. Trinervine 69, 
which retained the basic sarpagine skeleton, and contained a unique hemiketal ring 
formed between the C-17 (OH group) and the ketone at C-19 was synthesized from 
intermediate 68 on stirring it with 10 equivalents of 1 N aqueous HCl in refluxing THF 
(80% yield). The acidic conditions at reflux released the free amine, cleaved the TIPS 
group, as well as catalyzed the hemiketal formation. The total synthesis of trinervine 69 
was, therefore, completed in enantiospecific fashion in an overall yield of 20% (from the 
ketone 50, see Scheme 6) in 10 reaction vessels (see Scheme 9). 
1.3.1.3. Improved total synthesis of macroline by Liao et al.128  
In an effort to decrease the amount of phosphine ligand employed for the cross coupling 
process, the Buchwald-Hartwig α-arylation129 conditions were studied. The original 
Buchwald conditions129 were modified by introducing DPEphos, a bidentate ligand with a 
large bite angle, a stronger base such as NaO-t-Bu and Pd(dba)2 as the catalyst. The 
improved route toward the synthesis of macroline is illustrated in Scheme 10. 
Previous to this, the same sequence of steps was carried out as depicted in Scheme 8, 
albeit under modified reaction conditions. The Na-methylvellosimine 74 was converted 
into affinisine 58 (Scheme 7) by NaBH4/EtOH reduction in 90% yield. Protection of the 
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OH group was carried out using TIPSOTf/2,6-lutidine in CH2Cl2 to provide the ether 62. 
Hydroboration followed by oxidation provided the secondary alcohols 75a and 75b. The  
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Nb-BH3 complex was cleaved by refluxing with 2 equivalents of acetic acid in THF to 
provide the free amine 75a,b. Because of the inconsistent results obtained in the Swern- 
oxidation of the secondary alcohols 75a,b130, Dess Martin oxidation was employed to 
furnish the desired ketone 65 in 82% yield. Treatment with methyl iodide in THF 
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provided the quaternary salt, which underwent a retro-Michael reaction to provide the 
macroline equivalent 66 in 20.4% overall yield from tryptophan methyl ester (not shown 
in Scheme). Removal of the TIPS group with TBAF monohydrate, provided 6 in 86% 
yield.  
1.3.2. A biomimetic total synthesis of (+)-Na-methyl vellosimine 74 by Martin et al.  
Scheme 11 
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van Tamelen62,131 reported a biogenetic-type synthesis of ajmaline 8 in which the key step 
was the conversion of acid 76 into a mixture of epimeric aldehydes represented by 74 
(Scheme 11). A proposition supported by a subsequent report of a biogenetic type 
synthesis of ajmaline was made later by van Tamelen and Olivier.132,133 This seminal 
cyclization to furnish the sarpagine skeleton proceeded via the proposed iminium ion 77, 
which was generated by decarbonylation of an activated form of the carboxyl group in 
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76. Aldehyde 74 was then converted into a relay compound which eventually was 
transformed into ajmaline 8. Twenty-five years after van Tamelen’s original work, 
Lounasmaa and coworkers reinvestigated this biogenetic-type cyclization.134 They did not 
observe the expected “biogenetic-type” cyclization of a related iminium ion. 
Consequently, Lounasmaa et al.134 reported they could not execute this type of 
cyclization and cast doubt on the biogenetic hypothesis of van Tamelen. It must be 
pointed out; however, Lounasmaa et al.134 did not employ the exact substrate of van 
Tamelen. The group in Milwaukee as well as Martin and coworkers realized that 
Lounasmaa’s work was not executed with the same substrate as van Tamelen. In order to 
solve this controversy, Martin et al.135 developed a biogenetic entry into Na-methyl 
vellosimine 74 which employed an iminium ion mediated cyclization similar to van 
Tamelen’s original proposal. 
As shown in Scheme 12, dihydrocarboline 31, which was readily obtained from 
commercially available D-tryptophan 37, was allowed to react with the vinyl ketene 
acetal to afford a single product and then directly converted into the t-butyl ester 78. The 
Nb-acylation of amine 78 with diketene furnished an intermediate β-keto amide that 
underwent facile cyclization via an intramolecular Michael reaction upon addition of 
potassium tert-butoxide to give keto amide 79.  
The E-ethylidene side chain in amide 80 was obtained in good yield by following the 
reduction/activation/elimination sequence to give a single geometric isomer, as depicted 
in Scheme 12. The lactam 80 was then methylated at the Na-indole position, after which 
the Na-methyl amide was reduced to the amine 81 in 90% yield. This was followd by 
selective acid catalyzed ester hydrolysis in the presence of methyl thioanisole which 
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proceeded smoothly to give the acid 82. The acid moiety in 82 was then transformed into 
the amide with NH4OH in the presence of EDCl in 86% yield followed by dehydration of 
the amide with trifluoroacetic anhydride to provide the nitrile 83 in 90% yield. The ester 
group in 83 was selectively reduced in the presence of the cyano group by reaction with 
lithium borohydride in THF and the subsequent oxidation of the hydroxyl group with 
Dess-Martin periodionane gave the aldehyde 84 in 83% yield. The aldehyde 84 was then 
converted into the silyl enol ether 85 with TBDMSCl in the presence of NaH. The α-
aminonitrile 85 was then treated with BF3·OEt2 in benzene and this was followed by 
exposure to aqueous potassium hydroxide in MeOH. The Na-methylvellosimine 74 was 
obtained in 54% yield. This biomimetic total synthesis of Na-methylvellosimine 74 
provided experimental support for the cyclization step originally proposed by van 
Tamelen as one of the key steps in the biosynthesis of the sarpagine and ajmaline 
alkaloids. It also illustrated the Lounasmaa’s criticism of the cyclization process134 may 
be unfounded since he did not use the exact same substrate as van Tamelen.131 
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2. Objectives and synthetic approach 
The unique and complex architecture of the indole alkaloids coupled with their largely 
unexplored potential in medicine or as tools for biological studies make these compounds 
attractive targets for total synthesis. The sarpagine alkaloids contain the common 
structural element of the parent pentacyclic sarpagan ring system.57 These indole 
alkaloids contain a double bond at C19-C20 and lack functionality at the C-21 position. 
In all known sarpagine indole alkaloids the stereochemistry at C-3 (S), C-5 (R) and C -15 
(R) has been established.These three stereochemical centers have a fixed configuration 
because of the rigid framework of the molecule. The double bond at C19-C20 has an E-
configuration. The alkaloid ervincidine belongs to the sarpagine class and has been 
isolated from the epigeal part of Vinca erecta Rgl. et Schmalh. 136 The UV spectrum is 
characteristic for indole bases. The IR spectrum has a broad band at 3000-3330 cm-1 due 
to the presence of OH and NH groups connected by a hydrogen bond. This alkaloid 
belongs to the akuammidine subgroup and is a hydroxyl derivative of tombosine. 136 
Figure 6. Sarpagine Type Indole Alkaloids 
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According to Glasby’s book of alkaloids 137 and the review by Lounasmaa,57 the structure 
of ervincidine has four stereocenters C-3 (S), C-5 (R) , C -15 (R) and C -16(R). The 
stereochemistry of the alcohol at the C-6 position was not assigned. The paper published 
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by Yunusov etal.,136 has reported the structure of ervincidine similar to that of the 
polyneuridine subclass with four stereocenters C-3(S), C-5(R), C-15(R) and C-16(S). But 
again the stereochemistry of the C-6 alcohol was not assigned. As illustrated in Figure 7, 
the proposed structure of ervincidine by Glasby5 and Lousnamaa57 has the functional 
group at C-16 (R) with the alpha stereochemistry and that of Yunusov136 has the 
functional group at C-16 (S) with the less stable beta stereochemistry which stimulated 
the interest in this indole alkaloid. The synthesis of this natural product was also 
challenging because the only information from the literature136 was the optical rotation 
which was +29.5°(c 0.6, MeOH). 138 No unequivocal spectral information (NMR, CHN 
analysis) was given. Another aspect which made the synthesis of this molecule important 
was the establishment of the stereochemistry of the C-6 alcohol function. Examination of 
both the reports from the literature40,136 did not assign the stereochemistry to the C-6 
alcohol. The mass spectrum and the molecular ion peak of ervincidine 136 was similar to 
the spectra of the sarpagine and tombosine alkaloids. 139 The difference of 16 m/e units 
indicated the presence of a hydroxyl group in ervincidine. The presence of an m/e ion 
peak at 169 in the mass spectrum suggested the presence of the hydroxyl group in the 
aliphatic part of the molecule possibly in ring C. On the basis of the comparison of the 
mass spectrum of ervincidine with that of tombosine, akuammidine and gardenine and 
with the proposed biogenentic interrelationship with gardnutine and hydroxygardnutine, 
140 the position of the hydroxyl group in ervincidine was probably at C-6.136 
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Figure 7. The Indole Alkaloid Ervincidine 
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a Ervincidine as proposed by Glasby 137                     b Ervincidine as proposed by Yunusov etal.136  
               and Lousnamaa 40 
             
The objective of this research was to complete the first enantiospecific , stereospecific 
total synthesis of the indole alkaloid ervincidine and correct the stereochemical ambiguity 
reported in the literature. This ambiguity as pointed out was because the stereochemistry 
of the CH2OH group at C-16 was not assigned unequivocally and neither was the 
hydroxyl group at C-6 position. Moreover, the design of a synthetic entry into the C-6 
alcohol stereospecifically, as well as an assessment (thermodynamic stability) of the 
stability of the C-6 hydroxyl group was of significant importance in indole alkaloid 
chemistry. As shown in Scheme 13, in a retrosynthetic sense, both the diastereomers 88 
and 89 might be available via a common intermediate, pentacyclic ketone 56. The 
chirality of 56 was to be employed to introduce the correct stereocenters in the target 
alkaloids 88 or 89.  
The ketone 56 could presumably be converted into vellosomine 14a, which could be 
employed as an intermediate in the total synthesis of 88. The synthesis of the axial 
alcohol E-16-epinormacusine B 112 could be achieved by a hydroboration/oxidation 
process. This intermediate once obtained, might further provide 6-hydroxy-16 
demethoxycarbonyl polyneuridine 89 via protection/deprotection of hydroxyl group, 
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selective oxidation by IBX at C-6 and a reduction. The chirality of 56 was to be 
employed to introduce the correct stereocenters in the target alkaloids 88 or 89. 
 
Scheme 13. Retrosynthetic Analysis of ervincidine 88 and 89 
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The important initial stereogenic centers would be established from the 1, 3 trans transfer 
of chirality in the asymmetric Pictet-Spengler reaction.141-146 The retrosynthetic strategy 
rests on the general approach which has been used to synthesize the macroline-sarpagine 
type alkaloids in Milwaukee. The thermodynamically stable α-aldehyde 14a would arise 
via Wittig reaction on the pentacylic ketone 56. The Na-H, Nb-H tetracyclic ketone 50 
should be available from D-(+)-tryptophan 37 on a large scale via the asymmetric Pictet-
Spengler reaction and the Dieckmann reaction as key steps.147-149 This synthetic strategy 
was an efficient way to provide 56 in gram quantities. The less stable β-axial alcohol 
could be synthesized using the pentacyclic ketone 56 via a Wittig reaction coupled with a 
hydroboration/oxidation following the published procedure. 122,150,151  
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3. Results and Discussion 
3.1. The First enantiospecific, stereospecific total synthesis of the sarpagine alkaloids 
related to structures of the proposed ervincidine (88 and 89) including ervindicine 
3.1.1. Synthesis of the (−)-Na-H, Nb-H tetracyclic ketone 50 on large scale 
As planned, the synthesis of isomers of ervincidine 88 and 89 began with the preparation 
of the (−)-Na-H, Nb-benzyl tetracyclic ketone 49 as the key building block on large scale 
following the procedure developed in Milwaukee. As illustrated in Scheme 14, Fischer 
esterification of (+)-37 with methanolic hydrogen chloride gave the methyl ester 90 on 
400 gram scale. This was then converted into Nb-benzyltryptophan methyl ester 91 on 
stirring with benzaldehyde (1.1 equivalents) at room temperature (6 hours), followed by 
reduction of the imine which resulted in situ with sodium borohydride [-10 oC to –8 oC 
(2-5 hours, according to the scale)]. The optical purity of the Nb-benzyltryptophan methyl 
ester 91 prepared in this manner was found to be greater than 98% ee as determined by 
comparison to data from authentic samples.149  
To introduce the desired stereocenter at C-1 the asymmetric Pictet-Spengler reaction141-
146 was employed with methyl 4,4-dimethoxy-butyrate 95,146 (which can be prepared on a 
kilogram scale) and Nb-benzyl tryptophan 91 to provide the trans diester 92b as a single 
diastereomer in 92% yield. This process was scaled up to the 400 gram level and 
purification was achieved by recrystallization from ethanol. As shown in Scheme 15, the 
lone pair of electrons of the Nb-nitrogen atom of 91 (Scheme 15) presumably attacked the 
oxonium ion and this was followed by loss of the elements of methanol to form the 
iminium ion intermediate 96. Attack of the iminium ion at the indole C-3 position could 
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form either the anti spiroindolenine 98b or the syn spiroindolenine 98a intermediate. The 
anti intermediate 98b could rearrange directly into the desired trans diester 91b; 
however, in the case of the disfavored syn spiroindolenine 98a,152 it was felt the 
rearrangement to the cis diester 92a would occur followed by the acid-catalyzed 
isomerization at C-1 to afford the more stable trans diester 92b.141 Consequently, during 
the process of this Pictet-Spengler reaction, the cis diester 92a derived from 97a was 
indeed detected by TLC but was converted entirely into the trans diester 92b, presumably 
via the carbocationic intermediate143 III as planned. After work up, the trans diester 92b 
was obtained as the only diastereomer in greater than 98% ee and high yield on 100 gram 
scale. 
When the trans diester 92b was treated with three equivalents of sodium hydride in the 
presence of excess methanol in refluxing toluene,106 the trans diester 92b was converted 
entirely into trans δ-lactam 100. No further change was observed (Scheme 16) on 
prolonged heating. However, when diester 92b was treated with nine equivalents of 
sodium hydride in the presence of excess methanol in refluxing toluene under these same 
reaction conditions for an extended period of time (72 hours), the desired Dieckmann β-
ketoester 102 was obtained in 88% yield. Presumably, the δ-lactam 100 formed and then 
underwent ring-opening10,101 to provide the trans diester 92b under these conditions. This 
diester 101a was in equilibrium with the cis intermediate 101b and the latter material was 
eventually converted into β-ketoester 102 via the Dieckmann process. 
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Scheme 15 
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Scheme 16 
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It was felt the δ-lactam 100 was favored in the equilibrium over intermediates 101a and 
101b; however, the irreversible formation of the enolate (see 102) in the Dieckmann 
cyclization gradually promoted completion of the process to provide the β-ketoester 102, 
exclusively (Scheme 16). Hydrolysis of the β-ketoester 102 and decarboxylation under 
acidic conditions was achieved in one step to provide the template (-)-Na-H, Nb-benzyl 
tetracyclic ketone 49 in 90% yield. The enantiomeric purity of ketone 49 was determined 
to be greater than 98% ee by conversion of it into (-)-Na-methyl, Nb-benzyl tetracyclic 
ketone 25 whose enantiomeric purity had been determined previously by Zhang.10,106,153  
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D-(+)-Tryptophan methyl ester 90 can also be diastereospecifically converted (via 92b) 
into azabicyclononone 49 in greater than 98% ee in a two pot process on multihundred 
gram scale, as depicted in Scheme 17. More specifically, after Nb-benzylation of 90 with 
benzaldehyde and sodium borohydride (1 eq) in methanol was completed, trifluoroacetic 
acid (TFA) was added to the reaction vessel at 0 oC to neutralize the alkaline mixture. 
After removal of the solvent under reduced pressure, CH2Cl2, TFA and acetal 95 were 
added to the vessel at 0 oC and the modified Pictet-Spengler reaction (600 g scale) was 
carried out to provide the trans diester 92b in 83% crystalline yield. In the second 
sequence (150 g scale), the Dieckmann cyclization was completed and the reaction 
solution was then cooled to 0 oC after which it was carefully quenched with glacial acetic 
acid. After removal of the solvent under reduced pressure, concentrated glacial acetic 
acid, aqueous hydrochloric acid and water were added to the residue in the same vessel at 
0 oC. The acidic hydrolysis and decarboxylation of 102 was then executed at reflux to 
provide (-)-49 in 80% crystalline yield in greater than 98% ee.10 The benzyl group in 
tetracyclic ketone 49 was removed by converting 49 first into its hydrochloride salt. The 
HCl salt of 49 was then subjected to the conditions of catalytic debenzylation [Pd/C, H2 
(1 atm), bench top] to furnish the Na-H, Nb-H tetracyclic ketone 50 in 95% yield (Scheme 
17).           
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In conclusion, the basic tetracyclic core of the Na-H, Nb-H tetracyclic ketone 50, which 
contained rings ABCD required for the synthesis of the C-19 methyl substituted 
sarpagine indole alkaloids was constructed enantiospecifically and stereospecifically via 
the asymmetric Pictet-Spengler/Dieckmann protocol on large scale.119,147,148 
3.1.2. Synthesis of the -Na-H pentacyclic ketone 56 
Nb-alkylation of the secondary amine 50 with (Z)-1-bromo-2-iodo-2-butene 51 under the 
conditions developed in Milwaukee (dry THF/K2CO3/ reflux)122 118,154 led to the 
formation of the desired product 52, but was very sluggish, and led to considerable 
formation of baseline impurities. Since substitution by amines on bromides was clearly 
an SN2 type process, it was then decided to increase the nucleophilicity of the amine by 
employing a more polar aprotic solvent. It was well known that the nucleophilic strength 
was dependent on the solvent employed in the SN2 reaction. Dry acetonitrile on the other 
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hand proved to be the most suitable solvent for this process for the reaction went to 
completion at room temperature to give 52 in 76% yield. In order to increase the yield, 
vinyl iodide 51 was used in excess (3-4 equivalents). But this reaction condition did not 
improve the yield but increased the base line impurities.  
Initially, the vinyl iodide 51 required for this route was synthesized according to a 
literature procedure.120 However, the free-radical hydrostannation of the propargyl 
alcohol was difficult and the desired iodide was extremely hard to purify. Importantly, as 
illustrated in Scheme 18, an improved method was recently developed122 to prepare 51 via 
α-iodination of an α,β-unsaturated aldehyde 103 under the conditions of Kraft82,155 which 
exclusively formed only the Z-isomer 104. This material without further purification 
underwent the subsequent reduction83 to provide the desired alcohol 105 in 97% overall 
yield. This alcohol 105 was treated with PBr3 in dry ether at 0 °C  for 12 hours to provide 
the desired  bromide 51 in 93% yield . The sequence was scaled up to the 200 g level 
scale starting from crotonaldehyde 103 to obtain the desired allylic bromide 51 on a large 
scale as well. 
The ketone 52 was initially converted into the desired ketone 56 in 80% yield via an 
intramolecular palladium (enolate mediated) cross-coupling reaction  analogous to the 
process developed by Wang et al.118,156,157 Further development for this palladium-
mediated cross coupling reaction was achieved when ketone 52 was subjected in 
combination with 5.0 mol% Pd2(dba)3 , 7.0 mol% DPEphos as a ligand and 1.5 equivalent 
of NaOtBu as a base in THF at 80 °C for 5 hours. The desired ketone 56 was obtained in 
83% yield which was superior to the previously reported results (Scheme 5).  
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A plausible Hartwig-Buchwald catalytic cycle for the enolate-driven palladium catalyzed 
α-vinylation reaction is illustrated in Scheme 19. It was felt the active Pd(0)L2 species 
was generated primarily by reduction of Pd(OAc)2 with triphenylphosphine in this 
phosphine-assisted catalytic cycle.158,159 The active Pd(0)L2 species could then undergo 
oxidative addition on the vinyl iodide to form a vinylpalladium(II) iodide complex. 
Ligation to the oxygen and rearrangement to the carbon atom at C(15) can then occur. 
Finally, reductive elimination of the carbon bound Pd(II) intermediate would furnish the 
desired E-olefin 56 while regenerating the active Pd(0)L2 species. A key to the success of 
this Pd-mediated cross coupling reaction rested on the enolate concentration. This must 
be high enough to permit ligand substitution to occur.125 It was well known that vinyl 
iodides would be quite reactive in the oxidative-addition step. If nucleophilic substitution 
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of the iodide by the nucleophilic enolate in the coupling process was comparably slow, the 
rate of byproduct formation would be significant. Eventually, a highly reproducible yield 
could be obtained by employing an excess of the phosphine ligand.160 In the case of 
different substrates, sometimes it was necessary to carry out the reaction with a 10:1 ratio 
of PPh3 (30 mol%) to Pd(OAc)2 (3 mol%). The process then took three days to go to 
completion in comparison to that of five hours required under the original conditions, but 
the amount of byproducts (Scheme 19) was decreased. The yield of the sequence in this 
series was 81%. Furthermore, the best solvent system to date was DMF/H2O (9/1), as 
compared to CH3CN, pure DMF, or DMF/H2O (4/1) which resulted in no reaction or low 
yields.127 Because the conditions employed for the enolate driven palladium coupling 
process were different from the recent Buchwald-Hartwig arylation reactions,160 efforts 
were directed toward intramolecular α-vinylation under the conditions of the arylation 
process.160 This might permit lower catalyst loading160 and be effective for both E and Z 
ethylidenes. The homogenous reaction conditions might permit a faster rate and thereby 
facilitate scaleup. In fact, Liao first reported a Pd(0) catalyzed α-vinylation process in 
which the cheaper DPEphos was employed in the case of a Z-ethylidene130 for the 
synthesis of (-)-koumidine.150 Moreover, utilization of this ligand for the synthesis of the 
E-ethylidene 56 was also executed by Liao et al. in 80% yield.150 However, a related 
approach has also been effective based on a palladium-catalyzed coupling of amino-
tethered vinyl halides with ketones reported by Solé, Bonjoch et al.161,162 In addition, 
another process was also carried out with ketone 52 in the presence of 6.0 mol% 
Pd(PPh3)4 and a base PhOK (which was generated previously in the reaction vessel from 
2.0 equivalent of PhOH and 1.5 equivalent of KOtBu). The most notable aspect of the  
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Different trace byproducts 52, 50 or 106 are ocassionally observed depending on what catalyst was 
employed and how much base was used.  
latter attempt was that it did not require an additional ligand. The intramolecular 
cyclization took place to afford ketone 56 in 80% yield again in stereospecific fashion. 
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The use of the weaker potassium phenolate base limited the presence of any acetylene 
byproduct formed from loss of HI from the halide 52.  
Ketone 56 was then subjected to the Wittig reaction with methoxymethyl 
triphenylphosphonium chloride and anhydrous potassium tert-butoxide to provide a 
mixture of two stereoisomeric enol ethers (not shown). After a short wash column, the 
mixture of enol ethers was hydrolyzed under acidic conditions to provide vellosimine 14a 
in 90% yield (overall yield for two steps). Since the aldehyde at C(16) was in the more 
stable alpha configuration because of a syn pentane interaction with the indole methylene 
bridge, the mixture was simply stirred until all of the β-epimer was converted into the 
more stable, natural epimer present in (+)-vellosimine 14a. The aldehyde function of 14a 
was then reduced with sodium borohydride to provide the alcohol normacusine B 106, 
the spectral data of which are in complete agreement with the natural product. The C (17) 
functionalized alcohol was then protected as the trisopropylsilyl ether employing 2,6 
lutidene as the base to provide the ether 107. Repeated attempts to oxidize the C-6 
position by DDQ on 108 were unsuccessful. The conditions employed with the first 
equivalent of DDQ deprotected the TIPS functional group forming alcohol 107 and the 
second equivalent oxidized the alcohol 107 to aldehyde 14a. Finally, the oxidation at the 
C (6) position was successfully accomplished by oxidation using IBX at 80°C (radical 
process as shown in Scheme 21) to form the desired ketone 108.130,163  
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The silyl analogue was then stirred in THF with tetrabutyl-ammonium fluoride 
monohydrate to provide the C-16 substituted monol 110. Illustrated in Figure 8 is the 
ORTEP view of the crystal structure of ketone 110.  
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Scheme 21 
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Figure 8.  ORTEP View of the Crystal Structure of the monol 110 
 
3.1.3. Completion of the regiospecific, stereospecific total synthesis of ervincidine 
proposed by Glasby and Lousnamaa 
The selective reduction of the ketone 110 was done by a Luche reduction164 using sodium 
borohydride in combination with cerium chloride heptahydrate to afford the final product 
88 with C-3 (S), C-5 (R) , C-6 (R), C -15 (R) and C -16(R) stereochemistry as a single 
diastereomer. Luche reduction is a selective reduction of 1,2 enones using NaBH4 in 
combination with CeCl3. For the methanolysis of NaBH4, CeCl3 which is a lewis acid 
catalyst is selected. The harder reducing agent (see Scheme 22) favor 1, 2 reduction thus 
leading to the formation of a single diastereomer regiospecifically.  Illustrated in Figure 
9 is the ORTEP view of the crystal structure of 88. However, the optical rotation of this 
diastereomer 88 was [α]26D +79° (c 0.6, in methanol) which is not in agreement with the 
value reported by Yunusov in the literature.40,137 The diastereomer 88 was stirred in 0.2N 
HCl at 0°C. Examination by TLC (silica gel; CH2Cl2: MeOH 9:1; Rf: 0.73) showed a 
new spot at lower Rf value (0.73) which indicated the complete epimerization of 111 at 
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the C-6 position. Unfortunately the new spot could not be isolated due to shortage of the 
material at this point. It is felt the C-6 alpha hydroxyl group is presumably the 
thermodynamically more stable isomer based on this preliminary experiment. 
Scheme 22 
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Figure 9.  ORTEP View of the Crystal Structure of the Diol 88 which shows the alpha 
hydrogen at C-6 with C-5 
 
Since the optical rotation of diastereomer 88 obtained was not in agreement with the 
literature which was +29.540,136,137 the focus of this research turned towards the synthesis 
of the Na-H axial alcohol at the C-16 position proposed by Yunusov136 in order to 
construct the diastereomer with the polyneuridine-related stereochemistry in an 
enantiospecific fashion. 
3.1.4.   Completion of the regiospecific, stereospecfic total synthesis of ervincidine 
proposed by Yunusov136 
The synthesis of E-16-epinormacusine B 112 began with the pentacyclic ketone 56. The 
E-16-epinormacusine B 112 was obtained from 56 via a Wittig reaction which was 
carried out with triphenylphosphonium bromide in benzene, in the presence of potassium 
t-butoxide to afford the diene 111 in 90% yield. When the two double bonds in the diene 
75 
 
111 are compared it was felt the less hindered double bond at C(16)-C(17) , relative to 
the ethylidene at C(19)-C(20) would be more easily oxidized with a hindered 
hydroborating reagent. This was in agreement with the earlier work of Magnus and Cook 
et al. Treatment of diene 111 with the 9-BBN reagent was chosen as the hydroborating 
agent to facilitate attack from the less hindered face of the C(16)-C(17) double bond 
relative to the C(19)-C(20) site. This also hinders the formation of the Nb-9-BBN 
complex which might hinder attack from the alpha face of the molecule. If it became 
important to obtain the alcohol with the alpha stereochemistry at C-6, simple 
epimerization (H+) should be effective based on the previous results shown here for the 
epimerization of 111. 
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The synthesis of ketone 114 from alcohol 112 was carried out analogous to the previous 
preparation of the TIPS derivative 108 from alcohol 107 in 90% yield. The oxidation of 
the C-6 position was achieved by radical oxidation using IBX165,166 in 85% yield.  
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Scheme 24 
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As shown in Scheme 25, the silyl group from ketone 114 was removed by treatment with 
wet TBAF in THF to give 115 in 90% yield. The selective reduction of the ketone 115 
was done by a Luche reduction to achieve the stereospecific synthesis of the natural 
product ervincidine 89 as a single diastereomer in 90% yield.  The optical rotation of 89 
[α]26D +29.00° (c 0.6, in methanol) was in agreement with that of the literature136 [α]26D 
+29.5° (c 0.6, in methanol) which completed the first enantiospecific, stereospecific total 
synthesis of the natural product ervincidine 89 (Scheme 25). The analysis of the spectral 
data of the alkaloid 89 follows here. 
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Figure 10: Proton spectrum of natural product Ervincidine 89
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Figure 11: Carbon spectrum of natural product ervincidine 89 
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To assign the stereochemistry of the C-6 alcohol a detailed study of the 1D and 2D 
NOESY experiments were carried out on the synthetic diol 89. The methyl group (3H-18) 
detected as a three proton doublet showed strong connectivity only to H-19. The proton 
of the aromatic ring at H-9 and H-6, showed a weak NOE. No NOEs were found between 
H-15 and H-6. The protons of H-15 exhibited a strong NOE with H-17, H-16, H-14 and 
H-18. The proton of H-6 showed strong NOE with H-5. A weak NOE was observed 
between the protons labeled H-6 and H-3. 
 
Figure 12. Selected NOEs of ervincidine 89 
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Figure 13. 1D NOEs Observed after Irradiation of Protons at H-3 
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Analysis of the 2D NOESY experiments (Figure 12) further confirmed, the result 
obtained by the 1D NOESY experiments. Good NOEs were found between H-3 and H-5 
(strong) and H-14 (strong). The irradiation of the proton at C-3 resulted in the 
enhancement of the signals at H-5 and H-14, indicating that the protons at H-3 and H-5 
(see Figure 13) were located in the pseudo axial position. These results were supported 
by examination of the 2D NOE spectrum for H-6 which exhibited cross peaks at H-5 
(strong). 
 
Figure 14. 1D NOEs Observed after Irradiation of Protons at H-15 
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The 1D NOE signals were observed between H-15 and H-18 (strong), H-17 (strong), H-
16 (strong) and H-14 (strong). The strong NOE between H-15 and with one of the H-17 
protons and not an NOE with the other proton at H-17 indicated that one proton at C-17 
was located in the α position while the other proton located at C-17 was found to be β. 
The NOE signals between H-15 and H-18 (strong), H-19 (weak) and H-5 (weak) were in 
agreement with the assignment.  
Figure 15. 1D NOEs Observed after Irradiation of Protons at H-17 
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The 2D NOE signals observed between the two proton at C-17 were very strong. The 
signals between H-17 and H-15 (strong), H-17 and H16 (strong) and H-17 and H-14 
(strong) were also strong.  
Figure 16. 1D NOEs Observed after Irradiation of Protons at H-6  
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The 1D NOE signal observed between H-6 and H-5 was very strong and the NOE 
between H-6 and H-3 was weak. No NOE is seen between H-6 and H-15. Weak NOE 
signals are found between H-6 and H-9 as well as H-6 and H-18. The NOE signal 
between H-5 and H-16 was strong with a coupling constant of 9.8 Hz, consequently the 
dihedral angle between the protons at H-5 and H-16 was close to 0˚ (eclipsed 
conformation). A weak NOE was observed between H-3 and H-6. The coupling constant 
between H-5 and H-6 was 5.1 Hz which indicated that both the protons were cis to each 
other. The angle between both the H-5 and H-6 protons was about 60 ˚ (staggered 
conformation) from models. Both the alcohol at C (17) and the proton at the C-6 position 
are trans to each other. If the OH were axial and the proton at H-6 were equatorial, a 
strong NOE would have been observed with H-15 which in this case was not seen. In 
summary, the 2D COSY, NOESY and 1D NOE experiments support the structure of 
ervincidine 89, as indicated in Scheme 25. 
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Figure 17. 1D NOE data H-15 irradiated 
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Figure 18. 2D NOESY of ervincidine 89  
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3.1.5. Completion of the regiospecific, stereospecfic total synthesis of the 
diasteromer (118) of Ervincidine 
To synthesize the diastereomer with the opposite stereochemistry to that of ervincidine 89 
at the C-6 position, diene 111 was treated with IBX to give the ketone 117 at the C-6 
position in 80% yield. In order to shorten the synthetic route and also synthesize the other 
isomer, 9-BBN was chosen which reduces the C-6 keto group to the alcohol and also acts 
as a hydroborating agent. 167,168 Since 9-BBN is a bulky group the attack might take place 
from the top face of the molecule. The boron might coordinate with the C-6 carbonyl 
oxygen as well as the Nb nitrogen atom thus leading to the formation of the alpha 
diastereomer 118. This process was executed as shown in scheme 26 in 70% yield The 
optical rotation of 118 [α]26D +17.00° (c 0.6, in methanol) was not in agreement with the 
literature. 40,137 It is entirely possible that 9-BBN complexed127,169 with the Nb-nitrogen 
function and blocked the attack from the bottom face of the ketone so that the carbonyl 
reduction occurred from the top face to give 118.  
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4. Conclusion 
In conclusion, the first enantiospecific, stereospecific total synthesis of ervincidine 89  
has been accomplished from commercially available D-(+)-tryptophan 37 which has 
served both as the chiral auxiliary and the starting material. Moreover, this is the first 
synthesis which unequivocally sets the stereochemistry of the hydroxyl group at C-6 in 
sterospecific fashion, as well as the C-16 hydroxy methyl group. The stereospecific 
conversion of D-(+)-tryptophan 37 into the key template (−)-Na-H, Nb-benzyl tetracyclic 
ketone 49 via the asymmetric Pictet-Spengler reaction (600 gram scale) and Dieckmann 
cyclization on multi-hundred gram scale was reduced to only two reaction vessels. The 
optically active tetracyclic ketone 49 was converted into the core pentacyclic framework 
56 using the intramolecular palladium-mediated enolate cross coupling reaction which 
was developed here in Milwaukee130 to afford the core pentacylic framework 56. This 
robust reaction could be scaled up to multigram scale in this series. Important to success 
here were the sequence of chemical reactions which included a Wittig reaction, a 
regiospecific hydroboration and protection/deprotection steps in order to provide 
regiospecific oxidation at C-6. The IBX mediated oxidation and the Luche reduction 
using CeCl3. 7H20 in the presence of NaBH4 afforded the first enantiospecific, 
stereospecific total synthesis of ervincidine 89. The indole alkaloid ervincidine 89 could 
be prepared from D-(+)-tryptophan 37 in 13 reaction vessels in 19.2% overall yield. 
Another important experiment was the epimerization of the C-6 alcohol with 0.2N HCl 
which indicated the care that must be employed in isolation of these alkaloids which 
contain a benzylic hydroxyl group. This research process developed here also provides a 
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general entry into C-6 hydroxy substituted indole alkaloids either alpha or beta 
stereochemistry. 
Two other diasteromers were made to rule them out as potential structures. This research 
corrects the errors in Glasby’s book137 and Lousnamma’s review 40 and clarifies the work 
of Yunusov et al as well as providing the correct absolute configuration of the C-6 
hydroxyl function in ervincidine 89. 136  
 
5. Experimental Details 
General Experimental Considerations: 
All reactions were carried out under an argon atmosphere with dry solvents using 
anhydrous conditions unless otherwise stated. Tetrahydrofuran (THF) and diethyl ether 
were freshly distilled from Na/benzophenone ketyl prior to use. Dichloromethane was 
distilled from calcium hydride prior to use. Methanol was distilled over magnesium 
sulfate prior to use. Benzene and toluene were distilled over Na prior to use. Acetonitrile 
was distilled over CaH2 prior to use. Reagents were purchased of the highest commercial 
quality and used without further purification unless otherwise stated. Thin layer 
chromatography (TLC) was performed using Dynamic Adsorbents Inc. UV active silica 
gel, 200 µm, plastic backed plates or; Dynamic Adsorbents Inc. UV active alumina N, 
200 µm, F-254 plastic backed plates. Flash and gravity chromatography were performed 
using silica gel P60A, 40-63 µm purchased from Silicycle. Basic alumina (Act I, 50-200 
µm) for chromatography was purchased from Dynamic Adsorbents. Neutral alumina 
(Brockman I, ~150 mesh) for chromatography was purchased from Sigma-Aldrich. TLC 
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plates were visualized by exposure to short wavelength UV light (254 nm). Indoles were 
visualized with a saturated solution of ceric ammonium sulfate in 50% sulfuric acid.170 
Elemental analyses were performed on a Carlo Erba model EA-1110 carbon, hydrogen, 
and nitrogen analyzer. All samples submitted for CHN analyses were first dried under 
high vacuum for a minimum of six hours using a drying pistol with isopropyl alcohol or 
benzene as the solvent with potassium hydroxide pellets in the drying bulb. Melting 
points were taken on a Stuart melting point apparatus SMP3 manufactured by Barloworld 
Scientific US Ltd. Proton (1H NMR) and carbon high resolution nuclear magnetic 
resonance spectra (13C NMR) were obtained on a Bruker 300-MHz or a GE 500-MHz 
NMR spectrometer. 1H NMR data are reported as follows: chemical shift, multiplicity (s 
= singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet of 
triplets, ddd = doublet of doublet of doublet, td = triplet of doublets, qd = quartet of 
doublets, sex = sextet, m = multiplet), integration, and coupling constants (Hz). 13C NMR 
data are reported in parts per million (ppm) on the δ scale. The low resolution mass 
spectra (LRMS) were obtained as electron impact (EI, 70eV), which were recorded on a 
Hewlett-Packard 5985B gas chromatography-mass spectrometer, while high resolution 
mass spectra (HRMS) were recorded on a VG Autospec (Manchester, England) mass 
spectrometer. HRMS recorded by electrospray ionization (ESI) methods were performed 
at the Laboratory for Biological Mass Spectrometery at Texas A&M University on a API 
QStar Pulsar model, manufactured by MDS Sciex. Optical rotations were measured on a 
JASCO Model DIP-370 digital polarimeter. Infra-red spectra were recorded on a Thermo 
Nicolet Nexus 870 FT-IR or a Perkin Elmer 1600 series FT-IR spectrometer. 
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37, D-tryptophan,
sat HCl/MeOH
reflux, 6 h;
14% aq NH4OH
91%
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N
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CO2Me
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D-(-)-Tryptophan methyl ester 90 
To a round bottom flask (5000 mL) which contained a freshly saturated solution of 
anhydrous methanolic hydrogen chloride (2500 mL), D-(+)-tryptophan 37 (400 g, 1.96 
mol) was added. The mixture which resulted was heated to reflux for 8 h and then 
allowed to cool to rt. The crystalline product which formed upon cooling was collected 
by filtration and washed with cold ether to provide D-(-)-tryptophan methyl ester.HCl. 
The free base 90 was prepared by treatment of the corresponding HCl salt with cold aq 
NH4OH (10%), followed by extraction with CH2Cl2 in methanol (4:1, 3 x 1000 mL). The 
solvent was evaporated under reduced pressure, after which the solid was redissolved in 
CH2Cl2 and dried (K2CO3). The DCM layer was removed under reduced pressure to 
provide D-(-)-tryptophan methyl ester 90 (392 g, 91%). mp 92-93 °C (free base);  [α]D27 
= -37.2 (c 1.0 in MeOH); IR (KBr) 1730 cm-1; 
1
H NMR (250 MHz, CDCl3, free base) δ 
1.62 (2H, s), 3.05 (1H, dd, J = 14.5, 7.5 Hz), 3.29 (1H, dd, J = 14.6, 5.8 Hz), 3.74 (3H, s), 
3.86 (1H, dd, J = 7.5, 4.8 Hz), 7.04-7.23 (3H, m), 7.35 (1H, d, J = 7.5 Hz), 7.61 (1H, d, J 
= 7.5 Hz), 8.24 (1 H, s); 
13
C NMR (62.8 MHz, CDCl3, free base) δ 30.83, 51.86, 55.06, 
111.19, 118.73, 119.49, 122.11, 122.87, 127.57, 136.37, 175.71; EIMS (m/e, relative 
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intensity) 218 (M+, 78), 159 (57), 130 (100), 117 (33). Anal. Calcd. for C12H14O2N2: C, 
66.06; H, 6.42, N, 12.84. Found: C, 66.14; H, 6.33; N, 12.77.  
PhCHO/CH3OH, rt, 6 h;
NaBH4, -10 °C, 4 h,
90% (one vessel)
90
N
NH2
CO2Me
H
91
N
HN
CO2Me
H
Ph
 
D-(+)-Nb-Benzyltryptophan methyl ester 91 
To a round bottom flask (3000 mL) which contained a solution of D-(-)-tryptophan 
methyl ester 90 (408 g, 2.0 mol) in dry CH3OH (1500 mL), benzaldehyde (260.0 g, 2.3 
mol) was added. The solution which resulted was stirred with an overhead stir for 6 h at 
22 °C, until examination by TLC (silica gel) indicated the disappearance of 90. The 
mixture was then cooled in an ice-salt bath to -5 °C [It was much easier to maintain the 
inside temperature between -10˚C to -5˚C by the employment of a dry ice bath (without 
solvent)]. If the temperature falls below -15˚C, a large amount of solid will appear and it 
is too difficult to stir the reaction mixture. Sodium borohydride (42 g, 1.1 mol) was then 
added portionwise at -5 °C over a period of 2.5 h [The slow addition and lower 
temperature of this process are critical to avoid racemization of the chiral center]. The 
solution was allowed to stir for 3 h and then followed by the addition of ice water (50 
mL). The solvent was removed under reduced pressure. The residue was dissolved in 
CHCl3 (2000 mL) and washed with brine (2 x 500 mL). The organic layer was dried 
(K2CO3) and the solvent was removed under reduced pressure to give the free base 3 (525 
g, 90%) which could be further purified by crystallization from EtOH. mp 109-110 °C; 
96 
 
[α]D22 = + 9.07° (c 1.0 in CH3OH), [lit.
152 [α]D22 = +8.65° (c 1.0 in CH3OH)]; IR (film) 
1745 cm
-1
; 
1
H NMR (250 MHz, CDCl3) δ 2.10 (1H, s), 3,15 (2H, m), 3.65 (3H, s), 3.75 
(3 H, s), 3.80 (3H, m), 6.90 (1H, s), 7.10 (1H, t, J = 8.2 Hz), 7.25 (5H, m), 7.55 (1H, d, J 
= 8.2 Hz); 
13
C NMR (62.8 MHz, CDCl3) δ 29.35, 51.68, 52.20, 61.38, 111.18, 111.38, 
118.84, 119.45, 122.07, 122.88, 127.03, 127.62, 128.19, 128.32, 136.30, 139.79, 175.36; 
EIMS (m/e, relative intensity) 308 (M+, 28), 249 (22), 178 (57), 130 (100).   
Anal. Calcd. for C19H20O2N2: C, 74.03; H, 6.49; N, 9.08. Found: C, 73.99; H, 6.56; N, 
8.99. 
CO2Me
O2N CO2Me
CO2Me
OMe
MeO
NaH, MeOH, 
0 °C,
H2SO4/MeOH,
- 45 °C to - 50 °C, 
2 h, 90%
0.6 N aq NaOH,
CH3NO2, CH2Cl2,
rt, 48 h, 30%
2.1 kg
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Preparation of methyl 4,4-dimethoxybutyrate 95171 
To a round bottom flask (12 L) equipped with an overhead stir which contained a 
solution of methyl acrylate 93 (1075 g, 12.5 mol) and nitromethane (762.5 g, 12.5 mol) in 
CH2Cl2 (2500 mL) at 0 °C, was added a solution of NaOH (60 g) in water (2500 mL) at 0 
°C. The mixture which resulted was stirred at rt for 48 h. The organic layer was separated 
and washed with water (2 x 500 mL) and dried (MgSO4). The solvent was then removed 
under reduced pressure and the residue was distilled under reduced pressure (95-100 °C/8 
mm of Hg) to give the pure methyl γ-nitro butyrate 94 (540 g, 30%). This was dissolved 
in methanolic sodium methoxide [5400 mL, 0.8 N, freshly prepared from 173 g of NaH 
(60% dispersion in mineral oil)] and the solution which resulted was added dropwise with 
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an overhead sitr at a rate of 1 drop per second to a round bottom flask (12 L) which 
contained a solution of conc sulfuric acid (1350 mL) in methanol (4050 mL) at -45 to –50 
°C. After the addition was completed, the reaction mixture was poured into CH2Cl2 (8 L). 
The organic layer was separated and washed with ice water (2 x 1000 mL), aq 4 N NaOH 
(2 x 600 mL) and dried (K2CO3). The solvent was removed under reduced pressure and 
the residue was distilled (110-115 °C/8 mm of Hg) to provide methyl 4,4-
dimethoxybutyrate 95 (540 g, 90%). 
1
H NMR (250 MHz, CDCl3) δ 1.92 (2H, q, J = 7.5 
Hz), 2.37 (2H, t, J = 7.5 Hz), 3.31 (6H, s), 3.66 (3H, s), 4.38 (1H, t, J = 15.8 Hz); 
13
C 
NMR (62.8 MHz, CDCl3) δ 27.92, 29.07, 51.45, 53.14, 103.14; CIMS (m/e, relative 
intensity) 375 (M+ + 1, 100). The spectral data for 95 were identical to the published 
values. 171 
(CH3O)2CHCH2CH2CO2CH3 (95)
TFA (2.4 eq), CH2Cl2, 
rt, 10 d, 92%
or CHCl3, reflux, 12h
trans diester only, > 98% de
N N
CO2Me
Ph
H H
MeO2C91
92b
N
HN
CO2Me
H
Ph
 
Diastereospecific preparation of the trans-(1S,3R)-(-)-2-benzyl-3-methoxycarbonyl-
1-methoxycarbonylethyl-1,2,3,4-tetrahydro-9H-pyrido-[3,4-b]indole (92b) via the 
newly modified Pictet-Spengler reaction. 
 To a round bottom flask (5000 mL) which contained a solution of optically active Nb-
benzyl-D-tryptophan methyl ester 90 (400 g, 1.3 mol) in CH2Cl2 (2500 mL) was added 
methyl 4,4-dimethoxybutyrate acetal 95 (315 g, 1.9 mol) and TFA (180 g, 2.4 eq) at 0 ˚C 
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with stirring. The reaction mixture which resulted was allowed to stir at rt for 10 d and 
then cooled in an ice bath and brought to pH = 8 with a cold aq solution of NaOH (3 N). 
The aq layer was separated and extracted with CH2Cl2 (3 x 1500 mL). The combined 
organic layers were washed with brine (2 x 600 mL) and dried (K2CO3). The volume of 
the solution was reduced to 300 mL under reduced pressure and EtOAc (100 mL) and 
hexanes (300 mL) were added to the above solution. The solution was cooled to –20 ˚C. 
The trans diester 109b (402 g, 76%) precipitated out as white crystals and the mother 
liquor was concentrated. The residue which resulted was purified by flash 
chromatography (silica gel, EtOAc/hexane, 1/4) to provide additional 109b (83 g, 16%). 
The combined yield of 92b (485 g) was 92%. mp 152-153 °C; [α]D27 = -35.7° (c 1.4, in 
CHCl3), [lit.
114[α]D27=-38.0˚ (c 1.0 in CHCl3)]; IR (film) 3310, 1731, 1707 cm
-1
; 
1
H 
NMR (250 MHz, CDCl3) δ 1.85-2.15 (2H, m), 2.20-2.50 (2H, m), 3.03 (1H, dd, J = 15.8, 
5.3 Hz), 3.12 (1H, dd, J = 15.8, 8.8 Hz), 3.48 (3H, s), 3.59 (1H, d, J = 13.6 Hz), 3.75 (3H, 
s), 3.84 (1H, d, J = 13.6 Hz), 3.87-3.93 (1H, m), 3.98 (1H, dd, J = 8.8, 5.3 Hz), 7.07-7.35 
(8H, m), 7.43 (1H, d, J = 7.2 Hz), 7.98 (1H, s); 
13
C NMR (62.8 MHz, CDCl3) δ 21.39, 
28.94, 29.88, 51.45, 51.85, 53.51, 54.81, 56.79, 107.51, 110.99, 118.16, 119.51, 121.77, 
127.08, 127.13, 128.28, 129.13, 134.26, 136.50, 139.41, 173.42, 174.18; EIMS (m/e, 
relative intensity) 406 (M+, 60), 347 (45), 319 (100), 169 (50).   
Anal. Calcd. for C24H26O4N2: C, 70.91; H, 6.45; N, 6.89. Found: C, 70.88; H, 6.47; N, 
6.91. 
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N N
H H
H
OH
CO2Me
Ph
N N
CO2Me
Ph
H
MeO2C
reflux, 3 d, 88%
92b 102  
Dieckmann cyclization of the Na-H diester 92b to provide (6S,10S)-(-)-methyl-9-oxo-
12-benzyl-6,7,8,9,10,11-hexahydro-6,10-imino-5H-cyclooct[b]indole-8-carboxy-late 
102 
To a round bottom flask (5000 mL) which contained a solution of Na-H, trans diester 92b 
(100 g, 0.25 mol) in toluene (3000 mL), which had been predried by azeotropic removal 
of H2O by a DST (refluxed 6 h), was added sodium hydride (88.7 g, 2.2 mol, 60% 
dispersion in mineral oil) at 0 ˚C. Anhydrous CH3OH (174 mL, 4.3 mol) was then added 
into the above mixture dropwise under Ar at 0 ˚C. The solution which resulted was held 
at reflux for 72 h (the flask was covered with aluminum foil on the top to keep the 
temperature at reflux without carbonizing any compound on the sides of the flask). 
The reaction was quenched with ice. The aq layer was extracted with CH2Cl2 (3 x 1 L). 
The combined organic extracts were washed with brine and dried (K2CO). The solvent 
was removed under reduced pressure and the mineral oil was separated by decantation. 
The residue which resulted was purified by flash chromatography (silica gel, 
EtOAc/hexane, 1/4) to provide the Na-H, β-ketoester 102 (82 g, 88%). mp 149-150 °C; 
[α]D27 = -177.4° (c, 1.0 in CHCl3); IR (KBr) 1670, 1630cm
-1
; 
1
H NMR (250M Hz, 
CDCl3) δ 2.30 (1H, d, J = 15.6 Hz), 2.82 (1H, dd, J = 15.5, 5.6 Hz), 2.90 (1H, d, J = 15.3 
Hz), 3.18 (1H, dd, J = 15.9, 5.9 Hz), 3.66 (3H, s), 3.71 (1H, d, J = 13.4 Hz), 3.77 (1H, d, 
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J = 5.3 Hz), 3.82 (1H, d, J = 13.4 Hz), 3.98 (1H, d, J = 5.4 Hz), 7.11 (1H, t, J = 7.1 Hz), 
7.16 (1H, t, J = 7.0 Hz), 7.24-7.39 (6H, m), 7.50 (1H, d, J = 7.1 Hz), 7.63 (1H, s), 11.98 
(1H, s); 13C NMR (75.5 MHz, CDCl3) δ 22.2, 28.6, 49.7, 51.3, 55.2, 55.9, 94.3, 106.2, 
110.8, 118.1, 119.5, 121.6, 127.0, 127.2, 128.4, 128.7, 133.4, 135.7, 138.3, 171.6, 172.5; 
CIMS (CH4) (m/e, relative intensity) 389 (M
+ + 1, 100).   
Anal. Calcd. for C23H22N2O3: C, 73.78; H, 5.92; N, 7.48. Found: C, 74.19; H, 6.23; N, 
7.35. 
N N
H H
H
OH
CO2Me
Ph
N N
H H
H
Ph
O
HOAc, HCl, H2O, reflux, 8 h
91%, > 98% ee
102
49  
Preparation of (6S,10S)-(-)-9-oxo-12-benzyl-6,7,8,9,10,11-hexahydro-6,10-imino-5H-
cyclo-oct[b]indole 49 via acid mediated hydrolysis of the Na-H, β-ketoester 102 
To a round bottom flask (500 mL) which contained the Na-H, β-ketoester 102 (45.0 g, 
0.12 mol) was added glacial acetic acid (167 mL), aq hydrochloric acid (245 mL, conc.) 
and water (65 mL) with stirring (magnetic stir). The solution which resulted was heated 
at reflux for 8 h.  After removal of the solvent under reduced pressure, the residue was 
brought to pH = 9 with a cold aq solution of NaOH (3 N). The mixture which resulted 
was extracted with CH2Cl2 (4 x 250 mL) and the combined organic extracts were washed 
with a saturated aq solution of NH4Cl (100 mL), brine (2 x 100 mL) and dried (K2CO3). 
Removal of the solvent under reduced pressure afforded an oil. After a short wash 
column on silica gel, the Na-H, Nb-benzyltetracyclic ketone 49 (24.5 g, 64%) was 
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crystallized from EtOAc/ hexane (1:4, 30 mL). The mother liquor was concentrated under 
reduced pressure and the residue was chromatographed on silica gel with EtOAc/hexane 
(1:4) to provide additional ketone 49 (10.5 g, 27%). The combined yield of 49 (35.0 g) 
was 91%. [α]D27 = -246.7˚ (c 1.05 in CHCl3); IR (KBr) 2933, 1715 cm
-1
; 
1
H NMR (250 
MHz, CDCl3) δ 2.02(1H, m), 2.15 (1H, m), 2.49 (2H, m), 2.71 (1H, d, J = 16.9 Hz), 3.27 
(1H, dd, J = 16.9, 6.8 Hz), 3.78 (2H, s), 3.80 (1H, s), 4.02 (1H, s), 7.17 (1H, dt, J = 7.3, 
1.0 Hz), 7.23 (1H, dt, J = 7.6, 1.0 Hz), 7.30-7.38 (6H, m), 7.54 (1H, d, J = 7.6 Hz), 7.81 
(1 H, s); 
13
C NMR (62.8  MHz, CDCl3) δ 20.40, 30.37, 34.51, 49.40, 56.13, 65.22, 
106.73, 110.94, 118.21, 119.72, 122.01, 126.86, 127.42, 128.43, 128.60, 131.98, 135.85, 
138.25, 210.40; CIMS (m/e, relative intensity) 317 (M+ + 1).  
Anal. Calcd. for C21H20N2O: C, 79.72; H, 6.37; N, 8.85. Found: C, 79.51; H, 6.37; N, 
8.85.  
N
NH2
CO2Me
H
N N
CO2Me
Ph
H H
MeO2C
N N
H H
H
O
Ph
PhCHO/CH3OH, rt, 6 h;
NaBH4, -10 °C, 4 h;
(CH3O)2CHCH2CH2CO2CH3
TFA(2.4 eq), CH2Cl2, rt,
10 d, 83% one pot
toluene, NaH (8 eq), 
dry CH3OH, reflux, 72 h; 
HOAc, HCl, H2O, reflux, 
10 h, 80% overall yield
(150 g scale)
49, >98% ee
600 g scale
90
92b
N NH
H H
H
O
sat HCl/EtOH,
Pd/C (5 mol%),
H2 (1 atm), EtOH,
10 h, 95%
50  
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One pot process for converting D-(-)-tryptophan methyl ester 90 into trans-(1S,3R)-
(-)-2-benzyl-3-methoxycarbonyl-1-methoxycarbonylethyl-1,2,3,4-tetrahydro-9H-
pyrido-[3,4-b]indole 92b10 
To a round bottom flask (12 L) which contained a solution of D-(-)-tryptophan methyl 
ester 90 (400 g, 1.83 mol) in CH3OH (5000 mL) was added benzaldehyde (230 g, 2.2 
mol) with stirring (overhead stir). The solution which resulted was stirred for 6 h at rt.  
The mixture was then cooled to –10 ˚C and sodium borohydride (55 g, 1.3 mol) was 
added portionwise over a period of 3 h. The internal pot temperature was kept between -
10 ˚C and -5 ˚C with a dry ice bath (solid dry ice). After analysis by TLC (silica gel, 
EtOAc/hexane, 1/1) indicated the disappearance of imine, the mixture was allowed to stir 
for an additional 0.5 h followed by the slow addition of CF3COOH (260 mL) at 0 ˚C. The 
solvent was removed under reduced pressure and the residue was dissolved in CH2Cl2 
(3000 mL). After the solution which resulted was cooled to 0 ˚C, methyl 4,4-
dimethoxybutyrate acetal 95 (324 g, 2.0 mol) and TFA (500 g, 2.4 eq) were added to this 
vessel at 0 ˚C. The reaction mixture was stirred at rt for 10 d, after which it was cooled in 
an ice bath and brought to pH = 8 with a cold aq solution of NaOH (3 N). The aq layer 
was separated and extracted with CH2Cl2 (3 x 5000 mL). The combined organic layers 
were washed with brine (2 x 200 mL) and dried (K2CO3). The volume of the solution was 
reduced to 300 mL under reduced pressure and EtOAc (100 mL) and hexanes (300 mL) 
were added to the above solution. The solution was cooled to –20 ˚C. The trans diester 
92b (510 g, 69%) precipitated as white crystals and the mother liquor was concentrated 
and the residue which resulted was purified by flash chromatography (silica gel, 
EtOAc/hexane, 1/4) to provide additional 92b (114 g, 14%). The combined yield of 92b 
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(624 g) was 83% and the solid was identical to the trans diester 92b obtained from Nb-
benzyl-D-tryptophan methyl ester 90 in an earlier experiment. 
One pot process for converting trans-(1S,3R)-(-)-2-benzyl-3-methoxy carbonyl-1-
methoxycarbonylethyl-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole 92b into (6S,10S) -
(-)-9-oxo-12-benzyl-6,7,8,9,10,11-hexahydro-6,10-imino-5H-cyclooct[b] indole 49 10 
The trans diester 92b (150 g, 246 mmol) was dissolved in dry toluene (3500 mL) in a 
round bottom flask (5000 mL) equipped with an overhead stirrer, Dean Stark trap (DST) 
and a reflux condenser. The solution which resulted was heated to reflux for 6 h with 
stirring. The above predried solution was cooled to 0 ˚C and sodium hydride (150 g of 
60% dispersion NaH in mineral oil) was added to the above vessel under an atmosphere 
of Ar. Dry CH3OH (170 mL) was added carefully (a large amount of H2 was evolved at 
this point). The mixture was stirred at rt for 0.5 h, and then heated to reflux for an 
additional 72 h. Note: The top of the flask was covered with aluminium foil to keep 
the reflux and prevent carbonization of the lactam intermediate during the 
Dieckmann process. After analysis by TLC (silica gel, EtOAc/hexane, 1/4) indicated the 
disappearance of 92b, the reaction mixture was cooled to 0 ˚C and then quenched 
carefully with glacial acetic acid (300 mL). The solvent was removed under reduced 
pressure and glacial acetic acid (480 mL), aq hydrochloric acid (750 mL, conc.) and 
water (200 mL) were added to the above vessel. The mixture which resulted was heated 
at reflux for 8 h. After removal of the solvent under reduced pressure, the residue was 
brought to pH = 9 by addition of an aq solution of cold NaOH (3 N). The mixture which 
resulted was extracted with CH2Cl2 (4 x 1000 mL) and the combined organic extracts 
were washed with brine (2 x 500 mL) and dried (K2CO3). Removal of the solvent under 
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reduced pressure afforded an oil which was chromatographed on silica gel with 
EtOAc/hexane (3:7) to provide the tetracyclic ketone 50 (90 g, 80%), which was identical 
to the ketone obtained from ketoester 102 (see above). Note: A lactam intermediate is 
formed first in the Dieckmann reaction which must open up to isomerize and 
undergo the Dieckmann reaction. Do not mistake this first product (lactam) for the 
β-keto ester intermediate by TLC. 
N N
H H
H
O
Ph
49, >98% ee
N NH
H H
H
Osat HCl/EtOH,
Pd/C (5 mol%),
H2 (1 atm), EtOH,
10 h, 95%
50
 
Catalytic debenzylation of 49 to provide (6S,10S)-(-)-9-oxo-12-H-6,7,8,9,10,11-
hexahydro-6,10-imino-5H-cyclooct[b]indole 50 over Pd/C/H2 
Tetracyclic ketone 49 (40 g, 127 mmol) was dissolved in anhydrous ethanol (1300 mL). 
A saturated solution of EtOH/HCl (g) was then added dropwise into the above mixture 
until the solid completely dissolved. The solvent was then removed under reduced 
pressure to furnish an HCl salt. The residue was then dissolved in dry ethanol (1000 mL) 
and the solvent was removed under reduced pressure to remove the excess HCl. This 
process was repeated 3 times to make sure there was no excess HCl. The HCl salt was 
degassed under reduced pressure at rt and back filled with argon (2 times). Dry Pd/C 
(10% by wt, 8.1 g, 60 mmol) was added to the above HCl salt, followed by addition 
(slow addition, initially) of dry ethanol (1300 mL). The mixture was degassed under 
reduced pressure at rt and back filled with H2 (3 times). The mixture which resulted was 
allowed to stir on bench top at rt under an atmosphere of H2 (balloon) for 10 h. Analysis 
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by TLC (silica gel plate was exposed to NH3 vapours) indicated the absence of starting 
ketone 49. The catalyst was removed by filtration (Celite) and washed with ethanol (3 x 
100 mL). The solvent was removed under reduced pressure. The residue was dissolved in 
a mixture of CHCl3 and brought to pH = 8 with 10% aq NH4OH. The aq layer was 
extracted with CHCl3 (3 x 400 mL). The combined organic layers were washed with 
brine (2 x 200 mL) and dried (K2CO3). The solvent was removed under reduced pressure 
to afford the crude amine which was chromatographed (flash) on silica gel (CHCl3/EtOH, 
9/1) to provide pure Na-H, Nb-H tetracyclic ketone 50 (27.2 g, 95%). FTIR (NaCl) 3393, 
3382, 1705 cm-1, 1H NMR (300 MHz, CDCl3) δ 2.08-2.15 (2H, m), 2.36-2.50 (3H, m), 
2.80 (1H, d, J = 16.4 Hz), 3.09 (1H, dd, J = 16.5, 6.8 Hz), 3.92 (1H, d, J = 6.7 Hz), 4.27 
(1H, d, J = 3.9 Hz), 7.10 (1H, d, J = 7.4 Hz), 7.16 (1H, d, J = 7.4 Hz), 7.29 (1H, d, J = 7.9 
Hz), 7.44 (1H, d, J = 7.62 Hz), 8.06 (1H, bs), 13C NMR (75.5 MHz, CDCl3) 211.0, 
135.7, 134.0, 126.9, 122.1, 119.7, 118.1, 110.9, 107.5, 59.8, 46.1, 35.0, 32, 25.8; CIMS 
(m/e, relative intensity) 227 (M++1, 100%). 
Anal. Calcd. For C14H14N2O: C, 74.31%; H, 6.24%; N, 12.38%. Found: C, 74.39%; H, 
6.35%; N, 12.41%. 
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Pd2(dba)3 (5 mol %), DPEPhos 
(7 mol %), t-BuONa (1.5 equiv), 
THF, 80 °C, 5 h, 83%
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H
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56
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CH3
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105103
THF-H2O (1:1)
0°C-rt, 5h
NaBH4, THF-H2O (9:1) PBr3, Et2O
0°C-rt, 93%
H
O
I
0°C, 97% overall yield
in two steps
I2, K2CO3,DMAP
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(Z)-1-bromo-2-iodobut-2-ene 51155 
A solution of crotonaldehyde 103 (300mL. 3.63 mol) in THF-H2O (1:1, 1500mL) was 
cooled to -15 to -20 °C (dry ice). To the cold solution was added K2CO3 (600g, 4.45 mol, 
1.2 equiv), I2 (1383g, 5.45 mol, 1.5 equiv) and DMAP (88.6g, 0.726 mol, 0.2 equiv) 
successively (the temperature was increased, controlled by the rate of addition of I2). The 
reaction was allowed to stir for 12 h until the disappearance of starting material (TLC, 
silica gel, I2) during which the temperature was allowed to increase to rt. Then solid 
Na2S2O3 (600g) and a saturated solution of Na2S2O3 (about 5L) was added until the 
reaction mixture became colorless. The mixture was extracted with EtOAc (3x8L) and 
the organic layers were combined. The majority of the solvent was removed under 
reduced pressure. The residue 104 was dissolved in THF-H2O (9:1, 8L) and cooled to -5 
to -10 °C (dry ice) after which NaBH4 (70g, 1.8 mol, 0.5 equiv) was added in portions 
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and the temperature maintained at 0°C. The mixture was extracted with EtOAc (3x8L) 
and dried (MgSO4). The solvent was removed under reduced pressure to provide a brown 
oil. After a simple wash column to remove some baseline material, iodide 105 was 
obtained as light yellow oil 105 (650g, 90%). 1H NMR (300 MHz, CDCl3) δ 6.02 (q, 1H, 
J =3.9Hz), 4.30 (s, 2H), 1.85 (t, 3H, J=6.3Hz). The spectral properties of this iodide were 
identical to the published values.120 (Z)-2-Bromo-2-buten-1-ol 105 (2 g, 10 mmol) was 
dissolved in anhydrous ethyl ether (20 mL). Phosphorus tribromide (0.380 mL, 4 mmol) 
was added dropwise to this solution at 0°C. This reaction mixture which resulted was 
stirred for 18 h at rt. The reaction was quenched with a cold aq solution of K2CO3 and 
extracted with ethyl ether after which it was washed with brine. The organic layer was 
dried (Na2SO4) and concentrated in vacuuo to give 51 (2.45 g, 93% yield) which was 
directly used in the next step.172 1H NMR: 6.08 (q, J = 6.4 Hz, 1H); 4.36 (s, 2H); 1.81 (d, 
J = 6.4 Hz, 3H). The spectral properties of this bromide were identical to the published 
values.121 This was directly used in the following alkylation.  
 
 K2CO3 (4 equiv), 
CH3CN, rt, 76%
Br
I
 (1.3 equiv)
N
H
NH
H
H
O
50
N
H
N
H
H
O
I
52  
Alkylation of (6S,10S)-(-)-9-oxo-12-H-6,7,8,9,10,11-hexahydro-6,10-imino-5H-
cyclooct[b] indole (50) to provide (6S,10S)-(-)-9-oxo-12-(Z-2' -iodo-2' -butenyl)-
6,7,8,9,10,11-hexahydro-6,10-imino-5H-cyclooct[b] indole 52 
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A solution of the Na-H, Nb-H tetracyclic ketone 50 (1.5g, 6.637mmol) was dissolved in  
dry CH3CN (20mL). To this mixture, K2CO3 (3.66g, 26.54 mmol) and Z-1-bromo-2-
iodo-2-butene 51 (2.6g, 9.95mmol) were added. This reaction mixture was stirred for 14h 
at rt. Analysis by TLC indicated the absence of tetracyclic ketone. The K2CO3 was 
removed by passing the mixture through a bed of celite with EtOAC. After removal of 
the solvent under reduced pressure, the crude product was purified by flash 
chromatography (silica gel, hexane:EtOAC = 9:1) to provide Nb-Z-2′-iodo-2′-butenyl 
tetracyclic ketone 52 (2.04g, 76%). FTIR (NaCl) 3393, 1705, 1450cm-1; 1H NMR (300 
MHz, CDCl3) δ 1.73 (3H, d, J=6.27Hz), 2.19-2.05 (2H, m), 2.37-2.47 (2H,m), 2.65(1H, 
d, J=16.87Hz), 3.05 (1H, dd, J=16.94, 6.72 Hz), 3.19-3.37 (2H,m), 3.64 (1H, d, 
J=6.37Hz), 3.96 (1H, bs), 5.76 (1H, q, J=6.17Hz), 6.97-7.16 (2H, m), 7.25 (1H, d, 
J=7.72Hz), 7.40 (1H, d, J=7.52Hz), 8.05 (1H, bs); 13C NMR (75.5 MHz, CDCl3) δ 20.60, 
21.71, 30.35, 34.49, 49.73, 63.36, 64.07, 106.69, 108.47, 110.94, 118.09, 119.62, 121.97, 
125.72, 132.11, 132.76, 135.79, 210.40; CIMS (m/e, relative intensity) 407 (M++1, 
100%). Anal. Calcd. For C18H19N2O: C, 53.22%; H, 4.71%; N, 6.90%. Found: C, 
53.15%; H, 4.80%; N, 6.64%. 
N
N
H
H
52
H
O
I
N
N
H
H
H
O
56
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DPEphos, 
Pd2(dba)3, 83%
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Palladium catalyzed cyclization of (6S, 10S)-(-)-9-oxo-12-(Z-2’-iodo-2’butenyl)- 
6,7,8,9,10,11-hexahydro-6,10-imino-5H-cyclooct [b] indole (52) to provide 
pentacyclic ketone (56) 
The Nb-Z-2' -iodo-butenyl tetracyclic ketone 52 (1 g, 2.46 mmol) was dissolved in 
anhydrous THF (20mL). To this mixture NaOtBu (0.354 g, 3.69 mmol), DPEphos 
(0.0927 g, 7.0 mol %) and Pd2 (dba)3 (0.112g, 5.0 mol %) was added. This reaction 
mixture was degassed 3-4 times under vacuum and back filled with argon and placed in a 
preheated oil bath at 80 °C for 5hrs. The reaction was quenched with water and ethyl 
acetate. The organic layer was separated and dried (Na2SO4). The EtOAc was then 
removed under reduced pressure and the residue was flash chromatographed with 
CH2Cl2/MeOH (4.5:0.5) to provide the coupling product 56 (0.569g, 83% yield).  1H 
NMR (300 MHz, CDCl3) δ 1.63 (3H, J=6.86 Hz, d), 2.15-2.20 (1H, m), 2.38 (1H, t, 
J=9.9 Hz), 2.97 (1H, dd, J=15.58, 6.20 Hz), 3.27 (1H, d, J=14.43 Hz), 3.37 (1H, bs), 
3.59 (1H, d, J=5.70 Hz), 3.78 (2H, bs), 4.26 (1H, d, J=59.11 Hz), 5.49 (1H, q, J=6.85 
Hz), 7.05-7.15 (2H, m), 7.25 (1H, d, J=7.25Hz), 7.47 (1H, d, J=4.7Hz), 7.93 (s, 1H); 13C 
NMR (75.5 MHz, CDCl3) δ 12.68, 22.39, 36.40, 44.55, 50.83, 55.24, 64.17, 105.62, 110. 
89, 118.54, 119.69, 121. 26, 122.00, 126.88, 131.88, 135.87, 136. 34, 217.00; CIMS 
(m/e, relative intensity) 291 (M+ +1, 100%); EIMS (m/e, relative intensity) 278 (M+ , 
10%), 250 ,75%), 249 (85%), 182 (6%), 169 (100%), 168 (5%). HRMS C18H18N2O: 
calcd. 278.1419; found 278.1437. This material was used directly in the next step. 
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equiv), benzene/THF;
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 2 N aq HCl/THF, 
55 °C, 90%
56 14a  
Conversion of the pentacyclic ketone (56) into (+)-3-ethylidene-1,3,4,7,12,12b-
hexahydro-2H, 6H- 2,6-methano-indole[2,3,-α]-quinolizine-13-carboxaldehyde[(+)- 
vellosimine, 14a] via the Wittig reaction followed by acid mediated hydrolysis. 
A mixture of anhydrous potassium t-butoxide (12.8g, 0.114 mol) and methoxylmethyl 
triphenylphosphonium chloride (36g, 0.105 mol) in dry benzene (500mL) was allowed to 
stir at rt for 1h. The pentacyclic ketone 56 (4g, 14.4mmol) in THF (160mL) was then 
added into the above orange colored solution dropwise at rt. The mixture which resulted 
was stirred at rt for 24h. The mixture was diluted with EtOAc (3x700mL), washed with 
H2O (3x50mL), brine (50mL) and dried (K2CO3). The solvent was removed under 
reduced pressure to afford an oil. The solvent was removed under reduced pressure and 
the residue was dissolved (without further purification) in a solution of aq HCl (2N) in 
H2O-THF (1:1, 400mL). The solution which resulted was refluxed 55 °C (oil bath 
temperature) under an atmosphere of argon for 6h. The reaction mixture was brought to rt 
and concentrated under reduced pressure. The reaction mixture was diluted with water 
and extracted with ether to remove the triphenyl phosphine oxide. The aq layer was 
brought to pH 8 with an ice cold aq solution of NaOH (1N). The aq layer was extracted 
with CH2Cl2 and the combined organic layers were washed with H2O (3x100mL), brine 
(100mL) and dried (K2CO3). The solvent was removed under reduced pressure to afford 
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an oil which was crystallized to provide the aldehyde 14a (3.78g, 90%).  The spectral 
data for (+)-vellosimine 14a were in good agreement with the published values.19,173 
NaBH4 (1.4 equiv), 
EtOH, 0 °C, 8 h
90%
N
H
N
H
H
H
CHO
H
N
H
N
H
H
H
H OH
14a 107  
Sodium borohydride mediated reduction of (+)-3-ethylidene-1,3,4,7,12,12b-
hexahydro-2H,6H-2,6-methano-indole[2,3-α]-quinolizine-13-carboxaldehyde[(+)- 
vellosimine, 14a] to provide the (+)-3-ethylidene-1,3,4,7,12,12b-hexahydro-13-
hydroxymethyl-2H,6H-2,6-methano-indole [2,3-α]-quinolizine [(+)-normacusine B, 
107]. 
The (+)-vellosimine 14a (100mg, 0.34mmol) was dissolved in EtOH (5mL). The NaBH4 
(12mg, 0.33 mmol) was added to the above solution at 0 °C in one portion. The mixture 
was then stirred for 8 h. The reaction mixture was diluted with CH2Cl2 (50mL) and 
poured into cold water (10mL). The aq layer was extracted with additional CH2Cl2 
(3x20mL) and the combined organic layers were washed with brine (10mL) and dried 
(K2CO3). The solvent was removed under reduced pressure to afford the crude product 
which was chromatographed to provide normacusine B 107 (90mg, 90%). [α]D28 = +40.5 
° (c=0.75, C2H5OH); lit [α]D =+42 ° (c=1.0, C2H5OH)174: FTIR (NaCl) 3198 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 1.57 (3H, d, J=6.76 Hz), 1.66 (1H, dt, J =12.54, 3.69 Hz), 
1.78 (1H, q, J=7.49 Hz), 1.93 (1H, t, J=10.00Hz), 2.61(1H, d, J=15.37Hz), 2.72 (1H, s), 
2.74 (1H, d, J=6.51 Hz), 3.03 (1H, dd, J=15.39, 5.10 Hz), 3.43-3.49 (4H, m), 4.07 (1H, d, 
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J=10.29Hz), 5.26 (1H, q, J=6.68Hz), 7.03-7.14 (1H, m), 7.28 (1H, d, J=6.00Hz), 7.42 
(1H, d, J=7.00Hz), 8.22 (1H, s); 13C NMR (75.5 MHz, CDCl3) δ 12.75, 26.95, 27.58, 
33.37, 44.14, 050/48, 54.47, 55.85, 64.90, 0104.52, 110.99, 116.84, 118.07, 
119.35,121.44, 127.59, 135.33, 136.33, 137.80; EIMS (m/e, relative intensity) 294 (M+, 
84%), 293 (85%), 279 (10%), 263 (30%), 169 (100%), 168 (79%). HRMS C19H22N2O: 
calcd. 294.1732; found 294.1705. The spectral data were identical to that reported in the 
literature.174 
N
H
N
H
H
H
H OH
107
CH2Cl2, TIPSCl
2, 6lutidine, 90% NH
N
H
H
H
H OTIPS
108  
Synthesis of 3-ethylidiene-13-(triisopropylsilanyloxymethyl)-1,3,4,7,12,12b- 
hexahydro-2H,6H-2,6-methano-indolo [2,3-α] quinolizine 108 from normacusine B 
107 with 2,6-lutidine and triisopropylsilyl chloride. 
A solution of normacusine B 107 (1.0g, 3.4mmol) was stirred in dry CH2Cl2 (30mL) in a 
125mL round bottom flask. At 0 °C, 2, 6–lutidine (1.58mL, 13.6mmol), followed by 
triisopropylsilyl chloride (1.82mL, 6.8mmol) were added. The reaction mixture was 
allowed to stir for 2h until analysis of the mixture by TLC indicated the absence of 
starting material. Water (50.0mL) was added to the solution to quench the reaction 
mixture and it was extracted with CH2Cl2 (3x200mL). The organic layer was separated 
and dried (Na2SO4). The organic layer was removed under reduced pressure and the 
residue was purified by flash chromatography (silica gel, CH2Cl2/MeOH (95:5) to 
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provide 108 (1.38g, 90%).  [α]D = +45.14 ° (c=0.14 in CH2Cl2); 1H NMR (300 MHz, 
CDCl3) δ 1.05 (m, 21H), 1.62 (d, 3H, J=6.7Hz), 1.74 (m, 2H), 2.05 (t, 1H, J=10.1Hz), 
2.70 (d, 1H, J=15.5Hz), 2.79 (m, 2H), 3.08 (dd, 1H, J=15.3 and 5.3Hz), 3.60 (m, 4H), 
4.17 (d, 1H, J=7.5Hz), 5.39 (q, 1H, J=6.8Hz), 7.13 (m, 2H), 7.34 (d, 1H, J=7.5Hz), 7.48 
(d, 1H, J=7.4Hz), 8.03(br, 1H); 13C NMR (75.5 MHz, CDCl3) δ 11.83, 12.73, 17.96, 
27.10, 27.29, 33.56, 44.26, 50.55, 54.93, 56.05, 65.56, 104.72, 110.76, 116.44, 118.03, 
119.20, 121.23, 127.74, 135.48, 136.18, 137.87; MS (EI) m/e (relative intensity) 450 (M+, 
16), 263 (45), 182 (31), 169 (89), 168 (100). Anal.Calcd. for C28H42N2OSi: C, 74.61; H, 
9.39; N, 6.22. Found: C, 74.46; H, 9.31, N, 6.06 
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108 109  
IBX mediated oxidation to provide (6S,11S,11aR,E)-9-ethylidene-11-
((triisopropylsilyl)oxy)methyl)-6,8,9,10,11,11a-hexahydro-6,10-methanoindolo[3,2-
b]quinolizin-12(5H)-one (109) 130 
To a solution of triisopropylsilyl ether 108 (100mg, 0.22mmol) in EtOAc/DMSO 
(10mL/5mL) was added IBX (0.552mg, 0.88mmol) in one portion at rt. The mixture 
which resulted was stirred at 80°C overnight and the reaction progress was monitored by 
TLC (silica gel, EtOAc). The reaction mixture was cooled at 0 °C and quenched with a 
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saturated solution of aq NaHCO3 (4mL), followed by treatment with a saturated solution 
of aq Na2S2O3 (5mL). After this, the mixture was stirred for an additional 10min at 0°C. 
The aq layer was extracted with additional amounts of EtOAc (3x10mL) and the 
combined organic layers was washed with brine (10mL) and dried (K2CO3). The solvent 
was removed under reduced pressure to provide the crude oil which was purified by flash 
chromatography [silica gel, hexane: EtOAc (1:1)] to provide the benzylic ketone 109 
(87mg, 85%). 1H NMR (300 MHz, CDCl3) δ 1.05 (m, 21H), 1.66 (d, 3H, J=6.3Hz), 1.82 
(d, 1H, J=6.3Hz), 2.13 (t, 1H, J=9.9Hz), 2.86 (d, 1H, J=7Hz), 3.17 (s, 1H), 3.5 (m, 3H), 
3.8 (dd, 1H, J1=9.6Hz, J2=4.2Hz ), 4.3 (d, 1H, J=8.4Hz), 5.47 (q, 1H, J=7Hz), 7.39 (t, 
2H, J=7Hz ), 7.49 (t, 1H, J=7Hz), 7.96 (d, 1H, J=7Hz), 8.14 (d, 1H,  J=7.2Hz ), 9.6 (br, 
1H); 13C NMR (75.5 MHz, CDCl3) δ 11.91, 12.97, 18.03, 29.72, 32.50, 42.63, 50.48, 
54.85, 63.92, 64.60, 106.49, 111.64, 118.52, 121.64, 122.74, 123.61, 124.47, 132.30, 
136.14, 154.67, 192.01; HRMS (ESI) calculated for C28H41N2O2Si : 465.2937; found : 
465.2950. 
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THF, TBAF.H2O
O°C-rt, 85%
O
109 110  
Synthesis of (6S,11R,11aR,E)-9-ethylidene-11-(hydroxymethyl)-6,8,9,10,11,11a-
hexahydro-6,10-methanoindolo[3,2-b]quinolizin-12(5H)-one (110) 
A solution of benzylic ketone 109 (20mg, 0.043mmol) was stirred in THF (1 mL) in a 
5mL round bottom flask. At 0°C, excess TBAF hydrate was then added to the mixture and it 
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was allowed to warm to rt. The reaction mixture was stirred for 2h until analysis of the 
mixture by TLC indicated the absence of starting material. The reaction was quenched 
with water (10mL) and extracted with EtOAc (3x10mL), washed with brine and dried 
(Na2SO4). After removal of the solvent under reduced pressure, the residue was purified 
by flash chromatography [EtOAc : hexane (4:1)] to provide the target monol 110 (0.011g, 
85%) . 1H NMR (300 MHz, CDCl3) δ 1.68 (d, 3H, J=6Hz), 1.87 (d, 1H, J=12Hz), 2.12 
(br, 1H), 2.28 (t, 1H, J=12Hz), 2.84 (d, 1H, J=6 Hz), 3.25 (s, 1H), 3.66 (m, 5H), 4.35 
(dd, 1H, J1=9Hz, J2=3Hz ), 5.55 (q, 1H, J=7.5Hz), 7.25 (m, 2H ), 7.43 (d, 1H, J=7Hz), 
7.98 (d, 1H, J=8.4Hz); 13C NMR (75.5 MHz, CDCl3) δ 11.60, 12.52, 19.30, 29.17, 
42.58, 50.19, 54.38, 63.17, 64.32, 105.38, 111.63, 117.97, 120.54, 122.24, 123.19, 
124.29, 133.29, 136.80, 156.43, 193.70; HRMS (ESI) calculated for C19H21N2O2 : 
309.1603; found : 309.1588. This material was used in a later step. The structure of 
ketone 110 was confirmed by X-ray analysis (see Figure 8). 
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MeOH, CeCl3.7H20
NaBH4, -78°C-rt, 90%
110 88  
Preparation of (6S,11R,11aR,12R,E)-9-ethylidene-11-(hydroxymethyl)-
5,6,8,9,10,11,11a,12-octahydro-6,10-methanoindolo[3,2-b]quinolizin-12-ol (88) 
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A solution of alcohol 110 (15mg, 0.049mmol) was stirred in MeOH (1 mL) in a 5mL 
flask. At -78°C, CeCl3.7H20 (19mg, 0.054mmol) and NaBH4 (2mg, 0.049mmol) was 
added to the mixture and it was allowed to warm to rt. The reaction mixture was stirred 
for 3h until analysis of the mixture by TLC indicated the absence of starting material. The 
reaction was quenched with aq NH4Cl (5mL) and extracted with CH2Cl2 (3x10mL), 
washed with brine and dried (Na2SO4). After removal of the solvent under reduced 
pressure, the residue was purified by flash chromatography [CH2Cl2 : MeOH (90:10)] to 
provide the target diol 88 (13mg, 90%) ; Rf  0.75 (silica gel, CH2Cl2/MeOH, 9 : 1); [α]25D 
+79° (c 0.6 MeOH); 1H NMR (300 MHz, CDCl3) δ 1.67 (d, 3H, J=6.6Hz), 1.80 (td, 1H, 
J1=12.6Hz, J2=6Hz), 2.13 (m, 1H), 2.2 (m, 1H), 2.7 (t, 1H, J=6.6 Hz), 3.01 (s, 1H), 3.5 
(m, 3H), 3.6 (m, 2H),  4.10 (d, 1H, J=8Hz ), 5.23 (d, 1H, J=6Hz), 5.47 (q, 1H, J=6.6 Hz), 
7.04 (m, 2H), 7.3 (d, 1H, J=7.8Hz), 7.78 (d, 1H, J=7.8Hz); 13C NMR (75.5 MHz, 
CDCl3) δ 11.60, 27.20, 32.46, 39.18, 50.16, 55.58, 59.71, 63.85, 65.98, 102.27, 110.61, 
116.86, 118.64, 119.18, 120.78, 126.51, 135.19, 136.91, 138.54; HRMS (ESI) calculated 
for C19H23N2O2 : 311.1760; found : 311.1758. The structure of diol 88 was confirmed by 
X-ray analysis (see Figure 9). 
 
N
H
N
H
H
H
O
N
H
N
H
H
H
CH3PPh3Br (7.3 
equiv), t-BuOK (7.9 
equiv) benzene/THF
90%
56 111  
117 
 
Synthesis of (+)-3-ethylidene-12-methyl-1,3,4,7,12,12b-hexahydro-2H,6H-2,6-
methano-13-methylene-indole[2,3-a]quinolizine (111)  via the Wittig reaction.  
A mixture of anhydrous potassium tert-butoxide (3.24g,-2.75mmol) and  
methyltriphenylphosphonium bromide (8.93 g, 2.5 mmol) in dry benzene (150 mL) was 
allowed to stir at rt for 1 h. The pentacyclic ketone 56 (1.46 g, 0.50 mmol) in THF (50 
mL) was then added into the above orange-colored solution dropwise at rt. The mixture 
which resulted was stirred at rt for 4 h. The mixture was diluted with EtOAc (500 mL), 
washed with H2O (3 x 50 mL), brine (100 mL), and dried (K2CO3). The solvent was 
removed under reduced pressure and the oil which resulted was flash chromatographed 
(silica gel, CHCl3/MeOH ) 40:1) to provide the olefin 111 (1.30 g, 90%): FTIR (CHCl3) 
3439 cm-1; 1H NMR (300 MHz, CDCl3) δ 1.67 (dt, 3H, J = 6.8, 1.8 Hz), 1.87 (dt, 1H, J 
= 9.2, 2.8 Hz), 2.25 ( ddd, 1 H,  J = 11.8, 10.0, 1.7 Hz), 3.02 (dd,  1 H, J = 15.4, 1.3 Hz), 
3.24 (dd,  1 H, J = 15.5, 5.2 Hz), 3.35 (m, 1 H), 3.60 (s, 3 H), 3.84 (m, 2 H), 3.93 (m, 1 
H), 4.35 (dd, 1 H, J = 9.9, 2.3 Hz), 4.86 (t, 2 H,  J = 2.4 Hz, 5.34 (q, 1 H,  J =7.0 Hz), 
7.08 (td, 1 H,  J = 6.9, 1.2 Hz), 7.20 (td, 1 H, J = 6.9, 1.1 Hz), 7.27 (d, 1 H, J = 7.6 Hz), 
7.50 (td, 1 H, J = 7.6 Hz); 13C NMR (75.5 MHz, CDCl3) δ  12.4, 26.2, 29.2, 35.3, 36.3, 
49.6, 56.1, 56.8, 103.8, 105.4, 108.7, 115.4, 118.1, 118.8, 120.9, 127.0, 136.4, 137.3, 
138.2, 151.6; EIMS (m/z, relative intensity) 290 (M+, 100), 275 (13), 182 (76). Anal. 
Calcd for C20H22N2: C, 82.72; H, 7.04; N, 9.65. Found: C, 82.84; H, 7.29; N, 9.46. 
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Synthesis of (E) 16-epinormacusine B 112 from (+)-3-ethylidene-12-methyl-
1,3,4,7,12,12b-hexahydro-2H,6H-2,6-methano-13-methylene-indole[2,3-a]quinolizine 
(111)   
To a solution of olefin 111 (200 mg, 0.72 mmol) in THF (20 mL) was added 9-BBN (0.5 
M in THF, 7.23 mL, 3.6 mmol) dropwise at 0 °C. The solution was allowed to warm to rt 
and stirred for 1.5 h. The reaction mixture was then cooled to 0 °C and NaBO3· 4H2O 
(1.67g, 10.8mmol) was added (Kabalka process) and the reaction temperature allowed to 
warm to rt. The mixture which resulted was stirred for 2 h at rt, diluted with CH2Cl2 (200 
mL), washed with H2O (3 x 50 mL) as well as brine (100 mL), and dried (K2CO3). The 
solvent was removed under reduced pressure and the residue was chromatographed 
(silica gel, CH2Cl2/MeOH; 9:1) to provide alcohol 112 (149 mg, 70%). FTIR (CHCl3) 
3200, 2918 cm-1; [α]D = +6.92° (c 0.25, MeOH) [lit.1 [α]D = +3° (c 0.25, MeOH)]; 1H 
NMR (300 MHz, CDCl3) δ  1.64 (dt, 3 H, J = 6.8, 1.8 Hz), 1.84 (m, 2 H), 2.24 (m, 1 H), 
2.89 (q, 1 H, J = 2.8 Hz), 3.01 (m, 2 H), 3.27 (dd, 1 H, J = 10.5, 8.5 Hz), 3.48-3.76 (m, 4 
H), 4.22 (dd, 1 H, J = 9.0, 4.2 Hz), 5.23 (q, 1 H, J = 6.8 Hz), 7.08 (td, 1 H, J = 7.1, 1.3 
Hz), 7.16 (td, 1 H, J = 7.1, 1.3 Hz), 7.36 (d, 1 H, J =7.3 Hz), 7.49 (d, 1 H, J =7.3 Hz), 8.60 
(s, 1 H); 13C NMR (75.5 MHz, CDCl3) δ  12.7, 22.3, 26.1, 27.0, 41.8, 50.1, 52.8, 55.9, 
60.9, 105.6, 111.2, 114.9, 118.1, 119.3, 121.7, 126.0, 135.6, 136.4, 137.4; Anal. Calcd 
for C19H22N2O: C, 77.52; H, 7.53; N, 9.52. Found: C, 77.80; H, 7.79; N, 9.34 
 
 
119 
 
N
H
N
H
H
H
H
TIPSCl, CH2Cl2
2,6-Lutidine
90%
OTIPS
N
H
N
H
H
H
H
112
OH
113  
Preparation.of.(6S,11S,11aS,E)-9-ethylidene-11-(((triisopropylsilyl)oxy)methyl)-5, 6, 
8, 9, 10, 11, 11a,12-octahydro-6,10-methanoindolo[3,2-b]quinolizine (113) 
The synthesis of 113 (TIPS derivative) from monol 112 was carried out analogous to 
the preparation of 108 from 107 in 90% yield. 1H NMR (300 MHz, CDCl3) δ 1.03 (d, 
21H, J=3Hz), 1.57 (d, 3H, J=6Hz), 2.01 (m, 1H), 2.08 (m, 1H), 2.26 (t, 1H, J=12Hz), 
2.81 (s, 1H), 2.97 (d, 1H, J=15Hz), 3.30 (m, 3H),  3.57 (m, 3H), 4.76 (d, 1H, J=9Hz), 
5.21 (q, 1H, J=9Hz), 7.28 (m, 2H), 7.45 (d, 1H, J=9Hz), 9.88 (br, 1H); 13C NMR (75.5 
MHz, CDCl3) δ 12.69, 22.80, 26.53, 27.44, 42.99, 50.12, 52.25, 56.65, 61.76, 106.78, 
110.55, 112.93, 118.21, 121.23, 126.73, 136.38, 137.26, 141.34; HRMS (ESI) calculated 
for C28H43N2OSi : 451.3145; found : 451.3172. This material was employed directly in 
the next step. 
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Preparation of (6S,11S,11aR,E)-9-ethylidene-11-((triisopropylsilyl)oxy)methyl)-
6,8,9,10,11,11a-hexahydro-6,10-methanoindolo[3,2-b]quinolizin-12(5H)-one (114) 
The synthesis of ketone 114 from TIPS derivative 113 was carried out analogous to 
the preparation of 109 from 108 in 85% yield.  1H NMR (300 MHz, CDCl3) δ 0.96 (d, 
21H, J=2.7Hz), 1.66 (d, 3H, J=7Hz), 1.81 (t, 1H, J=11Hz), 2.06 (dd, 1H, J1=9.9Hz, 
J2=3.3Hz), 2.25 (m, 1H), 3.35 (d, 1H, J=2),  3.47 (t, 1H, J=11), 3.74 (d, 2H, J=2.4Hz), 
3.78 (s, 1H), 3.84 (dd, 1H, J1=10.2Hz, J2=4.8), 4.14 (dd, 1H, J1=10.5Hz, J2=4.5), 5.32 
(q, 1H, J=6.9Hz), 7.27 (m, 3H), 8.13 (d, 1H, J=6.9Hz), 8.9 (br, 1H); 13C NMR (75.5 
MHz, CDCl3) δ 11.85, 12.72, 17.94, 25.99, 27.81, 38.52, 50.07, 55.52, 59.87, 63.54, 
108.57, 111.27, 114.29, 121.77, 122.82, 123.50, 123.88, 135.75, 139.17, 155.29, 191.47; 
HRMS (ESI) calculated for C28H41N2OSi : 465.2937; found : 465.2914. This material 
was employed directly in the next step. 
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Preparation of (6S,11S,11aR,E)-9-ethylidene-11-(hydroxymethyl)-6,8,9,10,11,11a-
hexahydro-6,10-methanoindolo[3,2-b]quinolizin-12(5H)-one (115) 
The synthesis of monol 115 from TIPS derivative 114 was carried out analogous to 
the preparation of 110 from 109 in 85% yield 13H NMR δ 1.68 (td, 3H, J1=6.6Hz, 
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J2=3.9Hz), 2.06 (m, 2H), 2.26 (m, 1H), 3.3 (m, 1H), 3.67 (dd, 1H, J1=11Hz, J2=5Hz), 
3.77 (m, 3H), 4.28 (dd, 1H, J1=11Hz, J2=5Hz ), 5.4 (q, 1H, J=6Hz), 7.27 (m, 2H ), 7.47 
(m, 1H), 8.01 (m, 1H); 13C NMR (75.5 MHz, CD3OD) δ 11.47, 24.85, 27.60, 38.07, 
49.51, 54.62, 58.32, 63.23, 107.63, 111.63, 114.36, 120.63, 122.40, 123.30, 123.48, 
136.70, 138.16, 156.29, 191.83 ; HRMS (ESI) calculated for C19H21N2O2 : 309.1603; 
found : 309.1588. This material was employed directly in the next step. 
N
H
N
H
H
H
H
OH
N
H
N
H
H
H
H
OH
O OH
MeOH, CeCl3.7H20
NaBH4, -78°C-rt, 90%
115 89   
Preparation of (6S,11S,11aR,12R,E)-9-ethylidene-11-(hydroxymethyl)-
5,6,8,9,10,11,11a,12-octahydro-6,10-methanoindolo[3,2-b]quinolizin-12-ol (89)  
The synthesis of 89 from 115 was carried out analogous to the preparation of 88 
from 110 in 85% yield. Rf  0.71 (silica gel, CH2Cl2/MeOH, 9 : 1); [α]25D +29.0° (c 0.6 in 
MeOH); [lit.136 [α]D22 = +29.5° (c 0.6 in CH3OH)]; 
1H NMR (300 MHz, CD3OD) δ 1.70 
(d, 3H, J=6.9Hz), 1.94 (m, 2H), 2.26 (m ,1H), 2.9 (q, 1H, J=2.4 Hz), 3.14 (dd, 1H, 
J1=11.4Hz, J2=6Hz), 3.61 (dd, 1H, J1=10Hz, J2=5.4Hz ), 3.6 (s, 3H), 3.8 (m, 1H), 4.2 
(dd, 1H, J1=8.4Hz, J2=4Hz ), 5.4 (m, 2H), 7.0 (t, 1H, J=7Hz ), 7.08 (t, 1H, J=7Hz), 7.32 
(d, 1H, J=8.1Hz ), 7.76 (d, 1H, J=7.8Hz); 13C NMR (300MHz, CD3OD) δ 11.48, 26.31, 
28.15, 42.53, 50.10, 55.66, 58.72, 61.00, 67.33, 110.22, 110.58, 114.22, 118.64, 119.68, 
120.85, 125.04, 136.17, 136.99, 138.87; HRMS (ESI) calculated for C19H23N2O2: 
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311.1760; found : 311.1773. The optical rotation and mass spectrum were in excellent 
agreement with the natural product. 136 
N
H
N
H
H
H
111
N
H
N
H
H
H
O
EtOAc:DMSO
IBX, 80°C, 8h, 80%
116  
Synthesis of (6S,11aR,E)-9-ethylidene-11-methylene-6,8,9,10,11,11a-hexahydro-6,10-
methanoindolo[3,2-b]quinolizin-12(5H)-one (116) 
To a solution of diene 111 (100mg, 0.36mmol) in EtOAc/DMSO (5mL/2.5mL) was 
added IBX (0.225mg, 1.44mmol) in one portion at rt. The mixture was stirred at 80°C 
overnight and the reaction progress was monitored by TLC (silica gel, EtOAc). The 
reaction mixture was cooled at 0 °C and quenched with a saturated solution of aq 
NaHCO3 (4mL), followed by treatment with a saturated solution of aq Na2S2O3 (5mL). 
After this, the mixture was stirred for an additional 10min at 0°C. The aq layer was 
extracted with additional amounts of EtOAc (3x10mL) and the combined organic layers 
was washed with brine (10mL) and dried (K2CO3). The solvent was removed under 
reduced pressure to provide the crude oil which was purified by chromatography [silica 
gel, hexane: EtOAc (3:1)] to provide the benzylic ketone 116 (84mg, 80%). 1H NMR 
(300 MHz, CDCl3) 1.66 (d, 3H, J=6Hz), 1.9 (m, 1H), 2.36 (m, 1H), 3.6 (m, 3H), 4.0 (m, 
1H),  4.9 (d, 1H, J=2Hz), 5.0 (d, 1H, J=2Hz), 5.39 (q, 1H, J=6.8Hz), 7.27 (m, 2H), 7.4 
(m, 1H), 7.6 (m, 2H), 8.0 (m, 1H); 13C NMR (75.5 MHz, CDCl3) δ 11.13, 34.44, 38.50, 
50.13, 54.41, 67.44, 105.89, 106.23, 124.30, 128.49, 128. 65, 131.60, 131.74, 132.39, 
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135.75, 136.72, 145.10, 155.95, 190.17; HRMS (ESI) calculated for C19H19N2O : 
291.1497; found : 291.1513. This material was employed directly in the next step. 
 
N
H
N
H
H
H
H
OH
N
H
N
H
H
H
O OH9-BBN (5 equiv), 0 °C to rt, 
1.5 h; NaBO3⋅4H2O, 
0 °C to rt, 2 h
70%
116 117  
Preparation of (6S,11S,11aR,12S,E)-9-ethylidene-11-(hydroxymethyl)-
5,6,8,9,10,11,11a,12-octahydro-6,10-methanoindolo[3,2-b]quinolizin-12-ol (117)  
To a solution of olefin 116 (100 mg, 0.344 mmol) in THF (10 mL) was added 9-BBN 
(0.5 M in THF, 1.63 mL, 1.72 mmol) dropwise, at 0 °C. The solution was allowed to 
warm to rt and stirred for 1.5 h. The reaction mixture was then cooled to 0 °C and 
NaBO3· 4H2O (0.795g, 5.16mmol) was added and the reaction temperature allowed to 
warm to rt. The mixture which resulted was stirred for 2 h at rt, diluted with CH2Cl2 (50 
mL), washed with H2O (3 x 50 mL) as well as brine (50 mL), and dried (K2CO3). The 
solvent was removed under reduced pressure and the residue was chromatographed 
(silica gel, CH2Cl2/MeOH; 9:1) to provide alcohol 117 (74mg, 70% yield). Rf  0.73 (silica 
gel, CH2Cl2/CH3OH, 9 : 1); [α]25D = +17.0° (c 0.6 in CH3OH); [lit.
136 [α]D22 = +29.5° (c 
0.6 in CH3OH)]; 
1H NMR (300 MHz, CD3OD) δ 1.70 (d, 3H, J=6Hz), 1.92 (m, 2H), 
2.27 (m ,1H), 2.9 (s, 1H), 3.16 (dd, 1H, J1=11.4Hz, J2=6Hz), 3.61 (m, 3H), 3.8 (m, 1H), 
4.2 (m, 1H), 5.3 (q, 1H, J=6.6Hz), 5.36 (d, 1H, J=4.8Hz), 7.0 (m, 2H), 7.35 (s, 1H), 7.82 
(d, 1H, J=7.5Hz ); 13C NMR (300MHz, CD3OD) δ 11.48, 26.35, 28.22, 42.59, 50.06, 
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55.69, 58.72, 59.17, 61.07, 67.42, 110.23, 110.57, 114.09, 118.62, 119.67, 120.81, 
125.07, 136.35, 136.98, 139.12; HRMS (ESI) calculated for C19H22N2O2 : 311.1760; 
found : 311.1748  
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1. Introduction 
The GABAA /benzodiazepine receptor (BzR) is the major neurotransmitter in the central 
nervous system which is inhibitory in action.1 This receptor is involved in many 
functions of the CNS as well as in many diseases.2 Many of these diseases occur due to 
the improper balance of neurotransmitters which can be restored using therapeutics. The 
benzodiazepines continue to be the most widely used drug to treat various disorders such 
as anxiety disorders3 and epilepsy4 but they have side effects including muscle 
relaxant/ataxic,  sedative-hypnotic effects, hypersensitive behavior, phobias, along with 
effects which lead to or complicate drug abuse5.  
The γ-aminobutyric acid (GABAA) receptors are heteroligomeric membrane-bound 
protein complexes that are composed of several subunits and are termed type A, type B 
and type C. In the case of type A receptors, the inhibitory effects of GABA mediated by 
these receptors can be modulated by a number of pharmacological agents that selectively 
bind to allosteric sites on these ion channels.6-9 GABAA receptors are pentameric 
assemblies of proteins derived from a family of subunits (6α3β3γ1δ1π1θ1ε and 3ρ) 
which form the chloride ion channel. The most common form of native GABAA 
receptors contains α, β, and γ subunits in a 2:2:1 stoichiometry.10-12 It has been shown 
that recombinant receptors which contain these subunits most closely mimic the 
biological, electrophysiological and pharmacological properties of native GABAA 
receptors which contain a benzodiazepine recognition site (GABAA/Bz receptors).13The 
benzodiazepine binding site is located at the interface between 14,15α and γ subunits.16 
While it is clear the γ subunit is also required for benzodiazepine binding,11,13 the fact 
that most native GABAA receptors contain a γ2 subunit is in agreement with the α 
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subunit as the key determinant of benzodiazepine binding and efficacy. However, it is 
clear the gamma subunit is also required for benzodiazepine binding (see Figure 1) was 
mentioned. Recent advances in molecular biology have identified 21 subunits which 
comprise a series of GABAA/BzR subtypes (ion channels).17-21 Importantly, it has now 
been found that certain disease states, as well as tolerance and dependence are related to 
the up or down regulation of specific subunits.  
 
      
Figure 1.  Absolute subunit arrangement of the α1β2γ2 GABAA receptor when viewed 
from the synaptic cleft.  The GABA binding sites are located at the β+α− subunit 
interfaces and the modulatory Bz BS (Bz) is located at the α+γ subunit interface. 22,23 
1.2. Benzodiazepine pharmacology 
Ligands that bind to the BZ site can influence the binding of GABA to its receptor and 
thereby alter the flux of chloride ions through the ion channel.24 Ligands at the BZ site 
are categorized as agonists, inverse agonists, or antagonists. Agonists enhance the 
effects of GABA by increasing the frequency of channel opening to provide a net 
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hyperpolarization of the neuron and a decreased excitability. BZ inverse agonists have 
the opposite effect and decrease the flow of chloride ions (negative modulators, NAM) 
which results in a depolarization and an increased neuronal excitability. Between the 
two efficacy extremes, there is a continuum of partial agonists and partial inverse 
agonists as well as antagonists, the latter of which do not alter chloride flow and are 
functionally silent. These different efficacies are reflected in different behavioral effects 
of BzR site ligands in mammalian species. The schematic diagram of subunits and 
ligands of the benzodiazepine-GABA receptor-chloride channel complex can be seen in 
Figure 2.  
 
Figure 2.  The schematic diagram of subunits and ligands of the benzodiazepine-GABA 
receptor-chloride channel complex. Reprinted with permission of the author. 
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The interaction with benzodiazepines (BZ, Figure 3) has been a major influence in 
studies on GABA receptors because of the long history of the therapeutic application of 
BZs as anxiolytics, anticonvulsants, sedative-hypnotics, and muscle relaxants.9,25 
Although the BZs were first introduced into clinical practice in the early 1960s, it  was  
not  until 1975 that  these  drugs  were shown to act by potentiating the inhibitory 
actions of GABA in the brain. 1,25  The presence of high-affinity specific binding sites 
for BZs in the mammalian brain was then demonstrated by Squires, Haefely et al. 6,26,27 
Converging lines of evidence established that these sites were contained in the same 
macromolecule as the GABA sites and the chloride channel, moreover, that all three 
elements were coupled allosterically.28-30 The term "GABA/BZ receptor" came into use 
for this complex (and is still encountered). Until recently, progress in this field was 
driven by the synthesis of a vast range of BZs and BZ-like drugs, which acted at the 
allosteric BZ sites in the brain. GABAA receptors exhibited clinical anxiolytic or 
sedative properties which correlated to their binding potencies in the CNS.31 The 
structures of some ligands which act at the BZ site are shown in Figure 3.  
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Figure 3. GABA, diazepam, triazolam and midazolam. 
BDZs, such as diazepam(2), are the most potent anticonvulsent, muscle relaxant, 
sedative-hypnotic and anxiolytic compounds in clinical use.32 They do not substitute for 
GABA, but instead enhance the inhibitory effects of GABA. BDZ’s allosterically bind 
to the receptor at a different location than GABA does and enhance the chloride 
channels conductance by increasing the frequency of gated channel opening.33-37 BDZ 
and compounds interacting with the benzodiazepine site of GABAA receptors can only 
modulate ongoing GABAergic activity (see Figure 4). These compounds cannot elicit 
chloride ion flux in the absence of GABA33,37 and thus can exhibit an extremely low 
degree of toxicity. Many different classes of compounds have been shown to interact 
with the BDZ binding site of GABAA receptors.38-42 In each of these classes, compounds 
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could be identified that enhanced or reduced the action of GABA on GABAA receptors, 
as mentioned above.   
 
Figure 4: Mode of action of benzodiazepines. Reprinted with permission of the author 
1.3. Molecular Modeling 
An extensive study of the BzR pharmacophore has been carried out in Milwaukee.42-47 
Based on data from at least 166 ligands at BzR, a unified BzR pharmacophore receptor 
model of the BDZ receptor has been developed. Outlined in Figure 5 are the proposed 
descriptors required for high affinity binding to the inclusive pharmacophore.43,48 The 
important points of the model include three anchor points which were termed L1, H1, and 
H2; region L1 represents a center of lipophilic interaction with the ligands, while H1, H2 
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and A2 represent two hydrogen bond donor sites and one hydrogen bond acceptor site on 
the receptor protein, respectively, in the receptor binding domain.49 Three additional 
lipophilic regions were also proposed, termed L2, L3 and LDi, which are important for 
binding affinity and selectivity as well as efficacy of ligands. It is noteworthy to mention 
that lipophilic interactions between a ligand and the receptor include vander Waals 
interactions, as well as potential π-π and p-π stacking between the aromatic moieties of 
the ligand and groups on the receptor protein.   
 
Figure 5. Diazepam in the Pharmacophore/Receptor Model for the BzR Site. 
Pyrazolo[3,4-c]quinolin-3-one CGS-9896 (dotted line), a diazadiindole (thin line), and 
diazepam (thick line) fitted to the inclusive pharmacophore model for the BzR. Sites H1 
and H2 represent hydrogen bond donor sites on the receptor protein complex, while A2 
represents a hydrogen bond acceptor site necessary for potent inverse activity in vivo. 
L1, L2, L3 and LDi are four lipophilic regions in the binding pharmacophore. 
Descriptors S1, S2, and S3 are regions of negative steric repulsion. 
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Areas of negative steric repulsion with the protein are described as S1, S2, and S3. 
Examination of the included volumes indicated that the shapes of binding pockets for 
α1, α2 and α3 subtypes are very similar to each other. Region L2 for the α5 containing 
subtype appeared to be larger in size than the analogous region of the other receptor 
subtypes. The LDi region in contrast appeared to be larger in the α1 subtype than in the 
other subtypes. 50 The receptor subtype descriptor termed the DI site is related to α4 and 
α6 BzR, which is devoid of or has a very small lipophilic pocket L3 in comparison to the 
other four (α1, α2, α3, and α5) subtypes The DI region appears to be near the outside of 
the receptor binding cleft and may be important as well for interactions at the α1 subtype 
which results sometimes in increased α1 subtype selective affinity. With the aid of these 
models, several series of ligands have been synthesized and evaluated 
pharmacologically to determine the interaction with the GABA/benzodiazepine receptor 
subtype selective ligands.  
2. Objective of this research 
Benzodiazepines and related drugs have been documented to disrupt memory in human 
and non-human subjects. 10,13,47,51Broadly stated, administration of Bz-type drugs can 
result in a loss of the ability to form new memories.  The memory deficits induced by 
Bz-type drugs are strikingly similar to those associated with lesions of the 
hippocampus.52 Neurons in the hippocampus express structurally diverse GABAA 
receptors.53,54 The highest density of α5GABAA receptors is found in the hippocampus 
proper (see Figure 6) and these receptors are mostly extra-synaptic.53 The distribution of 
α5GABAA receptors in the hippocampus raises the possibility that this subtype plays a 
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distinct role in memory deficits induced by Bz-type drugs.55  While memory deficits 
induced by Bz-type drugs represent a clinical burden, understanding the mechanisms 
underlying these deficits might represent a therapeutic boon.  
 
 
Figure 6: Distribution of α5 receptor in the Hippocampus. Reprinted with permission of 
author. 
 
In this regard, there is increasing evidence that inverse agonists with selectivity for the 
α5GABAA receptor subtype may enhance cognition.
56 Since α5 GABAA subtypes 
modulate memory processes, the specific aim of this research is to synthesize α5 
subtype selective ligands which can be used to treat disorders such as cognitive 
dysfunction which includes Alzheimer’s disease devoid of side effects (sedative, 
addictive, hypnotic, muscle relaxant and convulsant effects).  A key rationale for this 
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approach is that GABA neurons in the hippocampus and temporal cortical areas are 
largely preserved in patients 57,58 with Alzheimer’s disease (AD), and these preserved 
neurons contain α5GABAA receptor subtypes that are only moderately reduced in 
number in AD.58 
Another critical therapeutic goal of this research is to synthesize ligands which would 
also reduce anxiety. In fact, BZ-type drugs are commonly given to dementia patients 
exhibiting “agitation” (usually defined as “inappropriate verbal, vocal, or motor activity 
not explainable by apparent needs or confusion”).59 Thus, in addition to enhancing 
cognition, it would be advantageous to develop analogs which may provide a unique 
approach to reduce agitation/anxiety in patients with cognitive disorders.  
3. Results and Discussion 
3.1. Synthesis of α5 selective 1, 4 benzodiazepines 
The need for α5 selective ligands to study the hippocampus, as well as results based on 
previous structure-activity relationships60-64 prompted a study of agonist selectivity by 
modification of 7-substituted benzodiazepines.60-63 Earlier in this laboratory,49,62-66 a 
series of acetylene based α5 selective inverse agonists were prepared.67 These agents 
were among the most α5 selective ligands ever reported.67 Because the acetylene 
function (interaction in lipophilic pocket L2) enhanced selectivity at α5 BzR, it was 
decided to effect a similar change with orally active benzodiazepines to extend the SAR. 
In the past two decades computer modeling has evolved into a full-fledged discipline 
independent from traditional structure-activity-relationships (SAR) and molecular 
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biology and proven to be a valuable tool in drug discovery.68-76 This technique was 
important in the development of selective ligands for GABA/BzR subtypes due to the 
diversity of structural classes of active ligands which bound to these subtypes.31,74,76 For 
this the unified pharmacophore/receptor model (see Figure 5) which was described 
previously was used.  
In order to develop orally active high affinity selective ligands for α5 containing 
isoforms at the BzR, diazepam was chosen as the starting point.  According to classical 
structure-activity-relationships,77 diazepam does not bind to α4 and α6 containing 
isoforms (these are termed “diazepam insensitive sites”),77,78 consequently, interaction at 
α4 and α6 sites was retarded from the beginning.  It was felt diazepam bound to all 
diazepam sensitive (DS) receptor subtypes at the three anchor points: H1, H2 and 
L1.65,71,79 The imine nitrogen atom was believed to be hydrogen bonded to a hydrogen 
bond donor site on the receptor protein(H2), the carbonyl oxygen was felt to be hydrogen 
bonded to another hydrogen bonding descriptor(H1), while the benzene A-ring interacted 
with the receptor protein at a lipophilic site (L1). In addition, it was felt diazepam also 
interacted in lipophilic pockets L2 and L3, as shown in Figure 7. Lipophilic pocket L3 
was believed to be very small in α4 and α6 containing isoforms which retarded affinity 
of 1,4-benzodiazepines at these subtypes.49,79,80 When the agonist QH-II-066 11 was 
aligned in the included volume of pharmacophore/receptor for α2β3γ2 and α5β3γ2 
subtypes, the fit was excellent (Figure 9 and Figure 10) respectively. 
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Figure 7.  Diazepam (2) aligned in the pharmacophore model.75,81 
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Figure 8: The ligand QH-II-66, (11, a 7-acetylenyl-1, 4-benzodiazepine, in black), was 
designed to offer better occupation of this region and exhibit α5 selectivity. Note that 
diazepam shown in the Figure was intentionally offset from its original position, which 
had overlapped completely with QH-II-066, solely for the sake of visualization.65,66 
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Figure 9. The ligand, QH-II-66 11, aligned in the included volume of the 
pharmacophore/receptor model for the α2β3γ2 subtype. 
 
 
Figure 10. The ligand, QH-II-66 11, aligned in the included volume of the 
pharmacophore/receptor model for the α5β3γ2 subtype. 
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Based on the findings at α5 containing isoforms64,74,76,81 and the results in the 
imidazobenzodiazepine series described previously,61-63 a diazepam analog with an 
acetylenic function at position-7(QH-II-066, 11) was prepared, and better selectivity in 
vitro for α5 containing isoforms was immediately achieved in the agonist series.74-76,82 It 
was felt that lipophilic pocket L2 was larger in α5 containing subtypes as compared to 
α1 containing isoforms,47,74-76  hence the α5 subtype tolerated a larger lipophilic group 
in region L2. To develop ligands more selective for α5 containing BzR subtypes, 
interactions at H1, H2 or L3 must be modified since not many changes can be done at the 
L2 pocket. 
3.1.2. Synthesis of gram quantities of the 1, 4 benzodiazepine (QH-II-
066) 
The large scale synthesis here of this α5β3γ2 selective ligand 11 (Scheme 1), which 
began from 2-aminobenzophenone 5 and followed the classic work of Fryer, Sternbach 
et al.83,84 as modified by Huang and Liu, was carried out.65,85 Benzophenone 5 was 
acylated on 100 gram scale by bromoacetylbromide. The bromoacetamide 6 which 
resulted was then treated with a saturated solution of ammonia (gas) in methanol at 
reflux to afford benzodiazepine 7 in 99% yield. Regioselective bromination84 of this 
ligand at position-7 was realized after treatment with 2 equivalents of bromine in acetic 
acid in the presence of 2 equivalents of concentrated sulfuric acid at room temperature. 
After the reaction was allowed to stir for seven days, ninety percent of the 
monobrominated benzodiazepine 8 was obtained after alkaline workup. It was necessary 
to stir the reaction with only 2 equivalents of bromine for several days to prevent 
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dibromination. Attempts to use additional bromine or to heat the reaction mixture 
resulted in polybromination. It was difficult to remove the dibrominated side product 
from the desired 1, 4-benzodiazepine 8, consequently, the reaction was run over several 
days. The bromide 8 then was reacted with trimethylsilyacetylene in the presence of a 
palladium catalyst to provide trimethylsilyl analog 9.62,86,87 This TMS-protected material 
9 was then methylated with methyl iodide/sodium hydride to give the N-methyl 
benzodiazepine 10. In this manner the acetylenic function was not methylated. This 
material was subjected to fluoride-mediated disilation on 20 g scale to furnish gram 
quantities of 11 (QH-II-066) for studies in rodents and primates. 
In agreement with the molecular modeling, QH-II-066 11 indeed bound more potently to 
α5β3γ2 subtypes than to α1β3γ2 GABA/BzR receptor sites. This important result 
indicated that perhaps QH-II-066 might exhibit anxiolytic activity but would exert less 
sedative-hypnotic, muscle relaxant or ataxic effects when compared to the control 
(diazepam 2).  
Scheme 1: Synthesis of QH-II-066 
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Table 1.  In Vitro Receptor Binding Data of Diazepam (2) and QH-II-066 (11). Binding 
Affinity at αxβ3γ2 GABAA/BzR Receptor Subtypes (Values are Reported in nM) 
 ND: not determined yet. aBinding at α4 and α6 subtypes has not been determined, but since the 6-phenyl  
  group is present, the ligand will not bind to α4 and α6 subtypes. 
Studies by Lelas and Cook et al.88  reflect that QH-II-066 11 has functional selectivity in 
vivo with diazepam-like efficacy at α5 and partial efficacy at the α1 subtype. This study 
showed that QH-II-066 had anxiolytic activity with reduced sedative effects compared 
to diazepam 2. This study also indicated that the 7-acetyleno substituted diazepam 
analog exhibited less potency against ECS induced seizures relative to diazepam than 
against PTZ-induced seizures. Hence α1 subtype may play an important role in ECS-
induced seizures than in PTZ-induced seizures (see Appendix II).  
Recent studies by Weiss and Cook et al.89 show that activation of GABA (A) receptors 
induces apoptosis in neuroblastoma. The mechanism by which GABA-A activation 
inhibited the growth of neuroblastoma cells was assessed.  To enhance the signal readout 
of this pathway, α5 selective GABA-A receptor agonist QH-II-066 was used.  Apoptosis 
was induced in both LAN-5 (high GABA-A expression levels) and Kelly cells (low 
GABA-A expression levels) (Figure 11 A and B), as assessed by annexin V flow 
cytometry.  Immunoblotting revealed that upon addition of GABA and QH-II-066, 
Compound α1 α2 α3 α4 α5 α6 
Diazepam (2) 14 7.8 13.9 NDa 13.4 NDa 
QH-II-066 (11) 76.3 42.1 47.4 NDa 6.8 >3000 
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cleaved PARP, an indicator of apoptosis, was increased.  Notably, immunoblotting 
revealed a decrease in activity of the PI3K/AKT and MAPK pro-growth and survival 
pathways, indicated by decreased phosphorylation levels of Akt and Erk, respectively 
(Figure 11 C).  Together these data suggest that specific activation of the GABA-A 
receptor decreases cell viability, induces apoptosis, and suppresses pro-growth and 
survival signaling pathways in neuroblastoma cell lines (see Appendix III). 
 
Figure 11. GABA activation decreases viability and induces apoptosis in 
neuroblastoma cells   (A)   Lan5 and Kelly cells were treated with GABA 100 μM or 
the selective ligand for GABA (QH-II-066, 11) 1 μM or both and analyzed by annexin 
V-FITC flow cytometry for apoptosis after 72h.  (B)   Percentages of positive cells for 
apoptotic marker annexin V are mean ± s.e. for triplicate samples with treatments 
indicated. (C)  Cells analyzed by immunoblot using antisera indicated show decreased 
phosphorylation of Akt and Erk.  
 
157  
3.1.3. Synthesis of PS-1-37  
Since the α5 in vitro selectivity and efficacy of QH-II-066 11 was increased in regard to 
the potent controls, it was decided to maintain the acetylenic function at C (7) and 
determine this potential effect at L2 of other orally active BZ agonists.  
PS-I-37 is a stable analog of XHe-II-053 related to an agonist developed by Upjohn, and 
was prepared for study. A mixture of the bromo benzodiazepine 3 was taken up in 
pyridine and phosphorous pentasulfide to form the thione 12.  This was further reacted 
with glycine, Na2CO3 in ethanol and a water mixture to form acid 13 as a yellow solid. 
This was suspended in dry CH2Cl2 and DCC was added. The suspension which resulted 
was stirred at 40°C for 2hrs. The solvent was removed under vacuum to give the ketone 
14 as brown oil. The cyclized product was dissolved in benzene, after which  
dimethylformamide diethyl acetal and triethyl amine were added. The residue was then 
crystallized from ethyl acetate to give amine 15.  A solution of 15 in dry toluene was 
treated with 1-methyl piperazine and refluxed for 5hrs and then the solvent was removed 
under vacuum to give a gum which was crystallized to furnish 16. To the suspension of 
compound 16 in acetonitrile and triethyl amine was added bis(triphenylphosphine) 
palladium(II) acetate to furnish the trimethylsilyl analogue 17. The trimethyl silyl was 
removed using TBAF in THF to provide the acetylenic product 18 (PS-I-37) and this 
material was anxiolytic in monkeys (Dr.Rowlett, Harvard). 
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Scheme 2: Synthesis of PS-1-37 
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Table 2. In Vitro Receptor Binding Data on Diazepam (2) and PS-1-37 (18). Binding 
Affinity at αxβ3γ2 GABAA/BzR Receptor Subtypes (Values are Reported in nM) 
 ND: not determined yet. aBinding at α4 subtypes has not been determined, but since the 6-phenyl  
  group is present, the ligand will not bind to α4 and α6 subtypes. 
 
Compound α1 α2 α3 α4 α5 α6 
Diazepam (2) 14 7.8 13.9 NDa 13.4 NDa 
PS-1-37 (18) 193 35 435 NDa 22 5000 
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Figure 12. The Oocyte Efficacy Data on PS-1-37(18). 
Table 3. EC50 and Hill Slope for Modulation of Control GABA EC3 by PS-1-37 (18) in 
Xenopus Oocytes Expressing Different GABAA Receptor Subtypes. Results Represent 
EC50 (95% Confidence Interval for EC50) and Hill Slope (Nh) ± SD from at Least Four 
Cells from Two Batches. 
 
  α1β3γ2 α2β3γ2 α3β3γ2 α4β3γ2 α5β3γ2 α6β3γ2 
 
PS-I-37 
EC50 
95%CI 
>1,1µM 
 
>228nM 
 
>2,3µM 
 
 87nM 
48-158 
 
Nh       
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Table 4. Modulation of Control GABA EC3 by Diazepam and PS-1-37 (18) on Xenopus 
Oocytes Expressing Different GABAA Receptor Subtypes. Values are Presented as 
Mean ± SEM of at Least Four Oocytes from at Least Two Batches 
All the above values were significantly different from the respective control currents (p<0.01, Student’s- 
 t-test) except where indicated (n.s.). NS means not significant. 
 
3.1.4. Synthesis of 8-substituted imidazobenzodiazepines 
As mentioned above, the α5 subtypes are primarily found in the hippocampus90 which is 
important for memory and learning91.  Studies done by Mohler et al. 92on α5 knockin 
mice provided strong evidence that hippocampal extrasynaptic α5 GABAA receptors 
play a critical role in associative learning.92 The 8-substituted imidazobenzodiazepines 
such as RY-23 and RY-24 exhibited a greater affinity and selectivity at the α5 subtype. 
Previously, the subtype selective inverse agonist activity60-64,85 of a series of α5 subtype 
selective ligands [(20, RY-023), (21, RY-024), (22, RY-079) and (23, RY-080)] was 
  α1β3γ2 α2β3γ2 α3β3γ2 α5β3γ2 
 
   
Diazepam(2)  
  10nM 135±4% 193±5% 167±8% 160±2% 
100nM 246±16% 400±22% 461±34% 322±7% 
    1µM 345±27% 508±29% 776±44% 420±12% 
  10µM 366±27% 520±14% 749±29% 377±14% 
 
PS-1-37 (18) 
  10nM 114±2% 119% ns 136±1% 
100nM 144±1 % 172±3% ns 259±16% 
    1µM 272±3 % 271±15% 324±9% 438±12% 
  10µM 402±12% 311±1% 402±29% 345±4% 
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reported. The design was based on the structure of 19 (Ro 15-4513) and, in addition, 
McKernan, Atack et al. (see 24) reported several related ligands as well.93,94 These 
ligands are BzR inverse agonists in vivo and have been shown to enhance cognition.17-21 
One of these ligands was shown by Bailey et al. 91 to be important in the acquisition of 
fear conditioning and provided further evidence for the involvement of hippocampal 
GABAA/benzodiazepine receptors in learning and anxiety. This was supported by the 
work of DeLorey et al.95  in a memory model with a ligand closely related to α5 subtype 
selective inverse agonists 20 and 21.  
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Figure 13. Ro 15-4513 (19), RY-023 (20), RY-024 (21), RY-079 (22), RY-80 
(23) and the Merck compound (24). 
 
The ligands 20-23 and 24 depicted in Figure 13 were 40-70 fold more selective for α5 
subtypes in comparision to α1 subtypes; however, better selectivity remains a goal of 
paramount importance. In collaboration with Sieghart et al. the efficacy of inverse 
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agonist RY 24 (21) was determined (Figure 46). It was demonstrated that RY 24 (21) 
was a potent inverse agonist at α5 subtypes in oocytes with a much weaker efficacy at 
the other subtypes.  
 
  
Figure 14. Subtype selective efficacy of RY-24 (21); dose response curves for RY-24 in 
oocytes expressing different subunit combinations of GABAA receptors. Subtype 
combinations are indicated in legends. cRNA–injected Xenopus oocytes were held at –
60 mV under two-electrode voltage clamp. Increasing concentrations of RY-24 were 
superfused together with a GABA concentration eliciting ~ 20% of the maximal current 
amplitude. RY-24 was pre-applied for 30 sec before the addition of GABA, which was 
co-applied with the drugs until a peak response was observed. Data were normalized for 
each curve assuming 100% for the response in the absence of RY-24. RY-24 was made 
up and diluted as stock solution in DMSO. Final DMSO concentrations perfusing the 
oocyte were 0.1%. Values are presented as mean ± SD of at least 4 oocytes from at least 
2 batches. 
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Inspection of the data in Table 4 reveals some observations worth noting.  While the 
lipophilic substituent at R8 of RY-24 21 and RY-80 23 decreased the affinity for 
α1, α2 and α3 subtypes, it retained affinity for α5 and actually increased affinity for the 
α6 subtype. This data again supports the importance of the occupation of the lipophilic 
pocket L2 for potent selectivity at the α5 subtype.  
 
Table 5. In Vitro Receptor Binding Data of α5 ligands. Binding Affinity at αxβ3γ2 
GABAA/BzR Receptor Subtypes (Values are Reported in nM) 
 
 
Ligand 
 
         R8 
 
R3 
Ki (nM)a 
α1 α2 α3 α5 α6 
RY-24 (21)    H t-Bu 26.9 26.3 18.7 0.4 5.1 
RY-23 (20)  TMS t-Bu 197 143 255 2.61 58.6 
RY-80 (23)   H Et 28.4 21.4 25.8 0.49 28.8 
RY-79 (22) TMS Et 121 142 198 5.0 114 
a "Synthesis and Pharmacological Properties of Novel 8-Substituted Imidazobenzo-diazepines: 
High Affinity, Selective Probes for α5 Containing GABAA Receptors,"Liu, R.; Hu, R.; Zhang, 
P.; Skolnick, P.; Cook, J. M., J. Med. Chem., 39, 1928-1934 (1996). 
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In agreement with previous studies,61 these α5  selective ligands were highly selective in 
suppressing ethanol-maintained responding (Figure 25).96 As previously stated, the 
hippocampus contains the greatest concentration of α5-containing receptors in the 
CNS,90,97  and it is possible that these hippocampal α5 receptors may regulate alcohol-
motivated responding following systemic administration of an α5-selective agent. 
Furthermore, RY-24 also antagonized the motor-impairing and sedative effects of 
ethanol in Long-Evans rats. Combined with additional studies within the ventral 
pallidum (VP), it has been proposed that the GABAergic systems within the VP and 
hippocampal pathways may represent new extensions of the mesolimbic ethanol reward 
circuitry. Although these data do not strongly support a direct role for the modulatory 
influences of intrinsic efficacy in the behaviors examined, the synthesis of α5 subtype 
selective ligands provides researchers a unique opportunity to explore the role of this 
subtype in the neurobehavioral effects of alcohol.61,98  However, the efficacy (inverse 
agonist, negative modulation) of RY-23 and RY-24 at α1 and α2 subtypes precludes 
potential clinical uses of such agents for both agents are proconvulsant and RY-24 is 
also convulsant. 
Additional behavioral studies of RY-24 were performed by Helmstetter et al. and 
provided further support for the role of the hippocampus in anxiety and learning.91  
Moreover, the data suggested that Bz BSs within the hippocampus are important for the 
acquisition of fear conditioning.  Although this subtype selective ligand has been shown 
to be an inverse agonist at the α5  subtype,62,99 this study suggested that RY-24 may act 
as an agonist at other alpha subtypes because larger doses of RY-24 were not as 
anxiogenic as the smaller doses and resulted in decreased learning.  Consistent with the 
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studies of Stephens et al. using α5 knock-out mice100  and the efficacy studies of 
Lüddens, June and Cook et al.,101 these findings support the concept that the 
pharmacology observed depends upon the dose, behavioral paradigm employed and 
subunit composition activated.  Ligands such as RY-24 have proven to be valuable in 
the study of the biochemical and pharmacological properties of GABAA receptors and 
have permitted insight into the role this protein plays in anxiety and learning. 
In brief, isatoic anhydride 25 and sarcosine were heated in DMSO to form 
benzodiazepine 26 in 84% yield.  Benzodiazepine 26 was treated with bromine in the 
presence of CH3COOH and H2SO4 to provide the bromide 27 in 80% yield as illustrated 
in Scheme 3. Deprotonation of 27 with  KOtBu in THF followed by treatment with 
diethyl chlorophosphate provided the intermediate enol phosphate.102 The enol 
phosphate was stirred with a solution of t-butyl isocyanoacetate and KOtBu to yield the 
imidazobenzodiazepine 28 in 70% yield.  This bromide was converted into 20 by a 
Heck-type coupling reaction60,62using bis(acetate) bis(triphenylphosphine) palladium(II) 
to provide TMS analog RY 23 (20) and the silyl group was removed in high yield on 
treatment with TBAF/H2O/THF to provide RY 24 (21).60 
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Scheme 3: Synthesis of RY-23 and RY-24 
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4. Synthesis of α5 selective BzR bivalent ligands  
Bivalent ligands have been termed as compounds that contain two pharmacophores 
joined through a connecting unit. The general structure for bivalent ligands is P-X-P (P: 
pharmacophore; X: spanner).103-105 They may exhibit enhanced selectivity and potency 
relative to their monovalent analogues (P-X) when a suitable spanner X is employed. 
The study by Portoghese et al. on bivalent ligands that bind to different opioid receptor 
subtypes was among one of the most successful reported to date.103-105  
A linker of 3 CH2- groups is often called the Leonard linker from its founder Nelson J. 
Leonard. 
 
To enhance subtype selectivity, the bivalent form103,104,106 of RY024 (17),60,62  that is 
1,3-bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imidazo-[1,5a][1,4]- 
benzodiazepine-3-carboxy) propyl diester, (33, XLi093) was designed and prepared. The 
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synthesis, α5 subtype selectivity and antagonist properties of this ligand are described 
below.  
Deprotonation of 27 with KOtBu in THF followed by treatment with diethyl 
chlorophosphate provided the intermediate enol phosphate.  The enol phosphate was 
stirred with a solution of ethyl isocyanoacetate and KOtBu to yield the 
imidazobenzodiazepine 29 in 70% yield.102  This bromide was converted into 22 by a 
Heck-type coupling reaction60,62 and the silyl group was removed to provide acetylene 
23 in high yield on treatment with TBAF/H2O/THF.60 Hydrolysis of the ester function of 
23 provided the acid 32 in excellent yield and this material was subjected to a standard 
CDI-mediated coupling reaction with a three carbon linker to furnish bivalent ligand 
XLi093 33 in 73.4% yield on gram scale.  
Scheme 4: Synthesis of Bivalent Ligand XLi-093 
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The binding affinity of XLi093 (33) in vitro was determined on α1-6β3γ2 Ltk- cells and 
is illustrated in Table 6. This ligand XLi093 33 bound to α5β3γ2 subtypes with a Ki of 
15 nM, but exhibited little or no affinity at other BzR/GABAA subtypes. Although the 
efficacy at all receptor subtypes was decreased by incorporation of the pharmacophore 
of 23 into the bivalent structure, the loss of affinity at α1, α2, α3, α4 and α6 subtypes 
was profound. Presumably, since the second unit of XLi093 33 lies in the extracellular 
domain of the BzR, the enriched selectivity is entropic. This has been the most selective 
α5 subtype selective ligand reported, to date. Depicted in Figure 15 is the ORTEP 
drawing of the crystal structure of XLi093 (see Appendix VI for coordinates).  The J 
values (J = 5.38) calculated from the dihedral angles were in excellent agreement with 
those from the solution determined NMR spectrum (J=6.39), hence support for the 
conformation as shown (Figure 16) derives from the NMR data. This conformation of 
XLi093 was then placed in the BzR/GABAA α5 pharmacophore receptor model 
previously reported42,72,76 from this laboratory; the fit was excellent. 
Based on the binding affinity of XLi093 (33) and the fit at the α5 subtype, a study of the 
efficacy of Xli093 was then pursued in oocytes by Sieghart, Furtmueller, Li, Cook et 
al.107 The effects of XLi093 (33) on chloride currents in GABAA receptors was 
determined.108 The activity of XLi093 on GABAA receptors was characterized using 
Xenopus oocytes expressing the GABAA receptor subunits alpha 1 to alpha 6 in 
combination with beta 3 and gamma 2 subunits. Using the two electrode voltage clamp 
method, currents in the µA range were measured for all subunits. 
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Figure 15.  Crystal Structure of Bivalent Ligand XLI093 (33). 
 
 
 
Figure 16. XLi093(33) Aligned in the Included Volume of the Pharmacophore/Receptor 
Model for the α5β3γ2 Subtype. 
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Table 6.  In Vitro Binding Affinities at GABAA/BzR Subtypes. aValues Reported are in 
nM. 
Ligand α1 α2 α3 α4 α5 α6 
RY079 (22) 121 142 198 159 5.0 114 
RY080 (23) 28.4 21.4 25.8 53 0.49 28.8 
       
XLi093 (33) >1000 >1000 858 1550 15 >2000 
 
aKi values represent the mean of two determinations which differed by less than 10%.  
Data were generated using Ltk- cell membranes expressing human αxβ3γ2 receptors 
combinations in response to application of a saturating concentration of GABA (10 
mM). Two electrode voltage clamp experiments were performed to test whether XLi093 
triggered chloride currents,108,109 modulated GABA-induced currents or antagonized the 
effects of benzodiazepines in oocytes that express GABAA receptors. 
   Bivalent ligand XLi093 33 at concentrations up to 1 µM did not trigger chloride 
currents in any of the tested subtypes of the GABAA receptor. This dimer, however, at 
micromolar concentrations modulated GABA-induced currents in an alpha subtype 
specific manner. To test for agonistic or inverse agonistic effects of XLi093, the 
compound was coapplied with a concentration of GABA that induced app. 3% of the 
maximum current amplitude. At concentrations of XLi093 33 up to 100 nM, this ligand 
caused no significant modulation of GABA-induced currents in any subtype of GABAA 
receptors tested. At a concentration of 1 µM, XLi093 33 caused a significant increase in 
GABA-induced currents in the GABAA receptor subtypes α4β3γ2 [+37.6 ± 2.6 % 
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(SEM), p < 0.0001 in four oocytes] and α6β3γ2 [+ 17.0 ± 2.5 % (SEM), p = 0.0014 in 
four oocytes]. Furthermore, 1 µM XLi093 caused a reduction in GABA induced currents 
in the subtype α5β3γ2 [-4.0 ± 1.5 % (SEM), p = 0.0075 in six oocytes]. However, 1 µM 
of XLi093 caused no significant modulation of GABA-induced currents in the GABAA 
receptor subtypes α1β3γ2, α2β3γ2 and α3β3γ2. 
 Ligand XLi093 (33) shifted the dose response curve for diazepam in a subtype specific 
manner. To test for benzodiazepine antagonistic effects of XLi093, dose response 
experiments for the stimulation of GABA-induced currents by diazepam in the absence 
or presence of 1 µM XLi093 33 were performed. Similar conditions for different 
subtypes were provided by using a concentration of GABA that induced app. 3% of the 
maximum current amplitude in the respective cell. In oocytes expressing GABAA 
receptors of subunit combination α5β3γ2, the presence of 1 µM XLi093 (33), shifted the 
dose response curves for the stimulation of GABA induced currents by diazepam to the 
right (Figure 17). Even high concentrations of diazepam could not fully overcome this 
inhibition since maximum current stimulations in the presence of XLi093 (33) reached 
only app. 85% of current stimulations that were seen in the absence of XLi093 (33). 
The dose response curves for diazepam with and without 1 µM XLi093 (33) in oocytes 
expressing different subunit combinations of GABAA receptors are depicted (Figure 17). 
cRNA–Injected Xenopus oocytes were held at –60 mV under two-electrode voltage 
clamp. Increasing concentrations of diazepam with or without 1 µM of XLi093 (33) 
were superfused together with a GABA concentration eliciting app. 3% of the maximal 
current amplitude. Diazepam and XLi093 were preapplied for 30 sec before the addition 
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of GABA, which was coapplied with the drugs until a peak response was observed. Data 
were normalized for each curve assuming 100% for the response in the absence of 
diazepam and XLi093. Drugs were made up and diluted as stock solutions in DMSO. 
Final concentrations of DMSO perfusing the oocyte were 0.1%. Values are presented as 
mean ± SD of at least four oocytes from at least two batches. 
 
Figure 17. Effects of XLi093 (33) on GABAA receptors were tested by two-electrode 
voltage clamp experiments in cRNA injected Xenopus oocytes that functionally 
expressed several subtype combinations of GABAA receptors. In oocytes expressing 
GABAA receptors of the subtypes α1β3γ2, α2β3γ2, or α3β3γ2, 1 µM XLi093 (33) 
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caused only marginal shifts of dose response curves for the stimulation of GABA-
induced currents by diazepam. 
Receptor binding studies indicated that the bivalent ligand XLi093 33 bound almost 
exclusively to the α5 subtype of GABAA receptors. In summary, the effect of this 
compound on various GABAA receptors expressed in Xenopus oocytes was fully 
investigated by electrophysiological studies. Analysis of the data indicated that bivalent 
ligand XLi093 up to a concentration of 1 µM did not trigger chloride currents in any one 
of the tested GABAA receptor subtypes. At 1µM, XLi093 did not modulate GABA 
induced chloride flux in α1β3γ2, α2β3γ2, α3β3γ2 but stimulated GABA-induced 
currents in α4β3γ2 and α6β3γ2 and slightly inhibited currents in α5β3γ2. At 1 µM, 
XLi093 only marginally influenced diazepam stimulation of GABA-induced current in 
α1β3γ2, α2β3γ2 and α3β3γ2, but shifted the diazepam dose response curve to the right 
in α5β3γ2 receptors. The slight reduction in the maximal diazepam stimulation in the 
presence of 1µM XLi093 might have been due to the previously described reduction in 
current stimulation at high diazepam concentration109 or might indicate interaction of 
XLi093 via two different binding sites. Importantly, bivalent ligand XLi093 was able to 
dose dependently and completely inhibit diazepam stimulated currents in α5β3γ2  
receptors. It was a quite selective benzodiazepine receptor site antagonist at α5 
receptors. As noted, ligands such as XLi093 have been important in the determination of 
which physiological function(s) are subserved by this GABAA α5β3γ2 subtype. There 
are many scientists who have reversed the amnesic effects of diazepam in vivo with XLi-
093 in rodents and primates by Savic, Rowlett and Platt et al (see below). 
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4.1. Binding Studies of XLi-093 (33) in vivo by Rowlett and Cook et al.55  
Recent studies by Rowlett and Cook et al. 55 have shown that diazepam significantly 
impaired performance in a hole board memory task, in which mice learned the location 
of 4 baited holes (out of 16 possible) over the course of 4 trials.  
 
Figure 18: In vivo binding of Xli-093. The memory-impairing effects of diazepam were 
blocked (Figure 18) by a dose of (33; 3.0 mg/kg) that occupied ~66% of α5 GABA(A)  
binding sites but less than 25% (non-significant) of the α1 GABA(A) and 
α2/α3GABA(A) binding sites. Memory impairment measured via the holeboard task 
occurred at a dose of diazepam that resulted in a relatively high degree of α5 GABA(A)  
binding site occupancy (64%). Interestingly, even at a saturating dose of diazepam (10 
mg/kg), XLi-093 (33) was still able to block the memory impairing effects of diazepam.  
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Figure 19: XLi-093 (3.0 mg/kg) blocked the DZ-induced suppression of performance 
ratio on the holeboard task.  Note that XLi-093 showed no effect when administered 
with vehicle.   
 
This performance impairment suggested that diazepam-induced a working memory 
deficit. The novel antagonist XLi-093 (33) was able to antagonize this deficit and 
showed appreciable subtype selectivity for the α5 GABAA receptor in vivo consistent 
with previous findings. In vivo binding studies with XLi-093 showed negligible 
occupancy of α1GABA(A)  and α2/3GABA(A)  binding sites; however, occupancy of 
α5GABA(A)  binding sites was significant at 1.0 mg/kg and above (see Figure 18). 
 
The data suggests α5 GABA(A)  receptors play an important role in diazepam-induced 
memory impairments. Identification of compounds with reduced α5 GABA(A)  activity 
may result in sedative-anxiolytics that lack memory-impairing effects of classical 
benzodiazepines. 
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In vivo binding studies (see Table 7) with XLi-093 (33) showed negligible occupancy of 
α1 GABAA and α2/3GABAA binding sites; however, occupancy of α5 GABA(A)  
binding sites was significant at 1.0 mg/kg and above. The ability of a novel α5 GAB(A)  
subtype selective antagonist, XLi-093 (33; 0.3-10.0mg/kg), to occupy α5 GABA 
receptors in vivo (in vivo [3H]L-655,708 binding) had been evaluated. Based on percent 
binding occupancy, the ability of a range of XLi-093 doses to reverse impairments 
induced by the minimal effective dose of diazepam (DZ (3.0 mg/kg)) was assessed. 
Ligand XLi-093 (33) reversed DZ-induced impairments at doses of 1.0 and 3.0 mg/kg, 
which occupied ~50-65% of [3H]L-655,708 binding. In contrast, these doses resulted in 
only ~20% occupancy of α1 GABA and α2/3 GABA(A)  receptors in cerebellum and 
spinal cord, respectively, (determined by in vivo [3H]flumazenil binding). These 
findings are consistent with a key role for α5GABA(A)  receptors in BZ agonist induced 
impairments in learning and memory. 
 
Table 7: Percent of α5GABA (A) binding sites occupied by XLi-093 and DZ at doses 
used in the behavioral studies. 
 
Ligand (Dose, i.p.) 
% α5GABAA 
Occupancy 
XLi (3.0) 65.8 
DZ (1.0) 63.8 
DZ(3.0) 83.5 
DZ (10.0) 99 
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It had been demonstrated that bivalent ligand XLi-093 bound tightly to α5β3γ2 receptor 
subtypes illustrated that bivalent ligands will bind to BzR and since the second unit of 
this bivalent ligand presumably lies in the extracellular domain of the BzR, this ligand 
had very poor or no affinity at the other subtypes. It is now obvious that this is the first 
α5 bivalent ligand which was not only orally active, but also passed through the blood 
brain barrier. This was an important result for these bivalent ligands in regard to use in 
science. 
 
Scheme 5: Synthesis of Bivalent Ligands XLi-356 and XLi-210 
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 The bivalent ligand XLi356 (34) was obtained from XLi093 (33) in 99% yield via 
catalytic hydrogenation (Pd/C, H2).  While XLi093 was found to be an antagonist, ligand 
XLi356 is an inverse agonist in α5β3γ2 oocytes and a weak agonist at α1β3γ2 sites.  
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Figure 20: Subtype selective efficacy of XLi356 (34), Dose response curves for XLi356 
in oocytes expressing different subunit combinations of GABAA receptors. Subtype 
combinations are indicated in legends. cRNA–injected Xenopus oocytes were held at –
60 mV under two-electrode voltage clamp by Sieghart et al. 
Table 8. In Vitro Binding affinities of bivalent ligands at GABAA/BzR subtypes. 
aValues Reported are in nM. 
Ligand α1 α2 α3 α4 α5 α6 
XLi356 (34) 1851.5 4202.5 8545 ND 100.5 5000 
 
XLi210 (35) 231 661 2666 ND 5.4 54.22 
 
XLi093 (33) >1000 >1000 858 1550 15 >2000 
 
aKi values represent the mean of two determinations which differed by less than 10%.  
Data were generated using Ltk- cell membranes expressing human αxβ3γ2 receptors. 
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DeLorey has recently shown that XLi-356 (34) does potently reverse scoploamine 
induced memory deficits in rodents.  XLi356 was found to reverse scopolamine induced 
memory deficits in mice.  When XLi356 was looked at in audio cued fear conditioning, 
the results show no activity.  This suggests that the effect of XLi356 is selective through 
α5 receptors which are abundant in the hippocampus which is highly associated with 
contextual memory.  Audio cued memory instead is amygdale-based, and is not affected 
by an α5 subtype selective compound.110 
Figure 21: Visual and audio que data for XLi356 
As illustrated in Figure 21, scopolamine (1 mg/kg) reduced freezing (ie. impairs 
memory) typically caused by pairing the context (the cage) with a shock.  The drug 
XLi356 when given at 10mg/kg attenuates the impairment of memory returning the 
freezing to the level that one typically sees the mouse freeze at (i.e. veh). In the audio 
cued paradigm, memory was triggered by sound not the context.  XLi356 was not able 
to reverse this type of memory effect which is amygdale driven. 
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The biology of a bivalent ligand with a 3-carbon linker XLi-093 (33) led us to 
synthesize the analogous bivalent ligand with a 5-carbon linker. The synthesis of XLi-
210 (35) was done analogous to the conditions employed for XLi-093. The acid 32 was 
subjected to a standard CDI-mediated coupling reaction using a 5-carbon linker to 
furnish bivalent ligand XLi210 35 in 60% yield in dry DMF (Scheme 5). 
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Figure 22: Subtype selective efficacy of XLi210 (35): dose response curves for XLi210 
in oocytes expressing different subunit combinations of GABAA receptors. Subtype 
combinations are indicated in legends. cRNA–injected Xenopus oocytes were held at –
60 mV under two-electrode voltage clamp. 
 
This bivalent ligand (35) showed 50 fold selectivity at α5 over α1 (see Table 8). The 
efficacy data shows that the ligand is an agonist. This ligand should have properties 
exactly opposite that of PWZ-029 which is an inverse agonist (NAM). Positive controls 
and an α5 antagonist render this a very strong approach to hippocampal-mediated drug 
design in regard to the development of agents to treat cognition deficits in Alzheimer’s 
and age-related memory deficits. 
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Table 9. EC50 and Hill Slope for Modulation of Control GABA EC3 by XLi 210 (35) in 
Xenopus Oocytes Expressing Different GABAA Receptor Subtypes. Results Represent 
EC50 (95% Confidence Interval for EC50) and Hill Slope (Nh) ± SD from at Least Four 
Cells from Two Batches. 
 
  α1β3γ2 α2β3γ2 α3β3γ2 α5β3γ2 
 
XLi-210 
EC50 
95%CI 
262nM 
(15-4543) 
>324nM 
 
175nM 
(7-4210) 
 
Nh 0.89  0.94  
 
 
 
 
Table 10. Modulation of Control GABA EC3 by XLi 210 (35) on Xenopus Oocytes 
Expressing Different GABAA Receptor Subtypes. Values are Presented as Mean ± SEM 
of at Least Four Oocytes from at Least Two Batches. 
All the above values were significantly different from the respective control currents (p<0.01, Student’s- 
 t-test) except where indicated (n.s.). n.s. means not significant. 
 
 
  α1β3γ2 α2β3γ2 α3β3γ2 α5β3γ2 
 
XLi210 (35) 
  10nM ns ns ns ns 
100nM 115±6 % 117±7% 121 110±3% 
    1µM 143±18 % 133±9% 150±25% 111±2% 
  10µM 153±20% 144±4% 156±19% 123±6% 
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5. Synthesis of Bivalent Ligands with Oxygen Linkers 
 
In order to enhance water solubility and potency, bivalent ligands with a oxygen atom in 
the linker were synthesized. The insertion of an oxygen atom into the linker might 
increase the water solubility and hence enhance the molecular hydrophilicity which 
should play an important role in the pharmacokinetic properties of the ligand. 
Scheme 6: Synthesis of Bivalent Ligands with Oxygen Linkers XLi-347, XLi-374 
and SR-II-35 
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The oxygen linked analog XLi 347 (36) and SR-II-35 (42) were synthesized analogous 
to the conditions employed for the preparation of XLi-093 (33), the synthesis of the 5-
carbon atom linked dimer 35 (XLi210) had been was carried out. The acid (32) available 
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from Scheme 4, was subjected to a standard CDI-mediated coupling reaction to furnish 
bivalent ligands XLi 347 (36) and SR-II-35 (39) in 60% yield in dry DMF (see Scheme 
6).  
For the synthesis of XLi 374 (39) , the preparation of the required oxygen-substituted 
linker (a dibromodimethylether) was based on the method of Tischtschenki  and  
Rabcevitsch-Zubkovski111,112.  Bromine was added slowly to water over a four hour 
period, to which a mixture of paraformaldehyde (37) and red phosphorus was also added 
at a comparable rate. The reaction mixture was ice-water-cooled during this process. The 
temperature was maintained at 0°C. The final reaction mixture was allowed to stand for 
20 hours. The heavy crude dibromo ether layer was then separated, saturated with 
hydrogen bromide, and dried over P2O5 for one day. Distillation at 158°C at 1 atm 
provided the ether from one fraction as pure dibromodimethyl ether (a colorless liquid). 
With the dibromodimethyl ether in hand, acid 32 was dissolved in dry dimethyl-
formamide (DMF). To this solution the dibromodimethyl ether (38) was added, and this 
was followed by addition of TEA. After the mixture stirred for 26 hours at ambient 
temperature, the solvent was removed under reduced pressure and the residue was 
distributed between CH2Cl2 and water. The organic layer was washed multiple times 
with water and dried over Na2SO4, and the solvent was removed under reduced pressure 
almost to dryness. Subsequent flash chromatography of the crude oil provided the 
bivalent oxygen (C-O-C) dimer XLi374 (39) as a white solid. 
The nature of the functional groups in a ligand plays an important role in receptor 
binding, of course, as well as the conformation in solution. The more the information 
about the stable conformation(s) of molecules, the better is the understanding of the 
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structure-activity relationships.  It was essential from the beginning of the present study 
to determine the conformation of these bivalent ligands, which contained 3 to 5 atom 
linkers, since the steric requirements for affinity to the Bz receptor must be satisfied. In 
traditional medicinal chemistry, computer assisted molecular modeling programs and X-
ray analysis contribute greatly in the search for stable conformations. However, some 
problems with these methods should not be neglected. Using computer modeling to 
determine the stable conformation of molecules containing many freely rotating bonds, 
such as those contained in bivalent ligands is difficult.  Although X-ray crystallography 
is the ultimate arbiter of chemical structure, it has many limitations beyond the obvious 
need for crystals: it often does not reflect accurately the conformation in solution, nor is 
it informative regarding conformational equilibria. This information is crucial in drug 
design.  However, NMR spectroscopy is a powerful technique in drug discovery and its 
role in conformational analysis cannot be surpassed by other spectroscopic 
methods.42,113  
5.1. Low Temperature NMR studies and X-ray Analysis 
Herein is described a method utilizing low temperature NMR for the determination of 
the solution stable conformation of a series of GABAA-benzodiazepine bivalent ligands 
with different monomeric units and linkers. The conformations in solution were 
determined by NMR spectroscopy and compared with those in the crystal structure. The 
combination of low temperature NMR and X-ray analysis provided accurate structural 
information required for understanding structure-activity relationships and drug design. 
The influence of the molecular structure of the linker on the conformation is also 
discussed. 
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5.2. Results 
 
Recently it was shown the active dimers XLi093 (33) and DMH-D-053 (31) existed in a 
linear conformation in the solid state while dimer  dm-III-96 (43) with a oxygen 
containing linker folded back upon itself, as illustrated in Figure 23.114 
Since the bioactive conformation in solution may or may not parallel that in the crystal 
structure, the lowest energy solution structure must be established in order to correlate 
conformation with biological activity. Thus, NMR experiments at variable temperatures 
were performed and data were collected in different solvents. In methylene chloride or 
chloroform at room temperature, only a single set of signals was detected for both 
bivalent ligands 33 and 42.   
Table 11. In Vitro binding affinities of bivalent ligands at GABAA/BzR subtypes. 
aValues Reported are in nM. 
Ligand α1  α2  α3  α4  α5  α6  
RY-080 (23) 28.4 21.4 25.8 5.3 0.49 28.8 
XLi-093 (33) >1000  >1000  858  1550 15 >2000 
XLi-374 (39) 3795 2694 1864 ND 76.14 ND 
XLi-347 (36) 828.05 690.2 ND ND 13.87 ND 
SR-II-35 (42) 200.7 47.03 94.66 ND 38.38 ND 
XHe-II-053 (30) 287 45 96 1504 13.8 1000 
dm-III-96 (43) 460 5000 ND ND 5000 5000 
DMH-D-053 (31) 236 7.4 272 >5000 194.2 >5000 
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2 (XLi-093)
8 (DMH-D-053) 
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Figure 23. Crystal structures of XLi-093, DMH-D-053, and DM-III-96. 
At low temperature, it was found that the linear dimer 33 exhibited only a small splitting 
of about 3 Hz for some of the aromatic protons in the 1HNMR spectra( see Figure 24),114 
while two clearly separated sets of signals were observed for the folded dimer 43 (Figure 
25). For example, as seen in Figure 25 for 43, the signal of 1H (7.92 ppm at 298 K) was 
split into two peaks at δ7.91 and 7.88 ppm, respectively, at 273° K. The doubling of the 
signals is consistent with disruption of the symmetry between the two domains of the 
molecule as expected if 43 adopted a static folded structure similar to the crystalline 
state.  
 
 
(33, Xli-093) 
(43, DM-III-96) 
31, DMH-D-053) 
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Table 12. The molecular composition and stable conformation of various Bz BS 
bivalent ligands.  ND = not determined yet. 
 
N
N
N
O
O
O
N
N
N
O
O
B
N
N
Cl
N
O
O
O
CA  
Ligand Monounit 1 Monounit 2       Linker Conformation 
in solution 
Crystal 
structure 
32, RY-080 
33, XLi-093 
A 
A 
- 
A 
- 
(CH2)3 
- 
linear 
     - 
      linear 
35, XLi -210 A A (CH2)5 linear ND 
36, XLi -347 A A (CH2)2O(CH2)2 folded ND 
39, XLi-374 A A      CH2OCH2 folded ND 
30, XHe-II-053 B -             -    -  - 
31, DMH-D-053 B B         (CH2)3 linear linear 
43, dm-III-96 B B (CH2)2O(CH2)2 folded      folded 
42, SR-II-35 C C      CH2OCH2 folded ND 
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Figure 24.  Aromatic region of 1HNMR spectra of XLi-093 (33) in CD2Cl2 at variable 
temperatures. 
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Figure 25.  Aromatic region of 1HNMR spectra of SR-II-35 (42) in CD2Cl2 at variable 
temperatures. 
However, the possibility could not be ruled out that the split in the signals was caused by 
slowing a dynamic process within each domain, such as conformational interconversion 
of the seven-membered ring.   
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Figure 26.  Aliphatic region of 1HNMR spectra of SR-II-35 (42) in CD2Cl2 at variable 
temperatures. 
The analysis of these data indicated that the line broadening at the lowest temperature 
was due to one of the conformational processes mentioned above, whereas the doubling 
of the peaks in 42 was caused by the presence of two domains. Certainly an interdomain 
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interaction existed between the two heterocyclic units of 42.  It was therefore concluded 
the internal mobility of the molecule decreased as expected, when the temperature was 
lowered which permitted observation of the two sets of signals of 42 on the NMR time 
scale. It was thus suggested that only when the molecule preferred the folded 
conformation in solution were two sets of signals observed. The preferred conformations 
of the molecules in CDCl3 and CD2Cl2 correlated quite well with those observed in the 
crystal structures (Table 12).     
The study was then expanded by varying the nature of the linker and monomer.   It was 
found that 31, 33, 34, and 35 exhibited only one set of NMR signals at low temperature, 
whereas the NMR signals of ligands 43 and 42 split into two sets at low temperature. 
Low temperature NMR studies were performed in CD2Cl2.  It was concluded that 43 and 
42 preferred a folded conformation, while 32, 33, 34, and 35 assumed a linear 
conformation.  These conclusions are supported by a crystal structure obtained for 
bivalent ligand 33 which indicated 33 was present in a linear conformation in the solid 
state.  These results are illustrated in Table 12. 
Attempts to run the NMR experiments in water failed since the ligands were not 
sufficiently soluble in D2O.  However, the spectra of both the linear and folded dimer 33 
and 42 respectively could be carried out in MeOH-d4. The solvating properties of 
methanol, of course, more closely resemble those of water and this more closely mimics 
aqueous physiological conditions as well. The conformations of dimers in MeOH-d4 
were consistent with conformations in hydrophobic solvents. 
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5.3. Discussion 
 
From the results described above, it is clear that dimers which contain an oxygen atom 
in the linker tend to adopt a folded conformation.  Analysis of these data indicated in the 
hydrophilic solvent, 43 also had a higher tendency to fold back upon itself than 33, as it 
did in the hydrophobic media (Figure 23). In fact, the tendency of 43 to assume a folded 
structure appeared to be higher in methanol than in CD2Cl2 or CDCl3, as the free rotation 
of the molecule was limited (Figure 25). On the other hand, for dimer 33, which 
preferred a linear structure in the solid state and in lipophilic solvents, only one set of 
signals was observed at room temperature in MeOH-d4 (Figure 27).  
It is interesting to note that in the preparation of the samples, dimer 33 was less soluble 
in MeOH-d4 than was 42 and 43. It has been established that ligands are easier to 
dissolve in a solvent when the ligands surface energy can be minimized.  Bivalent 
ligands 42 and 43 were more polar than dimer 33 and had a higher tendency to fold 
back. Consequently, 42 was presumably, easier to dissolve in methanol because its 
surface energy was minimized.  On the other hand, when ligand 33 was dissolved in a 
more polar solvent such as methanol, the surface energy may be forced to be minimized.  
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Figure 27. Aromatic region of 1H NMR spectra of XLi-093 (33) in MeOH-d4 at 
different temperatures. 
Since the conformation of molecules XLi-093 (33) and SR-II-35 (42) in methanol agree 
with those in CD2Cl2 or CDCl3, the behavior of these ligands in CD2Cl2 or CDCl3 should 
reflect those in aqueous solution. The stable conformation of the compounds determined 
in CD2Cl2 or CDCl3 were correlated with the newly generated receptor binding data 
(Table 11). In the pharmacophore/receptor model, the bivalent ligands in the linear 
conformation align well (Figure 28).  
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Figure 28. Bivalent ligand XLi093 (33) aligned in the included volume of the 
pharmacophore/receptor model for the α5β3γ2 subtype. 
 
Importantly, bivalent ligands 31, 33, 34, and 35 with carbon only linkers preferred the 
linear conformation as the stable conformation, independent of the number of linker 
atoms. In contrast, replacing the middle carbon of either linker (CH2)3 or (CH2)5 with an 
oxygen atom altered the stable conformation of the molecules 42 and 43 from linear to 
folded. The only difference between bivalent pairs 33 and 39 with linear and folded 
conformations as the stable ones, respectively, was the center atom.  In compound 33 
(XLi-093) the middle atom was carbon, while in 39 (XLi-374) oxygen was present.  
Consequently, it was decided to focus attention on the conformational difference 
between carbon and oxygen containing linkers.  
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It was well-known115,116 that the carbon chain in both small molecules and polymers 
favored the anti-conformation which results in a linear arrangement of atoms. From 
examination of the linkers (Figure 29), it was easily seen that linkers C and D can be 
regarded as oligomers of oxymethylene (OCH2)2 and oxyethylene (OCH2CH2)2.  
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Figure 29. The linkers of the bivalent ligands. 
 
It was well documented that the preference for the gauche-gauche conformation117-119 of 
a simple open-chain acetal such as dimethoxymethane (CH3OCH2OCH3) could be 
predicted on the basis of the anomeric effect and related stereoelectronic effects.  In this 
conformation the polar Χ−Ο bonds are favorably oriented such that a lone pair orbital of 
the oxygen atom was almost antiperiplanar to the Χ−Ο bond (Figure 30, lone pair orbital 
and Χ−Ο bond in same color). This permitted maximum overlap of the n orbital of the 
oxygen atom with the σ* orbital of the Χ−Ο bond.  This was not possible in the anti-anti 
or gauche-trans conformations and the two rabbit-ear interactions117-121 (Figure 30) 
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engendered by each pair of adjacent oxygen atoms in the anti-anti conformer are 
avoided.  
O
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H
O
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O O
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anti-anti
 
Figure 30. The conformations for dimethoxymethane. 
Furthermore, in the related polymer of dimethoxymethane with the two-bond repeating 
sequence, poly(oxymethylene) (POM), the gauche conformation was, in fact, markedly 
preferred over trans and the polymer existed in a helical (all gauche) conformation116,122-
124 rather than in the all-anti one.   
Similarly, much effort has been spent on the investigation of the conformational 
characteristics of 1,2-dimethoxyethane (glyme, CH3OCH2CH2OCH3) as a model 
molecule for understanding the conformations of poly(oxyethylene) , POE. It had long 
been established that POE chains have a large fraction of bonds in gauche conformation 
and assumed a helical conformation overall.115,116,122-124 It has been proposed that the 
oxygen gauche effect116,125,126 and 1, 5-CHO interaction127-129 within the molecule were 
responsible for the gauche-rich conformations. 
Based on this pioneering work, the correlation was made that the conformation of the 
linkers in the bivalents 33-39 and 42-43 adopt anti (B), gauche-gauche (C), trans-
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gauche-trans (D) conformations, respectively, regardless of the monomeric units which 
comprise them. The arrangement in space (disregarding the direction) of every unit in 
the linkers is depicted in Figure 31.  The end-to-end distance of each unit (C and D) 
which adopted the gauche conformation was shorter than the one in the anti-conformer. 
The more units in the linker, the shorter the gauche linker becomes.  Moreover, it was 
recognized that the Χ−Ο bond length (1.43Å) is often appreciably shorter than the C-C 
bond (1.54 Å).130  Therefore, it was believed that the linkers with the oxygen atom in the 
middle favored the helical conformation and rendered the two monomeric units in each 
dimer sufficiently close to each other with suitable dihedral angles to facilitate the 
intramolecular lipophilic-lipophilic (aromatic-aromatic) interaction.  This was regarded 
as one of the most important factors to stabilize the folded structure as the preferred 
conformation.131-135 For these same reasons, bivalent ligands with the linker B adopted 
the linear conformation.  
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Figure 31. Newman projection for linkers B, C and D. 
 
For the higher analog of POM and POE, namely, poly(trimethylene oxide) [(CH2)3O]x 
(POM3), trans-gauche-gauche-trans was slightly preferred over all-trans and trans-
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trans-gauche-trans comformers in the crystalline state.116  The preference for the gauche 
state in this case was only 0.2 kcal/mol  were as in the POM and POE examples was 1.5 
and 0.4 kcal/mol, respectively.122   Since the energy difference between gauche and 
trans was low, the linker A had more flexibility than the other linkers (C and D) to 
rotate freely and less tendency to occur as gauche.   This could lead to improper end-to-
end distances or dihedral angles for the interaction between the aromatic monounits. 
Hence dimers connected with linker A could not be stabilized in the folded 
conformation even though the same aromatic monomeric units were contained in the 
molecules.  
Bivalent ligands were evaluated in competition binding assays for specific GABAA 
membrane proteins using [3H] flunitrazepam as the radiolabel.  This assay measured the 
ability of the ligand to displace flunitrazepam.  Data is reported as Ki according to the 
Cheng-Prusoff equation.136  Biological data are presented in Table 11 for dimers 
synthesized using different spanners (or linkers).  The linkers in 42 (SR-II-35) and 43 
(dm-III-96) contained an oxygen atom.  Compounds 31, 33, 34, and 35 contained all 
carbon linkers.  Binding data indicated decreased affinity when bivalents contained an 
oxygen atom in the linker. Bivalent Ligand 33 (XLi-093) and 35 (XLi-210) showed 
increased selectivity for the α5 subtype as compared to parent monomer 23.  Bivalent 
ligand 39 (XLi-374) which was analogous to 33 (XLi-093) with the exception of the 
oxygen atom present in the linker, bound with less affinity at the α5 subtype.  Likewise 
bivalent ligand 31 (DMH-D-053) showed increased selectivity versus monomer 30 
(XHe-II-53).  However, the bivalent 43 (dm-III-96) containing an oxygen atom in the 
linker did not bind.  The data suggests that dimers which contain a single oxygen atom 
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in the linker bind less (decreased affinity) to the Bz/GABA (A) receptor.  This is due to 
their propensity to adopt a folded conformation.  One strategy to increase hydrophilicity 
and avoid a folded conformation is to extend the linker length and insert two opposing 
oxygen atoms.  This approach is currently underway. 
Comparison of the results of low temperature NMR studies to crystal structures has 
provided enough information to demonstrate that low temperature NMR can be used as 
a quick method to identify dimeric ligands with a tendency to fold back upon 
themselves, as compared with those preferring a linear conformation.  A correlation with 
binding data shows that the suitability of a ligand in the α5 BzR/Gabaergic subtype is 
heavily influenced by its conformation in solution.  Variable temperature NMR thus can 
be used as a tool for screening bivalent ligands for their in vivo suitability.   It was also 
clear the presence of one oxygen atom in the linker was the principle cause for the dimer 
to fold back onto itself.   
6. Synthesis of α5 subtype selective inverse agonist PWZ-029 on 
multigram scale  
PWZ-029 (47) was effective in improving memory and cognition, especially in models 
with baseline cognitive deficits. The high specificity of PWZ-029 (47) for α5-containing 
GABAA receptors has successfully mitigated adverse side effects of seizures and 
sedation, which are commonly observed with typical benzodiazepines (BZ) and 
nonselective inverse agonists of the GABAA complex. The novel ligand PWZ-029, 
which was synthesized on large scale and characterized electrophysiologically, 
possesses in vitro binding selectivity and moderate inverse agonist functional selectivity 
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at α5-containing GABAA receptors. This ligand has also been examined in rats in the 
passive and active avoidance, spontaneous locomotor activity, elevated plus maze and 
grip strength tests, primarily predictive of the effects on the memory acquisition, basal 
locomotor activity, anxiety level and muscle tone, respectively. The improvement of 
task learning was detected at the dose of 5 mg/kg in the passive, but not the active 
avoidance test. The inverse agonist PWZ-029 had no effect on anxiety nor muscle tone, 
whereas at higher doses (10 and 20 mg/kg) it decreased locomotor activity in this one 
paradigm. This effect was antagonized by flumazenil and also by the lower (but not the 
higher) dose of an agonist (SH-053-2’F-R-CH3) selective for GABAA receptors 
containing the α5 subunit. The hypolocomotor effect of PWZ-029 was not antagonized 
by the antagonist ß-CCt exhibiting a preferential affinity for α1-subunit containing 
receptors. These data suggest that moderate negative modulation at GABAA receptors 
containing the α5 subunit is a sufficient condition for eliciting enhanced 
encoding/consolidation of declarative memory, while the influence of higher doses of 
modulators at these receptors on motor activity shows an intricate pattern whose 
relevance and mechanism wait to be defined. 
One desirable property in this regard is the pro-amnesic activity of BZ site inverse 
agonists, repeatedly reported in animal models,137,138 as well as in human 
volunteers.139,140 However, this desirable effect is confounded by different concomitant 
psychomotor effects (increased vigilance, anxiogenic and/or proconvulsant state), some 
of which have been described in memory studies with non-selective inverse agonists in 
humans, urging their early termination.139  Point mutated mice could not be used to 
identify the receptor subtypes mediating the promnesic activity of inverse agonists 
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because an unexplained switch to the agonist mode of action occurs when an inverse 
agonist at wild type diazepam-sensitive recombinant GABAA receptors is tested at the 
respective point-mutated receptors.141,142 Thus, inverse agonists exerted agonistic-like 
sedative and anticonvulsant effects in mice with the point-mutated α1 subunits,142 while 
the corresponding experiments in models of learning and memory were not 
performed.142 Nevertheless, behavioral examination of genetically modified animals 
conducted to date has indicated the α1 and α5 subunit-containing GABAA receptors 
comprise the ‘memory-modulating’ population of these receptors.143,144  It is notable that 
GABAA receptors containing the α5 subunit are abundantly expressed in the 
hippocampus,11,145,146 the structure substantially involved in memory formation.147  
Recent evidence from animal studies with affinity-selective148 or efficacy-selective 
ligands149-151 has confirmed that the α5 subunit was significantly involved in cognition 
enhancement mediated by the negative modulation of GABAA receptor functions. 
Moreover, it was shown in humans that pre-treatment with an α5 efficacy-selective 
inverse agonist significantly reduces the amnesic effect of alcohol on learning a word 
list.152  However, the affinity- or efficacy-selectivity of the ligands, as well as the 
diversity of the behavioral tasks used in their characterization to date, were of limited 
extent, which necessitated screening of newer BZ site negative modulatory ligands, to 
determine the putative therapeutic role of such compounds in various disorders with 
diminished cognitive capabilities in humans.56 
In this regard, the BZ site ligand PWZ-029 was synthesized (Scheme 7) and prepared on 
large scale. A mixture of 5-chloroisatoic anhydride 44 and sarcosine in DMSO was 
heated to reflux to furnish benzodiazepine 45 in 84% yield.  Potassium t-butoxide was 
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added to a solution of 45 in THF at 0 oC and stirred for 20 min.  The reaction was cooled 
to -35oC and diethylchlorophosphate was added slowly. After stirring at 0oC for 30 min, 
the reaction mixture was cooled to -78oC and ethyl isocyanoacetate was added followed 
by potassium t-butoxide to form 40 in 89% yield. A solution of imidazobenzodiazepine 
40 can be reduced with LiBH4 to furnish alcohol 46 in 67% yield as colorless crystals. 
To a slurry of KOH in DMSO at room temperature were added alcohol 46 and CH3I to 
give PWZ-029 (47) , as an off-white powder in 95% yield on 1-15 gram scale. The 
alcohol was dissolved in a solution of KOH in DMSO and treated with CH3CH2I at 
room temperature to give SR-II-81 (48).  
Scheme 7: Synthesis of PWZ-029  
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Electrophysiology experiments in Xenopus oocytes demonstrated that PWZ-029, at a 
concentration of 1 μM, significantly reduced GABA initiated control currents, thereby 
indicating a partial inverse agonist effect of PWZ-029 on GABAA receptors possessing 
the α5 isoforms (Figure 32). Illustrated in Figure 32, are the concentration–effects curve 
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for modulation of GABAA elicited currents by PWZ-029 on Xenopus oocytes expressing 
GABAA receptor subtypes α1β3γ2, α2β3γ2, α3β3γ2, and α5β3γ2. Concentrations of 
GABAA that elicit 3% of the maximum GABAA-triggered current of the respective cells 
were applied alone and with various concentrations of PWZ-029. Control currents 
represent responses in the absence of PWZ-029. Data points represent means±SEM from 
4 oocytes from ≥2 batches [1 μMPWZ-029 resulted in 114±4%, 105±8%, 118±5% and 
80±4% of control current (at GABAA EC3) in α1β3γ2, α2β3γ2, α3β3γ2, and α5β3γ2 
receptors, respectively]. All these values except the one for α2β3γ2 receptors were 
significantly different from that of the respective control currents (p<0.01, Student's t-
test). Note that 100 nM is the pharmacologically relevant concentration. 
Table 13. In Vitro Binding Affinities of bivalent ligands at GABAA/BzR subtypes. 
aValues Reported are in nM. 
 
 
 
Code MW α1 α2 α3 α4 α5 α6 
Merck 291.73 >300 >300 >300 ND 38.8 >300 
Moltech 291.73 920 ND ND ND 30 ND 
UNC-Roth 291.73 362.4 180.330 328.2 ND 6.185 ND 
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Figure 32. Oocyte data for PWZ-029 by Sieghart et al.153 
This ligand as mentioned, has also been examined in rats in the passive and active 
avoidance, spontaneous locomotor activity, elevated plus maze and grip strength tests, 
primarily predictive of the effects on the memory acquisition, basal locomotor activity, 
anxiety level and muscle tone, respectively. The improvement of task learning was 
detected at the dose of 5 mg/kg in the passive avoidance task (Figure 33).  The passive 
avoidance task is a one trial fear-motivated avoidance task in which the mouse learns to 
refrain from stepping through a door to an apparently safer but previously punished dark 
compartment. The latency to refrain from crossing into the punished compartment serves 
as an index of the ability to avoid, and allows memory to be assessed. 
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Figure 33. Fear conditioned contextual memory of PWZ-029 
 
The PWZ-029 at 5 mg/kg, administered before the acquisition session, significantly 
increased retention session latency relative to the control group.154 
The inverse agonist PWZ-029 (47) had no effect on anxiety or muscle tone, whereas at 
higher doses (10 and 20 mg/kg) it decreased locomotor activity. This effect was 
antagonized by flumazenil and also by the lower (but not the higher) dose of an agonist 
(SH-053-R-CH3-2′F) selective for GABAA receptors containing the α5 subunit. The 
hypolocomotor effect of PWZ- 029 (47) was not antagonized by the antagonist βCCt, 
which exhibits a preferential affinity for α1- subunit-containing receptors. These data 
suggest that moderate negative modulation at GABAA receptors containing the α5 
subunit is a sufficient condition for eliciting enhanced encoding/consolidation of 
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declarative memory, while the influence of higher doses of modulators at these receptors 
on motor activity shows an intricate pattern whose relevance and mechanism await to be 
defined.154  In fact, in the conflict paradigm in Rowlett’s lab in rhesus monkeys, PWZ-
029 was a weak anxiolytic with no sedation observed in either the suppressed or 
nonsuppressed portion of the test.  Recently, Stables et al. at NINDS has shown PWZ-
029 to be a weak anticonvulsant. The PWZ-029 (47) an α5 inverse agonist cannot be 
proconvulsant or convulsant (see Appendix IV) and consequently will not exhibit the 
side effects of other inverse agonists (NAM). 
 
 
Figure 34. Passive avoidance task154 
 
The effects of DMCM (0.2 mg/kg) and PWZ-029 (2, 5 and 10 mg/kg) on retention 
performance in a passive avoidance task (*p<0.05 compared to solvent (SOL) group). 
Number of animals per treatment group: 10. 
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6.1. CANTAB  Approach (Rowlett, Rallapalli and Cook et al.)155 
Recent studies by Rowlett, Rallapalli and Cook et al. on PWZ-029 showed that this 
ligand acted as an inverse agonist at α5GABAA receptor subtypes which enhanced 
memory. Rowlett’s used several primate models, including the Cambridge 
Neuropsychological Test Automated Battery, or CANTAB.  A clear strength of the 
CANTAB approach is that its tasks are based on corresponding procedures developed 
for human patients, which greatly facilitate the ultimate goal of translating findings from 
monkeys to humans.  
Because PWZ-029 has been shown to be safe and to have cognitive-enhancing effects in 
rodents154 experiments were initiated with this compound in rhesus monkeys as 
mentioned.  Initial results, shown in Figure 35, are quite provocative and exciting:  
PWZ-029 enhanced performance in the DNMS (Delayed non-matching to sample) to 
task using the 10-min delay with distracters (Figure 35A) and although it had no effect 
alone, PWZ-029 completely reversed the scopolamine-induced deficit in the ORD 
(Object Retrieval with Detours ) task (Figure 35B).  Interestingly, PWZ-029 induced 
anti-conflict (anxiolytic) effects in monkeys without the concomitant response rate-
suppressing effects characteristic of BZ-type drugs (Figure 35C).  It is felt that these 
latter effects are due to PWZ-029’s partial agonist effects at α2/3GABAA receptor 
subtypes, whereas the cognition-enhancing effects of this compound are due to inverse 
agonist (NAM) action at α5GABAA receptors. 
PWZ-029 (47) provides an important lead compound based not only on potential 
effectiveness against cognitive impairment, but also as a potential treatment for anxiety 
and agitation in patients with dementias, similar to the anxiolytic effects of classical BZs 
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(Meehan et al. 2002).  Studies will continue with PWZ-029 and expand them to include 
comparative studies with non-selective agonists and α5GABAA-preferring agonists; as 
well as with pre-treatments with α5GABAA-preferring antagonists such as XLi-093 
(33).  In addition, in our initial screens compounds will be sought with similar, and 
hopefully improved, efficacy profiles.  For example, a compound that is an α5GABAA 
partial inverse agonist, an α2/3GABAA-preferring partial agonist, but ineffective at 
α1GABAA receptors is both desirable and feasible in our synthesis/screening program. 
          
 
Figure 35: Preliminary profile of cognitive enhancing and anxiolytic like effects of 
PWZ-029 in monkeys. Data are from n=2 monkeys (A &C) and n=4 monkeys (B). Red 
arrow indicates the dose (0.01mg/kg, i.v.) of PWZ-029 tested in A & B 
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Importantly, in the ORD task, PWZ-029 showed only a modest trend for enhancement 
of performance (Fig. 36A), but when task difficulty was increased by testing with 
difficult trials only, PWZ-029 robustly increased performance (Fig. 36B).  This 
enhancement was reversed by administration of the α5GABAA-preferring antagonist 
XLi-093, and this antagonism, in turn, was reversed by increasing the dose of PWZ-029 
(Fig. 36C).  Finally, PWZ-029 completely reversed deficits in performance induced by 
the memory-impairing anti-cholinergic scopolamine (Fig. 36D).   
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Figure 36.  Cognitive-enhancing effects of PWZ-029 in the rhesus monkey Object 
Retrieval with Detours (ORD) task (N=5 monkeys).  A. Effects of PWZ-029 on ORD 
tests consisting of both easy and difficult trials .No effect of the compound was observed 
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(mean % correct first reaches, p>0.05, repeated measures ANOVA).  B. PWZ-029 
enhanced performance in the ORD task when tested with difficult trials only (*p<0.05 
vs. vehicle, V, Bonferroni t-tests).  C.  Enhancement of ORD performance by 0.018 
mg/kg of PWZ-029 was attenuated by the α5GABAA-preferring antagonist XLi-093, 
and this antagonism was surmountable by increasing the PWZ-029 dose (*p<0.05 vs. 
vehicle, **p<0.05 vs. 0.018 mg/kg PWZ-029, Bonferroni t-tests).  D.  PWZ-029 
reversed performance impaired by 0.01 mg/kg of scopolamine. (*p<0.05 vs. vehicle; 
**p<0.05 vs. scopolamine alone, Bonferroni t-tests). 
6.2. Synthesis of PWZ-029 analogs 
The chemistry used to design fluoro analogs of PWZ-029 (47) can be adapted to design 
ligands of XHE-II-053 (30) with less potential for metabolization by esterases.  Fluorine 
atoms in place of the carbonyl group satisfy current included volumes and 
electronegativity requirements of the Milwaukee-based pharmacophore receptor model.  
The covalent radius of a hydrogen is 37 pm whereas a fluorine is 71 pm. 
This approach is in agreement by a recent compounds patented by Roche.156  Several 
new analogs have been proposed and docked in the Milwaukee based pharmacophore by 
Clayton et al. 157 
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Figure 37: Binding affinity data of PWZ-029 (47) and Roche difluoro ligand 49 
The new analogs of PWZ-029 are of strong interest due to the recent contextual memory 
impairment data wherein doses of scopolamine decreased memory while the α5 ligand 
reversed this (see Scheme 8). 
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Scheme 8: Synthesis of various analogs of PWZ029 
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The synthesis of amine analog of PWZ-029 can be seen in Scheme 9. A mixture of 
imidazobenzodiazepine was refluxed with methyl amine in anhydrous CH2Cl2 to give 
SR-II-097 (57) in 78% yield. The efficacy data evaluated by Sieghart et al. (shown in 
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Figure 38) indicated that the ligand SR-II-097 (57) was an inverse agonist at α5 and was 
an agonist at α1 when compared to PWZ-029 (see Figure 38 and Table 15).  
Scheme 9: Synthesis of SR-II-097 
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Figure 38: Oocyte data of SR-II-097 
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Table 14. EC50 and Hill Slope for Modulation of Control GABA EC3 by SR-II-097 (57) 
in Xenopus Oocytes Expressing Different GABAA Receptor Subtypes. Results represent 
EC50 (95% confidence interval for EC50) and Hill Slope (Nh) ± SD from at least four 
cells from two batches. 
 
  α1β3γ2 α2β3γ2 α3β3γ2 α5β3γ2 
 
SR-II-097 (57) 
 
EC50 
95%CI 
378nM 
(58-2426) 
>6µM 
 
>18µM 
 
95nM 
(0.01-6000) 
Nh 0.80   -3.5 
 
 
Table 15. Modulation of Control GABA EC3 by SR-II-097 (57) on Xenopus Oocytes 
Expressing Different GABAA Receptor Subtypes. Values are presented as mean ± SEM 
of at least four oocytes from at least two batches. 
All the above values were significantly different from the respective control currents (p<0.01, Student’s- 
 t-test) except where indicated (n.s.). n.s. means not significant. 
 
 
  α1β3γ2 α2β3γ2 α3β3γ2 α5β3γ2 
 
SR-II-097(57) 
  10nM ns ns ns ns 
100nM   ns ns ns ns 
    1µM 121±2 % ns ns 88±5% 
  10µM 123±5% 119±1% 125±13% 88±4% 
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The fluoro analog SR-III-38 was prepared using DAST (diethylaminosulfur trifluoride) 
in anhydrous CH2Cl2 at room temperature in 70 % yield.  
 
Scheme 10: Synthesis of SR-III-38 
N
N
N
Cl
O CH3
CH2OH
N
N
N
Cl
O CH3
46
CH2F
58 (SR-III-38)
DAST, CH2Cl2
 rt, 70%
 
Examination of the oocyte data (shown in Figure 39) indicated no significant subtype 
selective efficacy.  
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Figure 39: Oocyte data on SR-III-38 by Sieghart et al. 
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Table 16. EC50 and Hill Slope for Modulation of Control GABA EC3 by SR-III-38 (58) 
in Xenopus Oocytes Expressing Different GABAA Receptor Subtypes. Results represent 
EC50 (95% confidence interval for EC50) and Hill Slope (Nh) ± SD from at least four 
cells from two batches. 
  α1β3γ2 α2β3γ2 α3β3γ2 α5β3γ2 
 
SR-III-38 (58) 
 
EC50 
95%CI 
>0.6µM 
 
 >43µM  
Nh 0.4  1.5  
 
 
Table 17. Modulation of Control GABA EC3 by SR-III-38 (58) on Xenopus Oocytes 
Expressing Different GABAA Receptor Subtypes. Values are presented as mean ± SEM 
of at least four oocytes from at least two batches. 
All the above values were significantly different from the respective control currents (p<0.01, Student’s- 
 t-test) except where indicated (n.s.). n.s. means not significant. 
 
 
  α1β3γ2 α2β3γ2 α3β3γ2 α5β3γ2 
 
SR-III-38 (58) 
  10nM ns ns ns ns 
100nM 105±1 % ns ns ns 
    1µM 112±10 % ns 105±3% ns 
  10µM 115±7% ns 115±17% ns 
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To improve the selectivity, the difluoro analog SR-III-61 was synthesized from an 
aldehyde (59). The alcohol 46 was treated with Dess Martin periodinane in dry CH2Cl2 
to afford aldehyde 59 in 96% yield. Treatment of aldehyde in dry CH2Cl2 with DAST 
resulted in the difluro analog SR-III-61 (49) in 65% yield.   
Scheme 11: Synthesis of SR-III-61 
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Figure 40: Oocyte data of SR-III-61 by Sieghart et al. 
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Table 18.  EC50 and Hill Slope for Modulation of Control GABA EC3 by SR-III-61 (49) 
in Xenopus Oocytes Expressing Different GABAA Receptor Subtypes. Results represent 
EC50 (95% Confidence interval for EC50) and Hill Slope (Nh) ± SD from at least four 
cells from two batches. 
 
  α1β3γ2 α2β3γ2 α3β3γ2 α5β3γ2 
 
SR-III-61 (49) 
 
EC50 
95%CI 
>10µM >3nM 
(1-27nM) 
 >0.03µM 
Nh  0.8   
 
Table 19.  Modulation of Control GABA EC3 by SR-III-61 (49) on Xenopus Oocytes 
Expressing Different GABAA Receptor Subtypes. Values are presented as mean ± SEM 
of at least four oocytes from at least two batches. 
All the above values were significantly different from the respective control currents (p<0.01, Student’s- 
 t-test) except where indicated (n.s.). n.s. means not significant. 
 
 
  α1β3γ2 α2β3γ2 α3β3γ2 α5β3γ2 
 
SR-III-61(49)  
  10nM ns 109±4 % ns 102±7 % 
100nM ns 119±6% 112±2 % 107±5% 
    1µM 110±4 % 116±1% 116±2% 109±8% 
  10µM 113±4% 113±1% 144±16% 110±9% 
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Data of SR-III-61 (49) from the electrophysiology indicated (in oocytes) was an agonist 
at α3 subtypes at high concentrations. However at a pharmacologically relevant 
concentration (100nM, -7) the ligand demonstrated efficacy at all subtypes. 
Unfortunately, the efficacy data showed no significant subtype selectivity. The synthesis 
of the other PWZ analogs is currently underway.  
 
7.  Conclusions 
 
In this study, it was clear that QH-II-066 (11) which is α5 subtype selective ligand is an 
agonist. It was shown88 that QH-II-066 (11) exhibited functional selectivity in vivo with 
potent diazepam-like efficacy at α5 subtypes and partial efficacy at  the α1 subtype. 
Recent studies by Weiss and Cook et al.89 have shown that activation of GABA (A) by 
QH-II-066 (11) induces apoptosis in neuroblastoma. This is very important finding. The 
mechanism by which GABA-A activation inhibited the growth of neuroblastoma cells 
was assessed by Cho, Cook et al.  QH-II-066 (11), an α5 agonist passes through the 
blood brain barrier which opens up the potential to apply in neurology and psychology 
as chemotherapeutic agent.  These results also highlight a possible connection between 
the role of neurotransmitters in nervous system development and the regulation of 
neuroblastoma growth as shown by Weiss, Rallapalli and Cook et al. (unpublished, see 
Appendix III). 
 Bivalent ligand XLi-093 (33) has clearly been shown to be the first subtype selective 
antagonist at α5 subtypes which is known (Rowlett, Savic et al.) to cross the blood brain 
barrier. Rowlett showed that the memory impairing effects of diazepam were blocked by 
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a dose of XLi-093 (3.0mg/kg) that occupied about 66% of the α5 GABAA binding sites. 
A series of bivalent ligands with oxygen linker were synthesized based on α5 selectivity 
of XLi-093 (33). Comparison of the results of low temperature NMR studies to crystal 
structures has provided enough information to demonstrate that low temperature NMR 
can be used as a quick method to identify dimeric ligands with a tendency to fold back 
upon themselves, as compared with those preferring a linear conformation.  A 
correlation with binding data shows that the suitability of a ligand in the α5 
BzR/Gabaergic subtype is heavily influenced by its conformation in solution.  Variable 
temperature NMR thus can be used as a tool for screening bivalent ligands for their in 
vivo suitability.   It is also clear the presence of one oxygen atom in the linker was the 
principle cause for the dimer to fold back onto itself, consequently resulted in 
diminished activity. From the recent work of Rowlett, it was demonstrated that novel α5 
selective inverse agonist PWZ-029 (47) enhanced cognition in rhesus monkeys in the 
CANTAB paradigm. This ligand had the ability to reverse cholinergic deficits in 
performance induced by the antimuscarinic scopolamine under mixed trial conditions. In 
the ORD task, PWZ-029 showed only a modest trend for enhancement of performance.  
But when task difficulty was increased by testing with difficult trials only, PWZ-029 
robustly increased performance.  This enhancement was reversed by administration of 
the α5 GABA (A) subtype selective antagonist XLi-093 and this antagonism in turn was 
reversed by increasing the dose of PWZ-029. In addition, PWZ-029 enhanced 
performance in the DNMS task using the 10 minute delay with distracters. This ligand 
also exhibited anxiolytic activity in some primates and was a weakly active 
anticonvulsant in rats (NINDS, Jim Stables et al. see Appendix IV).These findings are 
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consistent with a role for PWZ-029 (47) α5 GABAA receptors in the treatment of age-
associated memory impairment and Alzheimer’s disease. It is the subject of an SBIR 
grant submitted December 5th, 2012 by Physiogenix (see Appendix VII). 
8. General Experimental Details  
All reactions were carried out under an argon atmosphere with dry solvents using 
anhydrous conditions unless otherwise stated. Tetrahydrofuran (THF) and diethyl ether 
were freshly distilled from Na/benzophenone ketyl prior to use. Dichloromethane was 
distilled from calcium hydride prior to use. Methanol was distilled over magnesium 
sulfate prior to use. Benzene and toluene were distilled over sodium and acetonitrile was 
distilled over CaH2 prior to use. Reagents were purchased of the highest commercial 
quality and used without further purification unless otherwise stated. Thin layer 
chromatography (TLC) was performed using Dynamic Adsorbents Inc. UV active silica 
gel, 200 µm, plastic backed; Dynamic Adsorbents Inc. UV active alumina N, 200 µm, F-
254 plastic backed plates. Flash and gravity chromatography were performed using 
silica gel P60A, 40-63 µm purchased from Silicycle. Elemental analyses were performed 
on a Carlo Erba model EA-1110 carbon, hydrogen, and nitrogen analyzer. All samples 
submitted for CHN analyses were first dried under high vacuum for a minimum of six 
hours using a drying pistol with isopropyl alcohol or benzene as the solvent with 
potassium hydroxide pellets in the drying bulb. Melting points were taken on a Stuart 
melting point apparatus SMP3 manufactured by Barloworld Scientific US Ltd. Proton 
(1H NMR) and carbon high resolution nuclear magnetic resonance spectra (13C NMR) 
were obtained on a Bruker 300-MHz or a GE 500-MHz NMR spectrometer. 1H NMR 
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data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, dd = doublet of doublets, dt = doublet of triplets, ddd = doublet of 
doublet of doublet, td = triplet of doublets, qd = quartet of doublets, sex = sextet, m = 
multiplet), integration, and coupling constants (Hz). 13C NMR data are reported in parts 
per million (ppm) on the δ scale. The low resolution mass spectra (LRMS) were 
obtained as electron impact (EI, 70eV), which were recorded on a Hewlett-Packard 
5985B gas chromatography-mass spectrometer, while high resolution mass spectra 
(HRMS) were recorded on a VG Autospec (Manchester, England) mass spectrometer. 
HRMS recorded by electrospray ionization (ESI) methods were performed at the 
Laboratory for Biological Mass Spectrometery at Texas A&M University on an API 
QStar Pulsar model, manufactured by MDS Sciex.  
5-Phenyl -1,4 benzodiazepine-2-one (7) : The 2-amino-benzophenone 5 (100.6g, 
0.51mol) and NaHCO3 (128.6g, 1.5mol)  were suspended in dry CH2Cl2 (1.3L) at rt.  A 
solution of bromoacetyl bromide (113.2g, 0.56mol, 48.9mL) in dry CH2Cl2 (200mL) 
was added dropwise over 30 min and the mixture was allowed to stir for another 3h. The 
reaction was allowed to stir until analysis by TLC (silica gel) indicated the absence of 
starting material, after which the above reaction mixture was concentrated under vacuum 
to provide amide intermediate 6 which was added directly to a saturated solution of 
anhydrous ammonia in CH3OH (1.5L). The mixture was heated to reflux for 6h until 
analysis by TLC (silica gel) indicated the absence of the 2-bromoacetyl intermediate 6 
prepared above. After the solvent was removed under reduced pressure, the solid which 
remained was washed with hexane/EtOH (1:4) to provide pure benzodiazepine 7 (107g, 
95%) as a white powder. 3: mp: 135-145 °C; IR (KBr) 3454, 3185, 3063, 2891, 1681, 
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1614, 1467 cm-1 ; 1H NMR (CDCl3, , 300MHz) δ 9.68 (s, 1H), 7.09-7.59 (m, 9H), 4.31 
(s, 2H)  MS (EI) m/e 236 (M+, 93), 208 (100), 180 (28), 152 (19); Anal. Cald for 
C15H12N2O: C, 76.25; H, 5.12; N, 11.86; Found C, 76.21; H, 5.19; N, 11.94. The 
spectral data were in agreement with the literature.65  
7-Bromo-5-phenyl-1,4-benzodiazepine-2-one 8: Benzodiazepine 7 (61.4g, 0.274mol) 
was dissolved in acetic acid (1L) and was treated with H2SO4 (15.2mL, 0.55mol, 36N) 
and bromine (87.1 g, 0.55mol). After stirring at rt for 10d, the reaction mixture was 
poured into ice water and brought to pH 5-6 with an aq solution of 6N NaOH. The crude 
bromide 4 precipitated and was collected by vacuum filtration and recrystallized from 
EtOH to provide the bromide 8 as a white solid in 90% yield. 8: mp: 188-194 °C; IR 
(KBr) 3466, 3173, 3075, 2953, 1687, 1602, 1480 cm-1: 1H NMR (DMSO-d, 300MHz) δ 
10.95(s, 1H), 7.11-7.89 (m, 8H), 4.25 (s, 2H). MS (CI) m/e 316 (M+ +1, 78), 265 (15), 
237 (100), Anal. Cald for C15H12N2O: C, 57.16; H, 3.52; N, 8.89; Found C, 57.56; H, 
3.49; N, 8.82. This material was identical to that reported in the literature. 65 
7-Trimethylsilylacetyleno-5-phenyl-1,3-dihydrobenzo[e]-1,4-diazepine-2-one 9:The 
6- Bromo-benzodiazepine 8 (5g, 15.86mmol) was dissolved in dry triethyl amine 
(108mL) and acetonitrile (68mL). This mixture was degassed 3-4 times under vacuum 
and back filled with argon. To this degassed mixture, bis (triphenylphosphine) palladium 
(II) acetate (0.713g, 1.1mmol) and trimethylsilylacetylene (4.48mL, 31.72 mmol) was 
added and the mixture was heated to reflux under argon. After 12 h the reaction mixture 
was cooled to rt and filtered through a bed of celite with EtOAc. The filtrate was 
concentrated in vacuuo and the residue was purified via flash chromatography [silica 
gel, EtOAc:hexane (1:1)] to furnish the TMS analog 9 as a yellow powder (4.5g, 85%): 
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mp: 190.0-191.5 °C; IR (KBr) 3011, 2281, 1686, 1610, 1486 cm-1: 1H NMR (CDCl3, 
300 MHz) δ10.17 (s, 1H), 7.21-7.61 (br, 7H), 7.09 (d, 1H, J=8.25Hz), 4.31 (s, 2H), 0.21 
(s, 9H) ; MS (CI) m/e (relative intensity) 333 (M+ +1, 100). Anal. Cald for 
C20H20N2OSi: C, 72.25; H, 6.06; N, 8.43; Found C, 72.20; H, 6.11; N, 8.52 
1-Methyl- 7 - trimethylsilylacetyleno-5- phenyl - 1,3-dihydrobenzo[e]-1,4-diazepine-
2-one 10: The acetyleno amine 9 (1g, 3mmol) was dissolved in dry THF (15mL) at -
15°C and NaH (60% mineral oil, 144mg, 3.6mmol) was added to the solution in one 
portion. The slurry was then stirred for 30 min and then CH3I (0.28mL, 4.5mmol) was 
added to the mixture and this mixture was allowed to warm to rt. After the mixture was 
allowed to stir overnight, the reaction was quenched with water (200mL) and EtOAc 
(100mL). The mixture was extracted with EtOAc and then washed with brine and dried 
(Na2SO4). After the removal of the solvent under reduced pressure, the residue was 
purified by flash chromatography [hexane:EtOAc (75:25)] to provide the TMS-analog 
10 (0.9g, 85%) as a white solid : mp: 177-178 °C; IR (KBr) 2954, 2147, 1687, 1612, 
1491 cm-1: 1H NMR (CDCl3, 300 MHz,) δ 7.20-7.27 (m, 3H),  7.07 (d, 1H, J=8.58Hz), 
7.05 (s,1H), 4.60 (d, 1H, J=10.8Hz), 3.54 (d, 1H, J=10.8 Hz), 3.18 (s, 3H); MS (EI) m/e 
346 (M+, 90), 318 (100), 303 (19), 165 (22), 151 (20). Anal. Cald for C21H22N2OSi: C, 
72.79; H, 6.40; N, 8.08; Found C, 72.50; H, 6.68; N, 8.04 
1-Methyl-7-acetyleno-5- phenyl- 1,3-dihydrobenzo[e]-1,4-diazepine-2-one 11: A 
solution of trimethylsilyl acetyleno benzodiazepine 10 (0.87g, 2.5 mmol) was dissolved 
in THF (200mL) and the solution was cooled to -30°C . A solution of TBAF (1.0M in 
THF; 3.01mL, 3mmol) was then added to the mixture and it was allowed to warm to rt. 
After stirring at rt for 20min the reaction mixture was quenched with water (200mL) and 
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extracted with EtOAc (200mL), washed with brine and dried (Na2SO4). After removal of 
the solvent under reduced pressure the residue was purified by flash chromatography 
[EtOAc : hexane (1:1)] to provide the target compound 11 (QH-II-066) (0.62g, 90%) as 
light yellow crystals. mp: 163-165 °C; IR (KBr) 2965, 1680, 1605 cm-1: 1H NMR 
(CDCl3, 300 MHz) δ 7.62 (dd, 1H, J=8.5Hz, 2.0Hz), 7.35-7.45 (m, 4H), 7.27-7.42 (d, 
1H, J=8.5Hz), 4.80 (d, 1H, J=10.9Hz), 3.85 (d, 1H, J = 10.8Hz), 3.46 (s, 3H), 3.11 (s, 
3H); MS (EI) m/e 274 (M+, 100), 259(12), 246 (10), 189 (12), 122 (19), 105 (42). Anal. 
Cald for C18H14N2O.2/3H2O: C, 75.51; H, 4.89; N, 9.78; Found C, 75.59; H, 5.17; N, 
9.62. This material was identical to that reported in the literature. 47,65 
(Z)-8-Bromo-2-((4-methylpiperidin-1-yl)methylene)-6-phenyl-2,4-dihydro-1H-
benzo[f]imidazo[1,2-a][1,4]diazepin-1-one 16: A suspension of 7-bromo-1,3-dihydro-
5-phenyl-2H-1,4-benzodiazepin-2-thione 12 (1.6g, 4.83mmol), glycine (1.81g, 
24.2mmol) and Na2CO3 (1.84g, 17.4mmol) in EtOH (38mL)-H2O (16mL) was stirred at 
reflux for 1 h and then poured into water (100mL), after which the mixture was filtered 
to remove a small amount of 7-bromo-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-
one which remained. The filtrate was extracted with CHCl3. The CHCl3 extract was 
discarded and then the aq layer was adjusted to pH 4 with a solution of aq 2N HCl after 
which it was extracted with CHCl3 (3x25mL). Evaporation of the CHCl3 solution gave 
pure acid 13 (1.2g, 67%) as a yellow solid. Acid 13 (350mg, 0.941mmol) was suspended 
in dry CH2Cl2 (10mL) and DCC (223mg, 1.08mmol) was added. The suspension which 
resulted was stirred at 40°C for 2h and then cooled to 0°C. The mixture which resulted 
was filtered and the solvent was removed under vacuum to give 8-bromo-2,4-dihydro-6-
phenyl-1H-imidazo[1,2-a][1,4] benzodiazepine-1-one 14 as a brown oil. The cyclized 
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amide 14  (250mg) was dissolved in dry benzene (6mL), after which dimethylformamide 
diethylacetal (130mg, 0.883 mmol) and triethyl amine (89mg, 0.883 mmol) were added. 
The solution which resulted was stirred at rt for 1 h and the solvent was removed under 
vacuum. The residue was crystallized from EtOAc-MeOH to give 15 (200mg, 70%). A 
solution of 15 (180mg, 0.440 mmol) in dry toluene (5mL) was treated with 1-methyl 
piperazine (1mL) and heated to reflux for 5h. The solvent was removed under vacuum to 
give a gum which crystallized from CH2Cl2-Et2O to furnish 16 (146mg, 72%) as a 
yellow solid. mp >250 °C;   IR (KBr) 3324, 2932, 2787, 1692, 1624, 1475, 1402, 1297, 
1137, 933 cm-1; 1H NMR (CDCl3, 300MHz) δ 7.95 (d, 1H, J=8.8Hz), 7.72 (dd, 1H, 
J1=8.8Hz, J2=2.3Hz), 7.58-7.55 (m, 2H), 7.49-7.37 (m, 4H), 7.17 (s, 1H), 5.01 (d, 1H, 
J=12Hz), 4.50-4.60 (m, 1H), 4.20-4.30 (m, 1H), 4.16 (d, 1H, J=12Hz), 3.50-3.58 (m, 
2H), 2.40-2.60 (m, 4H), 2.34 (s, 3H); MS (m/z) 465 (100). Anal. Calcd. for 
C23H22N5OBr. 1/3H2O: C, 58.79; H, 4.95; N, 14.89. Found: C, 58.73; H, 4.86; N, 14.83. 
The spectral data of 16 were identical to the published results.158 
(Z)-2-((4-Methylpiperidin-1-yl)methylene)-6-phenyl-8-((trimethylsilyl)ethynyl)-2,4-
dihydro-1H-benzo[f]imidazo[1,2-a][1,4]diazepin-1-one 17: To a suspension of amide 
16 (140mg, 0.302mmol) in dry acetonitrile (4mL) and triethylamine (3mL) was added 
bis (triphenylphosphine)-palladium (II) acetate (22.6mg, 0.03mmol). The solution which 
resulted was degassed and trimethylsilyl acetylene (0.1mL, 0.7mmol) was added. The 
mixture was heated to reflux and stirred overnight. After removal of the solvent under 
vacuum, the residue was dissolved in CH2Cl2 and washed with a saturated aq solution of 
NaHCO3 and brine. The organic layer was dried (Na2CO3), filtered and concentrated 
under vacuum. The residue was purified by flash column chromatography (EtOAc: 
227  
MeOH 9:1) to furnish the trimethylsilyl analog 17 (100mg, 69%) as a pale yellow solid. 
mp >250 °C;   IR (KBr) 3436, 2936, 2794, 2154, 1682, 1625, 1489, 1136, 847cm-1; 1H 
NMR (CDCl3, 300MHz) δ 8.80 (d, 1H, J=8.5Hz), 7.68 (dd, 1H, J=1.9Hz, 8.5Hz), 7.55-
7.59 (m, 2H), 7.37-7.49 (m, 4H), 7.16 (s, 1H), 4.99 (d, 1H, J=12Hz), 4.50-4.60 (m, 1H), 
4.20-4.30(m, 1H), 4.13 (d, 1H, J=12.4Hz), 3.48-3.58(m, 2H), 2.4-2.6 (m, 4H), 2.35 (s, 
3H), 0.23 (s, 9H); MS (m/z) 482 (100). Anal. Calcd. for C28H31N5OSi. H2O: C, 67.60; 
H, 6.54; N, 13.59. Found: C, 67.30; H, 6.66; N, 14.01. 
(Z)-8-Ethynyl-2-((4-methylpiperidin-1-yl)methylene)-6-phenyl-2,4-dihydro-1H- 
benzo [f]imidazo[1,2-a][1,4]diazepin-1-one 18 (PS-1-37): A solution of the 
trimethylsilyl analog 17 (65mg, 0.135mmol) in THF (15mL) was stirred with TBAF 
hydrate (45mg, 0.175mmol) at -5°C for 5min. After this, H2O (5mL) was added to the 
solution to quench the reaction and stirring continued at -5°C for one half h. The solution 
was then extracted with EtOAc (3x40mL) and the organic layer was washed with water. 
After removal of the solvent under reduced pressure, diethyl ether was added to the 
residue to precipitate a solid. The solid was filtered and washed with CHCl3-Et2O (1:15) 
to provide the acetyl target 18 (40mg, 73%). mp 223-224 °C;   IR (KBr) 3298, 2935, 
2786, 1695, 1628, 1364, 1136, 1002, 778cm; 1H NMR (CDCl3, 300MHz) δ 8.04 (d, 1H, 
J=8.5Hz), 7.71 (dd, 1H, J=1.9Hz, 8.5Hz), 7.55-7.58 (m, 2H), 7.36-7.48 (m, 4H), 7.17 (s, 
1H), 5.0 (d, 1H, J=12.1Hz), 4.5-4.6 (m, 1H), 4.2-4.3  (m, 1H), 4.16 (d, 1H, J=12.1Hz), 
3.5-3.6 (m, 2H), 3.08 (s, 1H), 2.4-2.6 (m, 4H), 2.35 (s, 3H); MS (m/z) (100). The 
spectral data of 14 were identical to the published results.159 
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4-Methyl-3,4-dihydro-1H- benzo[e][1,4]diazepine-2,5-dione(26): A mixture of isatoic 
anhydride 25 (20g, 101 mmol) and sarcosine (9.02g, 101 mmol) in DMSO (160mL) was 
heated at 150°C for 5 hr, after which the solution was cooled to rt and poured into ice 
water (750mL) to furnish a light brown solid. This solid was collected by filtration, 
washed with water (3x200mL) and dried. The benzodiazepine 26 was obtained as a light 
brown solid (19g, 84%).  This material was used directly in the next experiment. 
7-Bromo-4-methyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione(27): 
Benzodiazepine 26 (32.4g, 0.17mol) was added to a solution of acetic acid (400mL) in a 
3-neck reaction flask. Sodium acetate (27.9g, 0.34mol) was added to this solution. 
Bromine (13.1mL, 0.255mol) was added using an addition funnel and the solution which 
resulted was allowed to stir for 18h and then poured into ice water (200mL) to provide a 
white solid. This solid was collected by filtration and then washed (3x200mL) and dried 
(Na2SO4). The bromobenzodiazepine 27 (36.6g, 80%) was used directly in the next 
experiment. mp 240-242 °C; 1H NMR (DMSO-d6, 300MHz) δ10.54 (br s, 1H), 7.81 (d, 
1 H, J = 2.2 Hz), 7.67 (dd, 1 H, J = 2.4,8.6 Hz), 7.04 (d,l H,J = 8.7 Hz),3.87 (s,2 H),3.09 
(s,3 H); MS (CI) m/z 269 (M + H). 
tert-Butyl-8-bromo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-
a][1,4]benzodiazepine-3-carboxylate (28): The t-BuOK (7.50 g, 66.91 mmol) was 
added to a solution of benzodiazepine 27 (15 g, 55.76 mmol) in anhydrous THF (1500 
mL) at 0 °C and the mixture which resulted was stirred for 20 min. The reaction mixture 
was cooled to –35 °C and diethyl chlorophosphate (10.47 mL, 72.48 mmol) was added 
slowly. After stirring at 0°C for 30 min the mixture was cooled to –78°C and t-butyl 
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isocyanoacetate (8.926 mL, 61.33 mmol) was added, and this was followed by the 
addition of t-BuOK (6.88g, 61.33 mmol) at -78°C. After stirring at rt for 4 h the reaction 
was quenched with a saturated aq NaHCO3 solution (500 mL) and extracted with EtOAc 
(3 × 1000 mL). The combined organic layers were dried (Na2SO4) and concentrated to 
give a solid residue. This solid residue was triturated with Et2O (250 mL) and the ester 
28 precipitated as an off-white solid. The mother liquor was further purified by flash 
chromatography on silica gel (gradient elution 40– 60% EtOAc in hexane) to afford 
additional ester 28 in a combined yield of (15.3g, 70%). mp 180-183 °C; 1H NMR 
(CDCl3, 300MHz) δ 8.33 (s, 1H), 7.90 (s, 1H), 7.62 (d, 1H, J =10.8 Hz), 7.03 (d, 1H, J 
= 8.6 Hz),  4.71 (br, s, 1H), 4.13 (br, s, 1H), 3.10 (s, 3H), 1.56 (s, 9H); MS (EI) m/e 394 
(M+, 100). The spectral data for 28 were identical to the published values.  
tert-Butyl-8-(trimethylsilyl)-acetylene-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-
a][1,4]benzodiazepine3-carboxylate (20): A mixture of imidazobenzodiazepine 28 
(7.5g, 19.12mmol) was dissolved in dry triethyl amine (223mL ) and  acetonitrile 
(149mL; 3:2 ratio). This mixture was degassed under argon three times. To this 
degassed mixture, bis (triphenylphosphine)-palladium (II) acetate (1g, 7 mol %) was 
added. The mixture was again degassed (with vacuum) three times under argon. 
Trimethylsilyl acetylene (5.52mL, 38.24mmol) was added and this reaction mixture was 
heated to reflux for 8h under argon. The reaction mixture was cooled to rt and the 
solvents were concentrated under reduced pressure. This concentrated mixture was 
dissolved in ethyl acetate and passed through a bed of celite. After the  removal of 
solvent under reduced pressure  the residue was purified by flash chromatography (silica 
gel, EtOAc) to afford a yellow solid  of RY-23 (20) (6.5g, 83%). mp 199-200 °C. IR 
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(KBr) 2971, 2156, 1723, 1662, 1500 cm -1 ; 1H NMR (CDCl3, 300MHz) δ 8.13 (s, 1H), 
7.84 (s, 1H), 7.64 (d, 1H, J = 8.2 Hz), 7.32 (d, 1H, J = 8.2 Hz), 5.11 (br, 1H), 4.31 (br, 
1H),  1.63 (s, 9H), 0.25 (s, 9H); MS (EI) m/e 409 (M+, 4), 354 (19), 353 (82), 335 (45), 
307 (100), 279 (23), 251 (16), 143 (13), 160 (21), 107 (14); Anal. Calcd for 
C22H27N3O3Si: C, 64.52; H, 6.64; N, 10.26; Found C, 64.57; H, 6.70; N, 10.46. The 
spectral data for 20 were in excellent agreement with the literature. 85 
tert-Butyl-8-acetylene-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-
a][1,4]benzodiazepine3-carboxylate (21): A solution of 20 (1.2g, 2.93 mmol) in THF 
(360mL) was treated with a solution of TBAF solution (1.0M in THF; 
3.52mL,3.51mmol) at -30°C. The mixture which resulted was allowed to stir for 30 min 
at rt, after which the mixture was added to H2O (50mL) and extracted with EtOAc 
(3x100mL). The combined organic extracts were washed with brine (50mL) and dried 
(Na2SO4). After removal of the solvent under reduced pressure, the residue was purified 
by a wash column (silica gel, EtOAc) to give 21 (RY-24) as a yellow solid (0.89g, 
90%): mp 213-214 °C. 1H NMR (CDCl3, 300MHz) δ 8.16 (s, 1H), 7.85 (s, 1H), 7.69 (d, 
1H, J = 8.3 Hz), 7.35 (d, 1H, J = 8.3 Hz), 5.15 (br, 1H), 4.32 (br, 1H), 3.23 (s, 3H), 3.20 
(s, 1H), 1.63 (s, 9H); MS (EI) m/e 337 (M+, 2), 282(15), 281 (78), 264 (31), 263(56), 
235 (100), 229(22), 207 (36), 138 (16), 101(19); Anal. Calcd for C19H19N3O3: C, 
67.64; H, 5.68; N, 12.45; Found C, 67.50; H, 5.78; N, 12.41. The spectral data for 21 
were in excellent agreement with the reported values.                                                          
8-Ethynyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo [1,5-a][1,4] benzodiazepine-3-
carboxylic acid 32 :  Ethyl-8-ethynyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo [1,5-
a][1,4] benzodiazepine-3-carboxylate 23 (1.5g, 5.3mmol),available from the literature, 
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was dissolved in EtOH (100mL), after which an aq solution of 2N NaOH (15mL) was 
added to the solution. The mixture which resulted was heated to 70°C and allowed to stir 
for 1hr. The mixture was then allowed to cool to rt and the EtOH was removed under 
reduced pressure. Aq 2N HCl was added to the residue to bring the pH to approximately 
3-4. A precipitate formed which was removed by filtration, washed with water 
(3x50mL) and dried. The 3-carboxylic acid 32 was obtained as a white solid in 90% 
yield; mp 315-316 °C. 1H NMR (CD3OD, 300MHz) δ 8.20 (s, 1H), 7.80 (dd, 1H, J 
=2.5Hz, 10 Hz), 7.69 (s, 1H), 5.22 (br, 1H),  4.50 (br, 1H), 3.74 (s, 1H), 3.28 (s, 3H),  ; 
MS (EI) m/e 281 (M+, 80), 277(100), 263 (60), 235 (84), 207(55) Anal. Calcd for 
C15H11N3O3: C, 64.04; H, 3.94; N, 14.95; Found C, 64.40; H, 4.12; N, 14.76. The 
spectral data for 20 were in excellent agreement with the published reports. 160 
1,3-Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-
imidazo[1,5a][1,4]benzodiazepine-3-carboxy) propyl diester 33 (XLi-093) : To a 
solution of carbonyl diimidazole (230.3mg, 0.57mmol) in anhydrous DMF (5mL) was 
added 8-ethyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo [1,5-a][1,4] benzodiazepine-3-
carboxylic acid 24 (200mg, 0.71mmol). The solution which resulted was allowed to stir 
for 2h at rt.  Analysis of the material by TLC (silica gel) indicated the absence of starting 
material. To this solution, 1, 3 propanediol (27.1mg, 0.36mmol) in dry DMF (0.5mL) 
and DBU (114.2mg, 0.75mmol) in dry DMF (0.5mL) were added to the solution at rt. 
The mixture was allowed to stir for 12h until analysis by TLC (silica gel) indicated the 
absence of starting material. The reaction mixture was then poured into ice water 
(30mL) and extracted with EtOAc (3x50mL). The combined organic layers were washed 
with H2O (5x50mL) and dried (Na2SO4). The solvent was removed under reduced 
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pressure and the residue was purified by flash chromatography (silica gel, 
EtOAc/MeOH: 4:1) to provide the dimer 33 ( XLi-093 ; 157mg, 74%) as white solid. 
mp >230 °C (dec);   IR (NaCl) 3247, 1725, 1641, 1359, 1253, 1061 cm-1; 1H NMR 
(CD3OD, 300MHz) δ 8.20 (d, 2H, J=1.76Hz), 7.89 (s, 2H), 7.72 (dd, 2H, J =6.43Hz, 
1.86 Hz), 7.41 (d, 2H, J=8.3Hz), 5.31 (br, 2H), 4.57 (t, 4H, J=6.2Hz), 4.40 (s, 2H),  3.26 
(s, 6H), 3.24 (s, 2H), 2.37 (m, 2H); 13C NMR (CD3OD, 300MHz) δ 26.2, 34.4, 40.7, 
60.2, 78.7, 79.7, 120.4, 121.6, 127.1, 127.7, 130.1, 133.4, 134.1, 134.9, 161.3, 164.1; 
MS (FAB) m/e 603 (M+ +1, 100) Anal. Calcd for C33H26N6O6.2/3 CH3OH: C, 64.81; 
H, 4.63; N, 13.47; Found C, 64.56; H, 4.72; N, 13.76. The spectral data for XLi-093 
were identical to the published values. 160 
1,3-Bis(8-ethyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4] benzodiazepine-
3-carboxy) propyl diester 34: Bis (8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-
imidazo[1,5a][1,4]-benzodiazepine-3-carboxy) propyl diester 33 (500mg, 0.83mmol) 
was dissolved in EtOH (150mL) and degassed 3-4 times with a balloon of hydrogen 
after which Pd/C (176mg) was added to the solution at rt. The slurry was allowed to stir 
for 12h under H2. The catalyst was removed by filtration and washed with EtOH. The 
EtOH was removed under reduced pressure to furnish a residue. This material was 
purified by flash chromatography (silica gel, EtOAc:MeOH,  9:1) to provide (34)XLi-
356  (504mg, 99%) as white crystals: mp 125-133°C; IR (NaCl) 3407, 2964, 2358, 
1725, 1640, 1499 cm-1; 1H NMR (CDCl3, 300MHz) δ 8.15 (s, 1H), 7.89 (t, 4H, 
J=3.2Hz, 5.3Hz), 7.48 (d, 2H, J=1.8Hz), 7.33 (d, 2H, J=8.2Hz), 5.16 (br, 2H), 4.56 (t, 
4H, J=6.1, 12.2 Hz), 4.48 (br, 2H), 3.26 (s, 6H), 2.78 (dd, 4H, J=7.5, 15.1Hz), 2.39 (m, 
2H), 1.29 (m, 6H) ; MS (EI) m/e (relative intensity) 611 (M++1, 100); Anal Calcd for 
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C33H34N6O6.2H2O: C, 61.33; H, 5.92; N, 13.00. Found: C, 61.74; H, 5.91; N, 12.63. 
The spectral data of XLi-356 were identical to the published values. 160 
1,5-Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-
imidazo[1,5a][1,4]benzodiazepine-3-carboxy) pentyl diester 35: To a solution of 
carbonyl diimidazole (173mg, 1.06mmol) in anhydrous DMF (5mL) was added 8-ethyl-
5,6-dihydro-5-methyl-6-oxo-4H-imidazo [1,5-a][1,4] benzodiazepine-3-carboxylic acid 
32 (150mg, 0.534mmol). The solution which resulted was stirred for 2h at rt. Analysis of 
the mixture by TLC (silica gel) indicated the absence of starting material. To this 
solution, 1,5 pentanediol (27.8mg, 0.267mmol) in dry DMF (0.5mL) and DBU 
(114.2mg, 0.75mmol) in dry DMF (0.5mL) were added at rt. The mixture was allowed 
to stir for 12h until analysis by TLC (silica gel) indicated absence of starting material. 
The reaction mixture was then poured into ice water (30mL) and extracted with EtOAc 
(3x50mL). The combined organic layers were washed with H2O (5x50mL) and dried 
(Na2SO4). The solvent was removed under reduced pressure and the residue was purified 
by flash chromatography (silica gel, EtOAc/MeOH: 4:1) to provide the dimer 35 XLi-
210  (123mg, 89.2%) as a white solid. mp 132-138 °C ;   IR (NaCl) 3422, 3280, 2931, 
1714, 1635, 1487, 1249, 1064 cm-1; 1H NMR (CD3OD, 300MHz) δ 8.18 (s, 2H), 7.86 
(s, 2H), 7.70 (m, 2H), 7.36 (dd, 2H, J=8.1, 16Hz),  5.29 (s, 2H), 4.39 (s, 8H), 3.52 (s, 
2H), 3.24 (s, 6H), 1.90 (m, 4H); MS (FAB) m/e 631 (M+ +1, 100) Anal. Calcd for 
C35H30N6O6.5/3 H2O: C, 63.61; H, 4.83; N, 12.72; Found C, 63.16; H, 4.72; N, 13.06. 
 
Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine-
3-carboxy) diethylene glycol diester 36 (XLi-347). To a solution of carbonyl 
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diimidazole (243 mg, 1.50 mmol) in anhydrous DMF (8 mL) was added 8-ethynyl-5, 6-
dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine-3-carboxylic acid 32 
(351.4 mg, 1.25 mmol). This solution was stirred for 2 h at rt until analysis by TLC 
(silica gel) indicated the absence of starting material. To the solution which resulted was 
then added diethylene glycol (66.3 mg, 0.62 mmol) in dry DMF (0.5 mL) and also DBU 
(190 mg, 1.25 mmol) in dry DMF (0.10 mL) at rt. The mixture was stirred at rt for 8 h 
until analysis by TLC (silica gel) indicated the reaction was complete. The reaction 
mixture was then poured into ice water (30 mL) and extracted with CH2Cl2 (3 x 50 mL). 
The combined organic layer was washed with H2O (5 x 50 mL), brine and dried 
(Na2SO4). The solvent was removed under reduced pressure and the residue was purified 
by flash chromatography (silica gel, EtOAc/CH3OH, 4 : 1) to provide 36 (150 mg) as a 
white solid in 60% yield. 28: mp 118-121°C (dec.); IR (NaCl) 3247, 2880, 1725, 1639, 
1496, 1253, cm-1; 
1
H NMR (500 MHz, CDCl3) δ  8.19 (d, 2H, J=1.76Hz),  7.90(s, 2H), 
7.72(dd, 2H, J=1.8 Hz and J=8.3 Hz) , 7.39 (d, 2H, J=6.1 Hz), 5.20(br, 2H), 4.37(br, 
2H), 3.67 (t, 4H, J=5.1Hz), 3.23(s,6H), 3.21(s, 2H); 13C NMR (53.4 MHz, CD2Cl2) δ 
35.4, 42.3, 63.5, 68.9, 79.6, 81.3, 122.2, 122.4, 128.4, 129.4, 131.9, 135.1, 135.7, 135.8, 
136.0, 162.5, 165.2; MS (FAB,NBA) m/e (relative intensity) 633(M++1, 11). Anal. 
Calcd for C34H28N6O7 •1/3 C2H5OH: C, 61.38; H, 4.45; N, 12.39. Found: C, 60.99; H, 
4.62; N, 12.16.  
Dibromodimethyl ether 38111. Bromine (120 g) was added slowly via an addition 
funnel to a capped three-neck flask containing water (22.4 ml) in equal portion intervals 
over a 2 h period. Paraformaldehyde (120 g) and red phosphorus (27.2 g) were added to 
the bromine/water solution at a comparable rate in equal portions after each bromine 
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addition. The reaction vessel and vials containing the starting material were kept capped 
and only opened briefly to allow sample removal and addition.  The reaction mixture 
was ice water-cooled during the addition period of the process.  After completing the 
addition of all the starting material the final reaction mixture was set aside for 20 h. The 
heavy crude ether layer, dibromodimethyl ether, was separated, saturated with hydrogen 
bromide, and dried with phosphorus pentaoxide (P2O5) for 24 h.  Simple distillation at 
atmospheric pressure afforded the colorless dibromo-dimethyl ether 38 as a fraction with 
b. p. = 146-159 oC. The data for 38 were identical to the literature values.112  
Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine-
3-carboxy) dimethyl glycol diester 39 (XLi374). 8-Ethynyl-5, 6-dihydro-5-methyl-6-
oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine-3-carboxylic acid 32 (100 mg, 0.356 mmol) 
was dissolved in DMF (10 mL) and to this solution dibromodimethyl ether (36.3 mg, 
0.178 mmol) was added, followed by TEA(2.0 mL). After 26 h of stirring at ambient 
temperature the solvent was removed under reduced pressure and the residue was 
distributed between CHCl3 and water. The organic phase was washed multiple times 
with water and dried over Na2SO4. The dried crude ether was applied on a column of 
silica gel to afford dimer 39 (86 mg) in 80% yield. 39: mp >220 °C (dec.); IR (KBr) 
3419, 3237, 2910, 1714, 1635, 1561, 1498 cm-1; 
1
H NMR (500 MHz, CD2Cl2) δ 8.15 (s, 
2H), 7.90 (s, 2H), 7.74(dd, 2H, J=1.6Hz , J=8.2Hz), 7.40(d, 2H, J=8.1 Hz), 5.74 (s, 
4H), 5.29(br, 2H),  4.37 (br, 2H), 3.31(s,2H), 3.18(s, 6H); MS(FAB,NBA) m/e (relative 
intensity) 605(M++1, 100). Anal. Calcd for C32H24N6O7 •3/2 CH3COOC2H5: C, 61.99; 
H, 4.93; N, 11.41. Found: C, 61.36; H, 4.52; N, 11.96. 
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8-Chloro-5-methyl-6-Oxo-5,6-dihydro-4H-benzo-[f]-imidazo-[1,5-a]-[1,4]-
dizaepine-3-carboxylic acid (41). The ester 40  (2 g, 6 mmol) was dissolved in EtOH 
(150 mL) to form a solution and then 10% aq sodium hydroxide solution (40 mL) was 
added to the mixture. The mixture was heated to reflux for 0.5 h and the EtOH was 
removed under reduced pressure, after which the solution was allowed to cool. The pH 
was then adjusted to 4 by adding 10% aq HCl dropwise. The solid which precipitated 
was filtered and the solid acid was washed with water and ether. The solid was dried to 
provide acid 41: mp >260oC; IR (neat) 3100, 2424, 1661, 1642, 1562 cm-1; 1H NMR 
(300 MHz, DMSO) δ 8.35 (s, 1H), 7.77-7.88 (m, 3H), 5.28 (br s, 1H), 4.55 (br s, 1H), 
3.09 (s, 3H); MS (EI) m/e (relative intensity) 291 (M+, 44), 273 (61), 245 (100), 230 
(47), 217 (62), 75 (37). Anal. Calcd. for C13H10ClN3O3• 0.3CH2Cl2: C, 50.57; H, 3.37; 
N, 13.32. Found: C, 50.64; H, 3.25; N, 13.12. This material was used directly in a later 
step. 
Bis(8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine-3-
carboxy) diethylene glycol diester 42(SR-II-35). To a solution of carbonyl diimidazole 
(0.197g, 1.22 mmol) in anhydrous DMF (8 mL) was added 8-ethynyl-5,6-dihydro-5-
methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine-3-carboxylic acid 41 (0.297g, 
1.01 mmol). The solution which resulted was stirred for 2 h at rt until analysis by TLC 
(silica gel) indicated the absence of starting material. To the solution which resulted was 
then added diethylene glycol (48 mg, 0.46 mmol) in dry DMF (0.5 mL) and also DBU 
(186mg, 1.22 mmol) in dry DMF (0.10 mL) at rt. The mixture was stirred at rt for 8 h 
until analysis by TLC (silica gel) indicated the reaction was complete. The reaction 
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mixture was then poured into ice water (30 mL) and extracted with CH2Cl2 (3 x 50 mL). 
The combined organic layer was washed with H2O (5 x 50 mL), brine and dried 
(Na2SO4). The solvent was removed under reduced pressure and the residue was purified 
by flash chromatography (silica gel, EtOAc/CH3OH, 4: 1) to provide 41 (177 mg) as a 
white solid in 60% yield. 41: 
1
H NMR (300 MHz, CDCl3) δ   8.03 (d, 2H, J=2.4Hz),  
7.83(s, 2H), 7.72(dd, 2H, J=3.3 Hz and J=9.3 Hz) , 7.40 (s,1H), 7.35(s, 1H),  5.18 (br, 
2H), 4.55 (s,4H), 4.36 (br, 2H), 3.93 (t, 4H, J=4.8 Hz), 3.26 (s,6H); MS (EI) m/e 652 
(M+). 
7-Chloro-4-methyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (45): A mixture 
of 5-chloroisatoic anhydride 44 (20g, 101 mmol) and sarcosine (9.02g, 101 mmol) in 
DMSO (160mL) was heated at 150°C for 5 hr, after which it was cooled to rt and poured 
into ice water (750mL) to furnish a light brown solid. This solid was collected by 
filtration, washed with water (3x200mL) and dried (Na2SO4). The benzodiazepine 45 
was obtained as a light brown solid (19g, 84%).  This material was used directly in the 
next experiment. 
Ethyl-8-chloro-5, 6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-][1,4]benzodiazepine3-
carboxylate (40): t-BuOK (8.99 g, 80.14 mmol) was added to a solution of amide 45 
(15 g, 66.77 mmol) in anhydrous THF (1500 mL) at 0 °C and the solution allowed to stir 
for 20 min. The reaction mixture which resulted was cooled to –35 °C and diethyl 
chlorophosphate (12.48 mL, 86.80 mmol) was added slowly. After stirring at 0 °C for 30 
min, the mixture was cooled to –78 °C and ethyl isocyanoacetate (8.027 mL, 73.44 
mmol) was added and this was followed by the addition of t-BuOK (8.24g, 73.44 
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mmol). After stirring at rt for 4 h, the reaction mixture was quenched with a saturated aq 
solution of NaHCO3 (500 mL) and extracted with EtOAc (3 × 1000 mL). The combined 
organic layers were dried (Na2SO4) and concentrated to give a solid residue. This solid 
residue was treated with Et2O (250 mL) and the ester 40 was precipitated as an off-white 
solid. The mother liquor was further purified by flash chromatography on silica gel 
(gradient elution,  40– 60%,  EtOAc in hexane) to afford additional ester 40 with an 
overall yield of (19g, 89%). mp 192-193 °C; 1H NMR (CDCl3, 300MHz) δ 8.1 (d, 1H, J 
= 2.4 Hz), 7.90 (s, 1H), 7.62 (dd, 1H, J = 8.7, 2.5 Hz), 7.40 (d, 1H, J = 8.6 Hz), 5.23 
(br, s, 1H), 4.46 (q, 2H, J=7.12Hz), 4.13 (br, s, 1H), 3.27 (s, 3H), 1.47 (t, 3H, J=7.12Hz); 
MS (EI) m/e 319 (M+, 100). The data for this material were identical to the published 
values.161  
8-Chloro-5, 6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-α][1,4]benzodiazepine-3-
methyl alcohol (46). A solution of imidazobenzodiazepine 40 (5 g, 15.6 mmol) in a 
mixture of ethyl ether (50 mL), and THF (50 mL) was stirred with LiBH4 (2.0 M in 
THF, 9 mL, 18 mmol). The mixture which resulted was then heated to reflux for 30 min, 
after which it was cooled to rt  and treated with a saturated aq solution of NaHCO3 (5 
mL). The solvent was concentrated and the residue was taken up in EtOAc (100 mL). 
The organic layer was washed with water (2 × 20 mL), brine (20 mL) and dried 
(MgSO4). After removal of the solvent under reduced pressure the residue was purified 
by flash chromatography (silica gel, EtOAc) to afford alcohol 46 as colorless crystals 
(2.9 g, 67%): mp 252-253 °C; IR (KBr) 3500 (br, OH), 3100, 1667, 1612, 823 cm-1; 1H 
NMR (CDCl3, 300MHz) δ 8.00 (d, 1H, J = 2.4 Hz), 7.80 (s, 1H), 7.55 (dd, 1H, J = 8.7, 
2.4 Hz), 7.30 (d, 1H, J = 8.6 Hz), 4.70 (d, 2H, J = 4.2 Hz), 4.40 (s, 2H), 3.20 (s, 3H); 
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MS (EI) m/e 279 (M+, 41), 277 (M+, 100), 259 (84), 246 (55), 231(41). The data for this 
material were identical to the published values.19 
Methyl(8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-α][1,4] 
benzodiazepin-3-yl)methyl ether (47). To a slurry of KOH (2.41g, 44 mmol) in DMSO 
(56 mL) at rt were added alcohol 46 (3g, 11 mmol) and excess CH3I. The mixture which 
resulted was stirred for 5-10 min and then poured into ice water (100 mL) after which it 
was extracted with EtOAc (3 × 100 mL). The combined organic extracts were washed 
with brine (50mL) and dried (MgSO4). After removal of solvent under reduced pressure, 
the residue was purified by a wash column on silica gel (EtOAc) to give ether 47 (PWZ-
029) as an off-white powder (2.83g, 90%): mp 193-194 °C; IR (KBr) 3122, 2973, 1632, 
1611, 811 cm-1; 1H NMR (CDCl3, 300MHz) δ 8.00 (d, 1H, J = 2.4 Hz), 7.80 (s, 1H), 
7.55 (dd, 1H, J = 8.7, 2.5 Hz), 7.30 (d, 1H, J = 8.6 Hz), 4.55 (br, 2H), 4.38 (s, 2H), 3.42 
(s, 3H), 3.18 (s, 3H). The data for this material were identical to the published values.  
Ethyl (8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-α][1,4] benzodiazepin-
3-yl)methyl ether (48). To slurry of KOH (2.41g, 44 mmol) in DMSO (56 mL) at rt 
were added alcohol 46 (3g, 11 mmol) and excess C2H5I. The mixture which resulted was 
allowed to stir for 5-10 min, poured into ice water (100 mL), and extracted with EtOAc 
(3 × 100 mL). The combined organic extracts were washed with brine (50mL) and dried 
(MgSO4). After removal of the solvent under reduced pressure the residue was purified 
by a wash column on silica gel (EtOAc) to give ether 48 (SR-III-81) as an off-white 
powder (2.98g, 90%): mp 137-138 °C; IR (KBr) 31282, 2973, 1634, 1601, 810 cm-1; 1H 
NMR (CDCl3, 300MHz) δ 7.92 (d, 1H, J=2.4Hz), 7.86 (s, 1H), 7.50 (dd, 1H, J=8.5, 2.4 
Hz), 7.30 (d, 1H, J=8.6Hz), 4.55 (s, 2H), 3.60 (q, 2H, J=7.0Hz), 3.12 (s, 3H), 1.22 (t, 
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3H, J=7.0Hz). Anal. Calcd. For C15H16ClN3O2. 0.0235 H2O, C 58.84, H 5.28, N 
13.72. Found 58.94, H 5.40, N 13.32 
8-Chloro-N,5-dimethyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo-[1,5-
a][1,4]diazepine-3-carboxamide( 57): The ester 40 (100mg, 0.313 mmol) was 
dissolved in anhydrous CH2Cl2 (5mL). To this mixture, a solution of CH3NH2 
(0.147mL, 1.56 mmol) was added. This reaction mixture (in a sealed tube) was placed in 
a preheated oil bath at 45°C overnight. The solvent was then removed under reduced 
pressure and the residue was purified by flash chromatography with CH2Cl2/MeOH 
(4.5:0.5) to provide 3-N-methyl amide 57 (74mg, 78% yield).  1H NMR (CDCl3, 
300MHz) δ 8.1 (d, 1H, J = 2.4Hz), 7.90 (s, 1H), 7.62 (dd, 1H, J = 8.6, 2.5 Hz), 7.40 (d, 
1H, J = 8.6Hz), 5.23 (br, 1H), 5.23 (br, 1H), 3.28 (s, 3H), 3.02 (d, 3H, J=3.9Hz) ; MS 
(EI) m/e 304 (M+, 100). Anal. Calcd. For C14H13ClN4O2 . 0.28 H2O, C 54.25, H 4.41, 
N 18.07. Found 54.39, H 4.52, N 17.69 
8-Chloro-3-(fluoromethyl)-5-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-6(5H)-
one (58) : The alcohol 46 (100mg, 0.360mmol) was dissolved in anhydrous CH2Cl2 (5 
mL). At 0oC, DAST (diethylaminosulfur trifluoride, 0.07mL, 0.720mmol) 162 was added 
very slowly and the reaction was allowed to stir for 2h. The reaction mixture was then 
quenched with aq solution of NaHCO3 and allowed to stir for 1h at 0oC and then 
extracted with CH2Cl2.  The combined organic layers were washed with brine and dried 
(MgSO4). After removal of the solvent under reduced pressure the residue was purified 
by a wash column on silica gel (gradient elution 4:1 EtOAc: hexane) to afford the fluoro 
analog 58 (SR-III-38; 0.070mg, 70%). 1H NMR (CDCl3, 300MHz) δ 8.05 (dd, 1H, 
J=2.3Hz, 1.4Hz), 7.89  (d, 1H, J=1.4Hz), 7.62 (m, 1H), 7.37 (dd, 1H, J = 8.4, 1.2 Hz), 
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5.57 ( s, 1H), 5.41 (s, 1H), 4.40 (br, 2H ), 3.25 (d, 3H, J=1.3Hz); 19F NMR (CDCl3, 
282MHz) δ  -205.21 (t, 1F, J=52Hz);  MS (EI) m/e 279 (M+, 100). Anal. Calcd. For 
C13H11ClFN3O.0.13 (C2H5)2O, C 56.11, H 4.28, N 14.54. Found 55.86, H 3.97, N 14.17 
8-Chloro-3-(difluoromethyl)-5-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-
6(5H)-one 49: The alcohol 46 (1g, 3.6mmol) was dissolved in dry CH2Cl2 (100mL) and  
Dess-Martin periodinane163 (2.29g, 5.41mmol) was added in one portion at 0oC. This 
solution which resulted was stirred at rt for 2 h.  The reaction mixture which resulted 
was then quenched with a saturated aq solution of Na2S2O3, washed with NaHCO3 and 
extracted with CH2Cl2. The combined organic layers were washed with brine and dried 
(MgSO4). After removal of the solvent under reduced pressure, the residue was purified 
by a wash column on silica gel (gradient elution 1:9 EtOAc: hexane )  to afford the 
aldehyde 59 (0.953g, 96%). 1H NMR (CDCl3, 300MHz) δ 10.35 (s, 1H), 8.09  (d, 1H 
,J=2.43Hz), 7.94 s, 1H), 7.64 (dd, 1H, J=8.55, 2.41Hz), 7.41 (d, 1H, J=8.6Hz), 5.23 (br, 
s, 1H), 4.6 (br, s, 1H), 3.25 (s, 3H); HRMS (ESI) calculated for C13H11ClN3O2 : 
276.0540; found : 276.0536  The aldehyde 59 (100mg, 0.363mmol) was dissolved in 
anhydrous CH2Cl2 (5 mL). At 0oC DAST (diethylaminosulfur trifluoride, 0.07mL, 
0.725mmol) was added very slowly and the reaction was allowed to stir for 2h at 0oC. 
The reaction mixture was then quenched with an aq solution of NaHCO3 and allowed to 
stir for 1hr and extracted (CH2Cl2).  The combined organic layers were washed with 
brine and dried (MgSO4). After removal of the solvent under reduced pressure, the 
residue was purified by a wash column on silica gel (gradient elution 4:1 EtOAc: 
hexane) to afford the difluoro analog 49 (0.070mg, 65%).   1H NMR (CDCl3, 300MHz) δ 
8.05 (dd, 1H, J=2.4Hz), 7.88  (s, 1H), 7.62 (dd, 1H, J = 8.6 Hz, 2.4 Hz), 7.37 (d, 1H, J = 
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8.5Hz), 6.83 (t, 1H, J=55Hz), 4.55 (d, 1H, J= 14Hz), 4.45 (d, 1H, J=14Hz), 3.2 (s, 3H); 
13C NMR (CDCl3, 300MHz) δ 35.41, 42.01, 112.52 (t, J = 234Hz), 123.2, 128.11, 
130.38 (d, J=31.8Hz), 132.43, 132.67, 134.50, 134.80, 165.14; 19F NMR (CDCl3, 
282MHz) δ  -111.76 (dd, J(F-F)=309Hz, J(H-F) =55Hz), -109.78 (dd, J(F-F)=309Hz, J(H-F) 
=55Hz); HRMS (ESI) Calculated for C13H11ClF2N3O : 298.0559; found: 298.0561. 
8-Chloro-3-(difluoromethyl)-5-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-
6(5H)-one 60: The acid 41 (300mg, 1.02 mmol) was dissolved in dry CH2Cl2 (5mL) and 
at 0oC,  excess SOCl2  was added in one portion. The reaction mixture was heated to 
reflux for 2h until analysis of the mixture by TLC indicated the absence of starting 
material. The reaction mixture was concentrated under reduced pressure on a rotavapor a 
few times with CH2Cl2 to remove the excess SOCl2 and dried under vacuum. The solid 
which resulted was stirred in dry THF at -60oC. In a separate flask, bis[2-(N,N-
dimethylamino)ethyl] ether37 (0.239mL, 1.25mmol) was stirred in dry THF (5mL) and at 
0oC, EtMgBr (0.419mL, 1.25mmol) was slowly added over 15min. After stirring the 
reaction mixture for 5min, the mixture which resulted was quenched with an aq solution 
of NH4Cl and extracted with EtOAc (3x10mL). The combined organic layers were 
washed with brine and dried (MgSO4). After removal of the solvent under reduced 
pressure the residue was purified by a wash column on silica gel (gradient elution 4:1 
EtOAc: hexane) to afford the ketone 60 (0.167g, 53 %).   HRMS (ESI) Calculated for 
C15H14ClN3O2 : 304.0853; found:304.0861. The ketone 60 (100mg, 0.360mmol) was 
dissolved in anhydrous CH2Cl2 (5 mL). At 0oC, DAST (diethylaminosulfur trifluoride, 
0.07mL, 0.720mmol) 162  was added very slowly and the reaction was allowed to stir for 
2h. No product formation was observed. Addition of excess DAST (diethylaminosulfur 
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trifluoride) did not work either. When various fluorinating agents such as Xtal-fluor or 
Deoxo-fluor were employed they did not yield the product. Excess addition of these 
fluorinating agents also was futile. 
9. Computer Modeling 
The core structures of the ligands were taken from available X-ray crystallographic 
coordinates or generated using the SYBYL fragment library.164 The structures which 
resulted were energy minimized using MM2 (molecular mechanics program 2) or 
MMFF (Merck molecular force field), and the subsequent Monte Carlo conformational 
searches were carried out on MacroModel 6.0 on a Silicon Graphics Personal Iris 4D/35 
workstation or a Silicon Graphics Octane SI 2P 175 R10000 workstation, respectively. 
The low energy conformations were then fully optimized via molecular orbital 
calculations at the 3-21G basis set with torsional angles fixed. The structures which 
resulted were further calibrated with 6-31G* single point calculations at an 
“SCF=TIGHT” convergence criteria via Gaussian 92165 on a Silicon Graphics Indigo 
R4400 workstation, or Gaussian 94166 on a Silicon Graphics Octane SI2P175R10000 
workstation.43 
9.1. Competition Binding Assays (With Dr. Majumder and Dr. Roth) 
Competition binding assays were performed in a total volume of 0.5 mL at 4 °C for 1 h 
using [3H] flunitrazepam as the radiolabel. A total of 6 µg of cloned human GABAA 
receptor DNA containing the desired α subtype along with the β2 and γ2 subunits were 
used for transfecting the HEK 293T cell line using Fugene 6 (Roche Diagnostic) 
transfecting reagent. Cells were harvested 48 h after transfection, washed with Tris-HCl 
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buffer (pH 7.0) and Tris Acetate buffer (pH 7.4) and the resulting pellets were stored at -
80 °C until assayed. On the day of the assay, pellets containing 20-50 µg of GABAA 
receptor protein were resuspended in (50 mM Tris-acetate pH 7.4 at 4 °C) and incubated 
with the radiolabel as previously described.167 Nonspecific binding was defined as 
radioactivity bound in the presence of 100 μM diazepam and represented less than 20% 
of total binding. Membranes were harvested with a Brandel cell harvester followed by 
three ice-cold washes onto polyethyleneimine-pretreated (0.3%) Whatman GF/C filters. 
Filters were dried overnight and then soaked in Ecoscint A liquid scintillation cocktail 
(National Diagnostics; Atlanta, GA). Bound radioactivity was quantified by liquid 
scintillation counting. Membrane protein concentrations were determined using an assay 
kit from Bio-Rad (Hercules, CA) with bovine serum albumin as the standard. 
10. Experimental procedures for the electrophysiology using the two-
electrode voltage clamp (with Dr. R. Furtmüller and Dr. W. 
Sieghart)168-171 
Ligand effects on GABAA receptors were tested by two-electrode voltage clamp 
experiments in cRNA injected Xenopus oocytes that functionally expressed several 
subtype combinations of GABAA receptors.168 
10.1.1 Preparation of cloned mRNA  
Cloning of GABAA receptor subunits α1, β3 and γ2 into pCDM8 expression vectors 
(Invitrogen, CA) has been described elsewhere.172 GABAA receptor subunit α4 was 
cloned in an analogous way. cDNAs for subunits α2, α3 and α5 were gifts from P. 
Malherbe and were subcloned into a pCI-vector. cDNA for subunit α6 was a gift from P. 
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Seeburg and was subcloned into the vector pGEM-3Z (Promega). After linearizing the 
cDNA vectors with appropriate restriction endonucleases, capped transcripts were 
produced using the mMessage mMachine T7 transcription kit (Ambion, TX). The 
capped transcripts were polyadenylated using yeast poly(A) polymerase (USB, OH) and 
were diluted and stored in diethylpyrocarbonate-treated water at –70 °C. 
10.1.2 Functional expression of GABAA receptors 
The methods used for isolating, culturing, injecting and defolliculating of the oocytes 
were identical to those as described previously.109,168,173 Briefly, mature female Xenopus 
laevis (Nasco, WI) were anaesthetized in a bath of ice-cold 0.17 % Tricain (Ethyl-m-
aminobenzoate, Sigma, MO) before decapitation and removal of the frog ovary. Stage 5 
to 6 oocytes with the follicle cell layer around them were singled out of the ovary using 
a platinum wire loop. Oocytes were stored and incubated at 18 °C in modified Barths 
medium (MB, containing 88 mM NaCl, 10 mM HEPES-NaOH (pH 7.4), 2.4 mM 
NaHCO3, 1 mM KCl, 0.82 mM MgSO4, 0.41 mM CaCl2, 0.34 mM Ca(NO3)2) that was 
supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin. Oocytes with 
follicle cell layers still around them were injected with a total of 2.25 ng of cRNA. This 
solution contained the transcripts for the different α subunits and the β 3 subunit at a 
concentration of 0.0065 ng/nL as well as the transcript for the γ2 subunit at 0.032 ng/nL. 
After injection of the cRNA, oocytes were incubated for at least 36 h before the 
enveloping follicle cell layers were removed. To this end, oocytes were incubated for 20 
min at 37 °C in MB that contained 1 mg/mL collagenase type IA and 0.1 mg/mL trypsin 
inhibitor I-S (both Sigma). This was followed by osmotic shrinkage of the oocytes in 
doubly concentrated MB medium supplied with 4 mM Na-EGTA. Finally, the oocytes 
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were transferred to a culture dish containing MB and were gently pushed away from the 
follicle cell layer which stuck to the surface of the dish. After removal of the follicle cell 
layer, oocytes were allowed to recover for at least 4 h before being used in 
electrophysiological experiments.  
10.1.3. Electrophysiological experiments171,174 
For electrophysiological recordings, oocytes were placed on a nylon-grid in a bath of 
Xenopus Ringer solution (XR, containing 90 mM NaCl, 5 mM HEPES NaOH (pH 7.4), 
1 mM MgCl2, 1 mM KCl and 1 mM CaCl2). The oocytes were constantly washed by a 
flow of 6 mL/min XR which could be switched to XR containing GABA and/or drugs. 
Drugs were diluted into XR from DMSO solutions resulting in a final concentration of 
0.1 % DMSO perfusing the oocytes. Drugs were preapplied for 30 sec before the 
addition of GABA, which was coapplied with the drugs until a peak response was 
observed. Between the two applications, oocytes were washed in XR for up to 15 min to 
ensure full recovery from desensitization. For current measurements the oocytes were 
impaled with two microelectrodes (2–3 mΩ) which were filled with 2 mM KCl. All 
recordings were performed at rt at a holding potential of –60 mV using a Warner OC-
725C two-electrode voltage clamp (Warner Instruments, Hamden, CT). Data were 
digitized, recorded and measured using a Digidata 1322A data acquisition system (Axon 
Instruments, Union City, CA). Results of concentration response experiments were fitted 
using GraphPad Prism 3.00 (GraphPad Software, San Diego, CA). The equation used for 
fitting the concentration response curves was Y=Bottom + (Top-
Bottom)/(1+10^((LogEC50-X)*HillSlope)); X represents the logarithm of concentration, 
Y represents the response; Y starts at Bottom and goes to Top with a sigmoid shape.  
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10.2. Anticonvulsant screen (with Dr. James Stables)174 
The standard models incorporated into anticonvulsant screening include the maximal 
electroshock test (MES), the subcutaneous Metrazol test (scMET), and evaluations of 
toxicity (TOX)-which is sedation in this study. The data for each condition is presented 
as a ratio of either the number of animals protected or toxicity (loss of locomotor 
activity) over the number of animals tested at a given time point and dose. Experiments 
were performed in male rodents (albino Carworth Farms No. 1 mice (intraperitoneal 
route, ip) and albino Sprague-Dawley rats (oral route and ip). The mice weighed 
between 18 and 25 g, while rats were between 100 and 150 g. All animals had free 
access to food and water except during the actual testing period. Housing, handling, and 
feeding were all in accordance with recommendations contained in the “Guide for the 
Care and Use of Laboratory Animals”. All of the test ligands were administrated in 
suspensions of 0.5% (w/v) of methyl cellulose in water. The volumes administered were 
0.01 mL/g of body weight for mice and 0.04 mL/10 g for rats. Anticonvulsant activity 
was established using the maximal electroshock seizure (MES) and subcutaneous 
metrazole seizure threshold (scMET) tests.175,176  
10.3. In Vivo Experiments (with S. Lelas)88 
 
10.3.1. Subjects 
 All animals were maintained in accordance with the guidelines of the Committee on 
Animals of the Bristol-Myers Squibb Company and the “Guide for Care and Use of 
Laboratory Animals” (Institute of Animal Laboratory Resources, 1996).  Research 
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protocols were approved by the Bristol-Myers Squibb Company Institutional Animal 
Care and Use Committee. 
Male CDF rats weighing approximately 350 g at the time of the experiment (conflict), 
male Sprague-Dawley rats weighing 180-300 g (locomotor activity, rotorod studies, and 
drug discrimination studies) and male CF1 mice weighing 20-22 g at the time of the 
experiment (seizure studies) were purchased from Charles River Laboratories 
(Wilmington, Mass., USA).  For the conditioned fear studies, male Sprague-Dawley rats 
weighing approximately 225 g at the time of the experiment were purchased from 
Harlan (Indianapolis, Ind., USA).  Animals were housed in pairs or fours in clear plastic 
shoebox cages with Beta Chip bedding in rooms maintained at constant temperature (21-
23°C) and humidity (50 ± 10%) with a 12 h light/dark cycle (lights on at 0600 h, except 
for mice lights were on at 0500 h), except for the drug discrimination study for which 
animals were housed individually in suspended wire cages. 
Animals had ad libitum access to food and water throughout the studies, except for the 
conflict and drug discrimination studies in which animals were restricted to 9 g 
(conflict) or 12 g (drug discrimination) of laboratory rodent chow (Bio-Serv, 
Frenchtown, NJ) per day in addition to the food earned in operant box, with unlimited 
access to water.  All training and testing was done between 0600 and 1300 h Monday 
through Friday of each week. 
10.3.2. Procedures 
10.3.2.1. GABAA Binding Assay 
HEK293 cells were trypsinized and counted.  Cells were transfected using the Amaxa 
electroporator and 3 million cells per sample.  Each transfection was performed in 
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Amaxa solution “V” using electroporation program Q-01 (Amaxa Inc., Gaithersburg, 
Md., USA).  1 µg of each GABA subunit (α, β, and γ) was used per transfection.  
Following electroporation, cells were plated onto poly-lysin coated glass coverslips and 
used for the experiments. 
10.3.2.2. Electrophysiological Studies 
Whole-cell patch-clamp experiments were performed using HEK cell lines transiently 
expressing two different configurations of GABAA constructs, on the first or second day 
after the transfection.  Cells were plated onto 25 mm Petri dishes and viewed using 
Nikon TE200 inverted microscope, equipped with the mercury lamp to monitor GFP 
fluorescence.  Cells were continuously perfused with extracellular physiological solution 
containing (in mM): NaCl 140, KCl 2.5, CaCl2 2, MgSO4 2, Na2HPO4 1.25, HEPES 10, 
Glucose 11, pH 7.4 and 340 mOsm (modified from Brown et al., 2002).  Patch pipettes 
were pulled using Narishige vertical puller from fire-polished borosillicate glass 
capillaries.  Pipette resistance was between 3.5 and 6 MOm.  The intracellular solution 
contained (in mM): CsCl 140, HEPES 10, EGTA 5, MgATP 2, MgCl2 3, pH 7.3 and 340 
mOsm. 
Cells were voltage-clamped at -20 mV via an EPC10 amplifier (HEKA Electronics, 
Southboro, Mass.).  Preliminary experiments have shown that amplitude of the GABA-
induced current in these cells was not significantly different at -60, -40 or -20 mV 
holding potentials.  At the same time, -20 mV holding potential facilitated longer 
experimental time which enabled testing of several concentrations of the test 
compounds.  Drug solutions were applied to the cells via a multi-channel local perfusion 
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system (AutoMate Scientific, Inc., San Francisco, Calif.) with the estimated solution 
change time of 20 ms. 
GABA was applied to the cell for 20 s with a 60 s washout period between applications, 
which was found to be a sufficient time period to reverse any desensitization that may 
occur.  In addition, to ensure that there is no desensitization that may affect GABA 
responses at any given concentration of a GABA modulator, GABA was applied twice 
during control (no drug) and once at each concentration of the test compound.  Test 
compounds were applied in increasing concentrations (1, 10, 100, or 1000 nM) 60 s 
prior to GABA (3 µM) applications. 
10.3.3. Geller Conflict with Incremental Shock in Rats 
Experiments were conducted in 8 model E10-10 Coulbourn operant chambers 
(Coulbourn Instruments, Allentown, Penn., USA; 28 x 26 x 31 cm) with an electrified 
grid floor which were housed in light-proof, sound-attenuated, and fan-ventilated 
chambers.  On one wall of each operant chamber is a house light and a centrally placed 
food hopper 3 cm from the floor that delivered one 45-mg food pellet (Dustless 
Precision Pellets, Bio-Serv, Frenchtown, N.J., USA).  To the left was mounted a lever 
response module with cue lights above.  Foot-shock was delivered using an H13-16 
Universal Shocker.  Experiments were controlled with a Compaq DeskPro computer 
running Graphic State Notation software through Habitest Universal Linc interface 
equipment (Coulbourn Instruments).   
Rats were trained to stability on an alternating multiple Random Interval 30 s/Fixed 
Ratio 1 Food +Shock paradigm (RI15/FR1 F+S).  The paradigm ran through four cycles 
beginning with the Random Interval (RI) schedule which ran for 12 minutes then 
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switched to the Fixed Ratio (FR) schedule which was cued and ran for 3 minutes.  The 
RI had a range of 15 to 45 s with the food pellet being delivered with the first lever press 
after the expiration of the interval.  The FR schedule delivered a food pellet after each 
lever press along with a foot-shock that increased with each lever press beginning at 
zero on the first lever press then increasing to 0.05 mA on the second lever press and 
incrementing by 0.05 mA with each subsequent lever press.  The shock was reset to zero 
at the beginning of each RI/FR cycle.   
10.3.4. Protection against Pentylenetetrazole- and Shock-Induced Seizures in Mice 
Pentylenetetrazole (PTZ) was administered at 125 mg/kg s.c.  The number of animals 
surviving was recorded at 30 minutes and 60 minutes after administration of PTZ.  
Electroshock is administered using an Ugo Basile ECT, Unit 7801 seizure apparatus 
(Ugo Basile, Italy) and corneal electrodes soaked in 0.9% saline.  Mice received a shock 
of 30 mA for 0.3 s.  The number of animals that exhibited the hind-limb extensor 
component of the seizure was recorded. 
10.3.5. Conditioned Fear in Rats 
Experiments were conducted in standard modular test chambers (ENV-008, Med 
Associates, St. Albans, Vt., USA, 30.5 x 24.1 x 21 cm) with an electrified grid floor 
which were housed in light-proof, sound-attenuated, and fan-ventilated chambers.  Foot-
shock was delivered using a shocker/scrambler module (ENV-414).  Experiments were 
controlled with a desktop computer using Med-PC software through Smart Ctrl 
interface equipment (Med-Associates).   
On day 1, rats were placed in the test chambers for a 7-minute conditioning session 
consisting of 2.5 minutes of habituation, a 2-s foot-shock at 0.7 mA, followed by 2.5 
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minutes of no foot-shock, another 2-s, 0.7 mA foot-shock, and another 2 minutes with 
no foot-shock.  Twenty-four hours after the conditioning session, rats were placed in the 
test chamber again for 7 minutes with no foot-shocks and percent time freezing was 
quantified by video image analysis (Freezeview software using filter 25 and bout length 
of 0.75 s; Actimetrics and Coulbourn Instruments, Allentown, Penn., USA). 
10.3.6. Spontaneous Locomotor Activity in Rats 
The testing apparatus consisted of Plexiglas chambers (42 x 42 x 30 cm) equipped with 
Digiscan activity monitors (Omnitech Electronics, Columbus, Ohio, USA) that detect 
interruptions of eight photobeams spaced 5 cm apart and 2.5 cm above the floor.  
Horizontal activity was recorded in 5-minute bins for a total of 60 minutes and 
expressed as total distance covered (in cm).   
10.3.7. Rotorod Performance in Rats 
The degree of motor coordination or balance was determined using a standard 
accelerating rotorod treadmill (Ugo Basile, Comerio-Varese, Italy) that was 6 cm in 
diameter and 24 cm above the base.  The speed was increased gradually from 2 rpm to a 
maximum speed of 20 rpm.  The time each animal remained on the rotating rod was 
automatically recorded, up to a maximum of 5 minutes.  Three acclimation trials were 
conducted for each animal prior to administration of drugs.  The time on rotorod from 
the third trial was used to counterbalance animals for subsequent drug testing. 
10.3.8. Chlordiazepoxide Discrimination in Rats 
Twelve model E10-10 Coulbourn operant conditioning chambers (Coulbourn 
Instruments, Allentown, Penn., USA; 28 x 26 x 31 cm) were housed in light-proof, 
sound-attenuated, and fan-ventilated chambers.  Each operant conditioning chamber was 
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equipped with two non-retractable levers, requiring a downward force equivalent to 15 g 
(0.15 N), that were mounted 3 cm from the side wall, 3 cm above the metal grid floor, 
and 5 cm from a centrally placed food tray that delivered one 45-mg food pellet 
(Dustless Precision Pellets, Bio-Serv, Frenchtown, N.J.).  The experimental chambers 
were connected to a Micro PDP11/73 computer using a LAB LINC interface.  A SKED-
11 operating system (State System, Kalamazoo, Mich.) was used to record and control 
behavior. 
After habituation to the operant conditioning chamber, rats were trained to alternate 
daily between response levers on an FR 1 schedule of food reinforcement.  Once lever 
pressing was well established, the reinforcement contingency was increased 
incrementally to an FR 10 schedule of food reinforcement, while maintaining the lever 
alternation.  Rats were then trained to discriminate between an intraperitoneal (IP) 
injection of drug (5.0 mg/kg CDP) and vehicle (0.25% methylcellulose) administered 30 
minutes prior to the start of the session.  Ten consecutive responses on the injection-
appropriate lever resulted in food delivery.  Responses on the incorrect lever did not 
result in pellet delivery.  Following an injection of CDP, responding on the right lever 
was reinforced for half the rats and responding on the left lever was reinforced for the 
other rats.  In each two-week period there were five drug days and five saline days, with 
the constraint that there not be more than three consecutive drug or vehicle days. 
Drug test sessions were conducted once a week (Fridays) with training sessions 
scheduled on intervening days (Monday – Thursday).  The criterion for testing was 
achieved if no more than three incorrect responses occurred prior to the first reinforcer 
for at least 9 out of 10 consecutive sessions.  During test sessions, the lever on which the 
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rat first made 10 consecutive responses resulting in delivery of the first food pellet was 
designated the “selected “ lever and subsequent pellet delivery was made contingent on 
responding on this selected lever on an FR10 schedule.  The selected lever, the number 
of responses prior to the first food pellet delivery, and the total number of responses in 
the session were recorded for each rat.  The duration of test sessions was ten minutes.  
Dose-response functions were determined for CDP, diazepam, and QH-ii-066. 
 
11. Experiments of GABA signaling in neuroblastoma (Weiss and Cook 
et al.)89 
11.1. Methods Summary: 
Backcross mice were generated by crossing TH-MYCN transgenic FVB/N mice to wild-
type 129/SvJ, and subsequently crossing F1 offspring to wild-type 129/SvJ.  Mice were 
observed for at least one year to be considered tumor-free.  DNA was isolated from 
spleen and genotyped using a combination of microsatellite and SNP markers.  RNA 
from SCG was analyzed using Affymetrix Mouse Exon arrays.  Susceptibility linkage 
was analyzed using R-QTL.  Differential gene expression was assessed using 
Significance Analysis of Microarrays, and eQTL were calculated using custom software 
as described previously. 
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11.2. Supplementary Methods: 
 
11.2.1. Mice  All mice were obtained from the Jackson Labs (Bar Harbor, ME), and 
were housed and treated following UCSF IACUC guidelines. Tumor-negative backcross 
mice were followed until one year of age (the latest tumor was detected at 342 days).  
Superior cervical ganglia (SCG) were surgically isolated and snap-frozen in liquid 
nitrogen.  SCG were isolated from the parental control groups at 21 days. 
11.2.2. Taqman analysis of transgene expression:  Taqman expression analysis was 
performed on 6 mice (3 female, 3 male) from each strain.  Proprietary assays for human 
MYCN and controls L18 and mGUS were obtained from Applied Biosystems (Carlsbad, 
CA).    
11.2.3. Genotyping  DNA was isolated from spleen tissue using a proteinase K lysis 
followed by phenol chloroform extraction.  Microsatellite marker genotyping was 
carried out by the Marshfield Clinic (Marshfield, WI), and CIDR (Baltimore, MD).   
SNP genotyping was performed using template-directed primer extension with 
fluorescence polarization detection (FP-TDI, Acycloprime II, Perkin Elmer, Waltham, 
MA)   and SNPStream2 48-plex (Beckman Coulter, Brea, CA).  The marker set had an 
average spacing of 8 MB genome-wide (excluding the high density of markers on 
chromosome 10).   
11.2.4. Linkage analysis  Interval mapping was performed using the R-QTL3 package 
in the R statistical language.  Genotypes flagged as probable errors by R-QTL were 
discarded.  The genetic map positions were determined using the physical map positions 
(NCBI 37/mm9), followed by re-estimation of the map using R-QTL, and likely mis-
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mapped markers were discarded.  Linkage analysis was performed on a 1-cM grid.  
Genome-wide significance thresholds were determined by running 1000 permutations 
for each dataset.  Interval analysis was performed using the binary mode of the “EM” 
model.   All results reported as significant were significant at a 5% genome-wide error 
rate.  95% confidence intervals (CI) were determined using the lodint function in R-
QTL.  Genes within the confidence intervals were determined by counting all genes in 
the UCSC genome assembly mapping between markers flanking the 95% CI. 
11.2.5. Expression Arrays   RNA from superior cervical ganglia was isolated using the 
RNEasy kit (QIAGEN, Valencia, CA), as we found these buffers were more effective at 
disrupting the ganglia than Trizol.  1µg of RNA was used as a starting template for the 
RiboMinus rRNA subtraction (Invitrogen, Carlsbad, CA) followed by the ST labeling 
protocol (Affymetrix, Santa Clara, CA).  Labeled samples were hybridized to 
Affymetrix Mouse Exon 1.0 arrays.  Array quality control was performed using the 
Affymetrix Expression Console.  2-way comparisons between homogenous groups (e.g. 
male vs. females or 129/SvJ vs FVB/N males) were performed using the Significance 
Analysis of Microarrays (SAM) package4 using a 5% false discovery rate.   
11.2.6. eQTL analysis  Arrays were normalized using RMA in the XPS package 
(http://www.bioconductor.org/packages/2.6/bioc/html/xps.html). eQTL were calculated 
as described in 5; briefly, linkage between gene expression and loci was assessed by 
linear regression with genome-wide significance assessed using a FDR-based method. 
11.2.7. Cell Culture   Neuroblastoma cell lines were grown in RPMI media with 10% 
serum and antibiotics with the exception of SK-N-BE(2) (DMEM/F12, 10% serum) and 
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IMR-32 (DMEM, 10% serum plus non-essential amino acids).  Nor-NOHA was 
obtained from Bachem (Torrance, CA) and dissolved in DMSO.  GABA was obtained 
from Sigma (St. Louis, MO) and dissolved in H2O. Picrotoxin and bicuculline were 
obtained from Sigma and dissolved in DMSO.   
11.2.8. Western blotting   Equal amounts of total protein were loaded for 4%–12% 
SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. 
After blocking, membranes were blotted with Arg1 (R&D Systems, Minneapolis MN), 
GABA B R1, Erk (Santa Cruz Biotech, Santa Cruz, CA) , GABA A Rβ2/3, GABA B 
R2, β-tubulin (Millipore, Billerica, MA),  cleaved-PARP (Asp214), p-Akt (Ser473), Akt, 
pErk (Thr202/Tyr204) (Cell Signaling Technology, Danvers, MA), and GAPDH 
(Upstate Biotechnology, Lake Placid NY).  Antibodies were detected with HRP-linked 
anti-mouse, anti-rabbit (Amersham/GE, Piscataway, NJ), or anti-sheep IgG 
(Calbiochem/EMD, Gibbstown, NJ), followed by enhanced chemiluminescence 
(Amersham/GE, Piscataway, NJ). 
11.2.9. WST-1 assay   Cells were grown in 12-well plates and treated for 72 hours prior 
to the addition of WST-1 reagent (100µl per 1ml media).  Absorbance was read after 60 
minutes.  Results were plotted using Graphpad Prism software, and p-values were 
calculated using a two-tailed Student’s t-test. 
11.2.10. FACS   Cells were plated on 6-well dishes and treated as indicated for 24 
hours.  They were then harvested, fixed in 70% ethanol for 30 minutes, then stained with 
a propidium iodide (PI) dye and RNase solution.  All samples were analyzed on a 
FACSCaliber flow cytometer (Becton Dickenson, Franklin Lakes, NJ) and analyzed 
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using ModFit (Verity Software, Topsham ME).   Apoptosis was detected by flow 
cytometry for annexin V-FITC per manufacturer’s protocol (Annexin V-FITC detection 
kit, BioVision, Milpitas, CA) using FlowJo software (Tree Star, Inc, Ashland, OR). 
12. Behavioral experiments (with Savic et al.)154 
 
Experiments were carried out on male Wistar rats (Military Farm, Belgrade, Serbia), 
weighing 220-250 g. All procedures in the study conformed to EEC Directive 86/609 
and were approved by the Ethical Committee on Animal Experimentation of the Medical 
Faculty in Belgrade. The rats were housed in transparent plastic cages, six animals per 
cage, and had free access to pelleted food and tap water. The temperature of the animal 
room was 22±1ºC, the relative humidity 40-70%, the illumination 120 lux, and the 12/12 
h light/dark period (light on at 6:00 h). All handling and testing took place during the 
light phase of the diurnal cycle. Throughout the study the animals were used only once, 
with the exception of the grip strength measurement, which was done immediately after 
the tracking of behavior on the elevated plus maze. Spontaneous locomotor activity and 
elevated plus maze behavior were analyzed by the ANY-maze Video Tracking System 
software (Stoelting Co., Wood Dale, IL, USA). All drugs were dissolved/suspended with 
the aid of sonication in a solvent containing 85% distilled water, 14% propylene glycol, 
and 1% Tween 80, and were administered intraperitoneally in a volume of 1 ml/kg, 15 
min before behavioral testing (for active and passive avoidance test, before the 
acquisition session).  Time of administration, as well as, the doses of DMCM in various 
tests were chosen based on our previous studies (Savić et al., 2005a; 2005b; 2006). For 
interaction studies in the locomotor activity assay, the first treatment indicated in 
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combination was administered into the lower left quadrant of the peritoneum 20 minutes 
before testing, and the second treatment 5 minutes later into the lower right quadrant of 
the peritoneum. 
12.1. Passive Avoidance (PA) Paradigm  
 
The experiments were performed in an adapted Automatic reflex conditioner (Ugo 
Basile, Milan, Italy, Model 7051), as described earlier.177  In short, the apparatus 
consisted of a shuttle-box, equipped with a grid floor and divided with a sliding door 
into a lit and a dark compartment, and a programming unit. The animals were submitted 
to two, 24 hour – separated sessions. The acquisition session started by placing 
individual subjects in the illuminated compartment.  After 30 seconds, the entrance to 
the dark compartment was opened, and as soon as the rat had entered it with all four 
paws, the footshock (2 s, 0.3 mA) was delivered. Immediately afterwards, the rat was 
returned to its home cage. The same procedure was repeated 24 hours later (retention 
session), without footshock. A cut-off time of 180 seconds was used on the training day, 
whereas, on the retention trial, a ceiling of 300 seconds was imposed. 
13. Two-Way Active Avoidance (AA) Paradigm (with Savic 
et al.)154 
The AA test was performed in automated two-way shuttle-boxes (Campden Instruments, 
Sileby, UK), as described earlier.177 In short, the animals were submitted to two, 24-hour 
separated sessions. Training and test sessions were procedurally identical. Animals were 
placed singly into the shuttle box and left to freely explore for 15 minutes, and 
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habituation crossings were automatically counted. Afterward, they received 30 tone foot 
shock trials. During the first 5 seconds of each trial, a sound signal was presented 
(broadband noise of 69 dB), allowing the animal to avoid shocks by moving to the other 
compartment (avoidance response). If the animal did not respond within this period, a 
foot shock of 0.5 mA (7-s duration) was applied. Crossing to the adjacent compartment 
during the shock discontinued its delivery. The animal could move freely in the 
apparatus between trials (18-s intertrial intervals), and the intertrial crossings were 
automatically counted. 
14. Measurement of Locomotor Activity (with Savic et al.) 
Activity of single rats in a clear Plexiglas chamber (40 x 25 x 35 cm) under dim red light 
(20 lux) was recorded for a total of 30 minutes, without any habituation period, using 
ANY-maze software (as described above). For purposes of improving data analysis, the 
central 20% of the chamber (200 cm2) was virtually set as a central zone. The minimum 
percentage of animal that must have been in the zone for an entry to occur was set at 
70%, and 50% of the animal must have remained in the zone for an exit not to occur.  
15. Behavior on the Elevated Plus Maze (EPM) (with Savic 
et al.) 
The apparatus consisted of two open (50 x 10 cm, with a ledge of 0.3 cm) and two 
enclosed arms (50 x 10 x 40 cm), connected by a junction area (10 x 10 cm). The 
illumination in the experimental room was 10 lux on the surface of the arms. At the 
beginning of the experiment, single rats were placed in the center of the maze, facing 
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one of the enclosed arms, and their behavior was recorded for 5 min. An entry into an 
open or closed arm was scored when 90% of the animal crossed the virtual line 
separating the central square of the maze from the arm, whereas an exit occurred when 
more than 90 % of the animal left the respective arm. After each trial, the maze was 
cleaned with dry and wet towels. 
16. Grip Strength Test (with Savic et al.) 
Muscle strength was assessed by the grip strength meter (Ugo Basile, Milan, Italy, 
model 47105). When pulled by the tail, the rat grasps the trapeze connected to a force 
transducer, and the apparatus measures the peak force of experimenter’s pull (in g) 
necessary to overcome the strength of the animal’s forelimbs grip. Each animal was 
given three consecutive trials, and the median value was used for further statistics. 
16.1. Statistical Analysis 
All numerical data presented in the figures were given as the mean ± SEM, except for 
results from the PA test (median latency with 25th, 75th interquartile range; data were 
non-parametric because the procedure involved a cut-off). For electrophysiological data 
Student´s t-test was used for statistical analysis. Data from PA test were assessed by a 
Kruskal-Wallis non-parametric ANOVA, with post-hoc comparison relative to solvent 
control by a Dunn's test (α=0.05). Data from the AA, EPM, grip strength and activity 
assay were assessed by a one-way ANOVA. If the ANOVA was significant, each 
treatment condition was compared with control by a Dunnett's test (α=0.05). Where 
appropriate, the assessment of the antagonist influence on the inverse agonist effect was 
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conducted by a student’s t-test. Statistical analyses were performed with ANY-maze 
Video Tracking System software (Stoelting Co., Wood Dale, IL, USA) and SigmaStat 
2.0 (SPSS, Inc., Chicago, IL, USA). 
 
17. In vivo studies on XLi-093 in mice (Rowlett and Cook 
et al)55 
Subjects  
C57BL/6 Male Mice, 6 weeks old, n=8-10 per group  
17.1. Drugs  
1. Diazepam, Xli-093, flumazenil, bretazenil, and flunitrazepam were injected at doses 
between 03. and 30.0 mg/kg, i.p. and dissolved in a 50% PG and 50% distilled water 
vehicle  
2. [3H]Flumazenil (1.5µCi/30g mouse, i.v), [3H]L655-708 (1.5µCi/30g mouse, i.v.),  
both were dissolved in a saline vehicle  
17.2. HOLEBOARD MEMORY TASK  
Apparatus:  Holeboard insert containing 16 holes in a sound attenuated locomotor 
activity chamber (Med Associates, Inc.) 
Same 4 holes were baited for 4 consecutive 5-min sessions.  Baited holes are changed 
daily. Mice were trained for 14 days or until they reached criteria.  After training, testing 
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with DZ, XLi-093(XLi), DZ+ flumazenil (FLZ), or DZ+XLi-093 began. Performance 
was measured as a ratio of the number of novel correct holes (i.e., correct hole visited 
only once) /Total holes visited.  Perfect performance was indicated by a ratio of 1.0.    
 
17.3. IN VIVO BINDING ASSAY  
1. To determine binding site occupancy at α1 and α2/3GABAA receptors, mice were 
injected with [3H] flumazenil ([3H]FLZ) (1.5 µCi/mouse, i.v.).   Pretreatments (30 min):   
DZ (0.3-10.0 mg/kg, i.p.), XLi-093 (0.03-10.0 mg/kg, i.p.), flunitrazepam (30.0mg/kg, 
i.p., used to determine non-specific binding).  Mice were sacrificed 3 min after i.v. 
injection of tritiated ligand.  Cerebellum and spinal cord were quickly removed, 
homogenized, and stored in ScintiSafe.  All samples were processed with a Packard 
1900CA liquid scintillation analyzer.  
2. For binding site occupancy at α5GABA(A)receptors, methods followed those above 
using [3H]L655,708 (1.5µCi/mouse, i.v.).  Non-specific binding was determined using 
bretazenil (5.6 mg/kg, i.p.).  Mice were sacrificed 1 min after injection with tritiated 
ligand and the forebrain was quickly removed and prepared as described above.  
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18. CANTAB work (Rowlett and Cook et al.)155: 
Preferential inverse agonist action at α5GABAA receptors 
resulted in enhancement of performance on memory 
tasks. 
18.1. Subjects:  Experiments were conducted with adult male rhesus monkeys 
(Macaca mulatta), aged 10-15 years (corresponding roughly to “middle aged” 
monkeys), born and reared at the New England Primate Research Center breeding 
facility.  The monkeys were experimentally naïve at the beginning of the study.  
Monkeys were prepared with a non-allergic nylon vest (Lomir) and seated in primate 
chairs (Crisp Instruments) enclosed in ventilated, sound-attenuating chambers (Med 
Associates); or prepared with the non-allergic nylon vest attached to a flexible, stainless 
steel tether (Lomir) connected to the top of the monkey's home cage.  The restraint chair 
system was used in CANTAB studies, and the tether system was used in ORD, 
observational and MAP studies.  All monkeys were housed in a temperature- and 
humidity-controlled housing room and maintained on a 12-hr on/12-hr off light/dark 
schedule (lights on at 0600 hr).  Water was available continuously in the home cage. 
 
18.2. Food availability:  The protocol for food restriction developed by Taffe 
(2004) was used.  Briefly, the monkeys in all studies were weighed weekly, and these 
weights were used to calculate food (LabDiet 5038) allotments based on metabolic 
energy requirements for rhesus monkeys.  The calculation was based on the equation: 
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y=15.504x-0.8219, in which y=food biscuits/kg/day and x=body weight in kg (Taffe 2004).  
Monkeys were maintained at 100% of this allotment for at least 3 weeks or until weights 
are stable (no upward or downward trend over three weight determinations).  Once 
stable, the monkeys’ food allotments were gradually reduced to 70 to 85% (note that this 
was not a reduction in weight, rather a reduction in food allotment), an amount shown to 
result in stable and accurate performance in CANTAB tasks. Weekly weighing occured 
throughout the studies to adjust feeding (within the 70-85% range) based on a 
combination of weight, performance, and overall health (as determined by routine 
physical exams conducted by the Clinical Veterinary Staff). 
 
18.3. Surgery and drug delivery:  All compounds were administered via the 
intravenous (i.v.) route.  We used this route in order to minimize pharmacokinetic 
variables and to allow direct comparisons with other procedures at Harvard Medical 
School (NERPC) designed to study BZ effects in rhesus monkeys (e.g., i.v. self-
administration models of abuse potential).  Monkeys were implanted with venous 
catheters using the surgical procedures described by Platt et al. (2005).  Surgery was 
conducted under aseptic conditions using isoflurane/oxygen anesthesia.  Catheters were 
passed by way of a jugular, femoral or brachial vein to the level of the right atrium.  The 
distal end of the catheter was passed subcutaneously to a mid-scapular exit point.  
Catheters were flushed routinely with saline containing Heparin (100-150 U/ml), and 
physical exams were conducted that occasionally included contrast-dye infusion into the 
catheter, followed by X-ray to verify catheter patency and proper placement.  Using 
these procedures, catheters can remain patent for up to 3 years. 
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18.4.  General design and data analyses:  Separate groups of 6-8 monkeys were 
used in the CANTAB vs. the ORD/MAP/observation studies, with each monkey in a 
group receiving all treatments whenever possible. 
Dependent measures for the studies depended on the individual tasks, as described 
below.  The studies employed within-subjects design, in which each subject serves as its 
own control.  This design permits scientifically meaningful results to be obtained with 
fewer animals than would be required using most other approaches.  For individual 
subject analysis, data during test sessions were compared to data from control sessions 
and significance of effects were determined on the basis of 95% confidence intervals 
established under baseline conditions.  For comparison of doses within individual tasks, 
repeated-measures ANOVAs were used to evaluate statistical reliability when 
warranted.  For all studies, multiple comparisons were assessed for statistical reliability 
using a priori Bonferroni t-tests, when applicable.  Comparisons of drug potencies were 
conducted by computing ED50 values (dose engendering 50% of the maximum effect).  
The ED50s were computed using non-linear regression analysis techniques. 
 
18.5. CANTAB Tasks in Monkeys. 
18.5.1 Apparatus:  As described above, monkeys were trained to sit in primate chairs 
that will be placed in a sound-attenuating chamber.  Inside this chamber were a 
computer-controlled touch-screen monitor (Campden or Lafayette Instruments, Inc,), 
equipped with a dispenser to deliver 190-mg flavored food pellets (BioServe, Inc.).  
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Experimental events were controlled by the CANTAB software system on a computer in 
an adjacent room.   
18.5.2. Delayed non-matching to sample (DNMS).  The DNMS task was a 
short-term recognition memory task involving sets of visual discriminations.  A sample 
stimulus is presented in the center of the screen, and the animal must touch this stimulus 
within 30 sec.  After a touch, the screen was blanked and following a variable retention 
interval, two stimuli were presented on the lower left and right of the screen.  The 
retention interval consisted of 0, 1, 3, or 10 min; if performance was highly variable, the 
delays were adjusted for individual monkeys based on performance such that short, 
medium, and long delays were tested. Of the two “matching” stimuli, one stimulus was 
identical to the sample stimulus (“matching” stimulus) and the other was novel (“non-
matching” stimulus).  A touch directed to the non-matching stimulus was followed by 
reinforcer delivery.  In addition to the four retention interval conditions, a simultaneous 
condition was included in which the sample stimulus remained present while the 
matching and non-matching stimuli were present.  A session consisted of 10 trials of 
each retention interval, presented in a randomly intermixed fashion (total trials=50).  
The CANTAB software used 469 shapes and 7 colors to ensure that discriminations 
were unique for approximately 120,000 trials.  The primary dependent measured for the 
DNMS task are the percent correct responses at each delay and the latency to respond at 
each delay.  The number of trials completed also was recorded as a measure of 
motivation and/or ability to perform the task. 
18.5.3. Paired associated learning (PAL).  Large colored abstract stimuli were 
displayed in one of 4 positions (top center, bottom center, left middle, right middle).  
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The subject was required to touch the sample stimulus, which then disappeared.  After a 
1-sec delay, the same pattern reappears (choice phase) in two or more locations on the 
screen (the original location plus one or more novel locations).  The subject was 
required to touch the stimulus that was presented in the same location as the sample item 
to obtain a food pellet.  Task difficulty was increased by increasing the number of 
stimulus-location associations required on each trial.  Training was initiated with 
sessions that present 25 1-stimulus trials and 25 2-stimulus trials until performance 
averaged >50% correct trials on the 2-stimulus trials.  Next, monkeys received sessions 
of 25 2-stimulus trials and 25 3-stimulus trials until performance averaged >25% correct 
trials on the 3-stimulus trials.  This part of the PAL task measured memory for stimulus-
location associations.  
Next, a learning component is introduced in which a trial repeats if a mistake was made 
in attempting to complete this trial (i.e. the monkey gets 0-2 of 3 stimulus-locations 
correct in a 3-stimulus trial).  Up to 6 attempts at a given trial were allowed.  Finally, 4-
stimulus trials were added when performance of 3-stimulus trials exceeded 50% correct 
(thus, the PAL task measured both memory and learning of stimulus-location 
associations).  The dependent measures were the percent correct at each difficulty level 
and the latencies to respond. 
18.5.4. Intradimensional/extradimensional set shifting (ID/ED).  The 
ID/ED shift task evaluated the ability of a subject to attend to specific attributes of a 
stimulus, as well as the ability to shift attention to other attributes when required.  This 
task consisted of a series of eight discrimination learning stages wherein touching only 
one of two stimuli presented on the screen resulted in food pellet delivery.  Within any 
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given stage of the task, a pair of stimuli was presented and the same stimulus was 
associated with reinforcement (S+ stimulus) until the performance criteria were met (18 
of 20 consecutive trials correct).  Correct choices must be made within 30 sec, and 
following a correct choice the screen was blanked for 5 sec while an incorrect choice (S- 
stimulus) resulted in a 0.2 sec tone and a 9-sec period of blank screen.   
The task consisted of 4 levels of stimulus sets, each progressively more difficult.  In the 
first stimulus set (Level 1), two distinctly shaped stimuli were presented, with touches 
on one shape resulting in food pellet delivery.  This level (and all subsequent levels) 
included a stimulus reversal, in which the same two shapes are retained but pressing the 
S+ stimulus now does not result in reinforcement, whereas touching the former S- 
stimulus did result in food pellet delivery.  In Level 2, a compound discrimination was 
presented.  For this discrimination, the two shapes from Level 1 are present, but 
additional stimuli, consisted of lines, were superimposed onto the existing shapes.  
Because the shape discrimination from the previous stage did not change, the lines are 
irrelevant to this discrimination.  Level 3 consisted of the intra-dimensional (ID) shift 
stage.  For this discrimination, two new shapes with new lines were presented.  This was 
considered an ID shift due to the fact that despite new shapes and lines being introduced, 
the shape remained the relevant dimension for the discrimination.  In the final level, the 
extra-dimensional (ED) shift will be introduced.  Thus, in Level 4, new shapes and lines 
were presented; however, the lines—not the shape—were the relevant discriminative 
stimulus.  Performance was determined as the number of errors at each stage, and the 
data were subjected to a square root transformation to achieve normal distributions.  
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18.5.5. Progressive-Ratio (PR).  PR procedures consisted of response requirements 
that progressively increased across a session until responding ceases. The last response 
requirement completed, termed “break point”, provided a quantitative measure of the 
reinforcing effectiveness of a stimulus.  For these studies, a session was initiated by a 
colored box appearing in the middle of the screen.  Touching the box once resulted in 
food pellet delivery, and the response requirement were progressively increased 
following each reinforcer by an incremental value beginning at 1 and doubling after 8 
response requirements were completed successfully.  Thus, the response requirement 
sequences consisted of:  Increment= 1, response requirements= 1, 2, 3, 4, 5, 6, 7, 8; 
Increment = 2, response requirements = 10, 12, 14, 16, 18, 20, 22, 24; Increment = 4, 
response requirements = 28, 32, 36, 40, 44, 48, 52, 56; and so on.  Sessions were a 
maximum of 30 min, and were terminated if 3 min elapses without a response.  
Performance was measured as the break point and number of food pellets delivered per 
session.  This procedure provided a measure of the ability of the animal to respond, as 
well as an assessment of “motivation” to perform. 
18.5.6. Training.  Initial training began with shaping the basic response of touching 
the screen.  A large colored square was displayed that occupied most of the screen.  
Touching the screen inside the box was a “correct” response and results in food 
reinforcement.  With each correct response, the size of the square decreased until the 
monkey readily pressed a 1-in box in any location on the screen.  This initial training 
typically required up to 5 sessions. 
Currently 4 monkeys were trained at various stages of the DNMS and ID/ED task.  
These monkeys initiated training on PAL (a task that requires a lengthy training period, 
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Taffe et al. 2004) with “reminder” trials for DNMS and ID/ED scheduled one day per 
week.  We anticipated approximately 5-6 more months of training for PAL performance 
to reach acceptable performance. 
For new monkeys, CANTAB training was initiated by gradually introducing different 
tasks, and also incorporate training on the ORD task. In the first phase of training, the 
PAL task was introduced 5 days/week.  After approximately 6 months, the DNMS task 
was introduced on days 1-4 of the week, with PAL training continuing on day 5.  In our 
experience, DNMS training typically took up to 3 months, once criterion performance 
was met, DNMS training was initiated on days 1-3, with PAL training scheduled for 
days 4 and 5, respectively.  PAL training may take up to and over 12 months, therefore, 
after 9 months the ID/ED task was introduced into the sequence once or twice per week 
on randomly chosen days (this task did not require special training, Weed et al., 1999).  
In the final phase of training, two tasks per day were introduced and the PR schedule 
introduced according to the schedule: day 1: PR/PAL; day 2:  DNMS/PR; day 3: PAL; 
day 4: DNMS/PR; day 5: ID/ED/PR.   
 
Table 20: Schedule of CANTAB tests for a single dose of compound plus vehicle 
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18.5.7.  Testing.  Once training criteria were reached on all tasks, the 8-day cycles 
shown in Table 20 were initiated.  The two cycles shown in the Table allowed a dose of 
test compound and vehicle to be determined twice in all tasks.  For each compound, 
vehicle plus at least 4 doses were evaluated.  All doses of a compound (or dose of 
compound plus antagonist) were tested in irregular order, with a compound finished 
prior to moving to the next compound.  A test session consisted of i.v. injections of 
compound(s) at an appropriate pretreatment time prior to the session.  Based on the 
scheduling shown in Table 20, for CANTAB a dose-response function was required 
approximately 10 weeks to complete. 
 
19.  Object Retrieval with Detours (ORD) Task.  To augment 
CANTAB-based testing, parallel assessments were conducted using the ORD Task, 
which was a manual test sensitive to frontostriatal deficits (Taylor et al. 1990; Jentsch et 
al. 1999) and has been validated in pharmacological studies at NERPC. The task 
required the monkey to retrieve a small piece of palatable food from a transparent box 
that was open on one side only. The box was attached to a tray that can be positioned 
within easy reach of the monkey. Different levels of task complexity were achieved by 
varying the orientation of the open side of the box, the position of the box on the tray, 
and the position of the food relative to the opening. The level of cognitive complexity 
and motor difficulty of each task was rated a priori using the criteria of Taylor et al. 
(1990). The 12 task configurations varied from those characterized by high cognitive 
complexity/low motor difficulty to low cognitive complexity/high motor difficulty.  
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Training on the ORD task typically required 14-21 sessions, and tests were scheduled as 
described above in Table 20. The primary dependent measure for the ORD task was 
“percent success”, which was the total number of reaches minus “incorrect” (i.e., a reach 
in which the food item was not obtained) and “barrier” reaches (i.e., a reach in which the 
monkey contacted a closed side of the box), divided by total reaches and then multiplied 
by 100.  Barrier reaches were also analyzed separately as a measure of perseverative 
behavior, and reach latencies (i.e., time to obtain food or maximum trial length of 20 
seconds) were recorded as a measure of motor impairment.  
 
20.  Assessment of Motor Coordination and Behavioral 
Effects in Monkeys.   
20.1. MAP apparatus and procedure.  To evaluate fine motor coordination, 
monkeys were trained using the movement assessment panel (MAP) system developed 
by Gash and colleagues (Gash et al. 1999).  The MAP (Quanteon, Inc.) consists of a 
Lexan® box attached to a clear Lexan® panel that was mounted on to home cage 
(Figure 41).  Portals in the front panel and on the sides of the food receptacle allowed 
monkeys to retrieve small food objects (e.g., miniature marshmallows or raisins).  
Arrays of photocells are attached to the portals on the front panel (Portal A) and food 
receptacle (Portal B).  The amount of time that the photobeams for Portal A were broken 
was considered a measure of gross motor coordination, whereas the amount of time that 
the photobeams for Portal B were broken was considered a measure of fine motor 
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coordination (Gash et al. 1999).  MAP studies occurred in the home cage of monkeys 
prepared with the tether system.  The MAP apparatus fit the cage door, and monkeys  
received initial training by placing food treats in different parts of the apparatus until 
they consistently retrieved treats from the food receptacle.   
 
 
 
 
 
  
 
 
 
Training occurred 5 days per week until latencies retrieved the treat are stable (no 
upward or downward trends over 3 consecutive sessions) and testing occurred on day 2 
and day 5 of this 5-day cycle.   
20.1.1. Observation studies.  Observers were trained in the use of the behavioral 
scoring instrument developed in previous studies at NERPC. Each observer will undergo 
at least 20 hrs of observational training until they reached a > 90% reliability criterion 
based on percent agreement scores.  The scoring system included 19 categories 
 
 
A 
B 
 
Figure 41.  Movement Assessment Panel 
for rhesus monkeys. 
275  
encompassing a wide range of species-typical and drug-induced behaviors including 
locomotion, environmental manipulation, foraging, self-grooming, scratching, 
stereotypic behavior such as self-grasping, back flipping, and hair pulling, ataxia, sleep 
posture, moderate and deep sedation.  These behavioral categories have proven to be 
useful for characterization of the sedative and motoric effects of BZ-type compounds in 
previous research at NERPC. 
Observation studies occurred in the same monkeys that were trained on the MAP task.  
Observation studies were conducted in these monkeys in alternate weeks, on the 2nd and 
3rd day of the 5-day cycle (i.e., MAP testing occurred one week, observation tests 
occurred the following week, and so on).  Video cameras were used to record the 
monkeys’ behavior during observation sessions.  This provided an archival record of 
experimental sessions, permitted subsequent scoring of videotapes by independent 
observers, and eliminated the possibility that an observer’s presence disturbed the 
monkeys’ behavior.  All behaviors were scored during 5-min sampling periods as 
described above.  Each 5-min period was subdivided into twenty 15-s intervals, and 
frequency scores were calculated as the proportion of 15-s intervals in which a particular 
behavior occurred. Data was analyzed separately in individual subjects and for the group 
when appropriate used the statistical approach described earlier at NERPC. 
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III. Appendix I: Crystal Data for 110 and 111 
X-ray Crystal Structure Determination for 110 and 111 
 
Single-crystal X-ray diffraction data on 110 and 111 were collected at 296 and 100 °K 
respectively.  All data were collected using MoKα radiation (λ = 0.71073 Å) and a 
Bruker APEX 2 CCD area detector.  Samples were prepared for data collection by 
coating with high viscosity microscope oil (Paratone-N, Hampton Research).  The oil-
coated crystal was mounted on a MicroMesh mount (MiTeGen, Inc.) and transferred 
immediately to the diffractometer. Corrections were applied for Lorentz, polarization, 
and absorption effects.  All structures were solved by direct methods and refined by full-
matrix least squares on F2 values using the programs found in the SHELXTL suite 
(Bruker, SHELXTL v6.10, 2000, Bruker AXS Inc., Madison, WI).  Parameters refined 
included atomic coordinates and anisotropic thermal parameters for all non-hydrogen 
atoms.   
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Full information on data collection, refinement, and results of the x-ray studies are given 
in Tables 1 to 14 
Table 1.  Crystal data and structure refinement for 110. 
 
Empirical formula  C19H20N2O2 
Formula weight  308.37 
Temperature  296(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P 212121 
Unit cell dimensions a = 9.6247(4) Å α= 90° 
 b = 11.6485(5) Å β= 90° 
 c = 13.7072(5) Å γ = 90° 
Volume 1536.76(11) Å3 
Z 4 
Density (calculated) 1.333 Mg/m3 
Absorption coefficient 0.087 mm-1 
F(000) 656 
Crystal size 0.549 x 0.141 x 0.104 mm3 
Theta range for data collection 2.29 to 29.23° 
Index ranges -12<=h<=13, -15<=k<=15, -18<=l<=18 
Reflections collected 17885 
Independent reflections 4117 [R(int) = 0.0313] 
Completeness to theta = 29.23° 99.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9910 and 0.9537 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4117 / 0 / 208 
Goodness-of-fit on F2 1.051 
Final R indices [I>2sigma(I)] R1 = 0.0441, wR2 = 0.1120 
R indices (all data) R1 = 0.0560, wR2 = 0.1197 
Absolute structure parameter 0.9(14) 
Largest diff. peak and hole 0.275 and -0.226 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters (Å2 x 103) for 110.  
U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
N(1) 1218(2) 4427(1) 8185(1) 37(1) 
C(2) 2099(2) 5027(2) 8752(1) 33(1) 
C(3) 3328(2) 5685(2) 8403(1) 34(1) 
N(4) 3535(1) 6617(1) 9129(1) 34(1) 
C(5) 3857(2) 6092(1) 10089(1) 34(1) 
C(6) 2664(2) 5348(2) 10454(1) 35(1) 
O(6) 2569(2) 5140(1) 11332(1) 47(1) 
C(7) 1757(2) 4884(2) 9725(1) 33(1) 
C(8) 551(2) 4152(2) 9753(1) 33(1) 
C(9) -305(2) 3714(2) 10488(1) 42(1) 
C(10) -1425(2) 3030(2) 10227(2) 47(1) 
C(11) -1703(2) 2774(2) 9258(2) 49(1) 
C(12) -880(2) 3187(2) 8508(2) 43(1) 
C(13) 242(2) 3876(2) 8775(1) 35(1) 
C(14) 4643(2) 4903(2) 8333(1) 39(1) 
C(15) 5780(2) 5425(2) 8987(1) 37(1) 
C(16) 5253(2) 5408(2) 10054(1) 37(1) 
C(17) 6311(2) 5866(2) 10792(2) 53(1) 
O(17) 6185(2) 7054(1) 10952(1) 60(1) 
C(18) 8403(2) 6398(2) 7934(2) 60(1) 
C(19) 7098(2) 7033(2) 8158(1) 44(1) 
C(20) 6001(2) 6639(2) 8636(1) 37(1) 
C(21) 4712(2) 7351(2) 8821(2) 41(1) 
________________________________________________________________________________ 
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Table 3.  Bond lengths [Å] and angles [°] for 110. 
________________________________________________________________________________  
N(1)-C(2)  1.345(2) N(1)-C(13)  1.395(2) 
N(1)-H(1A)  0.8600 C(2)-C(7)  1.384(2) 
C(2)-C(3)  1.489(2) C(3)-N(4)  1.485(2) 
C(3)-C(14)  1.562(3) C(3)-H(3A)  0.9800 
N(4)-C(21)  1.480(2) N(4)-C(5)  1.484(2) 
C(5)-C(6)  1.523(2) C(5)-C(16)  1.563(2) 
C(5)-H(5A)  0.9800 C(6)-O(6)  1.231(2) 
C(6)-C(7)  1.432(2) C(7)-C(8)  1.441(2) 
C(8)-C(9)  1.398(2) C(8)-C(13)  1.411(2) 
C(9)-C(10)  1.387(3) C(9)-H(9A)  0.9300 
C(10)-C(11)  1.387(3) C(10)-H(10A)  0.9300 
C(11)-C(12)  1.384(3) C(11)-H(11A)  0.9300 
C(12)-C(13)  1.395(3) C(12)-H(12A)  0.9300 
C(14)-C(15)  1.541(3) C(14)-H(14A)  0.9700 
C(14)-H(14B)  0.9700 C(15)-C(20)  1.509(3) 
C(15)-C(16)  1.548(2) C(15)-H(15A)  0.9800 
C(16)-C(17)  1.531(3) C(16)-H(16A)  0.9800 
C(17)-O(17)  1.406(3) C(17)-H(17A)  0.9700 
C(17)-H(17B)  0.9700 O(17)-H(17C)  0.8200 
C(18)-C(19)  1.490(3) C(18)-H(18A)  0.9600 
C(18)-H(18B)  0.9600 C(18)-H(18C)  0.9600 
C(19)-C(20)  1.325(3) C(19)-H(19A)  0.9300 
C(20)-C(21)  1.514(3) C(21)-H(21A)  0.9700 
C(21)-H(21B)  0.9700 
C(2)-N(1)-C(13) 109.18(14) C(2)-N(1)-H(1A) 125.4 
C(13)-N(1)-H(1A) 125.4 N(1)-C(2)-C(7) 110.16(15) 
N(1)-C(2)-C(3) 125.62(14) C(7)-C(2)-C(3) 124.10(15) 
N(4)-C(3)-C(2) 105.51(13) N(4)-C(3)-C(14) 111.05(14) 
C(2)-C(3)-C(14) 111.26(14) N(4)-C(3)-H(3A) 109.6 
C(2)-C(3)-H(3A) 109.6 C(14)-C(3)-H(3A) 109.6 
C(21)-N(4)-C(5) 109.31(14) C(21)-N(4)-C(3) 109.49(14) 
C(5)-N(4)-C(3) 108.68(13) N(4)-C(5)-C(6) 111.59(14) 
N(4)-C(5)-C(16) 111.26(13) C(6)-C(5)-C(16) 111.64(13) 
N(4)-C(5)-H(5A) 107.4 C(6)-C(5)-H(5A) 107.4 
C(16)-C(5)-H(5A) 107.4 O(6)-C(6)-C(7) 124.21(16) 
O(6)-C(6)-C(5) 119.25(16) C(7)-C(6)-C(5) 116.46(14) 
C(2)-C(7)-C(6) 118.78(15) C(2)-C(7)-C(8) 106.74(14) 
C(6)-C(7)-C(8) 134.12(15) C(9)-C(8)-C(13) 118.55(16) 
C(9)-C(8)-C(7) 135.20(16) C(13)-C(8)-C(7) 106.24(14) 
C(10)-C(9)-C(8) 118.74(18) C(10)-C(9)-H(9A) 120.6 
C(8)-C(9)-H(9A) 120.6 C(11)-C(10)-C(9) 121.41(18) 
C(11)-C(10)-H(10A) 119.3 C(9)-C(10)-H(10A) 119.3 
C(12)-C(11)-C(10) 121.72(18) C(12)-C(11)-H(11A) 119.1 
C(10)-C(11)-H(11A) 119.1 C(11)-C(12)-C(13) 116.67(18) 
C(11)-C(12)-H(12A) 121.7 C(13)-C(12)-H(12A) 121.7 
C(12)-C(13)-N(1) 129.41(16) C(12)-C(13)-C(8) 122.91(16) 
N(1)-C(13)-C(8) 107.67(15) C(15)-C(14)-C(3) 108.01(14) 
C(15)-C(14)-H(14A) 110.1 C(3)-C(14)-H(14A) 110.1 
C(15)-C(14)-H(14B) 110.1 C(3)-C(14)-H(14B) 110.1 
H(14A)-C(14)-H(14B) 108.4 C(20)-C(15)-C(14) 106.53(15) 
C(20)-C(15)-C(16) 111.10(15) C(14)-C(15)-C(16) 108.14(14) 
C(20)-C(15)-H(15A) 110.3 C(14)-C(15)-H(15A) 110.3 
________________________________________________________________________________
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Table 3.  (continued) 
________________________________________________________________________________ 
C(16)-C(15)-H(15A) 110.3 C(17)-C(16)-C(15) 113.68(15) 
C(17)-C(16)-C(5) 111.96(15) C(15)-C(16)-C(5) 107.71(13) 
C(17)-C(16)-H(16A) 107.8 C(15)-C(16)-H(16A) 107.8 
C(5)-C(16)-H(16A) 107.8 O(17)-C(17)-C(16) 112.84(17) 
O(17)-C(17)-H(17A) 109.0 C(16)-C(17)-H(17A) 109.0 
O(17)-C(17)-H(17B) 109.0 C(16)-C(17)-H(17B) 109.0 
H(17A)-C(17)-H(17B) 107.8 C(17)-O(17)-H(17C) 109.5 
C(19)-C(18)-H(18A) 109.5 C(19)-C(18)-H(18B) 109.5 
H(18A)-C(18)-H(18B) 109.5 C(19)-C(18)-H(18C) 109.5 
H(18A)-C(18)-H(18C) 109.5 H(18B)-C(18)-H(18C) 109.5 
C(20)-C(19)-C(18) 127.06(19) C(20)-C(19)-H(19A) 116.5 
C(18)-C(19)-H(19A) 116.5 C(19)-C(20)-C(15) 126.46(17) 
C(19)-C(20)-C(21) 123.16(16) C(15)-C(20)-C(21) 110.16(14) 
N(4)-C(21)-C(20) 111.02(14) N(4)-C(21)-H(21A) 109.4 
C(20)-C(21)-H(21A) 109.4 N(4)-C(21)-H(21B) 109.4 
C(20)-C(21)-H(21B) 109.4 H(21A)-C(21)-H(21B) 108.0 
________________________________________________________________________________  
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Table 4.  Anisotropic displacement parameters (Å2 x 103) for 110.  The anisotropic displacement factor 
exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
N(1) 39(1)  46(1) 27(1)  0(1) 1(1)  -5(1) 
C(2) 33(1)  36(1) 30(1)  1(1) 2(1)  1(1) 
C(3) 34(1)  38(1) 30(1)  2(1) 2(1)  -4(1) 
N(4) 33(1)  33(1) 38(1)  2(1) 2(1)  1(1) 
C(5) 36(1)  34(1) 32(1)  -3(1) 0(1)  -4(1) 
C(6) 37(1)  36(1) 30(1)  -2(1) 3(1)  -1(1) 
O(6) 54(1)  58(1) 27(1)  -1(1) 2(1)  -13(1) 
C(7) 33(1)  37(1) 30(1)  1(1) 3(1)  -3(1) 
C(8) 33(1)  35(1) 31(1)  2(1) 1(1)  2(1) 
C(9) 42(1)  48(1) 36(1)  4(1) 5(1)  -1(1) 
C(10) 41(1)  47(1) 53(1)  8(1) 13(1)  -8(1) 
C(11) 40(1)  47(1) 59(1)  3(1) 0(1)  -11(1) 
C(12) 41(1)  43(1) 45(1)  -2(1) -4(1)  -6(1) 
C(13) 34(1)  37(1) 34(1)  0(1) 1(1)  1(1) 
C(14) 42(1)  36(1) 39(1)  -4(1) 10(1)  -2(1) 
C(15) 32(1)  32(1) 47(1)  2(1) 5(1)  3(1) 
C(16) 37(1)  33(1) 41(1)  5(1) -1(1)  -2(1) 
C(17) 50(1)  54(1) 54(1)  7(1) -13(1)  -5(1) 
O(17) 42(1)  63(1) 76(1)  -22(1) 1(1)  -12(1) 
C(18) 48(1)  61(1) 72(2)  -5(1) 20(1)  -5(1) 
C(19) 44(1)  42(1) 47(1)  1(1) 9(1)  -6(1) 
C(20) 35(1)  35(1) 42(1)  2(1) 0(1)  -3(1) 
C(21) 39(1)  33(1) 50(1)  8(1) 5(1)  -2(1) 
______________________________________________________________________________ 
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Table 5.  Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2 x 103) for 110. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1A) 1251 4390 7559 44 
H(3A) 3128 6019 7762 41 
H(5A) 3978 6719 10557 40 
H(9A) -127 3878 11140 50 
H(10A) -2001 2738 10711 56 
H(11A) -2462 2312 9109 58 
H(12A) -1066 3013 7859 52 
H(14A) 4421 4131 8550 47 
H(14B) 4963 4863 7663 47 
H(15A) 6643 4984 8929 44 
H(16A) 5050 4609 10225 44 
H(17A) 6188 5466 11407 63 
H(17B) 7241 5701 10558 63 
H(17C) 6767 7260 11352 91 
H(18A) 9023 6889 7577 90 
H(18B) 8190 5733 7548 90 
H(18C) 8838 6162 8531 90 
H(19A) 7048 7787 7939 53 
H(21A) 4904 7913 9325 49 
H(21B) 4462 7761 8231 49 
________________________________________________________________________________  
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Table 6.  Torsion angles [°] for cook106. 
________________________________________________________________________________  
C(13)-N(1)-C(2)-C(7) 0.8(2) C(13)-N(1)-C(2)-C(3) 176.81(16) 
N(1)-C(2)-C(3)-N(4) 152.43(16) C(7)-C(2)-C(3)-N(4) -32.1(2) 
N(1)-C(2)-C(3)-C(14) -87.0(2) C(7)-C(2)-C(3)-C(14) 88.4(2) 
C(2)-C(3)-N(4)-C(21) -177.83(13) C(14)-C(3)-N(4)-C(21) 61.50(17) 
C(2)-C(3)-N(4)-C(5) 62.83(16) C(14)-C(3)-N(4)-C(5) -57.84(17) 
C(21)-N(4)-C(5)-C(6) 178.61(14) C(3)-N(4)-C(5)-C(6) -61.93(16) 
C(21)-N(4)-C(5)-C(16) -55.97(17) C(3)-N(4)-C(5)-C(16) 63.48(16) 
N(4)-C(5)-C(6)-O(6) -158.11(16) C(16)-C(5)-C(6)-O(6) 76.7(2) 
N(4)-C(5)-C(6)-C(7) 25.1(2) C(16)-C(5)-C(6)-C(7) -100.12(18) 
N(1)-C(2)-C(7)-C(6) 173.05(16) C(3)-C(2)-C(7)-C(6) -3.0(3) 
N(1)-C(2)-C(7)-C(8) -1.0(2) C(3)-C(2)-C(7)-C(8) -177.07(16) 
O(6)-C(6)-C(7)-C(2) -169.54(18) C(5)-C(6)-C(7)-C(2) 7.1(2) 
O(6)-C(6)-C(7)-C(8) 2.5(3) C(5)-C(6)-C(7)-C(8) 179.14(18) 
C(2)-C(7)-C(8)-C(9) -178.1(2) C(6)-C(7)-C(8)-C(9) 9.1(4) 
C(2)-C(7)-C(8)-C(13) 0.80(19) C(6)-C(7)-C(8)-C(13) -171.94(19) 
C(13)-C(8)-C(9)-C(10) -0.2(3) C(7)-C(8)-C(9)-C(10) 178.7(2) 
C(8)-C(9)-C(10)-C(11) 0.2(3) C(9)-C(10)-C(11)-C(12) -0.1(3) 
C(10)-C(11)-C(12)-C(13) -0.1(3) C(11)-C(12)-C(13)-N(1) -178.39(19) 
C(11)-C(12)-C(13)-C(8) 0.2(3) C(2)-N(1)-C(13)-C(12) 178.43(18) 
C(2)-N(1)-C(13)-C(8) -0.3(2) C(9)-C(8)-C(13)-C(12) 0.0(3) 
C(7)-C(8)-C(13)-C(12) -179.15(17) C(9)-C(8)-C(13)-N(1) 178.81(16) 
C(7)-C(8)-C(13)-N(1) -0.32(19) N(4)-C(3)-C(14)-C(15) -4.76(18) 
C(2)-C(3)-C(14)-C(15) -121.97(15) C(3)-C(14)-C(15)-C(20) -56.62(17) 
C(3)-C(14)-C(15)-C(16) 62.88(17) C(20)-C(15)-C(16)-C(17) -65.57(19) 
C(14)-C(15)-C(16)-C(17) 177.85(16) C(20)-C(15)-C(16)-C(5) 59.09(18) 
C(14)-C(15)-C(16)-C(5) -57.49(17) N(4)-C(5)-C(16)-C(17) 121.05(16) 
C(6)-C(5)-C(16)-C(17) -113.56(17) N(4)-C(5)-C(16)-C(15) -4.63(18) 
C(6)-C(5)-C(16)-C(15) 120.75(15) C(15)-C(16)-C(17)-O(17) 90.4(2) 
C(5)-C(16)-C(17)-O(17) -31.9(2) C(18)-C(19)-C(20)-C(15) -5.5(4) 
C(18)-C(19)-C(20)-C(21) -179.5(2) C(14)-C(15)-C(20)-C(19) -108.6(2) 
C(16)-C(15)-C(20)-C(19) 133.8(2) C(14)-C(15)-C(20)-C(21) 65.96(18) 
C(16)-C(15)-C(20)-C(21) -51.6(2) C(5)-N(4)-C(21)-C(20) 65.37(19) 
C(3)-N(4)-C(21)-C(20) -53.6(2) C(19)-C(20)-C(21)-N(4) 164.91(18) 
C(15)-C(20)-C(21)-N(4) -9.9(2) 
________________________________________________________________________________ 
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Table 7.  Hydrogen bonds for 110 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(1)-H(1A)...O(6)#1 0.86 2.10 2.8409(19) 143.7 
 O(17)-H(17C)...N(4)#2 0.82 2.25 2.743(2) 119.5 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1/2,-y+1,z-1/2    #2 x+1/2,-y+3/2,-z+2       
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Table 8.  Crystal data and structure refinement for 111. 
 
Empirical formula  C21H30N2O4 
Formula weight  374.47 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P 21 21 21 
Unit cell dimensions a = 8.3186(7) Å α= 90° 
 b = 12.4731(10) Å β= 90° 
 c = 19.1532(16) Å γ = 90° 
Volume 1987.3(3) Å3 
Z 4 
Density (calculated) 1.252 Mg/m3 
Absorption coefficient 0.086 mm-1 
F(000) 808 
Crystal size 0.463 x 0.429 x 0.091 mm3 
Theta range for data collection 1.95 to 29.14° 
Index ranges -11<=h<=11, -17<=k<=16, -24<=l<=26 
Reflections collected 22977 
Independent reflections 5326 [R(int) = 0.0221] 
Completeness to theta = 29.14° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9931 and 0.9658 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5326 / 2 / 252 
Goodness-of-fit on F2 1.103 
Final R indices [I>2sigma(I)] R1 = 0.0356, wR2 = 0.1041 
R indices (all data) R1 = 0.0367, wR2 = 0.1055 
Absolute structure parameter 0.3(7) 
Largest diff. peak and hole 0.329 and -0.273 e.Å-3 
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Table 9.  Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters (Å2 x 103) for 111.  
U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
N(1) 8034(1) 7267(1) 1454(1) 19(1) 
C(2) 9226(1) 6894(1) 1016(1) 16(1) 
C(3) 9215(1) 5825(1) 663(1) 16(1) 
N(4) 10222(1) 5969(1) 23(1) 14(1) 
C(5) 11870(1) 6313(1) 231(1) 14(1) 
C(6) 11787(1) 7506(1) 449(1) 14(1) 
O(6) 13218(1) 7827(1) 813(1) 18(1) 
C(7) 10356(1) 7674(1) 908(1) 15(1) 
C(8) 9838(1) 8606(1) 1287(1) 17(1) 
C(9) 10416(1) 9662(1) 1352(1) 21(1) 
C(10) 9558(2) 10381(1) 1759(1) 25(1) 
C(11) 8144(2) 10067(1) 2108(1) 26(1) 
C(12) 7541(2) 9036(1) 2053(1) 23(1) 
C(13) 8393(1) 8315(1) 1633(1) 19(1) 
C(14) 9850(1) 4886(1) 1124(1) 19(1) 
C(15) 11491(1) 4539(1) 832(1) 18(1) 
C(16) 12574(1) 5545(1) 793(1) 17(1) 
C(17) 14318(1) 5261(1) 620(1) 22(1) 
O(18) 15055(1) 4601(1) 1132(1) 29(1) 
C(19) 12250(2) 2212(1) 268(1) 40(1) 
C(20) 11531(2) 3126(1) -134(1) 27(1) 
C(21) 11204(1) 4106(1) 107(1) 19(1) 
C(22) 10360(1) 4933(1) -348(1) 18(1) 
O(1S) 5487(1) 6196(1) 2188(1) 26(1) 
C(1S) 6066(2) 6072(2) 2882(1) 39(1) 
O(2S) 13630(1) 7920(1) 2198(1) 34(1) 
C(2S) 12416(2) 8163(1) 2687(1) 34(1) 
________________________________________________________________________________ 
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Table 10.  Bond lengths [Å] and angles [°] for 110. 
________________________________________________________________________________  
N(1)-C(2)  1.3796(14) N(1)-C(13)  1.3849(16) 
N(1)-H(1A)  0.8800 C(2)-C(7)  1.3681(15) 
C(2)-C(3)  1.4956(15) C(3)-N(4)  1.4957(14) 
C(3)-C(14)  1.5580(15) C(3)-H(3A)  1.0000 
N(4)-C(22)  1.4790(13) N(4)-C(5)  1.4898(14) 
C(5)-C(6)  1.5469(14) C(5)-C(16)  1.5569(15) 
C(5)-H(5A)  1.0000 C(6)-O(6)  1.4362(13) 
C(6)-C(7)  1.4942(14) C(6)-H(6A)  1.0000 
O(6)-H(6B)  0.8400 C(7)-C(8)  1.4366(15) 
C(8)-C(9)  1.4073(16) C(8)-C(13)  1.4191(16) 
C(9)-C(10)  1.3856(17) C(9)-H(9A)  0.9500 
C(10)-C(11)  1.4089(19) C(10)-H(10A)  0.9500 
C(11)-C(12)  1.384(2) C(11)-H(11A)  0.9500 
C(12)-C(13)  1.3988(16) C(12)-H(12A)  0.9500 
C(14)-C(15)  1.5377(16) C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 C(15)-C(21)  1.5081(17) 
C(15)-C(16)  1.5462(16) C(15)-H(15A)  1.0000 
C(16)-C(17)  1.5302(16) C(16)-H(16A)  1.0000 
C(17)-O(18)  1.4209(15) C(17)-H(17A)  0.9900 
C(17)-H(17B)  0.9900 O(18)-H(18A)  0.8400 
C(19)-C(20)  1.4994(19) C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 C(19)-H(19C)  0.9800 
C(20)-C(21)  1.3352(17) C(20)-H(20A)  0.9500 
C(21)-C(22)  1.5219(16) C(22)-H(22D)  0.9900 
C(22)-H(22E)  0.9900 O(1S)-C(1S)  1.4221(17) 
O(1S)-H(1S)  0.8400 C(1S)-H(1SC)  0.9800 
C(1S)-H(1SB)  0.9800 C(1S)-H(1SA)  0.9800 
O(2S)-C(2S)  1.4099(17) O(2S)-H(2S)  0.8402(10) 
C(2S)-H(2SA)  0.9800 C(2S)-H(2SB)  0.9800 
C(2S)-H(2SC)  0.9800  
C(2)-N(1)-C(13) 108.26(10) C(2)-N(1)-H(1A) 125.9 
C(13)-N(1)-H(1A) 125.9 C(7)-C(2)-N(1) 110.26(10) 
C(7)-C(2)-C(3) 124.79(10) N(1)-C(2)-C(3) 124.78(10) 
C(2)-C(3)-N(4) 105.01(8) C(2)-C(3)-C(14) 114.34(9) 
N(4)-C(3)-C(14) 111.40(9) C(2)-C(3)-H(3A) 108.6 
N(4)-C(3)-H(3A) 108.6 C(14)-C(3)-H(3A) 108.6 
C(22)-N(4)-C(5) 107.98(8) C(22)-N(4)-C(3) 109.36(8) 
C(5)-N(4)-C(3) 109.37(8) N(4)-C(5)-C(6) 107.96(8) 
N(4)-C(5)-C(16) 110.68(8) C(6)-C(5)-C(16) 114.89(9) 
N(4)-C(5)-H(5A) 107.7 C(6)-C(5)-H(5A) 107.7 
C(16)-C(5)-H(5A) 107.7 O(6)-C(6)-C(7) 109.63(8) 
O(6)-C(6)-C(5) 111.23(8) C(7)-C(6)-C(5) 109.26(9) 
O(6)-C(6)-H(6A) 108.9 C(7)-C(6)-H(6A) 108.9 
C(5)-C(6)-H(6A) 108.9 C(6)-O(6)-H(6B) 109.5 
C(2)-C(7)-C(8) 107.02(10) C(2)-C(7)-C(6) 122.41(10) 
C(8)-C(7)-C(6) 130.54(10) C(9)-C(8)-C(13) 119.14(10) 
C(9)-C(8)-C(7) 134.35(11) C(13)-C(8)-C(7) 106.46(10) 
C(10)-C(9)-C(8) 118.66(11) C(10)-C(9)-H(9A) 120.7 
C(8)-C(9)-H(9A) 120.7 C(9)-C(10)-C(11) 121.11(12) 
C(9)-C(10)-H(10A) 119.4 C(11)-C(10)-H(10A) 119.4 
C(12)-C(11)-C(10) 121.62(11) C(12)-C(11)-H(11A) 119.2 
C(10)-C(11)-H(11A) 119.2 C(11)-C(12)-C(13) 117.21(12) 
________________________________________________________________________________
305 
 
Table 10.  (continued) 
________________________________________________________________________________ 
C(11)-C(12)-H(12A) 121.4 C(13)-C(12)-H(12A) 121.4 
N(1)-C(13)-C(12) 129.79(11) N(1)-C(13)-C(8) 107.97(10) 
C(12)-C(13)-C(8) 122.22(11) C(15)-C(14)-C(3) 107.85(9) 
C(15)-C(14)-H(14A) 110.1 C(3)-C(14)-H(14A) 110.1 
C(15)-C(14)-H(14B) 110.1 C(3)-C(14)-H(14B) 110.1 
H(14A)-C(14)-H(14B) 108.5 C(21)-C(15)-C(14) 107.15(9) 
C(21)-C(15)-C(16) 109.83(9) C(14)-C(15)-C(16) 107.80(9) 
C(21)-C(15)-H(15A) 110.7 C(14)-C(15)-H(15A) 110.7 
C(16)-C(15)-H(15A) 110.7 C(17)-C(16)-C(15) 111.98(9) 
C(17)-C(16)-C(5) 110.40(9) C(15)-C(16)-C(5) 108.26(9) 
C(17)-C(16)-H(16A) 108.7 C(15)-C(16)-H(16A) 108.7 
C(5)-C(16)-H(16A) 108.7 O(18)-C(17)-C(16) 113.16(10) 
O(18)-C(17)-H(17A) 108.9 C(16)-C(17)-H(17A) 108.9 
O(18)-C(17)-H(17B) 108.9 C(16)-C(17)-H(17B) 108.9 
H(17A)-C(17)-H(17B) 107.8 C(17)-O(18)-H(18A) 109.5 
C(20)-C(19)-H(19A) 109.5 C(20)-C(19)-H(19B) 109.5 
H(19A)-C(19)-H(19B) 109.5 C(20)-C(19)-H(19C) 109.5 
H(19A)-C(19)-H(19C) 109.5 H(19B)-C(19)-H(19C) 109.5 
C(21)-C(20)-C(19) 126.91(14) C(21)-C(20)-H(20A) 116.5 
C(19)-C(20)-H(20A) 116.5 C(20)-C(21)-C(15) 127.85(11) 
C(20)-C(21)-C(22) 121.13(11) C(15)-C(21)-C(22) 110.94(9) 
N(4)-C(22)-C(21) 110.67(9) N(4)-C(22)-H(22D) 109.5 
C(21)-C(22)-H(22D) 109.5 N(4)-C(22)-H(22E) 109.5 
C(21)-C(22)-H(22E) 109.5 H(22D)-C(22)-H(22E) 108.1 
C(1S)-O(1S)-H(1S) 109.5 O(1S)-C(1S)-H(1SC) 109.5 
O(1S)-C(1S)-H(1SB) 109.5 H(1SC)-C(1S)-H(1SB) 109.5 
O(1S)-C(1S)-H(1SA) 109.5 H(1SC)-C(1S)-H(1SA) 109.5 
H(1SB)-C(1S)-H(1SA) 109.5 C(2S)-O(2S)-H(2S) 110.8(3) 
O(2S)-C(2S)-H(2SA) 109.5 O(2S)-C(2S)-H(2SB) 109.5 
H(2SA)-C(2S)-H(2SB) 109.5 O(2S)-C(2S)-H(2SC) 109.5 
H(2SA)-C(2S)-H(2SC) 109.5 H(2SB)-C(2S)-H(2SC) 109.5 
________________________________________________________________________________  
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Table 11.  Anisotropic displacement parameters (Å2 x 103) for 110.  The anisotropic displacement factor 
exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
N(1) 13(1)  25(1) 18(1)  -1(1) 4(1)  -1(1) 
C(2) 13(1)  21(1) 13(1)  1(1) 1(1)  1(1) 
C(3) 12(1)  19(1) 15(1)  3(1) 1(1)  -2(1) 
N(4) 13(1)  16(1) 14(1)  0(1) 0(1)  -1(1) 
C(5) 12(1)  17(1) 13(1)  1(1) 0(1)  0(1) 
C(6) 11(1)  19(1) 12(1)  0(1) 1(1)  -1(1) 
O(6) 14(1)  26(1) 14(1)  0(1) 0(1)  -5(1) 
C(7) 13(1)  19(1) 14(1)  0(1) 1(1)  1(1) 
C(8) 14(1)  22(1) 14(1)  -2(1) -1(1)  2(1) 
C(9) 19(1)  24(1) 21(1)  -3(1) -1(1)  -1(1) 
C(10) 24(1)  25(1) 28(1)  -8(1) -3(1)  2(1) 
C(11) 23(1)  33(1) 23(1)  -10(1) -1(1)  8(1) 
C(12) 18(1)  34(1) 18(1)  -5(1) 2(1)  4(1) 
C(13) 14(1)  26(1) 15(1)  -2(1) 0(1)  3(1) 
C(14) 18(1)  21(1) 18(1)  6(1) 2(1)  -1(1) 
C(15) 17(1)  19(1) 20(1)  5(1) 0(1)  1(1) 
C(16) 13(1)  20(1) 16(1)  5(1) -2(1)  2(1) 
C(17) 14(1)  27(1) 25(1)  5(1) -1(1)  3(1) 
O(18) 24(1)  32(1) 32(1)  5(1) -8(1)  9(1) 
C(19) 41(1)  25(1) 54(1)  3(1) -6(1)  13(1) 
C(20) 27(1)  24(1) 32(1)  -1(1) -3(1)  6(1) 
C(21) 17(1)  18(1) 23(1)  3(1) 0(1)  0(1) 
C(22) 20(1)  16(1) 17(1)  -1(1) -2(1)  -1(1) 
O(1S) 19(1)  37(1) 21(1)  6(1) 0(1)  -1(1) 
C(1S) 33(1)  57(1) 25(1)  9(1) -5(1)  0(1) 
O(2S) 29(1)  56(1) 18(1)  -3(1) -2(1)  11(1) 
C(2S) 38(1)  41(1) 23(1)  5(1) 7(1)  13(1) 
______________________________________________________________________________ 
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Table 12.  Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103) for 110. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1A) 7191 6900 1596 22 
H(3A) 8089 5657 516 19 
H(5A) 12571 6265 -192 16 
H(6A) 11666 7957 21 17 
H(6B) 13840 8142 535 26 
H(9A) 11375 9876 1123 25 
H(10A) 9928 11098 1802 30 
H(11A) 7592 10575 2390 31 
H(12A) 6589 8826 2290 28 
H(14A) 9965 5125 1614 23 
H(14B) 9087 4278 1111 23 
H(15A) 11990 3979 1136 22 
H(16A) 12547 5916 1256 20 
H(17A) 14347 4886 164 26 
H(17B) 14946 5931 572 26 
H(18A) 15198 4957 1500 44 
H(19A) 12363 1588 -40 60 
H(19B) 11547 2028 661 60 
H(19C) 13309 2421 445 60 
H(20A) 11281 2993 -610 33 
H(22D) 10974 5035 -785 21 
H(22E) 9274 4670 -472 21 
H(1S) 4845 6716 2172 39 
H(1SC) 6968 6564 2959 58 
H(1SB) 6429 5333 2951 58 
H(1SA) 5202 6236 3213 58 
H(2S) 13284(9) 7984(18) 1788(1) 51 
H(2SA) 12095 8915 2635 51 
H(2SB) 12826 8045 3161 51 
H(2SC) 11485 7699 2606 51 
________________________________________________________________________________ 
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Table 13.  Torsion angles [°] for 110. 
________________________________________________________________________________   
C(13)-N(1)-C(2)-C(7) 0.34(13) C(13)-N(1)-C(2)-C(3) -175.08(10) 
C(7)-C(2)-C(3)-N(4) -20.77(14) N(1)-C(2)-C(3)-N(4) 153.99(10) 
C(7)-C(2)-C(3)-C(14) 101.63(12) N(1)-C(2)-C(3)-C(14) -83.61(13) 
C(2)-C(3)-N(4)-C(22) 177.07(9) C(14)-C(3)-N(4)-C(22) 52.78(11) 
C(2)-C(3)-N(4)-C(5) 59.02(10) C(14)-C(3)-N(4)-C(5) -65.27(11) 
C(22)-N(4)-C(5)-C(6) 166.16(8) C(3)-N(4)-C(5)-C(6) -74.93(10) 
C(22)-N(4)-C(5)-C(16) -67.31(10) C(3)-N(4)-C(5)-C(16) 51.60(11) 
N(4)-C(5)-C(6)-O(6) 165.99(8) C(16)-C(5)-C(6)-O(6) 41.96(12) 
N(4)-C(5)-C(6)-C(7) 44.82(10) C(16)-C(5)-C(6)-C(7) -79.21(11) 
N(1)-C(2)-C(7)-C(8) -1.32(13) C(3)-C(2)-C(7)-C(8) 174.09(10) 
N(1)-C(2)-C(7)-C(6) -179.39(10) C(3)-C(2)-C(7)-C(6) -3.98(17) 
O(6)-C(6)-C(7)-C(2) -130.32(11) C(5)-C(6)-C(7)-C(2) -8.19(14) 
O(6)-C(6)-C(7)-C(8) 52.11(15) C(5)-C(6)-C(7)-C(8) 174.24(11) 
C(2)-C(7)-C(8)-C(9) -175.80(13) C(6)-C(7)-C(8)-C(9) 2.1(2) 
C(2)-C(7)-C(8)-C(13) 1.77(12) C(6)-C(7)-C(8)-C(13) 179.63(11) 
C(13)-C(8)-C(9)-C(10) 0.58(17) C(7)-C(8)-C(9)-C(10) 177.92(12) 
C(8)-C(9)-C(10)-C(11) 0.79(19) C(9)-C(10)-C(11)-C(12) -1.1(2) 
C(10)-C(11)-C(12)-C(13) -0.09(19) C(2)-N(1)-C(13)-C(12) 178.83(12) 
C(2)-N(1)-C(13)-C(8) 0.81(12) C(11)-C(12)-C(13)-N(1) -176.27(12) 
C(11)-C(12)-C(13)-C(8) 1.51(18) C(9)-C(8)-C(13)-N(1) 176.43(10) 
C(7)-C(8)-C(13)-N(1) -1.59(12) C(9)-C(8)-C(13)-C(12) -1.78(17) 
C(7)-C(8)-C(13)-C(12) -179.79(11) C(2)-C(3)-C(14)-C(15) -109.10(11) 
N(4)-C(3)-C(14)-C(15) 9.75(12) C(3)-C(14)-C(15)-C(21) -64.15(11) 
C(3)-C(14)-C(15)-C(16) 54.00(11) C(21)-C(15)-C(16)-C(17) -72.68(12) 
C(14)-C(15)-C(16)-C(17) 170.90(9) C(21)-C(15)-C(16)-C(5) 49.27(12) 
C(14)-C(15)-C(16)-C(5) -67.15(11) N(4)-C(5)-C(16)-C(17) 135.38(9) 
C(6)-C(5)-C(16)-C(17) -102.04(11) N(4)-C(5)-C(16)-C(15) 12.47(12) 
C(6)-C(5)-C(16)-C(15) 135.05(10) C(15)-C(16)-C(17)-O(18) -62.10(13) 
C(5)-C(16)-C(17)-O(18) 177.19(10) C(19)-C(20)-C(21)-C(15) 0.8(2) 
C(19)-C(20)-C(21)-C(22) -175.55(14) C(14)-C(15)-C(21)-C(20) -120.57(14) 
C(16)-C(15)-C(21)-C(20) 122.61(13) C(14)-C(15)-C(21)-C(22) 56.12(12) 
C(16)-C(15)-C(21)-C(22) -60.71(12) C(5)-N(4)-C(22)-C(21) 56.56(11) 
C(3)-N(4)-C(22)-C(21) -62.36(11) C(20)-C(21)-C(22)-N(4) -176.72(11) 
C(15)-C(21)-C(22)-N(4) 6.34(13) 
________________________________________________________________________________   
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Table 14.  Hydrogen bonds for 110 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(1)-H(1A)...O(1S) 0.88 2.02 2.8717(13) 163.7 
 O(6)-H(6B)...N(4)#1 0.84 1.92 2.7569(12) 172.2 
 O(18)-H(18A)...O(1S)#2 0.84 2.05 2.8593(15) 162.8 
 O(1S)-H(1S)...O(2S)#3 0.84 1.81 2.6472(15) 173.4 
 O(2S)-H(2S)...O(6) 0.8402(10) 1.880(3) 2.6783(13) 158.3(7) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x+1/2,-y+3/2,-z    #2 x+1,y,z    #3 x-1,y,z       
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ABSTRACT 
In order to investigate the possible role of GABAA/α5 receptors in behavioral 
effects of benzodiazepines (BZ), the effects of QH-ii-066, the GABAA/α5-preferring 
agonist, were compared with diazepam in binding and electrophysiology assays and 
behavioral models of anxiety, epilepsy, and side effects (activity, motor coordination, and 
subjective effects).  QH-ii-066, while having similar affinity for BZ-sensitive GABAA 
receptor subtypes, showed functional selectivity for GABAA/α5 receptors over 
GABAA/α1 receptors.  QH-ii-066 increased punished responding in the Geller conflict 
test in rats and protected against pentylenetetrazole (PTZ)-induced seizures in mice at 
doses similar to those of diazepam, but was less potent than diazepam in protecting 
against electroconvulsive shock (ECS)-induced seizures, suggesting that GABAA/α1 
receptors may play a bigger role in ECS- than PTZ-induced seizures.  QH-ii-066 showed 
a larger separation between doses effective in the conflict model and those effective in the 
conditioned fear, locomotor activity, rotorod, and chlordiazepoxide drug discrimination.  
In the case of locomotor activity and chlordiazepoxide drug discrimination, the decreased 
potency of QH-ii-066 compared with diazepam indicate that GABAA/α1 receptors play a 
more prominent role in sedative and chlordiazepoxide-like subjective effects of BZs.  
These data suggest that compounds like QH-ii-066 with reduced efficacy at GABAA/α1 
receptors may be effective anxiolytics with a reduced potential for side effects. 
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Although benzodiazepines (BZ) are the most frequently prescribed anxiolytics, their use is 
accompanied by significant side effects, most notably, sedation, ataxia, memory 
impairment, potentiation of their effects by ethanol, development of tolerance and 
dependence, and abuse liability.  Efforts to discover anxiolytics with reduced side effect 
profiles have centered on two types of compounds, those acting by a different mechanism 
(e.g., 5-HT1A receptor agonists and CRF1 receptor antagonists) and BZ-like compounds 
showing functional selectivity, i.e., acting with high efficacy at some GABAA receptors 
and with low or no efficacy on other GABAA receptors.  The latter approach assumes that 
the therapeutic and adverse effects of classical BZs are mediated by different GABAA 
receptors and that reducing binding affinity and/or efficacy at receptors mediating adverse 
effects will result in a superior anxiolytic compared with classical BZs. 
 Zolpidem and zaleplon, two compounds with selectivity for GABAA/α1 receptors, 
decrease sleep latency and increase sleep duration (e.g., Fry et al., 2000) and are marketed 
for treatment of insomnia.  In addition, recent studies with transgenic mice and GABAA 
receptor-selective compounds have indicated that GABAA/α1 receptors mediate 
sedative/ataxic effects of classical BZs (Rudolph et al., 1999; McKernan et al., 2000; 
Kralic et al., 2002). 
The role of other BZ-sensitive GABAA receptors, containing α2, α3, or α5 
subunits, in the behavioral effects of classical BZs is less clear.  Mice with a point 
mutation rendering GABAA/α2 receptors insensitive to diazepam (GABAA/α2 receptor 
knock-in mice) do not exhibit anxiolytic or myorelaxant effects when treated with 
diazepam, whereas GABAA/α3 receptor knock-in mice showed a normal anxiolytic 
response to diazepam, with reduced myorelaxant effects (Löw et al., 2000; Crestani et al., 
2001).  However, selective GABAA/α3 receptor inverse agonists appear to be anxiogenic 
(Collins et al., 2002), indicating that GABAA/α3 receptors may be involved in anxiolytic 
effects of BZs.  In addition, compounds with higher intrinsic efficacy at GABAA/α2 and 
GABAA/α3 receptors, and lower or no efficacy at GABAA/α1 and GABAA/α5 receptors, 
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show anxiolytic and anticonvulsant effects in rodents (Griebel et al., 2001).  These studies 
suggest that both GABAA/α2 and GABAA/α3 receptors may play a role in the anxiolytic 
effects of classical BZs.  Thus, an ideal compound, an anxiolytic with reduced motoric 
side effect profile, would have no affinity or, at least, no efficacy at the GABAA/α1 
receptors and high affinity and high efficacy at GABAA/α2 and GABAA/α3 receptors.   
The role of GABAA/α5 receptors remains to be elucidated.  Thus far, only one 
study used GABAA/α5 receptor knock-in mice to investigate the role of GABAA/α5 
receptors.  Collinson et al. (2002) showed that these mice show no overt phenotype: their 
baseline anxiety-related response, as measured by elevated plus maze, did not differ from 
those of wild-type mice, they showed no spontaneous seizures, no impairment in rotorod 
performance, and normal anxiolytic-like responses to chlordiazepoxide (CDP).  These 
animals did show faster learning of a Morris water maze task, suggesting that GABAA/α5 
receptors may play a role in the memory-impairing effects of classical BZs.  This result is 
consistent with the finding that most GABAA/α5 receptors are located in the hippocampus, 
a brain region shown to be involved in learning and memory.  Furthermore, inverse 
agonists at this site show memory-enhancing effects in animals (Chambers et al., 2003), 
and some of these compounds also show anxiogenic and proconvulsant effects (Navarro et 
al., 2002).   
As is the case with GABAA/α2- and GABAA/α3 receptor-selective compounds, 
studies with agonists selective for GABAA/α5 receptors are scarce.  QH-ii-066 (7-
acetyleno-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one), a compound with 
6-fold selectivity for GABAA/α5 receptors compared with GABAA/α2 and GABAA/α3 
receptors and 11-fold selectivity compared with GABAA/α1 receptors (Huang et al., 
2000), differs from classical BZs in that it did not share subjective effects with triazolam 
in squirrel monkeys (Lelas et al., 2002).  Like classical BZs, QH-ii-066 protected against 
seizures induced by BZ inverse agonists DMCM and RY-24 (Skolnick et al., 1997).   
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The present studies were designed to compare the effects of QH-ii-066 and 
diazepam in an array of in vitro and in vivo assays.  QH-ii-066 is a 7-acetyleno congener of 
diazepam (Figure 1) and thus, diazepam was chosen as the classical BZ for comparison.  
The two compounds were characterized in binding and electrophysiology functional assays 
(HEK whole-cell patch clamp) and in models of anxiety (conflict), pentylenetetrazole 
(PTZ)- and electroconvulsive shock (ECS)- induced seizures, learning and memory 
(conditioned fear), sedation (locomotor activity), ataxia (rotorod performance), and BZ-
like subjective effects (CDP drug discrimination) in rodents.  Differences observed 
between QH-ii-066 and diazepam in these assays would provide an indication of the 
potential contribution of GABAA/α5 receptors to these effects of classical BZs. 
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METHODS 
Subjects 
  All animals were maintained in accordance with the guidelines of the Committee 
on Animals of the Bristol-Myers Squibb Company and the “Guide for Care and Use of 
Laboratory Animals” (Institute of Animal Laboratory Resources, 1996).  Research 
protocols were approved by the Bristol-Myers Squibb Company Institutional Animal Care 
and Use Committee. 
Male CDF rats weighing approximately 350 g at the time of the experiment 
(conflict), male Sprague-Dawley rats weighing 180-300 g (locomotor activity, rotorod 
studies, and drug discrimination studies) and male CF1 mice weighing 20-22 g at the time 
of the experiment (seizure studies) were purchased from Charles River Laboratories 
(Wilmington, Mass., USA).  For the conditioned fear studies, male Sprague-Dawley rats 
weighing approximately 225 g at the time of the experiment were purchased from Harlan 
(Indianapolis, Ind., USA).  Animals were housed in pairs or fours in clear plastic shoebox 
cages with Beta Chip bedding in rooms maintained at constant temperature (21-23°C) and 
humidity (50 ± 10%) with a 12 h light/dark cycle (lights on at 0600 h, except for mice 
lights were on at 0500 h), except for the drug discrimination study for which animals were 
housed individually in suspended wire cages. 
Animals had ad libitum access to food and water throughout the studies, except for 
the conflict and drug discrimination studies in which animals were restricted to 9 g 
(conflict) or 12 g (drug discrimination) of laboratory rodent chow (Bio-Serv, Frenchtown, 
NJ) per day in addition to the food earned in operant box, with unlimited access to water.  
All training and testing was done between 0600 and 1300 h Monday through Friday of 
each week. 
 
 
 
   
316 
 
Procedures 
GABAA Binding Assay 
 HEK293 cells were trypsinized and counted.  Cells were transfected using the 
Amaxa electroporator and 3 million cells per sample.  Each transfection was performed in 
Amaxa solution “V” using electroporation program Q-01 (Amaxa Inc., Gaithersburg, Md., 
USA).  1 µg of each GABA subunit (α, β, and γ) was used per transfection.  Following 
electroporation, cells were plated onto poly-lysin coated glass coverslips and used for the 
experiments. 
Electrophysiological Studies 
 Whole-cell patch-clamp experiments were performed using HEK cell lines 
transiently expressing two different configurations of GABAA constructs, on the first or 
second day after the transfection.  Cells were plated onto 25 mm Petri dishes and viewed 
using Nikon TE200 inverted microscope, equipped with the mercury lamp to monitor GFP 
fluorescence.  Cells were continuously perfused with extracellular physiological solution 
containing (in mM): NaCl 140, KCl 2.5, CaCl2 2, MgSO4 2, Na2HPO4 1.25, HEPES 10, 
Glucose 11, pH 7.4 and 340 mOsm (modified from Brown et al., 2002).  Patch pipettes 
were pulled using Narishige vertical puller from fire-polished borosillicate glass 
capillaries.  Pipette resistance was between 3.5 and 6 MOm.  The intracellular solution 
contained (in mM): CsCl 140, HEPES 10, EGTA 5, MgATP 2, MgCl2 3, pH 7.3 and 340 
mOsm. 
 Cells were voltage-clamped at -20 mV via an EPC10 amplifier (HEKA 
Electronics, Southboro, Mass.).  Preliminary experiments have shown that amplitude of 
the GABA-induced current in these cells was not significantly different at -60, -40 or -20 
mV holding potentials.  At the same time, -20 mV holding potential facilitated longer 
experimental time which enabled testing of several concentrations of the test compounds.  
Drug solutions were applied to the cells via a multi-channel local perfusion system 
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(AutoMate Scientific, Inc., San Francisco, Calif.) with the estimated solution change time 
of 20 ms. 
 GABA was applied to the cell for 20 s with a 60 s washout period between 
applications, which was found to be a sufficient time period to reverse any desensitization 
that may occur.  In addition, to ensure that there is no desensitization that may affect 
GABA responses at any given concentration of a GABA modulator, GABA was applied 
twice during control (no drug) and once at each concentration of the test compound.  Test 
compounds were applied in increasing concentrations (1, 10, 100, or 1000 nM) 60 s prior 
to GABA (3 µM) applications. 
Geller Conflict with Incremental Shock in Rats 
Experiments were conducted in 8 model E10-10 Coulbourn operant chambers 
(Coulbourn Instruments, Allentown, Penn., USA; 28 x 26 x 31 cm) with an electrified grid 
floor which were housed in light-proof, sound-attenuated, and fan-ventilated chambers.  
On one wall of each operant chamber was a houselight and a centrally placed food hopper 
3 cm from the floor that delivered one 45-mg food pellet (Dustless Precision Pellets, Bio-
Serv, Frenchtown, N.J., USA).  To the left was mounted a lever response module with cue 
lights above.  Foot-shock was delivered using an H13-16 Universal Shocker.  Experiments 
were controlled with a Compaq DeskPro computer running Graphic State Notation 
software through Habitest Universal Linc interface equipment (Coulbourn Instruments).   
Rats were trained to stability on an alternating multiple Random Interval 30 
s/Fixed Ratio 1 Food +Shock paradigm (RI15/FR1 F+S).  The paradigm ran through four 
cycles beginning with the Random Interval (RI) schedule which ran for 12 minutes then 
switched to the Fixed Ratio (FR) schedule which was cued and ran for 3 minutes.  The RI 
had a range of 15 to 45 s with the food pellet being delivered with the first lever press after 
the expiration of the interval.  The FR schedule delivered a food pellet after each lever 
press along with a foot-shock that increased with each lever press beginning at zero on the 
first lever press then increasing to 0.05 mA on the second lever press and incrementing by 
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0.05 mA with each subsequent lever press.  The shock was reset to zero at the beginning 
of each RI/FR cycle.   
Protection against Pentylenetetrazole- and Shock-Induced Seizures in Mice 
Pentylenetetrazole (PTZ) was administered at 125 mg/kg s.c.  The number of 
animals surviving was recorded at 30 minutes and 60 minutes after administration of PTZ.  
Electroshock is administered using a Ugo Basile ECT, Unit 7801 seizure apparatus (Ugo 
Basile, Italy) and corneal electrodes soaked in 0.9% saline.  Mice received a shock of 30 
mA for 0.3 s.  The number of animals that exhibited the hind-limb extensor component of 
the seizure was recorded. 
Conditioned Fear in Rats 
Experiments were conducted in standard modular test chambers (ENV-008, Med 
Associates, St. Albans, Vt., USA, 30.5 x 24.1 x 21 cm) with an electrified grid floor which 
were housed in light-proof, sound-attenuated, and fan-ventilated chambers.  Foot-shock 
was delivered using a shocker/scrambler module (ENV-414).  Experiments were 
controlled with a desktop computer using Med-PC software through Smart Ctrl interface 
equipment (Med-Associates).   
On day 1, rats were placed in the test chambers for a 7-minute conditioning session 
consisting of 2.5 minutes of habituation, a 2-s foot-shock at 0.7 mA, followed by 2.5 
minutes of no foot-shock, another 2-s, 0.7 mA foot-shock, and another 2 minutes with no 
foot-shock.  Twenty-four hours after the conditioning session, rats were placed in the test 
chamber again for 7 minutes with no foot-shocks and percent time freezing was quantified 
by video image analysis (Freezeview software using filter 25 and bout length of 0.75 s; 
Actimetrics and Coulbourn Instruments, Allentown, Penn., USA). 
Spontaneous Locomotor Activity in Rats 
The testing apparatus consisted of Plexiglas chambers (42 x 42 x 30 cm) equipped 
with Digiscan activity monitors (Omnitech Electronics, Columbus, Ohio, USA) that detect 
interruptions of eight photobeams spaced 5 cm apart and 2.5 cm above the floor.  
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Horizontal activity was recorded in 5-minute bins for a total of 60 minutes and expressed 
as total distance covered (in cm).   
Rotorod Performance in Rats 
The degree of motor coordination or balance was determined using a standard 
accelerating rotorod treadmill (Ugo Basile, Comerio-Varese, Italy) that was 6 cm in 
diameter and 24 cm above the base.  The speed was increased gradually from 2 rpm to a 
maximum speed of 20 rpm.  The time each animal remained on the rotating rod was 
automatically recorded, up to a maximum of 5 minutes.  Three acclimation trials were 
conducted for each animal prior to administration of drugs.  The time on rotorod from the 
third trial was used to counterbalance animals for subsequent drug testing. 
Chlordiazepoxide Discrimination in Rats 
Twelve model E10-10 Coulbourn operant conditioning chambers (Coulbourn 
Instruments, Allentown, Penn., USA; 28 x 26 x 31 cm) were housed in light-proof, sound-
attenuated, and fan-ventilated chambers.  Each operant conditioning chamber was 
equipped with two non-retractable levers, requiring a downward force equivalent to 15 g 
(0.15 N), that were mounted 3 cm from the side wall, 3 cm above the metal grid floor, and 
5 cm from a centrally placed food tray that delivered one 45-mg food pellet (Dustless 
Precision Pellets, Bio-Serv, Frenchtown, N.J.).  The experimental chambers were 
connected to a Micro PDP11/73 computer using a LAB LINC interface.  A SKED-11 
operating system (State System, Kalamazoo, Mich.) was used to record and control 
behavior. 
 After habituation to the operant conditioning chamber, rats were trained to 
alternate daily between response levers on an FR 1 schedule of food reinforcement.  Once 
lever pressing was well established, the reinforcement contingency was increased 
incrementally to an FR 10 schedule of food reinforcement, while maintaining the lever 
alternation.  Rats were then trained to discriminate between an intraperitoneal (IP) 
injection of drug (5.0 mg/kg CDP) and vehicle (0.25% methylcellulose) administered 30 
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minutes prior to the start of the session.  Ten consecutive responses on the injection-
appropriate lever resulted in food delivery.  Responses on the incorrect lever did not result 
in pellet delivery.  Following an injection of CDP, responding on the right lever was 
reinforced for half the rats and responding on the left lever was reinforced for the other 
rats.  In each two-week period there were five drug days and five saline days, with the 
constraint that there not be more than three consecutive drug or vehicle days. 
Drug test sessions were conducted once a week (Fridays) with training sessions 
scheduled on intervening days (Monday – Thursday).  The criterion for testing was 
achieved if no more than three incorrect responses occurred prior to the first reinforcer for 
at least 9 out of 10 consecutive sessions.  During test sessions, the lever on which the rat 
first made 10 consecutive responses resulting in delivery of the first food pellet was 
designated the “selected “ lever and subsequent pellet delivery was made contingent on 
responding on this selected lever on an FR10 schedule.  The selected lever, the number of 
responses prior to the first food pellet delivery, and the total number of responses in the 
session were recorded for each rat.  The duration of test sessions was ten minutes.  Dose-
response functions were determined for CDP, diazepam, and QH-ii-066. 
 
Drugs 
GABA, diazepam, PTZ, and CDP HCl were purchased from Sigma (St. Louis, 
Mo., USA).  QH-ii-066 was synthesized by Xiaoyan Li, Wenyuan Yin, and Dongmei Han 
at the University of Wisconsin.  Compounds were prepared as suspensions in an aqueous 
vehicle of 0.25% methylcellulose (Type A15c, Dow Chemicals), except for diazepam in 
the conditioned fear study which was prepared in 40% propylene glycol / 10% ethanol / 
50% benzoic acid solution.  Stock suspensions were bead-milled overnight using three 
layers of 4-mm glass beads.  Dilutions were made using the 0.25% methylcellulose 
vehicle.  Compounds were administered orally by gavage (PO) 60 minutes before 
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behavioral testing in a volume of 2 ml/kg body weight.  Doses of all drugs were calculated 
and are expressed in terms of the free base weight.  
 
Data Analysis 
In the electrophysiology experiments, the amplitude of the IGABA in each cell was 
normalized to IGABA produced by 3 μM GABA in the absence of drug in the same cell.  
Data (% increase of IGABA) from 3-6 cells for each concentration were averaged and 
concentration-response curves for each test compound were constructed using ExcelFit.  
All data are presented as mean ± 1 SEM. 
Results for conflict, locomotor activity, and rotorod performance are expressed as 
the mean ± 1 SEM.   Results for the PTZ- and ECS-induced seizures are presented as the 
percent of animals protected from death and percent of animals protected from the hind-
limb extensor component of the seizure, respectively.   Results for the drug discrimination 
study are expressed as the percent of animals selecting the CDP-appropriate lever.  A drug 
was considered to substitute fully for CDP if 75% of the animals selected the CDP-
appropriate lever.  Response rates were expressed as percentage of control rate (average of 
the vehicle training session immediately before and the vehicle session immediately after 
the test) for individual animals, averaged across animals, and plotted as a function of dose 
(mean ± 1 SEM).  All data were subjected to analysis of variance (ANOVA) followed by 
individual mean comparisons using Fisher’s Least Significant Difference Test (Kirk, 
1968) where appropriate.  The significance level was set at P<0.05.  ED50 values were 
calculated by linear regression. 
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RESULTS 
GABAA Binding Assay  
 Binding affinities of QH-ii-066 and diazepam at different rat GABAA receptor 
subtypes are shown in Table 1.  QH-ii-066 showed similar affinity for the six rat GABAA 
receptors examined (range of Ki = 40-72 nM).  Similarly, diazepam showed comparable 
binding affinity at all GABAA receptor subtypes studied (range of Ki values was 20-28 
nM).  QH-ii-066 had a 2- to 3-fold lower affinity than diazepam at the six receptors 
studied. 
Electrophysiological Studies 
 Application of GABA resulted in a dose-dependent increase in Cl- currents in 
GABAA/α1β2γ2 and GABAA/α5β2γ2 receptors transiently expressed in HEK cells (data 
not shown).  The EC50 value for GABA was 7.55±0.58.  Diazepam and QH-ii-066 both 
potentiated GABA-induced Cl- currents at both GABAA/α1β2γ2 and GABAA/α5β2γ2 
receptors in a concentration-dependent manner (Figure 2).  At the GABAA/α1β2γ2 
receptors, maximum potentiation of IGABA by diazepam occurred at 1 µM and reached 
389% of control, whereas maximum potentiation of IGABA by QH-ii-066 occurred at 100 
nM and reached only 200% (at 1 µM, the potentation of IGABA by QH-ii-066 reached 180% 
of control).  In contrast, at the GABAA/α5β2γ2 receptors, maximum potentiation of IGABA 
by diazepam and QH-ii-066 occurred at the same concentration (1 µM) and reached 
similar levels (282% and 289% of control, respectively). 
Geller Conflict with Incremental Shock in Rats 
 Diazepam and QH-ii-066 increased punished responding without altering the rate 
of responding in the unpunished component (Figure 3).  Diazepam significantly increased 
responding in the punished component to 178% of control at the dose of 3.0 mg/kg PO 
[F(3,21)=3.38, P=0.04].  QH-ii-066 significantly increased punished responding to 149% 
of control at the dose of 10 mg/kg PO [F(3,15)=3.7, P=0.04].  Thus, QH-ii-066 is 3-fold 
less potent than diazepam in increasing punished responding in rats.  The doses of 
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diazepam and QH-ii-066 that produced a significant increase in punished responding did 
not alter rates of responding in the punished component [F(3,21)=1.72, P=0.19 for 
diazepam; F(3,15)=3.14, P=0.06 for QH-ii-066]. 
Protection from Pentylenetetrazole- and Shock-Induced Seizures in Mice 
 Diazepam and QH-ii-066 both fully protected against both PTZ- (at 1.0 and 10 
mg/kg PO, respectively) and ECS- (10 and 100 mg/kg PO, respectively) induced seizures 
in mice (Figure 4).  The ED50 values for the protective effects of diazepam and QH-ii-066 
are 0.27 mg/kg and <3 mg/kg against PTZ-induced seizures, respectively.  The ED50 
values for the protective effects of diazepam and QH-ii-066 are 0.88 mg/kg and 18.57 
mg/kg against ECS-induced seizures, respectively.  Thus, QH-ii-066 is approximately 11-
fold and 21-fold less potent in protecting against PTZ- and ECS-induced seizures, 
respectively, than diazepam.  Both compounds are more potent in protecting against PTZ- 
than ECS-induced seizures, 3-fold more potent in the case of diazepam and more than 6-
fold more potent in the case of QH-ii-066. 
Conditioned Fear in Rats   
For both diazepam and QH-ii-066 experiments, vehicle-treated rats showed an 
increase in freezing observed on test day (day 2) compared with animals who did not 
receive shock (diazepam study: F(1,95)=19.88, P<0.0001; QH-ii-066 study: 
F(1,95)=13.27, P<0.0004).  Diazepam significantly decreased freezing on test day relative 
to the vehicle-treated group (Figure 5, left panel).  A dose of diazepam comparable to that 
which was effective in the conflict model (2.5 mg/kg) decreased percent freezing by 44% 
(F(1,95)=6.46, P=0.01) and a higher dose (5.0 mg/kg) also significantly decreased percent 
freezing by 39% (F(1,95)=5.11, P=0.03).  Unlike diazepam, QH-ii-066 did not alter 
freezing on test day relative to the vehicle-treated group at doses up to and including 10 
mg/kg (Figure 5, right panel; F(1,95)=0.5, P=0.48), the lowest effective dose in the 
conflict model. 
 
   
324 
 
Spontaneous Locomotor Activity in Rats 
 Diazepam and QH-ii-066 dose-dependently decreased spontaneous locomotor 
activity recorded 60-120 minutes after oral administration (corresponding to the 60-min 
pretreatment time and 60-min test duration in the conflict test) [diazepam F(5,42)=16.66, 
P<0.0001, Figure 6, left panel; QH-ii-066 F(6,49)=4.17, P=0.002, Figure 6, right panel].  
The lowest effective dose of diazepam in the conflict model (3.0 mg/kg) did not alter 
locomotor activity; however, a 3-fold higher dose (10 mg/kg) resulted in a significant 
reduction of locomotor activity (by 34%, P=0.001), as did the doses of 30 and 100 mg/kg 
(38%, P=0.0004 and 75%, P<0.0001, respectively).  In comparison, the lowest effective 
dose of QH-ii-066 in the conflict model (10 mg/kg) also did not alter locomotor activity; 
however, a 10-fold higher dose (100 mg/kg) resulted in a significant decrease in locomotor 
activity (by 49%; P=0.04). 
Rotorod Performance in Rats 
 Diazepam dose-dependently decreased motor coordination in rats as measured by 
time on rotorod [F(3,28)=5.43, P<0.005, Figure 7, left panel].  The dose of 100 mg/kg of 
diazepam resulted in a significant decrease in time on rotorod to 72% of control 
(P=0.001).  The dose of 3.0 mg/kg of diazepam, the lowest effective dose of diazepam in 
the conflict model, did not alter the time on rotorod (P=0.84); thus, the difference between 
the lowest effective dose of diazepam in the conflict model compared with rotorod 
performance is 33-fold.   
Unlike diazepam, QH-ii-066 did not alter time on rotorod in rats up to 100 mg/kg 
[F(3,27)=1.0, P=0.41, Figure 7, right panel].  The lowest effective dose of QH-ii-066 in 
the conflict model (10 mg/kg) did not alter rotorod performance (P=0.96) and neither did 
the highest dose of QH-ii-066 tested (100 mg/kg, P=0.44).  Thus, the difference between 
the lowest effective dose of QH-ii-066 in the conflict model compared with rotorod 
performance is greater than 10-fold. 
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Chlordiazepoxide Discrimination in Rats 
All rats acquired stimulus control with the training dose of CDP of 5.0 mg/kg (IP, 
administered 30 minutes before session).  These data were reported by Lelas et al. (2003).  
Briefly, the mean response rates (responses/min ± SEM) for vehicle and CDP were 67.1 ± 
8.5 and 91.7 ± 9.8, respectively.  The ED50 value for CDP was 1.7 mg/kg.  All three doses 
of CDP significantly increased response rates relative to vehicle control rates. 
Both diazepam and QH-ii-066 dose-dependently increased the percent of rats 
selecting the CDP lever (Figure 8).  At the lowest effective dose of diazepam in the 
conflict model (3.0 mg/kg) 86% of animals selected the CDP lever, and at 10 mg/kg 100% 
of animals selected the CDP lever.  The ED50 value for diazepam is 2.82 mg/kg.  In 
comparison, the lowest effective dose of QH-ii-066 in the conflict model (10 mg/kg) 
resulted in 63% of animals selecting the CDP lever, and at 30 mg/kg 100% of animals 
selected the CDP lever.  The ED50 value for QH-ii-066 is 8.56 mg/kg.  Thus, in the case of 
diazepam, there is no separation between the doses effective in the conflict model and 
those resulting in CDP-lever selection, whereas for QH-ii-066 this separation is 3-fold. 
Diazepam increased mean response rates, expressed as percent of control, at 5.0 
mg/kg to 158% of control [t(6)=2.69, P=0.04)], but did not alter rates of responding at the 
lower (1.0 mg/kg) or the higher (10 mg/kg) dose tested.  The highest dose of QH-ii-066 
tested (30 mg/kg) decreased response rates to 77% of control [t(8)=2.38, P=0.04].
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DISCUSSION 
The purpose of the present studies was to compare the in vitro and in vivo profiles 
of diazepam, a non-selective classical BZ agonist, and QH-ii-066, a 7-acetyleno congener 
of diazepam.  In contrast to the previously published data (Huang et al., 2000), the present 
study showed that QH-ii-066 did not bind selectively to any GABAA receptor subtype.  
Affinity of QH-ii-066 at GABAA/α1, GABAA/α2, GABAA/α3, and GABAA/α5 receptors 
was similar, ranging between 40 and 72 nM.  Binding affinity of QH-ii-066 and diazepam 
at the GABAA/α1 and GABAA/α5 receptors was similar in the presence of either β2 or β3 
subunits.  In the previous publication (Huang et al., 2000), QH-ii-066 showed a 6-fold 
selectivity for GABAA/α5 over GABAA/α2 and GABAA/α3 receptors and 11-fold 
selectivity over GABAA/α1 receptors.  Thus, the difference in binding affinity for the 
GABAA/α5 receptors between the two studies is 6-fold.  It is possible that this discrepancy 
is due to the fact that the Huang et al. (2000) study used cells expressing human GABA 
receptors, whereas the present study used rat GABA receptors.  When compared with 
diazepam, binding data from the present study show that the 7-acetyleno congener of 
diazepam exhibits approximately 2-fold lower affinity for all BZ-sensitive GABAA 
receptor subtypes. 
In contrast to the binding data, electrophysiology studies showed a functional 
selectivity of QH-ii-066 compared with diazepam.  The intrinsic efficacy of QH-ii-066 at 
the GABAA/α5 receptor was similar to the efficacy of diazepam, as measured by 
potentiation of GABA-induced Cl- currents in HEK cells transiently expressing 
GABAA/α5 receptors.  However, QH-ii-066 was approximately half as efficacious as 
diazepam in HEK cells transiently expressing GABAA/α1 receptors.  Thus, while QH-ii-
066 did not show binding selectivity, it did exhibit functional selectivity, with diazepam-
like efficacy at GABAA/α5 receptors and partial efficacy at GABAA/α1 receptors. 
In vivo, the effects of QH-ii-066 and diazepam were compared directly in 
behavioral models of anxiety, epilepsy, and side effects (sedation, motor incoordination, 
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and subjective effects).  QH-ii-066 and diazepam administered orally significantly 
increased punished responding in the Geller conflict test with incremental shock, an index 
of anxiolytic-like activity in rats.  QH-ii-066 was 3-fold less potent in this model 
compared with diazepam.  This loss of potency could be accounted for by lower affinity of 
QH-ii-066 at all BZ-sensitive GABAA receptors.  The present data suggest that QH-ii-066 
retained anxiolytic-like activity despite loss of efficacy at the GABAA/α1 receptors.  These 
data support the conclusion from studies using the GABAA/α1 receptor knock-out or 
knock-in mice showing normal anxiolytic-like response to diazepam in these animals 
(Kralic et al., 2002; Rudolph et al., 1999; McKernan et al., 2000), suggesting that 
GABAA/α1 receptors do not play an important role in the anxiolytic effects of BZs.  While 
efficacy of QH-ii-066 at the GABAA/α2 or GABAA/α3 receptors was not investigated in 
the present study, the similar effects of QH-ii-066 and diazepam in the conflict model 
suggest that QH-ii-066 retained diazepam-like intrinsic efficacy at these receptors. 
In addition to the anxiolytic-like effects, QH-ii-066 and diazepam also showed 
protective effects against PTZ- and ECS-induced seizures.  Diazepam was 3-fold less 
potent in protecting against ECS-induced seizures compared with PTZ-induced seizures; 
this difference was increased to 6-fold in the case of QH-ii-066.  When the two 
compounds are compared in potency in protecting against each type of seizures, diazepam 
was 11-fold more potent than QH-ii-066 in protecting against PTZ-induced seizures and 
21-fold more potent against ECS-induced seizures.  Thus, it appears that the 7-acetyleno 
substituted diazepam analog QH-ii-066 showed a greater loss of potency in protecting 
against ECS-induced seizures relative to diazepam than against PTZ-induced seizures.  
These data  may suggest that GABAA/α1 receptors play a more prominent role in the ECS-
induced seizures than in PTZ-induced seizures.  SL651498, a compound with lower 
efficacy at GABAA/α1 receptors (Griebel et al., 2001), and bretazenil, a low-efficacy 
agonist at many GABAA subtypes including GABAA/α1 receptors (Martin et al., 1988), 
were also more potent in reversing PTZ- than ECS-induced seizures.  In addition, Griebel 
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et al. (1999) showed that β-CCT, an GABAA/α1 receptor-preferring antagonist, did not 
alter protective effects of diazepam and zolpidem against PTZ-induced seizures, whereas 
it blocked the effects of the agonists against isoniazid-induced seizures.  Taken together, 
these data suggest that PTZ-induced seizures are less dependent on the activity at the 
GABAA/α1 receptors than ECS-induced seizures. 
The conditioned fear model has been used to study “cognitive-affective” processes 
in anxiety disorders (e.g., Uys et al., 2003).  In this model, animals are exposed to pairings 
of a neutral stimulus (conditioned stimulus (CS); e.g., tone or context) with an aversive 
stimulus (unconditioned stimulus (UCS); e.g., shock).  Following acquisition, behaviors 
typically seen after the presentation of UCS (e.g., startle, freezing, or suppression of water-
drinking) are now seen when the CS is presented alone.  BZs reduced expression of UCS-
appropriate behaviors in the presence of the CS (e.g., Davis, 1979; Sanger and Joly, 1985).  
The same effects are obtained following administration of scopolamine (e.g., Rudy, 1996; 
Lindner et al., 2003), a memory-impairing agent without any anxiolytic-like activity, 
suggesting that the conditioned fear assay is more sensitive to memory-impairing rather 
than anxiolytic-like effects of BZs.  In the present study, diazepam at the doses of 2.5 and 
5.0 mg/kg PO resulted in a decrease in freezing, whereas QH-ii-066 did not affect freezing 
at the doses up to and including 10 mg/kg, PO.  Thus, QH-ii-066 appears to be 2-fold less 
potent in producing memory deficits in the conditioned fear test.  It has been suggested 
that GABAA/α5 receptors mediate memory-impairing effects of BZs (e.g., Collinson et al., 
2002).  Our electrophysiology studies showed comparable efficacy of QH-ii-066 and 
diazepam in potentiating the GABA currents through the GABAA/α5 receptors. The 
observed difference in potency in the conditioned fear assay could be due to lower affinity 
of QH-ii-066 at all GABAA receptors studied.  Therefore, higher doses of QH-ii-066 
would need to be tested to determine if lower efficacy of QH-ii-066 at GABAA/α1 
receptors compared with diazepam would result in lower potential to produce memory 
deficits in animals.  However, the present study indicates that QH-ii-066 may have a better 
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therapeutic index than diazepam with respect to memory impairment since the doses of 
diazepam effective in the conflict and conditioned fear models effects were, whereas QH-
ii-066 showed at least a 3-fold separation between doses effective in these tests.  
Effects of QH-ii-066 and diazepam on motoric behaviors were assessed using the 
locomotor activity assay as an index of sedative effects and the rotorod performance as an 
index of motor incoordination.  QH-ii-066 was 10-fold less potent than diazepam in 
reducing locomotor activity and at least 3-fold less potent in reducing time on rotorod.  
These differences in potency to produce sedation and motor incoordination lead to a better 
therapeutic index for QH-ii-066 compared with diazepam, despite a 3-fold loss of potency 
in producing anxiolytic-like effects (Table 2).  Thus, QH-ii-066 shows a 10-fold or greater 
separation between its effects on motoric behavior and its anxiolytic-like effects in rats.  
By comparison, diazepam showed only a 3-fold separation in dose between the sedative 
and anxiolytic-like effects and a better (33-fold) separation in dose between the ataxic and 
anxiolytic-like effects.   
Since QH-ii-066 has only 2-fold lower affinity for the six GABAA receptors 
compared with diazepam, the 10-fold loss of potency of QH-ii-066 in reducing locomotor 
activity suggests that diminished intrinsic efficacy of QH-ii-066 at the GABAA/α1 
receptors also contributed to its reduced potency in producing sedative effects.  These data 
support studies with transgenic mice and GABAA/α1-selective agonists in indicating that 
GABAA/α1 receptors mediate sedative/ataxic effects of classical BZs (e.g., Rudolph et al., 
1999; McKernan et al., 2000; Kralic et al., 2002; Fry et al., 2000).  
Finally, effects of QH-ii-066 and diazepam were compared in animals trained to 
discriminate CDP.  Drug discrimination may be used as an index of abuse liability when 
compounds of the same pharmacological class are compared.  In the present studies, 
animals were trained to discriminate CDP, a classical BZ with no apparent receptor 
selectivity.  Diazepam at 3.0 mg/kg and QH-ii-066 at 30 mg/kg fully substituted for CDP, 
suggesting that at some dose, both compounds produce CDP-like subjective effects.  As 
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was the case for locomotor activity, lower affinity of QH-ii-066 at GABAA receptors alone 
does not account entirely for the lower potency of QH-ii-066 compared with diazepam in 
substituting for CDP, suggesting that GABAA/α1 receptors may be an important part of 
the CDP stimulus in rat drug discrimination.  In addition, these data also suggest that 
compounds like QH-ii-066 with lower efficacy at GABAA/α1 receptors may have reduced 
abuse liability compared with classical BZs. 
In summary, QH-ii-066, the 7-acetyleno congener of diazepam, showed a 2-fold 
loss of affinity at all GABAA receptors studied relative to diazepam.  However, QH-ii-066 
also showed a loss of efficacy at the GABAA/α1 receptors compared with diazepam, while 
retaining diazepam-like efficacy at the GABAA/α5 receptors.  In vivo, QH-ii-066 showed 
anxiolytic-like and protective effects against PTZ-induced seizures in rodents at doses 
similar to those of diazepam.  QH-ii-066 was less potent than diazepam in protecting 
against ECS-induced seizures, indicating that ECS-induced seizures are mediated by 
GABAA/α1 receptors to a greater extent than PTZ-induced seizures.  QH-ii-066 was also 
less potent than diazepam in reducing activity and in producing CDP-like subjective 
effects, suggesting that QH-ii-066 and other compounds with lower intrinsic efficacy at 
the GABAA/α1 receptors may be effective anxiolytics in humans with a reduced potential  
for side effects.
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Table 1. 
Binding affinity of QH-ii-066 and diazepam for rat GABAA receptors. 
 GABAA Receptor Ki (nM) 
Compound α1β2γ2 α1β3γ2 α2β3γ2 α3β3γ2 α5β2γ2 α5β3γ2 
QH-ii-066 52±3* 56±1*** 51±2** 72±8** 44±1** 40±8*** 
Diazepam 18 20 20 28 22 20 
Ratioa 2.9 2.8 2.6 2.6 2.0 2.0 
*  n=5 determinations 
**  n=3 determinations 
***  n=2 determinations 
a  Ratio of binding affinity, QH-ii-066:diazepam 
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Table 2. 
Lowest effective doses (mg/kg) and therapeutic indices for QH-ii-066 and 
diazepam in behavioral models. 
Assay QH-ii-066 Diazepam Ratio 
Conflict 10 3.0 3-fold 
Conditioned Fear >10 2.5 >4-fold 
Locomotor Activity (LMA) 100 10 10-fold 
Rotorod >100 100 ≥3-fold 
Chlordiazepoxide 
Drug Discrimination (DD) 
30 3.0 10-fold 
Conflict:LMA Ratio 10-fold 3-fold  
Conflict:Rotorod Ratio >10 33-fold  
Conflict:DD Ratio 3-fold 0  
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LEGENDS FOR FIGURES 
Figure 1.  Chemical structures of QH-ii-066 and diazepam. 
 
Figure 2.  Effects of diazepam and QH-ii-066 on GABA-induced Cl- currents in two 
GABAA constructs (α1β2γ2 and α5β2γ2).  Abscissae: concentration (log, nM).  
Ordinates: Percent control (3 µM GABA without drug) IGABA for n=3-6 cells per 
concentration. 
 
Figure 3.  Anxiolytic-like effects of diazepam and QH-ii-066 in the Geller conflict with 
incremental shock test in rats.  Abscissae: dose (mg/kg).  Ordinates: mean (±SEM) 
response rates expressed as percent of control rates (vehicle training days) for n=6-8 
animals per dose.  Diazepam and QH-ii-066 were administered in 0.25% methylcellulose 
PO, 60 minutes prior to testing.  * P<0.05. 
 
Figure 4.  Effect of diazepam and QH-ii-066 on pentylenetetrazole- and electroconvulsive 
shock-induced seizures in mice.  Abscissae: dose (mg/kg).  Ordinates: percent animals 
protected for n=12 animals per dose.  Diazepam and QH-ii-066 were administered in 
0.25% methylcellulose PO, 60 minutes prior to testing. 
 
Figure 5.  Effect of diazepam and QH-ii-066 in conditioned fear test in rats.  Abscissae: 
dose (mg/kg).  Ordinates: mean (±SEM) percent time spent freezing for n=16-24 animals 
per dose.  Diazepam and QH-ii-066 were administered in 0.25% methylcellulose PO, 60 
minutes prior to behavioral testing.  * P<0.05. 
   
339 
 
 
Figure 6.  Effect of diazepam and QH-ii-066 on spontaneous locomotor activity in rats.  
Abscissae: dose (mg/kg).  Ordinates: mean (±SEM) distance traveled (in cm) for n=8 
animals per dose.  Diazepam and QH-ii-066 were administered in 0.25% methylcellulose 
PO, 60 minutes prior to behavioral testing.  * P<0.05. 
 
Figure 7.  Effect of diazepam and QH-ii-066 on motor coordination in the rotorod test in 
rats.  Abscissae: dose (mg/kg).  Ordinates: mean (±SEM) time on rotorod (in seconds) for 
n=7-8 animals per dose.  Diazepam and QH-ii-066 were administered in 0.25% 
methylcellulose PO, 60 minutes prior to behavioral testing.  * P<0.05. 
 
Figure 8.  Discriminative stimulus and rate-decreasing effects of chlordiazepoxide, 
diazepam, and QH-ii-066 in rats (n=7-12) discriminating between chlordiazepoxide and 
vehicle.  Abscissae: dose (mg/kg).  Ordinates: percent of rats selecting the 
chlordiazepoxide lever (upper panel) and mean response rates (± SEM) expressed as 
percent control rates (vehicle training days) (lower panel).  Chlordiazepoxide was 
administered in 0.25% methylcellulose IP, 30 minutes before testing.  Diazepam and QH-
ii-066 were administered in 0.25% methylcellulose PO, 60 minutes prior to behavioral 
testing.    * P<0.05.  The dashed line in the upper panel refers to 75% of animals selecting 
the drug lever (criterion for substitution). 
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V. Appendix III: Data on QH-II-066 
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Summary 
The signaling pathways driving neuroblastoma, a tumor derived from neural 
progenitors, remain largely unidentified.  In an engineered mouse model for 
neuroblastoma, susceptibility to tumors is strain-specific and genetically complex.  
To identify genes involved in tumor susceptibility, we analyzed genetic control of 
gene expression (eQTL) in the peripheral sympathetic nervous system.  Here we 
show that genes controlling GABA neurotransmitter signaling, including arginase 
(Arg1), co-localized with susceptibility loci. Activation of GABA-A receptors in 
human neuroblastoma cells induced apoptosis, while inhibition of arginase slowed 
proliferation.  These results demonstrate the ability of a neurotransmitter to 
regulate cell growth, and present novel neuroblastoma therapeutic targets.   
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Introduction 
 Neuroblastoma, a pediatric tumor of the peripheral nervous system, arises from 
sympathetic neural progenitors that normally differentiate into post-mitotic neurons 
shortly after birth.  Mutations that drive myeloid, epithelial, and glial tumors are largely 
not present in neuroblastoma, suggesting this tumor arises from disruption of growth 
pathways specific to the neural lineage.  In a transgenic model driven by the MYCN 
proto-oncogene, amplification of which is a hallmark of high-risk neuroblastoma1,2, mice 
develop tumors with histological and genomic characteristics of human neuroblastoma3,4.  
In this model, tumor incidence varies among mouse strains, and we exploited this genetic 
variance to identify novel molecular pathways driving neuroblastoma development.   
 In this study, genetic linkage analysis revealed a locus on chromosome 10 that 
interacted with numerous secondary loci to influence tumor susceptibility.  To identify 
candidate genes at these loci, we superimposed expression quantitative trail loci (eQTL) 
in sympathetic superior cervical ganglia (SCG) from backcross mice.  Liver arginase 
(Arg1), a component of both the urea cycle and the gamma-amino butyric acid (GABA) 
biosynthetic pathway, was the strongest eQTL at the primary chromosome 10 locus.  
Multiple genes and eQTL involved in GABA neurotransmitter signaling were located at 
the secondary susceptibility loci, providing an intriguing genetic link between  this 
pathway and neuroblastoma biology.  We tested this link using compounds targeting the 
Arg1-GABA pathway in human neuroblastoma cell lines.  Both nor-NOHA, an Arg1 
inhibitor, and, more strikingly, nanomolar concentrations of the neurotransmitter GABA, 
inhibited cell growth and viability in vitro.   The GABA response was dependent on 
GABA-A receptor expression and was rescued with GABA-A-specific antagonists.  
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Activation of GABA-A signaling induced apoptosis and was associated with decreased 
activity of PI3K/AKT and MAPK signaling, two central pathways in cell growth and 
survival.  The implication of arginine metabolism and GABA signaling in the 
pathogenesis of neuroblastoma presents a combination of therapeutic targets.  
Additionally, the demonstration that the neurotransmitter GABA inhibits growth of tumor 
cells derived from a neural lineage highlights an emerging role for neurotransmitters in 
regulating development of the peripheral nervous system. 
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Results 
Neuroblastoma penetrance in TH-MYCN mice is strain-dependent 
 Transgenic mice were generated on a Balb/c x C57B6/J background and showed 
~10% incidence of tumors.  As mice were crossed into strain FVB/NJ, incidence 
decreased to zero by 2 generations (Supplementary Figure 1A).  Conversely, penetrance 
of tumors steadily increased with each successive backcross into strain 129/SvJ, leveling 
out at ~60%5.   Levels of transgene expression were similar between genetic backgrounds 
(Supplementary Figure 1B).   
 We next crossed resistant transgenic FVB/NJ mice to susceptible wild-type 
129/SvJ.  The resulting F1 mice showed 4% incidence of tumors, suggesting that 
resistance was genetically dominant.  To generate a genetically diverse population for 
linkage mapping, we backcrossed transgenic F1 animals to wild-type 129/SvJ mice.  
Incidence of tumors in the resulting N1 backcross generation was 38% (N=203), with an 
average survival (109 days) identical to that of mice carrying the transgene in a pure 
129/SvJ background 5 
 
Linkage analysis identifies a tumor susceptibility modifier on chromosome 10 
 To identify genomic loci associated with tumor susceptibility, we genotyped 203 
mice using a combination of microsatellite and SNP markers (see Supplementary 
Methods).  Interval mapping for linkage to tumor susceptibility produced a maximum 
LOD (log of odds) score on chromosome 10 at marker RS36323433 (LOD=4.1, Figure 
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1A, B, significant at a 5% genome-wide error rate, see Supplementary Methods).  
However, at this locus, heterozygous mice were tumor prone (55%), while mice 
homozygous for the 129/SvJ allele were resistant (25% incidence) (Figure 1C).  
Additionally, tumor susceptibility was strongly influenced by gender.  Performing the 
analysis using sex as an interacting covariate increased the LOD score to 4.9.  When mice 
were segregated by sex and analyzed independently, this locus was not significant in 
female mice but was in males (LOD=4.3, N=82).  It may be relevant in this regard that 
neuroblastoma is slightly more prevalent in boys (1.3:1) than in girls6. 
Since the segregation of genotypes with tumor susceptibility at the chromosome 
10 locus did not match the patterns of tumor susceptibility in the parent strains, we next 
considered a more complex genetic model to explain susceptibility.  A 2-QTL test 
identified several loci that interacted with the chromosome 10 locus, with similar LOD 
scores (Figure 1D, Supplementary Table 1).  Interestingly, while all of these loci 
interacted with the chromosome 10 locus, they did not interact with each other.     
 
Expression QTL analysis identifies Arg1 as a candidate modifier 
The 95% confidence interval of the peak on chromosome 10 spanned 47Mb and 
contained over 281 genes (see Supplementary Methods), complicating identification of 
candidates.  Hypothesizing that susceptibility to tumors may be governed by differential 
expression of genes within this locus, we narrowed our field of candidates by comparing 
mRNA expression levels in neural crest-derived sympathetic superior cervical ganglia 
(SCG) from transgenic male and female 129/SvJ and FVB/NJ mice using Affymetrix 
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Mouse Exon arrays.  Surprisingly, only 8 genes were differentially expressed between 
sexes, and with the exception of a RIKEN clone on chromosome 2, all mapped to either 
the X or Y chromosomes (Supplementary Figure 1C, Supplementary Table 3), 
excluding gender-specific gene expression as a mechanism for the gender effect at the 
chromosome 10 locus.  When males of the two strains were compared, however, 9,820 
genes were differentially expressed genome-wide (Supplementary Figure 1D, 
Supplementary Table 3), including 137 within the 95% confidence interval for the 
chromosome 10 susceptibility locus (representing almost half of all genes within the 
locus). 
Gene expression levels can be influenced by complex interactions among cis- and 
trans- acting factors.  One method for distinguishing these factors involves generating a 
genetically heterogeneous population (such as our backcross population), measuring gene 
expression levels, and treating the expression level of each gene as a quantitative trait 
(expression QTL or eQTL7,8).  Using this method, the cis- and trans- acting alleles 
influencing gene expression are decoupled from each other, and genes whose differential 
expression is due to cis-acting factors at a locus can be distinguished from genes under 
the control of trans-acting factors at other loci.  Genes with eQTL overlapping with QTL 
for physiological phenotypes have been shown to control these phenotypes8,9. We thus 
utilized this technique to identify eQTL within our chromosome 10 locus, as well as at 
the numerous other secondary loci identified in the 2-QTL tumor susceptibility analysis.  
We measured mRNA expression levels in 116 SCG from the backcross 
population and tested for linkage between gene-level expression calls for each gene and 
germline variation, to identify 342 eQTL acting both locally and on another 
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chromosomes (Supplementary Table 4). Four eQTL mapped to the susceptibility locus 
on chromosome 10, with Arg1 (liver arginase) showing the strongest eQTL .  When this 
measurement was refined by interval mapping, Arg1 expression was linked to a QTL at 
chromosome 10 with a LOD score of 18.2 (Figure 2A).  Arg1 overlapped directly with 
our tumor susceptibility locus, making Arg1 our top candidate gene (Figure 2C, Table 
1).  Mice heterozygous at that locus had almost 2-fold higher expression of Arg1 
compared to mice homozygous for the 129/SvJ allele (Figure 2B).  Notably, among 137 
genes differentially expressed at the chromosome 10 locus in parental strains, only four 
showed significant eQTL mapping to the locus, with Arg1 showing the strongest eQTL in 
backcross animals.  These data suggest that differential expression of the other genes in 
the parents was due in part to trans-acting factors, illustrating the power of eQTL 
analysis in dissecting control of gene expression at a genetic locus and filtering candidate 
genes.   
 
eQTL for GABA-related genes map to secondary susceptibility loci 
 We next looked for eQTL that mapped to the secondary tumor susceptibility loci 
that interacted with the chromosome 10 locus, and noted eQTL for genes related to 
GABA neurotransmitter signaling at two of the loci (Table 1).  Notably, a trans-eQTL on 
chromosome 2 controlled expression of the Gabra3 receptor subunit on the X 
chromosome (Figure 3A-C).  This eQTL overlapped directly with the secondary 
susceptibility locus on chromosome 2 (Figure 3G, Supplementary Figure 2A, Table 1).  
Mice harboring alleles resulting in high Arg1 expression and low Gabra3 expression 
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showed the strongest susceptibility to tumors (Figure 3C).  Similarly, an eQTL for the 
GABA transporter Slc6a1 (Figure 3D-F) mapped to a secondary susceptibility locus on 
chromosome 4 (Figure 3G, Supplementary Figure 2B, Table 1), though the gene was 
on chromosome 6.  Importantly, the chromosome 2 and 4 secondary susceptibility loci 
showed the highest LOD scores in male mice (Supplementary Table 2). 
 We next investigated secondary susceptibility loci that lacked GABA-related 
eQTL candidates and found several GABA-related genes mapping within 10Mb of 
susceptibility peaks.  The locus on chromosome 1 (LOD 7.8) flanked by markers 
RS5056599 (116MB) and D1MIT1001 (131Mb) , LOD 7.8) is in close proximity to Dbi 
(diazepam binding inhibitor, 122Mb), a gene that modulates GABA receptor activity10.  
Similarly, the locus on chromosome 9 centered near 117Mb (D9MIT201, LOD 7.9) is 4 
Mb from the Trak1 gene, which encodes a trafficking factor that modulates GABA 
receptor homeostasis11.  The locus on chromosome 7 centered at 144Mb (RS13479509, 
LOD 6.4) is 4 MB from ornithine aminotransferase (Oat), which converts ornithine to 
glutamate (the substrate for GABA synthesis).  Finally, the locus on chromosome 17 
centered near 35Mb (D17MIT231, LOD 6.7) is 2 Mb from the GABA-B receptor 1.  
Together, at least 6 secondary susceptibility loci co-localized with genes in the GABA 
pathway, and/or eQTL controlling these genes (Table 1).   
  
Inhibition of Arg1 decreases viability of human neuroblastoma cells  
 The higher-expressing Arginase allele conferring tumor susceptibility is nested 
within an overall resistant genetic background in purebred mice (either FVB/NJ or 
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FVB/NJ x 129/SvJ F1).  The allelic variation in the secondary loci (harboring 
components of the GABA pathway) only showed an effect in combination with alleles at 
other loci.  This genetic complexity precluded validation in vivo.   The association of a 
gene with susceptibility to tumors does not necessarily imply an ongoing role in tumor 
maintenance.  Nevertheless, since our ultimate goal was to identify clinically-relevant 
biochemical pathways, we next analyzed Arg1 and GABA in human neuroblastoma cell 
lines.  As there is little precedent for these pathways in regulation of cell growth and thus 
little basis for the specific downstream pathways involved, we assessed the effect of 
compounds targeting this pathway on overall growth and viability. 
We detected Arg1 by western blot across a panel of human neuroblastoma cell 
lines (Figure 4A).  We treated this panel with the reversible arginase inhibitor nor-
NOHA (N-Omega-hydroxy-nor-arginine)12 to test whether inhibition of arginase could 
impair tumor growth.  Viability was decreased in CHP-126, SY5Y, and Kelly cells at 
100µM (Supplementary Figure 3A). Both Kelly and SY5Y cultures accumulated in G1 
phase with decreased numbers of cells in S phase, without a significant apoptotic fraction 
assessed by flow cytometry (Supplementary Figure 3B).  In SY5Y cells this effect was 
nearly equivalent to the potent PI3K/mTOR inhibitor PI-103.  We conclude that Arg1 
expression modulates viability and proliferation in human neuroblastoma cells.  
 
GABA-A activation induces apoptosis in neuroblastoma 
We next investigated the role of GABA signaling in the control of viability.  
While all neuroblastoma cell lines tested expressed the two human GABA-B receptors, 
354 
 
expression of the GABA-A receptor subunits was variable (Figure 4A).  In response to 
GABA, viability was unchanged in cell lines CHP-126, Kelly and SY5Y, all of which 
expressed low levels of the GABA-A receptor (Supplementary Figure 3C).  In contrast, 
the cell line LAN-5, which expressed high levels of the GABA-A receptor, was 
particularly sensitive to GABA, showing a 40% decrease in viability at doses as low as 
100nM.  To demonstrate that this effect was specific to the GABA-A receptor, we co-
treated cells with GABA and either picrotoxin or bicuculline.  Picrotoxin, a non-
competitive GABA-A channel blocker, was able to fully rescue the effects of both 
100nM and 1mM GABA.  In contrast, the competitive inhibitor bicuculline was able to 
reverse the effects of GABA in a dose-dependent manner; 10µM bicuculline reversed the 
effects of 100nM but not 1mM GABA treatment (Figure 4B).  The dose-dependent and 
independent effects of bicuculline and picrotoxin, respectively, are consistent with the 
pharmacological mechanisms of each molecule on the GABA-A receptor, and 
demonstrate the specificity of the GABA-A receptor’s role in cell viability. 
 We next assessed the mechanism by which GABA-A activation inhibited the 
growth of neuroblastoma cells.  To enhance the signal readout of this pathway, we 
utilized the potent, selective GABA-A receptor agonist QHii066, a benzodiazepine 
derivative13,14.  Apoptosis was induced in both LAN-5 (high GABA-A expression levels) 
and Kelly cells (low GABA-A expression levels) (Figure 4 C and D), as assessed by 
annexin V flow cytometry.  Immunoblotting revealed that upon addition of GABA and 
QHii066, cleaved PARP, an indicator of apoptosis, was increased.  Notably, 
immunoblotting revealed a decrease in activity of the PI3K/AKT and MAPK pro-growth 
and survival pathways, indicated by decreased phosphorylation levels of Akt and Erk, 
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respectively (Figure 4E).  Together these data suggest that specific activation of the 
GABA-A receptor decreases cell viability, induces apoptosis, and suppresses pro-growth 
and survival signaling pathways in neuroblastoma cell lines.            
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Discussion 
The pathways regulating development of the peripheral nervous system are 
distinct from those controlling epithelial and other cell types.  Perhaps as a consequence, 
common genomic aberrations driving tumorigenesis in epithelial and glial tumors rarely 
show abnormalities in neuroblastoma, a tumor of the sympathetic peripheral nervous 
system.   
Mouse model systems have provided a tremendous resource for the identification 
and validation of genes involved in cancer.  Though the influence of strain background 
on tumor penetrance is frequently observed in mouse models of cancer, only a handful of 
genes underlying this susceptibility have been identified15-20, mostly due to the limited 
resolution of quantitative trait linkage mapping.  To decipher biological mechanisms 
underlying genetic linkage to tumor susceptibility in our mouse neuroblastoma model, we 
investigated patterns of gene expression in peripheral sympathetic nervous tissue.  
Analysis of gene expression as a function of genotype (in other words, treating gene 
expression levels as heritable traits and performing linkage analysis) has facilitated 
identification of candidate genes for quantitative trait loci underlying physiological 
differences7-9.  Genetic control of gene expression is more direct than genetic influence 
over complex physiological phenotypes.  Thus, analysis of expression quantitative trait 
loci or eQTL provides a relatively strong signal in linkage analysis, enabling the direct 
identification of specific candidate genes among hundreds of genes at an overlapping 
QTL for a physiological phenotype.  eQTL analysis has identified several genes 
modifying tumor susceptibility in mouse models for cancer21-23.  In the current study, 
eQTL suggested candidate genes from a common biological pathway at multiple loci 
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simultaneously, including genes located on chromosomes that were controlled in trans by 
unidentified elements at the QTL loci, a phenomenon that would have been missed by 
conventional analysis of candidate genes at the susceptibility loci.   
eQTL analysis identified Arg1 as a candidate neuroblastoma modifier gene at 
chromosome 10.  One of the strongest secondary susceptibility loci, a locus on 
chromosome 2, overlapped with a particularly prominent eQTL governing expression of 
a GABA-A neurotransmitter receptor subunit.  Numerous other susceptibility loci 
overlapped with other GABA-related genes, suggesting a mechanism for the pattern of 
genetic linkage to tumor susceptibility and implicating an interaction between up-
regulation of arginase activity and down-regulation of GABA receptors as cooperating 
mechanisms promoting susceptibility to tumors.     
While Arg1 is associated with the urea cycle in liver, it is also expressed in a 
number of tissues that do not carry out the urea cycle, including sympathetic nerve 
ganglia24, suggesting a role in other biochemical pathways.  In neurons, Arg1 is part of 
the GABA synthesis pathway, producing ornithine, a precursor of glutamate and of 
GABA.  The biochemical link between Arg1 and the GABA pathway potentially explains 
our unique genetic pattern of several secondary loci interacting with a single gene/locus.  
Only one cytoplasmic arginase gene exists (Arg1).  However, the GABA signaling 
pathway may be perturbed at several genomic loci, including several components of the 
GABA-A receptor, genes for which are dispersed throughout the genome.  Thus, in a 
genetic model involving perturbation of arginase and GABA signaling, many GABA-
related genes could interact with the single Arg1 gene on chromosome 10 with similar 
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effects (disrupting two connected pathways), while GABA genes may not interact with 
each other (as multiple disruptions would have redundant effects on the same pathway).  
 While emerging evidence supports the role for GABA signaling in the control of 
neural cell growth (see below), a role for Arg1 is less obvious.  Several downstream 
outputs could account for increased expression of Arg1 predisposing mice to tumors.  
Arginase may act as an immunosuppressant25,26, a competitor for the substrate arginine 
with the growth-inhibitory nitric oxide synthases (NOSs) 27-30, or a producer of ornithine, 
the substrate for polyamine synthesis linked to tumorigenesis31 and neural proliferation32. 
The rate-limiting polyamine synthetic enzyme, ornithine decarboxylase (ODC), is a well-
established target for c-myc and MYCN33.  ODC inhibitors inhibit neuroblastoma 
development in vitro and in TH-MYCN mice34,35, and are currently in clinical trials for 
neuroblastoma (http://www.nmtrc.org/phase-i-dfmo/).  Ornithine is also a substrate for 
synthesis of glutamate and GABA.  Notably, ornithine aminotransferase (Oat), which 
converts ornithine to glutamate, maps to a susceptibility locus.  GABA inhibits neuronal 
growth and promotes differentiation36.  Thus, at least one ultimate output of Arg1 activity 
(GABA) could inhibit both induction and further growth of tumors, driving selection for 
secondary genetic lesions that disable this pathway.  
While Arg1 activity has not been studied extensively in cancer, inhibition of 
arginase has been shown to disrupt growth of breast cancer cells37.  Arginase expression 
has also been linked to neuronal viability.  Clinically, Arg1 mutations cause arginemia, 
characterized by neurodegeneration (OMIM 207800).  While hepatic production of 
neurotoxic metabolites are speculated to cause this neurodegeneration38,39, our data, 
coupled with detection of Arg1 expression in neural tissues24,40,41, suggest that Arg1 may 
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be involved in growth and survival signaling in neuroblasts, and inhibition of Arg1 may 
have an intrinsic cytotoxic effect in neurons and neuroblastoma cells.   
The observation that mice with lower expression of GABA-A receptor subunits 
are tumor prone is consistent with GABA’s known role in neuronal cell growth and 
differentiation36,42, and suggest that the association of down-regulation of GABA-A 
receptors with more aggressive human neuroblastomas has biological significance43.   
However, since the receptor is formed as a pentameric combination of 19 possible 
subunits, with changing expression patterns and biological roles42, testing this hypothesis 
is not straightforward.  GABA signaling has been shown to negatively regulate growth of 
neural crest stem cells36.  In our hands, neuroblastoma cells expressing the GABA-A 
receptor showed decreased viability, increased apoptosis, and diminished activity of 
mitogenic signaling pathways in response to GABA-A activation, supporting a role of 
GABA signaling in tumor cell growth and survival.  These results parallel the 
neurotrophin model, based on the observation that dysregulation of TRK neurotrophin 
receptors correlates with clinical outcome in neuroblastoma  44.  Our results are consistent 
with this paradigm, suggesting that decreased signaling through the GABA pathway 
(rather than TRKs) may promote neuroblastoma development.    
 Neuroblastoma is a common pediatric tumor with a unique biology, making the 
development of novel targeted therapeutics problematic.  As a result, improvements in 
clinical outcomes have been modest over the last several decades.  Arginase inhibitors are 
under investigation for highly prevalent diseases such as hypertension27.  Additionally, 
the implication of GABA and other neurotransmitters in regulating growth of 
neuroblastoma opens up the potential to apply numerous clinically-approved drugs used 
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in neurology and psychology as chemotherapeutic agents.  These results also highlight a 
possible connection between the role of neurotransmitters in nervous system development 
and the regulation of neuroblastoma growth. 
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Methods Summary: 
 Backcross mice were generated by crossing TH-MYCN transgenic FVB/N mice to 
wild-type 129/SvJ, and subsequently crossing F1 offspring to wild-type 129/SvJ.  Mice 
were observed for at least one year to be considered tumor-free.  DNA was isolated from 
spleen and genotyped using a combination of microsatellite and SNP markers.  RNA 
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from SCG was analyzed using Affymetrix Mouse Exon arrays.  Susceptibility linkage 
was analyzed using R-QTL.  Differential gene expression was assessed using 
Significance Analysis of Microarrays, and eQTL were calculated using custom software 
as described previously21.  Cell viability and cell-cycle status were assessed using a 
WST-1 assay and flow cytometry.  For details see Supplementary Methods.     
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Table 1:  Candidate genes at susceptibility loci 
A.   Candidate eQTL at susceptibility loci  
chromosome 
susceptibility 
locus (Mb) LOD eQTL gene 
eQTL locus 
(Mb) eQTL p-val perm. p-val 
10 28 5.0 Arg1 25 2.92E-20 <0.001 
2 166 7.0 Gabra3 178 5.57E-34 <0.001 
4 115 7.4 Slc6a1 129 2.81E-05 0.001 
 
B.  GABA genes at susceptibility loci 
 
chromosome 
susceptibility 
locus (Mb) LOD gene gene location (Mb) 
1 131 7.8 Dbi  122 
9 117 7.8 Trak1 121 
17 35 6.9 Gabbr1 37 
7 144 6.3 Oat 140 
 
C.  Gene descriptions 
gene 
location 
(chromosome) description 
Arg1 10 liver arginase 
Gabra3 X* GABA-A receptor, subunit alpha 3  
Slc6a1 6* GABA transporter, removes GABA from synaptic cleft 
Dbi 1 diazepam binding inhibitor;  modulates the action of the GABA receptor 
Trak1 9 trafficking protein, kinesin binding 1, regulates GABA receptor  
Gabbr1 17 GABA-B receptor, 1  
Oat 7 ornithine aminotransferase (produces glutamate, a GABA precursor) 
*controlled by trans eQTL 
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Figure 1.  A locus on chromosome 10 and multiple secondary loci are linked to 
tumor susceptibility.  (A) LOD plot for tumor susceptibility shows a single significant 
locus on chromosome 10.  Dotted line indicates 5% genome-wide significance threshold 
(LOD=2.81, 1000 permutations).  (B) LOD plot of chromosome 10 only.  Hash marks on 
the horizontal axis indicate marker positions.  Dotted line indicates 5% genome-wide 
significance threshold (LOD=2.81, 1000 permutations).  (C)  Effect plot for the marker 
closest to the maximum LOD score (RS36323433) showing incidence of tumors as a 
function of genotype.    (D) Two-QTL analysis using sex as an interacting covariate 
reveals that multiple secondary loci interact with the chromosome 10 locus.  The top left 
half shows the results of the additive model (no epistatic interactions), and the bottom 
right half shows results of the “full” model, which accounts for epistatic interactions.  
The bar on the right displays the correspondence between color on the chart and LOD 
scores (the left side of the bar corresponds to the additive analysis on the top left half of 
the plot, while the right side of the bar, with a different scale, corresponds to the full 
model analysis on the bottom right).   Locations of the maximum LOD scores are shown 
in Supplementary Table 1. 
 
Figure 2.  An eQTL for Arg1 co-localizes with the tumor susceptibility locus on 
chromosome 10.  (A)  Interval mapping for Arg1 expression, the most significant eQTL 
in the chromosome 10 region, showing a LOD score of 18.2 on chromosome 10, centered 
at the physical location of the Arg1 gene.  Line indicates 5% genome-wide significance 
threshold.  (B) Log2 Arg1 expression level as a function of genotype.  (C) A plot of LOD 
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scores on chromosome 10 for susceptibility (black line) and the Arg1 eQTL (blue line) 
showing co-localization of the peaks. 
 
Figure 3.  Secondary susceptibility loci co-localize with eQTL for GABA-related 
genes.   
(A) A trans-eQTL on chromosome 2 controls expression of the GABA-A receptor 
subunit 3 (Gabra3) on the X chromosome (arrow) (LOD=30.9).  (B)  Gabra3 expression 
as a function of D2MIT148 genotype.  (C) Plot of tumor incidence as a function of 
genotypes at the chromosome 2 and 10 loci.  (D) Expression QTL for the Slc6a1 GABA 
transporter on chromosome 4 (LOD=4.1).  Arrow indicates the physical location of 
Slc6a1 on chromosome 6.  (E)  Slc6a1 expression as a function of D4MIT203 genotype.  
(F)  Tumor incidence as a function of genotypes at loci on chromosomes 4 and 10.  (G)  
Genome-wide plot of LOD scores for the Gabra3 (black), Slc6a1 (green), Arg1 (blue) 
eQTL and tumor susceptibility for a single-locus model (purple) and the combined effect 
of the peak of the chromosome 10 locus plus points across the rest of the genome (red), 
showing correspondence between eQTL peaks and primary and secondary susceptibility 
loci.  Two-dimensional plots for Gabra3 and Slc6a1 are shown in Supplementary 
Figure 2.        
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Figure 4. GABA activation decreases viability and induces apoptosis in 
neuroblastoma cells (A) Western blot for Arg1, GABA-A, and GABA-B receptors in 
neuroblastoma cell lines.      
(B) GABA treatment of LAN-5, a GABA-A expressing cell line, results in decreased 
viability that is rescued by the GABA competitive inhibitor bicuculline (bic) at 10µM, in 
a GABA dose-dependent manner; and  by the non-competitive channel blocker 
picrotoxin (picro) at 100µM in a GABA dose-independent manner.  (C)   Lan5 and Kelly 
cells were treated with GABA 100 μM or the selective ligand for GABA QHii066 1 μM 
or both and analyzed by annexin V-FITC flow cytometry for apoptosis after 72h.  (D)   
Percentages of positive cells for apoptotic marker annexin V are mean ± s.e. for triplicate 
samples with treatments indicated. (E)  Cells analyzed by immunoblot using antisera 
indicated show decreased phosphorylation of Akt and Erk.        
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Supplementary Methods: 
 
Mice: All mice were obtained from the Jackson Labs (Bar Harbor, ME), and were housed 
and treated following UCSF IACUC guidelines. Tumor-negative backcross mice were 
followed until one year of age (the latest tumor was detected at 342 days).  Superior 
cervical ganglia (SCG) were surgically isolated and snap-frozen in liquid nitrogen.  SCG 
were isolated from the parental control groups at 21 days. 
Taqman analysis of transgene expression:  Taqman expression analysis was performed 
on 6 mice (3 female, 3 male) from each strain.  Proprietary assays for human MYCN and 
controls L18 and mGUS were obtained from Applied Biosystems (Carlsbad, CA).   
MYCN relative to mGUS is shown in Supplementary Figure 1B. 
Genotyping: DNA was isolated from spleen tissue using a proteinase K lysis followed 
by phenol chloroform extraction.  Microsatellite marker genotyping was carried out by 
the Marshfield Clinic (Marshfield, WI), and CIDR (Baltimore, MD).   SNP genotyping 
was performed using template-directed primer extension with fluorescence polarization 
detection (FP-TDI1, Acycloprime II, Perkin Elmer, Waltham, MA)   and SNPStream2 48-
plex (Beckman Coulter, Brea, CA).  Markers and map positions are shown in 
Supplementary Table 5.  The marker set had an average spacing of 8 MB genome-wide 
(excluding the high density of markers on chromosome 10).   
Linkage analysis: Interval mapping was performed using the R-QTL3 package in the R 
statistical language.  Genotypes flagged as probable errors by R-QTL were discarded.  
The genetic map positions were determined using the physical map positions (NCBI 
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37/mm9), followed by re-estimation of the map using R-QTL, and likely mis-mapped 
markers were discarded.  Linkage analysis was performed on a 1-cM grid.  Genome-wide 
significance thresholds were determined by running 1000 permutations for each dataset.  
Interval analysis was performed using the binary mode of the “EM” model.   All results 
reported as significant were significant at a 5% genome-wide error rate.  95% confidence 
intervals (CI) were determined using the lodint function in R-QTL.  Genes within the 
confidence intervals were determined by counting all genes in the UCSC genome 
assembly mapping between markers flanking the 95% CI. 
Expression Arrays:  RNA from superior cervical ganglia was isolated using the RNEasy 
kit (QIAGEN, Valencia, CA), as we found these buffers were more effective at disrupting 
the ganglia than Trizol.  1µg of RNA was used as a starting template for the RiboMinus 
rRNA subtraction (Invitrogen, Carlsbad, CA) followed by the ST labeling protocol 
(Affymetrix, Santa Clara, CA).  Labeled samples were hybridized to Affymetrix Mouse 
Exon 1.0 arrays.  Array quality control was performed using the Affymetrix Expression 
Console.  2-way comparisons between homogenous groups (e.g. male vs. females or 
129/SvJ vs FVB/N males) were performed using the Significance Analysis of 
Microarrays (SAM) package4 using a 5% false discovery rate.  Results are presented in 
Supplementary Table 3 and plotted in Supplementary Figures 1C and 1D. 
eQTL analysis: Arrays were normalized using RMA in the XPS package 
(http://www.bioconductor.org/packages/2.6/bioc/html/xps.html). eQTL were calculated 
as described in 5; briefly, linkage between gene expression and loci was assessed by 
linear regression with genome-wide significance assessed using a FDR-based method. 
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Cell Culture:  Neuroblastoma cell lines were grown in RPMI media with 10% serum and 
antibiotics with the exception of SK-N-BE(2) (DMEM/F12, 10% serum) and IMR-32 
(DMEM, 10% serum plus non-essential amino acids).  Nor-NOHA was obtained from 
Bachem (Torrance, CA) and dissolved in DMSO.  GABA was obtained from Sigma (St. 
Louis, MO) and dissolved in H2O. Picrotoxin and bicuculline were obtained from Sigma 
and dissolved in DMSO.   
Western blotting:  Equal amounts of total protein were loaded for 4%–12% SDS-
polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. After 
blocking, membranes were blotted with Arg1 (R&D Systems, Minneapolis MN), GABA 
B R1, Erk (Santa Cruz Biotech, Santa Cruz, CA) , GABA A Rβ2/3, GABA B R2, β-
tubulin (Millipore, Billerica, MA),  cleaved-PARP (Asp214), p-Akt (Ser473), Akt, pErk 
(Thr202/Tyr204) (Cell Signaling Technology, Danvers, MA), and GAPDH (Upstate 
Biotechnology, Lake Placid NY).  Antibodies were detected with HRP-linked anti-
mouse, anti-rabbit (Amersham/GE, Piscataway, NJ), or anti-sheep IgG 
(Calbiochem/EMD, Gibbstown, NJ), followed by enhanced chemiluminescence 
(Amersham/GE, Piscataway, NJ). 
WST-1 assay:  Cells were grown in 12-well plates and treated for 72 hours prior to the 
addition of WST-1 reagent (100µl per 1ml media).  Absorbance was read after 60 
minutes.  Results were plotted using Graphpad Prism software, and p-values were 
calculated using a two-tailed Student’s t-test. 
FACS: Cells were plated on 6-well dishes and treated as indicated for 24 hours.  They 
were then harvested, fixed in 70% ethanol for 30 minutes, then stained with a propidium 
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iodide (PI) dye and RNase solution.  All samples were analyzed on a FACSCaliber flow 
cytometer (Becton Dickenson, Franklin Lakes, NJ) and analyzed using ModFit (Verity 
Software, Topsham ME).   Apoptosis was detected by flow cytometry for annexin V-
FITC per manufacturer’s protocol (Annexin V-FITC detection kit, BioVision,  Milpitas, 
CA) using FlowJo software (Tree Star, Inc, Ashland, OR). 
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Supplementary Figure Legends 
Supplementary Figure 1.  Incidence of neuroblastoma and SCG gene expression, 
but not MYCN transgene expression, are dependent on strain.  (A) Incidence of 
tumors in FVB/NJ and 129/SvJ as a function of backcross number.  (B) Taqman 
expression showing equivalent levels of TH-MYCN transgene expression in all tissues 
tested.  Analysis of brain, adrenal gland, and superior cervical ganglia from each strain 
showed equivalent levels of expression (C)  SAM analysis showing 3 genes differentially 
regulated between male and female FVB/NJ mice (N=5 in each group)  (D)  SAM 
analysis showing 9,820  genes differentially expressed between strains in male ganglia 
Supplementary Figure 2.   Correspondence between Gabra3 and Slc6a1 eQTL and 
secondary susceptibility loci.  (A) 2-qtl lod scores are plotted for the intersection of 
chromosomes 10 (vertical) and 2 (horizontal) in the top panel, with the scale at right 
indicating LOD scores for the full (additive plus interaction) model.  The contour line 
indicates a 1.5 LOD drop from the maximal value for the chromosome (See Table 1).  
The bottom panel shows the eQTL LOD plot for Gabra3 expression, indicating that the 
peak LOD score falls within a 1.5-LOD (95%) confidence interval for the susceptibility 
locus.  (B) plot similar to A, showing chromosome 4 on the horizontal axis and the eQTL 
lod score for Slc6a1 in the bottom panel.   
Supplementary Figure 3.   Treatment of neuroblastoma cell lines with arginase 
inhibitors inhibits proliferation, while the effect of GABA on viability is GABRA-A 
expression dependent.  (A)  WST-1 assay showing a dose-dependent decrease in 
viability following 72h treatment of neuroblastoma cells with varying doses of the Arg1 
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inhibitor nor-NOHA.  (C) FACS plot showing increased G1 phase in Kelly and SY5Y 
cells treated with nor-NOHA for 24 hours.  The dual PI3K/mTOR inhibitor PI103 is 
shown for comparison.  (C)  Three neuroblastoma cell lines with low GABA-A 
expression show no change in viability in response to GABA.  Viability was assessed by 
WST-1 assay at 72h. 
 
Supplementary Tables: 
Supplementary Table 1:  Tumor susceptibility interaction LOD scores, all mice, sex 
as an interacting covariate. 
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Abstract 
Background:  Alcohol’s ability to potentiate the activity of γ-aminobutyric acid (GABA) at 
GABAA receptors has been implicated as a key mechanism underlying the behavioral 
effects of alcohol.  The complex molecular biology of these receptors raises the 
possibility that particular receptor subtypes may play unique roles in alcohol’s abuse-
related effects and that subtype-selective ligands with therapeutic specificity against 
alcohol might be developed.  This study evaluated the capacity of α5GABAA receptor 
ligands to alter selectively the reinforcing effects of alcohol.  Methods:  Two groups of 
rhesus monkeys were trained to orally self-administer alcohol or sucrose under fixed-
ratio schedules and limited daily access conditions.  Additionally, following daily self-
administration sessions, the behavior of each monkey was scored for both species-
typical and drug-induced behaviors.  Results:  Concentrations of 1-6% alcohol 
maintained self-administration above water levels, engendered pharmacologically-
relevant blood alcohol levels ranging from 90-160 mg/dl, and produced changes in 
behavior typical of alcohol intoxication.  Concentrations of 0.3-3% sucrose also reliably 
maintained self-administration.  The α5GABAA receptor agonist QH-ii-066 enhanced and 
the α5GABAA receptor inverse agonist L-655,708 inhibited alcohol but not sucrose 
drinking.  The changes in alcohol drinking could be reversed with the α5GABAA receptor 
antagonist XLi-093.  However, L-655,708 increased yawning in both alcohol- and 
sucrose-drinkers, possibly indicative of an anxiogenic effect.  Conclusions:  These 
findings suggest a prominent and specific role for α5GABAA receptor mechanisms in the 
reinforcing effects of alcohol.  Moreover, these results suggest that α5GABAA receptors 
may represent a novel pharmacological target for the development of medications to 
reduce drinking.  Of ligands modulating this receptor, α5GABAA receptor inverse 
agonists may hold the most promise as alcohol pharmacotherapies. 
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Introduction 
 Alcohol’s ability to potentiate the activity of γ-aminobutyric acid (GABA) at GABAA 
receptors has been implicated as a key mechanism underlying the abuse-related effects 
of alcohol in both human and non-human subjects (e.g., Hyytiä and Koob, 1995; June et 
al., 1995; 1998; Korpi, 1994; Söderpalm and Hansen, 1998).  Molecular biological 
studies have shown that the mammalian GABAA receptor is a pentamer consisting of 
subunits from at least five different families, including the α, β, and γ subunits (McKernan 
and Whiting, 1996; Pritchett et al., 1989; Rudolph et al., 2001).  In addition, most of 
these subunits have a number of different isoforms (e.g., α1-α6, β1-β3, γ1-γ3; Olsen and 
Sieghart, 2008).  The complex molecular biology of GABAA receptors raises the 
possibility that subtype-selective agents with therapeutic specificity against alcohol might 
be developed. 
 GABAA receptors expressing the α5 subunit (α5GABAA receptors) comprise only 
a small proportion of native GABAA receptors and are found primarily in the 
hippocampus (Sur et al., 1999; Uusi-Oukari and Korpi, 2010).  Projections from the CA1 
and CA3 hippocampal fields have been shown to innervate brain regions implicated in 
the reinforcing effects of alcohol (e.g., Sesack and Grace, 2010).  Several lines of 
evidence support a potential role for α5GABAA receptor mechanisms in the abuse-
related effects of alcohol.  In this regard, using data from the Collaborative Study on the 
Genetics of Alcoholism, Song and colleagues (2003) reported a significant association 
between GABRA5 (the gene encoding the α5 subunit of the GABAA receptor) and 
alcohol dependence.  In alcohol discrimination studies in squirrel monkeys, we have 
shown that the α5GABAA receptor-selective agonists QH-ii-066 and panadiplon 
mimicked the discriminative stimulus effects of alcohol (Platt et al., 2005).  Moreover, the 
discriminative stimulus effects of alcohol and the alcohol-like discriminative stimulus 
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effects of QH-ii-066 were dose-dependently blocked by L-655,708, an α5GABAA 
receptor-selective inverse agonist (Platt et al., 2005).  With respect to the reinforcing 
effects of alcohol, intrahippocampal or i.p. administration of other α5GABAA receptor-
selective inverse agonists decreased alcohol self-administration in rats at doses that did 
not disrupt self-administration of saccharin or water (June et al., 2001; McKay et al., 
2004).  Finally, mice lacking the α5 subunit of the GABAA receptor show both reduced 
preference for and reduced consumption of alcohol (Boehm et al., 2004). 
 The purpose of the present study was to evaluate the contribution of α5GABAA 
receptor mechanisms to the reinforcing effects of alcohol in rhesus monkeys.  We 
determined the ability of α5GABAA receptor-selective ligands to augment and/or 
attenuate alcohol self-administration.  The selective ligands included the agonist QH-ii-
066, the antagonist XLi-093 and the inverse agonist L-655,708.  Results with the 
α5GABAA receptor ligands were compared with results obtained with naltrexone, an 
FDA approved pharmacotherapy to treat alcohol dependence.  Drugs that reduce 
alcohol self-administration may have potential as candidate anti-alcohol medications.  An 
important consideration in the development of an alcohol pharmacotherapy is the 
pharmacological specificity of the candidate medication’s effects.  One technique used to 
evaluate the specificity of a medication’s effect is to compare the doses of a drug to 
reduce behaviour maintained by alcohol relative to behaviour maintained by a non-drug 
reinforce.  To that end, we investigated the extent to which L-655,708 modulated the 
reinforcing effects of alcohol at doses that did not alter sucrose self-administration.  
Finally, compliance with any medication regimen is tied closely with the extent to which 
the medication produces untoward side effects.  We evaluated the observable 
behavioral effects of α5GABAA receptor ligands in both alcohol- and sucrose-drinking 
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monkeys to assess the degree to which the drugs elicited behavioral effects that might 
limit their clinical utility (e.g., sedation, anxiety, convulsions).   
 
Materials and Methods 
Subjects.  Nine adult male rhesus monkeys (Macaca mulatta), weighing 9.5 to 
12.1 kg, were studied in daily experimental sessions.  Three of the monkeys (two 
assigned to the alcohol group; one assigned to the sucrose group) had prior experience 
in operant i.v. self-administration (either cocaine or midazolam) procedures.  The 
remaining monkeys were experimentally naive.  Monkeys were housed in a colony room 
with a 12-h light/dark cycle.  Monkeys had unrestricted access to water via the standard 
cage-associated automatic sipper line and were fed a diet of monkey chow (Harlan 
Teklad Monkey Diet, Harlan Teklad, Madison, WI), supplemented with fresh fruit.  All 
animals were maintained in accordance with the guidelines of the Committee on Animals 
of the Harvard Medical School and the “Guide for Care and Use of Laboratory Animals” 
of the Institute of Laboratory Animal Resources, National Research Council, Department 
of Health, Education and Welfare Publication No. (NIH) 85-23, revised 1996.  Research 
protocols were approved by the Harvard Medical School Institutional Animal Care and 
Use Committee. 
 
Apparatus.  Monkeys were housed individually in stainless steel primate cages 
that also served as the experimental chambers.  One side of the cage was customized 
to form an operant drinking panel.  The panel consisted of two retractable sippers (model 
#: ENV-652AM; Med Associates, Inc., Georgia, VT) equipped with solenoids to minimize 
dripping.  Each sipper was connected with Tygon tubing to a stainless steel liquid 
reservoir mounted on the outside of the drinking panel.  A response lever (Med 
Associates, Inc., Georgia, VT) was positioned below each sipper.  Each press of a lever 
 
391 
 
produced an audible click and was recorded as a response.  Colored lights mounted 
above the sippers could be illuminated to serve as visual stimuli.  In these experiments, 
only one side of the drinking panel was active. 
 
Alcohol self-administration.  Five monkeys were trained to respond under a 
fixed-ratio (FR) schedule of oral alcohol reinforcement.  In the presence of a white light, 
completion of every 10th response (FR 10) resulted in a change in illumination from white 
to red light and extension of the drinking spout.  Displacement of the drinking spout up, 
down, left or right during extension resulted in alcohol delivery.  Fluid flow continued for 
as long as the monkey displaced the spout or for 30-s, whichever was shorter.  Within 
the 30-s sipper extension time, the monkey could stop drinking (i.e., release the spout) 
and resume drinking (i.e., displace the spout) as many times as it wanted.  The actual 
duration and volume of intake, within the constraints of the schedule, were under the 
control of the subject.  Between extensions of the drinking spout, all lights were off 
briefly, and responses had no scheduled consequences.  Daily self-administration 
sessions lasted 3-h.  The reinforcing effects of a range of concentrations of alcohol (0.5 
– 16% w/v), as well as water, were evaluated initially in each monkey.  Each alcohol 
concentration (or water) was made available for a minimum of five consecutive self-
administration sessions and until stable intake was observed (i.e., no upward or 
downward trend in mls and/or g/kg consumed over a period of at least three consecutive 
days). 
The effects of pretreatment with varying doses of the α5GABAA agonist QH-ii-
066 (0.1 – 5.6 mg/kg), the α5GABAA antagonist XLi-093 (0.03 – 0.3 mg/kg) or the 
α5GABAA inverse agonist L-655,708 (0.1 – 1.8 mg/kg) and their vehicles were 
determined on self-administration of a 2% alcohol solution.  This alcohol concentration 
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was chosen because it maintained intakes significantly higher than that of water.  In 
addition, it was on the ascending limb of the alcohol concentration-response function, 
allowing for detection of both increases and decreases in intake as a consequence of 
drug pretreatment.  Each dose of QH-ii-066, XLi-093 and L-655,708 was studied for a 
minimum of five consecutive sessions and until intake was stable.  Between evaluation 
of different doses of the α5GABAA ligands, monkeys were returned to baseline self-
administration (i.e., a minimum of five days of self-administration of a 2% alcohol 
solution in the absence of any pretreatment).  This step allowed assessment of baseline 
levels of intake over the course of the study.  The α5GABAA ligands were studied in 
random order in individual animals, and all doses of a given ligand were studied before 
moving on to another drug.  For comparison, the effects of the opioid antagonist 
naltrexone (0.01 – 0.3 mg/kg) also were determined. 
Subsequently, maximally effective doses of QH-ii-066 (0.3 mg/kg) and L-655,708 
(1.8 mg/kg) and their vehicles were given as pretreatments before sessions in which a 
wider range of alcohol concentrations were made available for self-administration.  
These studies determined the degree to which the ligands altered the shape and/or 
position of the alcohol concentration-response function.  Finally, the capacity of XLi-093 
to reverse the effects of QH-ii-066 and L-655,708 was determined.  In all instances, the 
effects of the α5GABAA ligands at each alcohol concentration were studied for a 
minimum of five consecutive sessions and until intake was stable. 
 
Sucrose self-administration.  A separate group of four monkeys was trained to 
respond under a FR 10 schedule of oral sucrose reinforcement.  This schedule and 
solution delivery was identical to that for alcohol self-administration, except that a 
sucrose solution instead of alcohol was available for self-administration.  The reinforcing 
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effects of a range of concentrations of sucrose (0.1 – 3% w/v), as well as water, were 
evaluated initially in each monkey.  Each sucrose concentration (or water) was made 
available for a minimum of five consecutive self-administration sessions and until stable 
intake was observed. 
The effects of pretreatment with varying doses of the QH-ii-066 or L-655,708 and 
their vehicles were determined on self-administration of a 0.3% sucrose solution.  This 
sucrose concentration was chosen because it maintained intakes that were significantly 
higher than that of water and roughly equivalent to intakes maintained by 2% alcohol in 
the alcohol self-administration group.  Each dose of QH-ii-066 and L-655,708 was 
studied for a minimum of five consecutive sessions and until intake was stable.  Between 
evaluation of different doses of the α5GABAA ligands, monkeys were returned to 
baseline self-administration.  The α5GABAA ligands were studied in irregular order in 
individual animals, and all doses of a given ligand were studied before moving on to 
another test drug. 
 
Observable behavior.  Following daily self-administration sessions, the behavior 
of each monkey (regardless of whether the animal self-administered alcohol or sucrose) 
was scored during a five-min sampling period using a focal animal approach as 
described in Platt et al. (2000; 2002) and as modified for the rhesus monkey.  That is, 
after the self-administration session, an observer who was not informed about the drugs 
under investigation watched a specific animal for five min.  During this sampling period, 
the observer recorded each instance a particular behavior (Table 1) occurred in 15-s 
intervals during the period.  Scores were calculated from these data as the number of 
15-s intervals in which a particular behavior occurred (maximum possible score for each 
behavior was 20).  A randomization schedule was employed so that order effects 
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between animals were minimized.  Eight observers performed the scoring across the 
duration of the study.  Typically, two observers were used daily – one observing the 
alcohol drinkers, one observing the sucrose drinkers.  To ensure reliability across 
observers, each individual underwent at least 20 h of training until they reached an inter-
observer reliability criterion of ≥ 90% based on percent agreement scores calculated 
between all possible pairs.   
 
Blood alcohol levels (BAL).  At select time points across the study (e.g., once 
stable intake was obtained at a particular alcohol concentration or after a particular drug 
treatment), monkeys self-administering alcohol were anesthetized with ketamine 
immediately following the session and three – five mls of blood were collected from the 
femoral vein.  Samples were immediately centrifuged at 3200 rpm for 8-12 minutes.  The 
plasma was drawn off, transferred to polypropylene tubes, and then frozen until analysis.  
Triple determinations of BALs were conducted using a rapid high performance plasma 
alcohol analysis using alcohol oxidase with an AM1 series analyzer and Analox Kit 
GMRD-113 (Analox Instruments USA, Lunenberg, MA).  This process detects BAL 
ranges from 0 to 350 mg/dl using an internal standard of 100 mg/dl. 
 
Data analysis.  After each alcohol self-administration session, intake for 
individual subjects was determined in two ways: volume (mls) and alcohol dose (g/kg) 
consumed.  Dose was calculated as: [volume consumed (mls) X alcohol concentration 
(g/ml)]/weight (kg).  After each sucrose self-administration session, intake for individual 
subjects was the volume consumed (mls).  Data are expressed as mean intake over the 
last three sessions of water or alcohol/sucrose availability.  Because the intake 
measurements for alcohol self-administration are correlated, with the exception of Fig. 1, 
we present only the data representing alcohol dose.  A one-way repeated measures 
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ANOVA was used to evaluate the effect of alcohol/sucrose concentration on total volume 
consumed. 
To compare the effects of the α5GABAA ligands and naltrexone on alcohol self-
administration, intakes following pretreatment with QH-ii-066, XLi-093; L-655,708 or 
naltrexone were converted to % of baseline intake.  Baseline intake was considered to 
be the mean dose of alcohol consumed across the three days of no pretreatment 
immediately prior to tests with a given dose of a compound.  Separate one-way repeated 
measures ANOVAs followed by Bonferroni t-tests compared the effects of the 
pretreatment drugs to the effect of vehicle on intake.  In curve-shifting experiments, 
separate two-way repeated measures ANOVAs compared the effects of either QH-ii-066 
or L-655,708, alone or combined with XLi-093, to the effect of vehicle on intake. 
To compare the effects of the α5GABAA ligands on sucrose self-administration, 
intakes following pretreatment with QH-ii-066 or L-655,708 were converted to % of 
baseline intake.  Baseline intake was considered to be the mean mls of sucrose 
consumed across the three days of no pretreatment immediately prior to tests with a 
given dose of a compound.  Separate one-way repeated measures ANOVAs compared 
the effects of the pretreatment drugs to the effect of vehicle on intake. 
Observational data were treated in two ways.  To evaluate the effect of 
increasing intake of alcohol on observable behavior, frequency scores for each behavior 
were averaged across the alcohol self-administration subjects to obtain group means.  
Mean scores (± SEM) for each behavior then were plotted as a function of intake.  For 
these analyses, intake (g/kg) was converted to “number of drinks”.  We use an 
operational definition of a “drink” as 0.25 g/kg alcohol or 17 g alcohol in a 70 kg human, 
representing the upper range of worldwide definitions of a drink (cf. Grant and Bennett, 
2003; Kalant and Poikolainen, 1999).  To determine statistical reliability of treatment 
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effects on each behavior, the effect of drink number was determined by separate one-
way ANOVAs.  Only the behavioral data generated during determination of the alcohol-
concentration response function were included in these analyses.  To evaluate the effect 
of α5GABAA ligands on observable behavior, frequency scores for each behavior were 
averaged separately across the alcohol self-administration subjects and the sucrose 
self-administration subjects to obtain means.  For each group, mean scores (± SEM) for 
each behavior were plotted as a function of dose.  For normally distributed data (as 
assessed using the Shapiro-Wilk test), separate two-way mixed factor ANOVAs 
determined the effects of the between-group factor (alcohol vs. sucrose) and within-
group factor (dose) and their interaction on each behavior.  In all cases, significant main 
effects were examined post-hoc with Bonferroni t-tests.  The alpha level for all tests was 
P≤0.05. 
 
Drugs.  Ethanol (95%; Pharmco Products. Brookfield, CT) and diluted to the 
appropriate concentrations with tap water.  QH-ii-066 and XLi-093 were synthesized as 
described in Huang et al. (2000) and Li et al. (2003), respectively.  These compounds 
were dissolved in 50-80% propylene glycol/20-50% 0.9% saline solution.  L-655,708 
(Tocris Bioscience, Ellsville, MO) was dissolved in 50% propylene glycol/50% 0.9% 
saline solution.  Naltrexone HCl (Sigma/RBI, St. Louis, MO) was dissolved in 0.9% 
saline solution.  Intramuscular injection volumes were 0.02 – 0.05 ml/kg body weight.  
Pretreatment times were 10 min for the α5GABAA ligands and 30 min for naltrexone. 
 
Results 
Alcohol self-administration.  Oral presentation of alcohol maintained self-
administration in all monkeys under the FR schedule of alcohol delivery and limited 
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access conditions (Fig. 1).  As the concentration of alcohol was increased, intake first 
increased and then decreased, resulting in an inverted u-shaped concentration-response 
function.  For the group, alcohol concentrations between 1 and 6% (w/v) maintained 
intakes significantly higher than that during water availability (Fig. 1A; F(7,28)=17.6, 
P<0.001, Bonferroni t-tests, P<0.05).  At these concentrations, monkeys drank 
approximately 0.8 – 1.9 g/kg of alcohol (Fig. 1B).  Analysis of blood samples verified that 
the volumes consumed when concentrations ≥ 2% (w/v) were available produced BALs 
in excess of 80 mg/dl in all monkeys (Fig. 1C). 
In addition to producing orderly effects on drinking behavior, alcohol altered 
several observable behaviors (Fig. 2).  All five self-administration monkeys had self-
administration episodes resulting in intake of 1 – 8 drinks; while three of the five 
monkeys had self-administration episodes resulting in intake of nine or more drinks.  
These higher intakes were observed after 13% of the self-administration sessions.  
While intakes below the equivalent of 7 drinks failed to alter any observable behavior, 
intakes of at least 7 drinks produced reliable changes in measures of passive visual, 
locomotion, tactile/oral exploration, stereotypy, scratching, and ataxia compared to levels 
of these behaviors observed during water availability.  Locomotion, across a range of 7 – 
9 drinks, was significantly increased compared to levels observed during water 
availability (F(10,716)=6.2, P<0.001, Bonferroni t-tests, P<0.05).  At the highest intake (≥ 
10 drinks), though, locomotion returned to water levels, likely coinciding with a significant 
increase in passive visual behavior (F(10,716)=2.0, P<0.05, Bonferroni t-tests, P<0.05).  
During water availability, ataxia was not observed.  However, a significant drink-
dependent increase in ataxia occurred at intakes of ≥8 drinks (F(10,716)=4.0, P<0.001, 
Bonferroni t-tests, P<0.05).  Significant drink-dependent decreases in behaviors also 
were observed.  At intakes ≥7 drinks, scratching was significantly reduced compared to 
water levels (F(10,716)=8.0, P<0.001, Bonferroni t-tests, P<0.05).  Alcohol also 
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produced an overall drink-dependent decrease in levels of tactile/oral exploratory 
behavior (F(10,716)=2.2, P<0.05, Bonferroni t-tests, n.s.) and stereotypic behavior 
(F(10,716)=2.4, P<0.01, Bonferroni t-tests, n.s.).  Alcohol had no other significant effects 
on observable behavior over the range of intakes observed during determination of the 
alcohol concentration-response function. 
 
α5GABAA ligands and alcohol self-administration.  Daily pretreatment with 
the α5GABAA ligands or naltrexone produced qualitatively different effects on alcohol 
(2% w/v) intake depending on the compound (Fig. 3).  For example, the two lowest 
doses (0.1 and 0.3 mg/kg) of QH-ii-066 induced small but significant increases in alcohol 
consumption (125 – 135% of the baseline intake of 1.4±0.2 g/kg) compared to vehicle 
(F(5,20)=18.2, P<0.001, Bonferroni t-tests, P<0.05).  At higher doses of QH-ii-066, 
intake returned to baseline levels and did not differ from that following vehicle 
administration.  Problems with solubility prohibited testing higher doses of QH-ii-066.  In 
the case of XLi-093, none of the doses evaluated altered self-administration of alcohol 
compared to vehicle, and intake was maintained at baseline levels (1.8±0.02 g/kg).  In 
contrast, daily pretreatment with L-655,708 resulted in dose-dependent reductions in 
alcohol self-administration compared to vehicle (F(4,16)=37.6, P<0.001), with the two 
highest doses (1 and 1.8 mg/kg) producing significant decreases in intake (Bonferroni t-
tests, P<0.05).  At the highest dose of L-655,708, intake was suppressed maximally to 
approximately 40% of the baseline intake of 1.6±0.2 g/kg.  The suppression of alcohol 
self-administration by L-655,708 was similar to that induced by naltrexone.  As expected, 
naltrexone engendered dose-dependent decreases in alcohol self-administration that 
reliably differed from vehicle at doses of 0.1 and 0.3 mg/kg (F(4,16)=7.7, P<0.01, 
Bonferroni t-tests, P<0.05).  The highest dose of naltrexone maximally suppressed 
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alcohol self-administration to 38% of the baseline intake of 1.7±0.2 g/kg.  In general, for 
all drugs, the effect observed on the first day of a given pretreatment was similar to that 
observed on the final day of administration (5 – 7 days), providing no evidence of the 
development of tolerance to the effects of QH-ii-066, L-655,708 or naltrexone (data not 
shown). 
Based on the results of the study described above, doses of the α5GABAA 
ligands that maximally altered alcohol self-administration were studied in combination 
with a wider range of alcohol concentrations (Fig. 4).  In general, pretreatment with QH-
ii-066 (0.3 mg/kg) enhanced self-administration of 0.5 – 4% (w/v) alcohol solutions and 
resulted in a leftward shift in the ascending limb of the alcohol concentration-response 
function (Fig. 4, left).  By and large, this leftward shift could be reversed if the animals 
also received a pretreatment of the highest dose of XLi-093 (0.3 mg/kg).  These findings 
are confirmed by a significant alcohol concentration X treatment interaction (F(6,24)=5.2, 
P<0.01, Bonferroni t-tests, P<0.05).  In contrast, pretreatment with L-655,708 (1.8 
mg/kg) attenuated self-administration of 1 – 6% (w/v) alcohol solutions and resulted in 
an overall rightward shift in the ascending limb of the alcohol concentration-response 
function (Fig. 4, right).  As with QH-ii-066, pretreatment with the highest dose of XLi-093 
completely reversed the L-655,708-induced rightward shift in the alcohol concentration-
response function.  These findings are confirmed by a significant alcohol concentration X 
treatment interaction (F(6,24)=3.9, P<0.01, Bonferroni t-tests, P<0.05). 
 
α5GABAA ligands and sucrose self-administration.  Oral presentation of 
sucrose maintained self-administration in all monkeys under the FR schedule of sucrose 
delivery and limited access conditions (Fig. 5A).  As the concentration of sucrose was 
increased, intake also increased.  Patterns of responding were comparable to those 
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observed during alcohol self-administration (data not shown).  For the group, sucrose 
concentrations between 0.3 and 3% (w/v) maintained intakes significantly higher than 
that during water availability (F(4,12)=9.5, P<0.01, Bonferroni t-tests, P<0.05).  At 0.3% 
(w/v), individual subjects displayed intakes ranging from ~ 450 to 1100 mls.  The 
average intake (± SEM) for the group at this concentration was 839±157 mls and did not 
differ significantly from the intake of the alcohol self-administration group at 2% (w/v) 
(906 ± 92 mls; t(7)=0.4, P=n.s.).  Daily pretreatment with either QH-ii-066 or L-655,708 
did not markedly alter sucrose self-administration at any dose compared to their 
respective vehicles (Fig. 5B). 
 
α5GABAA ligands and observable behavior.  In the absence of drug 
pretreatment and under water availability, the alcohol- and sucrose-drinking monkeys did 
not differ from each other for the majority of behaviors (Supplemental Figure 1).  
However, the sucrose drinkers did exhibit significantly higher levels of tactile/oral 
exploration (t(7)=-4.3, P<0.005) and locomotion (t(7)=-2.4, P<0.05) and tended to 
present more (t(7)=-2.5, P<0.05).  Neither QH-ii-066 nor L-655,708, at any dose 
evaluated, markedly altered the majority of observable behaviors.  Likewise, naltrexone 
failed to alter any of the behaviors.  There were, however, two exceptions (Fig. 6A and 
6B).  QH-ii-066 dose-dependently decreased tactile/oral exploration in both the alcohol-
drinking and sucrose-drinking monkeys, with a dose of 3 mg/kg significantly reducing 
this behavior compared to vehicle levels.  This effect was confirmed by a significant main 
effect of QH-ii-066 dose on this behavior (Shapiro-Wilk Normality test – passed; 
F(4,28)=4.6, P<0.01, Bonferroni t-tests, P<0.05).  On the other hand, L-655,708 dose-
dependently increased yawning in both self-administration groups, with the highest dose 
(1.8 mg/kg) engendering significantly more yawning compared to vehicle (Shapiro-Wilk 
Normality test – passed; F(4,28)=2.8, P<0.05, Bonferroni t-tests, P<0.05). 
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Discussion 
In the present study, alcohol served as a reinforcer in all monkeys, maintaining 
intake levels above those of water.  At concentrations of ≥ 2% (w/v), monkeys self-
administered pharmacologically relevant doses of alcohol and produced BALs ranging 
from 90 – 160 mg/dl.  The overall intakes (i.e., g/kg) observed in this study are generally 
typical of intakes observed for macaques self-administering alcohol under limited access 
conditions (Grant and Johanson, 1988; Henningfield and Meisch, 1978; 1979; 1981; 
Katner et al., 2004; Vivian et al., 1999).  Differences in intake between the present study 
and those cited could be due to a number of methodological differences including length 
of self-administration session, addition of flavorants, induction techniques, 
concentrations of alcohol made available for self-administration, and the self-
administration apparatus itself.  In fact, the latter difference could be especially important 
in the cases where the intakes observed in the present study are higher than those of 
the cited studies.  In our procedure, the monkey must press a lever to gain access to a 
drinking spout connected to an alcohol reservoir.   Depression of the drinking spout 
during extension results in alcohol delivery and fluid flow continues for as long as the 
monkey displaces the spout or for 30-s, whichever is shorter.  The actual duration and 
volume of intake, within the constraints of the schedule, is under the control of the 
subject.  Depending upon the available alcohol concentration, we observed average 
volumes of 12.5 mls of alcohol delivered per spout extension (range: ~3.5 mls/extension 
at 16% w/v; ~21 mls/extension at 2% w/v; data not shown).  This average 
volume/delivery is much larger than the volumes/delivery in the cited studies in which the 
drinking spouts are designed to deliver a set amount of alcohol (typically 0.5 – 1 ml) 
each delivery.  Evidence from rats would suggest that alcohol intake should increases as 
the volume per reinforcement increases (Henningfield and Meisch, 1975).  
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When given the opportunity to consume a wide range of alcohol concentrations, 
monkeys drank sufficient quantities of alcohol to alter observable behavior.  In many 
instances, these behavioral changes mirrored the effects of alcohol in intoxicated 
humans or those exposed to an acute alcohol challenge.  For example, it is well-
established that alcohol has a biphasic effect on activity (e.g., Martin et al., 1993; 
Morean and Corbin, 2010) such that, in human subjects, alcohol-induced stimulant 
effects (e.g., feelings of energized, stimulated, vigorous) are generally observed at lower 
BALs on the ascending limb of the blood alcohol curve, and alcohol-induced sedative 
effects (e.g., feelings of heavy head, inactive, sluggish) are reported at higher BALs on 
the descending limb of the blood alcohol curve.  In monkeys, we observed a reliable 
increase in locomotor activity across a lower range of drinks (and presumably lower 
BALs) compared to the range where we observed increases in passive visual behavior 
and decreases in tactile/oral exploration, possible indices of sedative-like effects.  
Alcohol also is known to reduce the response to stressors and can produce anxiolytic-
like effects in humans (e.g., Eckardt et al., 1998; Thomas et al., 2003).  Similarly, alcohol 
produced a drink-dependent decrease in stereotypy and scratching, two behaviors that 
have been associated with anxiety in nonhuman primates and which are amenable to 
reduction by typical anxiolytics (e.g., Birkett et al., 2005; Castles et al., 1999; Schino et 
al., 1996; Tiefenbacher et al., 2005a; 2005b; Troisi, 2002).  Finally, alcohol has been 
shown to dose-dependently increase the amount of body sway or static ataxia in 
humans (e.g., Schuckit, 1985); likewise, in monkeys, observable ataxia increased in a 
drink-dependent manner.  Together, these findings illustrate and reinforce the 
translational nature of our non-human primate drinking model. 
Using this model and GABAA receptor subtype-selective ligands, we assessed 
the contribution of α5GABAA receptor mechanisms to the reinforcing effects of alcohol.  
We found that the agonist QH-ii-066 modestly increased, and the inverse agonist L-
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655,708 decreased, intake of alcohol (2% w/v).  Subsequently, the maximally effective 
dose of QH-ii-066 was found to enhance intake of a wider range of alcohol 
concentrations; whereas, the maximally effective dose of L-655,708 was found to inhibit 
intake of a wider range of alcohol concentrations.  Both leftward (QH-ii-066) and 
rightward (L-655,708) shifts in the alcohol concentration-response function were 
abolished by XLi-093, despite it not altering drinking on its own.  These observations are 
in agreement with results from rodent studies showing that other α5GABAA receptor 
inverse agonists can reduce drinking (June et al., 2001; McKay et al., 2004).  In 
conjunction with observations that α5GABAA receptor-subunit knockout mice exhibit 
reduced preference for and consumption of alcohol (Boehm et al., 2004), these findings 
suggest a prominent role for α5GABAA receptor mechanisms in the reinforcing effects of 
alcohol.  Moreover, the lack of effect on drinking behavior with XLi-093 alone raises the 
possibility that neutral efficacy (i.e., antagonism) at this specific GABAA receptor subtype 
is not sufficient to inhibit drinking, rather inverse efficacy is required. 
In our hands, L-655,708 was as effective as the prototypical alcohol 
pharmacotherapy naltrexone in reducing drinking in the monkeys.  Coupled with the 
observation that L-655,708 also can attenuate the subjective/interoceptive effects of 
alcohol (Platt et al., 2005), a growing body of research suggests that α5GABAA receptor 
inverse agonists may have potential as candidate anti-alcohol medications.  An 
important consideration in the development of an alcohol pharmacotherapy is the 
pharmacological specificity of the candidate medication’s effect.  One technique used to 
evaluate the specificity of a medication’s effect is to compare the doses of a drug 
needed to reduce behavior maintained by alcohol relative to behavior maintained by a 
non-drug reinforcer.  For example, if a drug reduces alcohol-maintained behavior to a 
greater extent than it reduces behavior maintained by the non-drug reinforcer, then the 
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drug may have selective effects on alcohol self-administration (c.f. Mello and Negus, 
1996).  In the present study, L-655,708, across the same dose range studied in the 
alcohol drinkers, did not alter drinking in the sucrose drinkers.  This result suggests that 
the inhibitory effects of L-655,708 are selective for alcohol.  Moreover, that sucrose 
drinking also was not modified by QH-ii-066 provides additional support for a key role for 
α5GABAA receptor mechanisms in modulating the abuse-related effects of alcohol in 
particular, rather than drinking behavior in general. 
Because adverse side effects can limit the utility of a pharmacotherapy, and 
because non-selective inverse agonists at the GABAA/benzodiazepine site often can 
have convulsant/proconvulsant effects (e.g., Braestrup et al., 1983), it was of interest to 
determine the behavioral profile of L-655,708.  In both alcohol- and sucrose-drinkers, L-
655,708 was relatively benign and there was no indication of any interaction between L-
655,708 and alcohol.  Notably, even with repeated administration, L-655,708 was devoid 
of convulsant activity.  This agrees with studies in rats showing that L-655,708 does not 
induce seizures on its own, nor does it alter the dose of pentylenetetrazole required to 
induce seizures (Atack et al., 2006).  The sole observable effect of L-655,708 was to 
increase yawning in both groups of monkeys.  In nonhuman primates, increases in 
yawning often have been interpreted as indicating increased stress and anxiety (Castles 
et al., 1999; Lutz et al., 2004), and yawning can be induced in monkeys with 
administration of an anxiogenic drug (Major et al., 2009).  Likewise, L-655,708 exhibited 
anxiogenic-like activity in mice in an elevated plus-maze procedure (Navarro et al., 
2002).  While the effects of L-655,708 have not been determined in alcoholics, there is 
evidence for transient anxiogenic effects of flumazenil, a benzodiazepine receptor 
antagonist, in alcoholics in early withdrawal (Nutt et al., 1993).  Taken together, these 
findings certainly would suggest that an α5GABAA receptor inverse agonist is likely to 
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have anxiogenic effects in humans.  While a relatively mild side effect, anxiogenesis 
would likely limit how an L-655,708-type drug might be used effectively in a treatment 
setting.  For example, given that stress-induced negative affective states and 
withdrawal-induced anxiety are important facilitators of relapse to excessive alcohol use 
(e.g., Breese et al., 2005; Heilig et al., 2010), a drug that induces anxiety would not be a 
practical anti-relapse medication.  Rather, our results would suggest that an α5GABAA 
receptor inverse agonist may be most useful as a pharmacotherapy to assist individuals 
with achieving abstinence. 
In summary, our findings suggest a prominent and selective role for α5GABAA 
receptor mechanisms in the reinforcing effects of alcohol.  The results implicate 
α5GABAA receptors as potential pharmacological targets for medications to reduce 
drinking and assist individuals in achieving abstinence.  In particular, α5GABAA receptor 
inverse agonists may hold the most promise as alcohol pharmacotherapies. 
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 Table 1.  Behavioral categories, abbreviations, and definitionsa. 
SPECIES-TYPICAL: 
Passive visual   (VIS)  Animal is standing or sitting motionless with eyes open 
Rest/Sleep posture  (RSP)  Idiosyncratic posture adopted by monkeys during rest or sleep; eyes closed, easily 
roused by external stimulation (e.g., tapping on cage) 
Locomotion    (LOC)  At least two directed steps in the horizontal and/or vertical plane 
Tactile/oral exploration  (TAC)  Any tactile or oral manipulation of the cage or environment 
Forage    (FOR)  Sweeping and/or picking through wood chip substrate 
Self-groom  (GRM)  Picking, scraping, spreading or licking of an animal’s own hair 
Scratch    (SCR)  Vigorous strokes of the hair with the finger or toenails 
Vocalization  (VOC)  Species-typical sounds emitted by monkey (not differentiated into different types) 
Yawn     (YWN)  To open mouth wide and expose teeth 
Present  (PRE)  Posture involving presentation of rump, belly, flank, and/or neck) to observer or other  
   monkey 
Threat/aggress  (THR)  Multifaceted display involving one or more of the following: open mouth stare with teeth  
   partially exposed, eyebrows lifted, ears flattened or flapping, rigid body posture,  
   piloerection, attack (e.g., biting, slapping) of inanimate object or other monkey 
Fear grimace  (FGR)  Grin-like facial expression involving the retraction of the lips exposing clenched teeth;  
   may be accompanied by flattened ears, stiff, huddled body posture, screech/chattering  
   vocalizations 
Body spasm  (BSP)  An involuntary twitch or shudder of the entire body; also “wet dog” shake 
Lip smack  (LIP)  Pursing the lips and moving them together to produce a smacking sound; often  
   accompanied by moaning 
Cage shake    (CSH)  Any vigorous shaking of the cage that may or may not make noise 
Stereotypy  (STY)  Any repetitive, ritualized pattern of behavior that serves no obvious function 
Other  (OTH)  Any notable behavior not indicated above (e.g., masturbation, nose rub, lip droop,  
   vomit/retch) 
PROCEDURE-RELATED: 
Lever press  (LVR)  Depression of lever manipulanda on the drinking panel 
Drink  (DRI)  Mouth contact to fluid delivery sippers 
DRUG-INDUCED: 
Ataxia     (ATX)  Any slip, trip, fall or loss of balance 
Procumbent posture  (PRO)  Loose-limbed posture (sitting or lying on cage bottom) accompanied by eye closure; not  
   easily aroused by external stimulation (e.g., tapping on cage) 
a Adapted from Novak et al., 1992; Weerts et al., 1998; Platt et al., 2000, 2002.                                                                         
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Figure Legends 
Figure 1 Oral self-administration of varying alcohol concentrations and water under a 
fixed-ratio schedule and limited access conditions in monkeys.  For each 
monkey, mean intakes for the last three sessions at each concentration were 
calculated.  Data points represent the mean intake ± SEM (A. mls; B. g/kg) for 
the group (N = 5).  * P<0.05 vs. water (gray bar = SEM for water availability).  C. 
Mean ± SEM blood alcohol levels (mg/dl) determined once stable intake was 
obtained at a particular alcohol concentration for the group (N = 5). 
Figure 2 Effects of increasing number of drinks on observable behavior (one drink = 0.25 
g/kg alcohol).  Data points represent the mean ± SEM at each drink (N = 34 – 
115).  * P<0.05 vs. water (gray bar = SEM for water availability). 
Figure 3 Effects of daily pretreatment with QH-ii-066, XLi-093, L-655,708 or naltrexone on 
intake maintained by a 2% (w/v) alcohol solution.  For each monkey, mean 
intakes for the last three sessions at each dose were calculated.  Data points 
represent the mean intake ± SEM presented as a % of baseline g/kg for the 
group (N = 5).  * P<0.05 vs. vehicle.  Baseline intake for QH-ii-066 = 1.4±0.2 
g/kg; XLi-093 = 1.8±0.02 g/kg; L-655,708 = 1.6±0.2 g/kg; naltrexone = 1.7±0.2 
g/kg  (one-way ANOVA; F(3,16)=0.97, n.s.). 
Figure 4 Modulation by QH-ii-066 and L-655,708, administered alone or in conjunction 
with XLi-093, of alcohol self-administration in monkeys.  Points are group means 
± SEM based on the last three sessions at each alcohol concentration in five 
monkeys.  * P<0.05 vs. vehicle. 
Figure 5 A. Oral self-administration of varying sucrose concentrations and water under a 
fixed-ratio schedule and limited access conditions in monkeys.  For each 
monkey, mean intakes for the last three sessions at each concentration were 
calculated.  Data points represent the mean intake ± SEM (mls) for the group (N 
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= 4).  * P<0.05 vs. water (gray bar = SEM for water availability).  B. Effects of 
daily pretreatment with QH-ii-066 or L-655,708 on intake maintained by a 0.3% 
(w/v) sucrose solution.  For each monkey, mean intakes for the last three 
sessions at each dose were calculated.  Data points represent the mean intake ± 
SEM presented as a % of baseline mls for the group (N = 4).  Baseline intake for 
QH-ii-066 = 739±178 mls; L-655,708 = 953±142 mls (t-test; t(6)=-0.94, n.s.). 
Figure 6 Observable effects of QH-ii-066 on tactile/oral exploration (A) and L-655,708 on 
yawning (B).  Bars/points are group means ± SEM in the sucrose self-
administration group (N = 4) and the alcohol self-administration group (N = 5).  * 
P<0.05 vs. vehicle. 
 
Supplemental Figure 1 Behavioral profile of alcohol and sucrose self-administration 
monkeys under water availability (see Table 1 for abbreviations).  
* P<0.05 
 
Figure 1: 
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Figure 6: 
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VIII. Appendix VI (a).  Crystal data and structure refinement for XLi093 (33). 
Identification code  (33) 
Empirical formula  C33 H26 N6 O6 
Formula weight  602.60 
Temperature  295(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2/n 
Unit cell dimensions a = 6.9314(1) Å α= 90°. 
 b = 9.2889(1) Å β= 95.316(1)°. 
 c = 22.5403(4) Å γ = 90°. 
Volume 1445.02(4) Å3 
Z 2 
Density (calculated) 1.385 Mg/m3 
Absorption coefficient 0.809 mm-1 
F(000) 628 
Crystal size 0.24 x 0.10 x 0.02 mm3 
Theta range for data collection 3.94 to 66.97°. 
Index ranges -7<=h<=7, -10<=k<=10, -22<=l<=26 
Reflections collected 7178 
Independent reflections 2450 [R(int) = 0.0286] 
Completeness to theta = 66.97° 95.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.984 and 0.823 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2450 / 0 / 211 
Goodness-of-fit on F2 1.045 
Final R indices [I>2sigma(I)] R1 = 0.0451, wR2 = 0.1276 
R indices (all data) R1 = 0.0574, wR2 = 0.1378 
Extinction coefficient 0.0020(6) 
Largest diff. peak and hole 0.369 and -0.181 e.Å-3 
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Appendix III(b). Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for XLi093(33). 
 
U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
_______________________________________________________________________  
C(1) 583(3) 4957(2) 3838(1) 60(1) 
N(2) -713(2) 5543(2) 4205(1) 66(1) 
C(3) 302(3) 6423(2) 4553(1) 63(1) 
N(4) 2206(2) 6468(2) 4437(1) 58(1) 
C(5) 3729(3) 7252(2) 4757(1) 56(1) 
C(6) 3678(3) 7399(2) 5366(1) 62(1) 
C(7) 5123(3) 8119(2) 5706(1) 64(1) 
C(8) 6661(3) 8721(2) 5433(1) 60(1) 
C(9) 6658(3) 8620(2) 4822(1) 60(1) 
C(10) 5230(3) 7871(2) 4466(1) 57(1) 
C(11) 5409(3) 7917(2) 3806(1) 63(1) 
O(11) 6076(2) 9000(2) 3588(1) 79(1) 
N(12) 4863(2) 6755(2) 3477(1) 68(1) 
C(13) 4333(3) 5396(2) 3747(1) 67(1) 
C(14) 2394(3) 5524(2) 3978(1) 57(1) 
C(15) -123(3) 3891(2) 3389(1) 62(1) 
O(15) -1791(2) 3537(2) 3294(1) 88(1) 
O(16) 1313(2) 3338(2) 3099(1) 66(1) 
C(17) 735(3) 2297(3) 2632(1) 68(1) 
C(18) 2500 1438(4) 2500 70(1) 
C(19) 5152(4) 6746(4) 2849(1) 103(1) 
C(20) 8236(3) 9416(2) 5781(1) 70(1) 
C(21) 9564(4) 9941(3) 6065(1) 92(1) 
________________________________________________________________________
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Appendix III(c). Bond lengths [Å] and angles [°] for  XLi093(33). 
_____________________________________________________  
C(1)-C(14)  1.371(3) 
C(1)-N(2)  1.386(3) 
C(1)-C(15)  1.468(3) 
N(2)-C(3)  1.295(3) 
C(3)-N(4)  1.369(2) 
N(4)-C(14)  1.370(3) 
N(4)-C(5)  1.423(2) 
C(5)-C(6)  1.384(3) 
C(5)-C(10)  1.403(3) 
C(6)-C(7)  1.377(3) 
C(7)-C(8)  1.397(3) 
C(8)-C(9)  1.379(3) 
C(8)-C(20)  1.437(3) 
C(9)-C(10)  1.401(3) 
C(10)-C(11)  1.504(3) 
C(11)-O(11)  1.229(2) 
C(11)-N(12)  1.344(3) 
N(12)-C(19)  1.448(3) 
N(12)-C(13)  1.464(3) 
C(13)-C(14)  1.491(3) 
C(15)-O(15)  1.203(2) 
C(15)-O(16)  1.342(2) 
O(16)-C(17)  1.457(3) 
C(17)-C(18)  1.513(3) 
C(18)-C(17)#1  1.513(3) 
C(20)-C(21)  1.177(3) 
 
C(14)-C(1)-N(2) 109.99(18) 
C(14)-C(1)-C(15) 131.11(18) 
N(2)-C(1)-C(15) 118.90(17) 
C(3)-N(2)-C(1) 105.25(16) 
N(2)-C(3)-N(4) 112.49(18) 
C(3)-N(4)-C(14) 106.56(16) 
C(3)-N(4)-C(5) 126.97(17) 
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C(14)-N(4)-C(5) 126.31(15) 
C(6)-C(5)-C(10) 120.76(18) 
C(6)-C(5)-N(4) 117.91(17) 
C(10)-C(5)-N(4) 121.33(18) 
C(7)-C(6)-C(5) 121.08(18) 
C(6)-C(7)-C(8) 119.6(2) 
C(9)-C(8)-C(7) 118.85(19) 
C(9)-C(8)-C(20) 120.46(18) 
C(7)-C(8)-C(20) 120.7(2) 
C(8)-C(9)-C(10) 122.81(18) 
C(9)-C(10)-C(5) 116.79(19) 
C(9)-C(10)-C(11) 115.74(17) 
C(5)-C(10)-C(11) 127.30(17) 
O(11)-C(11)-N(12) 122.2(2) 
O(11)-C(11)-C(10) 119.17(19) 
N(12)-C(11)-C(10) 118.64(18) 
C(11)-N(12)-C(19) 119.2(2) 
C(11)-N(12)-C(13) 122.06(19) 
C(19)-N(12)-C(13) 117.7(2) 
N(12)-C(13)-C(14) 110.26(17) 
N(4)-C(14)-C(1) 105.71(16) 
N(4)-C(14)-C(13) 117.83(16) 
C(1)-C(14)-C(13) 136.41(19) 
O(15)-C(15)-O(16) 123.6(2) 
O(15)-C(15)-C(1) 124.09(19) 
O(16)-C(15)-C(1) 112.30(17) 
C(15)-O(16)-C(17) 115.99(16) 
O(16)-C(17)-C(18) 108.60(16) 
C(17)#1-C(18)-C(17) 116.3(3) 
C(21)-C(20)-C(8) 177.6(3) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1/2,y,-z+1/2   
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Appendix III(d). Anisotropic displacement parameters  (Å2x 103) for XLi093 (33). 
The anisotropic displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h 
k a* b* U12 ] 
_________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
_________________________________________________________________________ 
C(1) 45(1)  62(1) 74(1)  0(1) 14(1)  -3(1) 
N(2) 42(1)  77(1) 81(1)  -6(1) 17(1)  -4(1) 
C(3) 43(1)  66(1) 82(1)  -6(1) 18(1)  -2(1) 
N(4) 40(1)  56(1) 79(1)  -6(1) 16(1)  -4(1) 
C(5) 43(1)  49(1) 77(1)  -1(1) 13(1)  0(1) 
C(6) 51(1)  60(1) 78(1)  1(1) 19(1)  -6(1) 
C(7) 59(1)  65(1) 70(1)  2(1) 13(1)  -6(1) 
C(8) 50(1)  57(1) 74(1)  1(1) 8(1)  -3(1) 
C(9) 45(1)  54(1) 81(1)  3(1) 14(1)  -4(1) 
C(10) 43(1)  52(1) 77(1)  0(1) 13(1)  -1(1) 
C(11) 45(1)  68(1) 79(1)  -2(1) 17(1)  -8(1) 
O(11) 76(1)  81(1) 81(1)  3(1) 21(1)  -24(1) 
N(12) 52(1)  80(1) 77(1)  -13(1) 23(1)  -12(1) 
C(13) 48(1)  62(1) 94(2)  -16(1) 23(1)  -5(1) 
C(14) 45(1)  53(1) 75(1)  -4(1) 15(1)  -1(1) 
C(15) 50(1)  70(1) 68(1)  3(1) 13(1)  -5(1) 
O(15) 49(1)  116(1) 100(1)  -28(1) 14(1)  -17(1) 
O(16) 53(1)  72(1) 73(1)  -10(1) 15(1)  -8(1) 
C(17) 63(1)  77(1) 65(1)  -4(1) 9(1)  -9(1) 
C(18) 78(2)  69(2) 66(2)  0 10(1)  0 
C(19) 94(2)  135(2) 87(2)  -28(2) 37(2)  -31(2) 
C(20) 61(1)  73(1) 77(1)  8(1) 10(1)  -12(1) 
C(21) 77(2)  114(2) 82(2)  12(2) 1(1)  -40(2) 
________________________________________________________________________
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Appendix III (e). Hydrogen coordinates ( x 104) and isotropic  displacement parameters 
(Å2x 10 3) for XLi093 (33). 
________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________ 
  
H(3) -205 6965 4848 75 
H(6) 2650 7006 5549 75 
H(7) 5076 8205 6116 77 
H(9) 7646 9068 4639 72 
H(13B) 5296 5148 4070 80 
H(13A) 4303 4633 3452 80 
H(17B) 199 2793 2276 82 
H(17A) -250 1659 2763 82 
H(18) 3010(40) 810(30) 2867(10) 84 
H(19A) 5480 7698 2726 155 
H(19B) 3983 6437 2623 155 
H(19C) 6186 6096 2780 155 
H(21) 10530(50) 10430(40) 6280(14) 119 
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Appendix III (f). Torsion angles [°] for XLi093(33). 
________________________________________________________________  
C(14)-C(1)-N(2)-C(3) -0.3(2) 
C(15)-C(1)-N(2)-C(3) 179.53(19) 
C(1)-N(2)-C(3)-N(4) 0.5(2) 
N(2)-C(3)-N(4)-C(14) -0.4(2) 
N(2)-C(3)-N(4)-C(5) -176.01(19) 
C(3)-N(4)-C(5)-C(6) 34.5(3) 
C(14)-N(4)-C(5)-C(6) -140.2(2) 
C(3)-N(4)-C(5)-C(10) -144.9(2) 
C(14)-N(4)-C(5)-C(10) 40.4(3) 
C(10)-C(5)-C(6)-C(7) -1.9(3) 
N(4)-C(5)-C(6)-C(7) 178.69(18) 
C(5)-C(6)-C(7)-C(8) 0.5(3) 
C(6)-C(7)-C(8)-C(9) 2.2(3) 
C(6)-C(7)-C(8)-C(20) -176.9(2) 
C(7)-C(8)-C(9)-C(10) -3.5(3) 
C(20)-C(8)-C(9)-C(10) 175.54(19) 
C(8)-C(9)-C(10)-C(5) 2.1(3) 
C(8)-C(9)-C(10)-C(11) 177.80(18) 
C(6)-C(5)-C(10)-C(9) 0.6(3) 
N(4)-C(5)-C(10)-C(9) -179.99(16) 
C(6)-C(5)-C(10)-C(11) -174.48(19) 
N(4)-C(5)-C(10)-C(11) 4.9(3) 
C(9)-C(10)-C(11)-O(11) -32.8(3) 
C(5)-C(10)-C(11)-O(11) 142.3(2) 
C(9)-C(10)-C(11)-N(12) 145.98(19) 
C(5)-C(10)-C(11)-N(12) -38.9(3) 
O(11)-C(11)-N(12)-C(19) 3.0(3) 
C(10)-C(11)-N(12)-C(19) -175.8(2) 
O(11)-C(11)-N(12)-C(13) 171.04(19) 
C(10)-C(11)-N(12)-C(13) -7.7(3) 
C(11)-N(12)-C(13)-C(14) 73.5(3) 
C(19)-N(12)-C(13)-C(14) -118.2(2) 
C(3)-N(4)-C(14)-C(1) 0.2(2) 
C(5)-N(4)-C(14)-C(1) 175.81(18) 
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C(3)-N(4)-C(14)-C(13) 178.00(19) 
C(5)-N(4)-C(14)-C(13) -6.4(3) 
N(2)-C(1)-C(14)-N(4) 0.1(2) 
C(15)-C(1)-C(14)-N(4) -179.8(2) 
N(2)-C(1)-C(14)-C(13) -177.1(2) 
C(15)-C(1)-C(14)-C(13) 3.0(4) 
N(12)-C(13)-C(14)-N(4) -64.7(3) 
N(12)-C(13)-C(14)-C(1) 112.3(3) 
C(14)-C(1)-C(15)-O(15) -176.2(2) 
N(2)-C(1)-C(15)-O(15) 3.9(3) 
C(14)-C(1)-C(15)-O(16) 4.6(3) 
N(2)-C(1)-C(15)-O(16) -175.23(18) 
O(15)-C(15)-O(16)-C(17) 2.4(3) 
C(1)-C(15)-O(16)-C(17) -178.41(17) 
C(15)-O(16)-C(17)-C(18) -161.41(18) 
O(16)-C(17)-C(18)-C(17)#1 -52.04(12) 
C(9)-C(8)-C(20)-C(21) -78(6) 
C(7)-C(8)-C(20)-C(21) 101(6) 
________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1/2,y,-z+1/2       
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IX. Appendix VII: SBIR grant by Physiogenix 
Research Strategy 
A. Significance 
Alzheimer’s disease (AD) is a complex and progressive neurodegenerative pathology 
that currently affects 5.4 million Americans at an estimated total cost of $200 billion 
[Alzheimer’s Association, 2012]. Although the monetary costs greatly impact our 
economy, the emotional and social burdens the disease imparts on individuals and their 
families are immeasurable. The complexity of the disease is due in part to the multiple 
stages of AD, ranging from pre-symptomatic to severe dementia. As the disease 
progresses into the symptomatic phase of pathogenesis, individuals begin losing basic 
cognitive and learning abilities, which eventually can lead to the complete loss of 
memory, cognition, and executive functions [1, 2]; a point at which many AD sufferers 
lose the freedom of independent living. Along with the complexity of defining the exact 
causes of AD, there is a multitude of controversies and gaps in our understanding of the 
disease progression, which has made the treatment and prevention of AD especially 
difficult. Furthermore, current treatments for AD have variable successes [2-5] and 
demonstrate efficacy in approximately half of the treated individuals [National Institute of 
Aging, Alzheimer’s Association, 2012], thus substantiating the need for new approaches 
to AD therapeutics [1, 2]. Here, we propose our ligand PWZ-029, an inverse agonist with 
functional selectivity at gamma-aminobutyric acid class A (GABAA) receptors containing 
α5 subunits, for the mitigation of cognitive deficits associated with AD and age-related 
dementias. 
Current treatments of Alzheimer’s disease are largely ineffective and recent 
approaches to treating and preventing the disease have lost momentum in clinical 
trials. Currently, there are five drug therapies that are FDA-approved for the treatment of 
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cognitive symptoms associated with AD. Cholinesterase inhibition is the mechanism of 
action utilized by four of the five AD therapies (e.g., donepezil) while N-methyl-D-
aspartate (NMDA) antagonism constitutes the action of memantine, which is prescribed 
to treat moderate to severe AD [2]. Unfortunately, the efficacy of these drugs is variable, 
with positive results reported in only half of the users [3-5]. Thus, the necessity to further 
characterize the mechanism of disease progression, which will theoretically identify 
novel targets for drug therapies, is increasingly evident. Since the mid-1990s, the bulk of 
AD drug development efforts have surrounded the amyloid cascade hypothesis, which 
postulates that the neurotoxicity associated with AD pathogenesis is largely the result of 
alterations in the processing of amyloid precursor proteins in the brain. The result of 
these alterations can lead to the production and eventual aggregations of plaque-forming 
amyloid-beta (Aβ) peptides [2, 6-9]. Although the presence of extracellular Aβ plaques 
and intracellular neurofibrillary tangles are generally recognized as hallmarks of AD, 
recent attempts to commercialize compounds that reduce the accumulation of or 
increase the clearance of Aβ have been met by failure during clinical trials [2]. Thus, new 
approaches to treating or preventing AD are of immediate need. Recent approaches to 
characterizing the neuronal processes and alterations that result in or from hallmark 
anatomical changes of AD pathology are gaining momentum [10-12], thereby leading to 
novel targets for treating and preventing AD, such as the GABAA receptor complex [2, 7, 
8, 13-15]. To this end, we aim to develop PWZ-029, a selective inverse agonist of 
α5GABAA receptors, to mitigate cognitive deficits associated with early (i.e., mild and 
moderate) stages of AD, as well as age-associated dementias.  
The GABAA receptor complex is the primary modulator of neuronal inhibition and 
possesses diverse functionalities. The pathogenesis of AD targets neuronal networks 
that are especially vulnerable to the toxic effects of disease progression. Cholinergic 
neurons of the forebrain and the glutamatergic receptors and neurons in the 
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hippocampus are prime examples of networks affected by AD pathology. These 
excitatory networks of the brain are predominantly modulated by gamma-aminobutyric 
(GABA) neurotransmissions. GABA is the chief inhibitory neurotransmitter of the 
mammalian central nervous system (CNS) [7, 8, 14, 16, 17] and is regulated by three 
classes of GABA receptors, GABAA, GABAB, and GABAC, with the GABAA receptor 
complex being the primary regulator of GABA-induced CNS depression [7, 8, 16] and 
the primary target for benzodiazepine (BZ) pharmaceuticals [7, 8, 14, 17].  
The GABAA receptor complex is a pentameric, chloride-ion-gated channel through which 
GABA regulates fast synaptic inhibitory neurotransmissions [7, 16]. The heterogeneity of 
this ionotropic receptor is due to the diversity of subunit compositions. Characterizations 
of the GABAA receptor complex define 8 subunits with a total of 20 different subtypes: 
α1-6, β1-4, γ1-3, ρ1-3, δ, ε, π , and θ [13, 16-24]. Although the exact characterization of 
subtype and subunit composition in relation to GABAA receptor functionality is yet 
unclear, research supports that the majority of these complexes are composed of at 
least two α and β subunits [14, 16, 25-27] and one γ subunit [8, 14, 16, 27]. These 
findings suggest that GABAA receptors have immense structural and functional diversity, 
and the implications for this diverse functioning potential have profound implications for 
the specificity and resulting pharmacological effects of ligands targeting the GABAA 
complex [14]. For instance, many established BZ drugs (e.g., diazepam) have non-
specific binding behaviors, which have been shown to elicit side effects like sedation, 
hypnotic behavior, and affected motor coordination [14]; side effects that are not 
attractive for AD therapeutics aiming to improve memory and cognition. The α1 subtype, 
for example, is ubiquitously distributed in mammalian CNS [13, 14, 16] and has been 
shown to play a paramount role in the sedative side effects associated with ligands of 
the GABAA receptor [13, 14, 28].  Conversely, α5 subtypes, which are targeted by PWZ-
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029, are predominantly concentrated in the hippocampus, specifically in the Ammon’s 
horn of the dorsal CA1 region of rodent brains [13, 14, 16], and are characterized as 
modulators of memory and cognition [13, 14, 16, 24, 29-31]. These findings support the 
hypothesis that highly specific ligands that selectively bind α5 subtypes are promising 
targets for potent mitigators of AD-associated cognitive decline [15]. Our preliminary 
data for PWZ-029 substantiates this hypothesis and shows practical evidence that our 
compound significantly improves cognition without the sedative side effects common to 
other BZ ligands. 
Down-regulating compensatory mechanisms related to AD pathology may reduce 
the cognitive impairments associated with mild and moderate stages of the 
disease. Neuronal death that is commonly observed in the brains of AD patients has 
been shown to be caused partly by overstimulation of NMDA and 2-amino-3-(3-hydroxy-
5-methyl-isoxazol-4-yl) propanoic acid (AMPA) receptors via toxic amounts of the 
excitatory neurotransmitter, glutamate [32, 33]. Researchers speculate that these over-
stimulated pathways lead to compensatory mechanisms that aim to maintain the 
excitatory/inhibitory (E/I) balance of the brain’s regulatory processes. In other words, a 
pathologically overactive excitatory pathway can lead to the compensatory up-regulation 
of inhibitory processes, specifically GABA-mediated CNS inhibition [7, 8]. These 
findings, in combination with research showing the relative conservation of the 
GABAergic hippocampal networks in AD pathology [7, 29, 34-37], suggest that inverse 
agonist ligands that selectively act on GABAA receptors to inhibit the action of GABA in 
the brain are excellent candidates for memory and cognition therapeutics [15], such as 
PWZ-029.   
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B. Innovation 
Preliminary preclinical data strongly suggests that PWZ-029 is effective in improving 
memory and cognition, especially in models with baseline cognitive deficits. The high 
specificity of PWZ-029 for α5-containing GABAA receptors has successfully mitigated 
adverse side effects of seizures and sedation, which are commonly observed with 
benzodiazepines (BZ). Furthermore, the unique functional selectivity of PWZ-029 has 
successfully overcome functional interference and side effects that have stopped 
previous attempts to commercialize nonselective inverse agonists of the GABAA complex. 
Furthermore, because the core chemical structure of PWZ-029 classifies it as a 
benzodiazepine (Figure 1A) we are confident that the safety and toxicology experiments 
proposed here would be consistent with the vast body of research demonstrating the 
established safety and toxicological profiles of the BZ class of compounds. 
Our collaborator, Dr. James Cook, synthesized PWZ-029 as part of an effort to explore 
the difference between the pharmacophores for the diazepam-sensitive versus the 
diazepam-insensitive GABAA receptors [38]. One of the products of his laboratory’s 
research was PWZ-029, which was designed to be a partial inverse agonist with 
functional selectivity for the α5 subunit-containing GABAA receptor [39]. Our approach to 
mitigating the cognitive impairments of AD is innovative because PWZ-029 acts with a 
novel GABA-reducing mechanism rather than targeting cholinergic, glutamatergic, or Aβ 
pathways. Success in the proposed experiments will drive our team towards 
commercializing a benzodiazepine drug that improves memory and cognition in AD 
patients without eliciting unwanted sedative and convulsive side effects. These strides in 
our research will not only lead to a marketable product with strong intellectual property, 
but we will also publish our sensitive findings so that scientific understanding for 
treatment and mitigation of AD will advance. 
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C. Approach 
C1. PHASE I FINAL REPORT/PRELIMINARY STUDIES 
Our successful Phase I milestone data combined with significant findings from our 
company-sponsored preliminary studies encouraged us to pursue a Phase II SBIR grant 
for our cognition-enhancing compound, PWZ-029.  In summary, our significant findings 
demonstrate: 1) a selective binding affinity of PWZ-029 to α5 subunits on GABAA 
receptors, which was substantiated by an auspicious in-vitro efficacy profile, 2) minimal 
behavioral side effects of PWZ-029 compared to benzodiazepines and other inverse 
agonists with non-specific binding affinities, and 3) the ability of PWZ-029 to improve 
cognition and overcome impaired baseline performance in a myriad of memory tests that 
were carried out in multiple species.  
In-vitro characterization of binding affinity and efficacy. Extensive in vitro binding 
and efficacy experiments that showed a selective affinity of PWZ-029 to α5GABAA 
receptors (Figure 1.); in vitro data that were exemplified by enhanced performance in 
behavioral assays [39], specifically the contextual fear conditioning paradigm [30] 
(Figure 3). These data, in addition to binding and electrophysiological assays carried out 
by our collaborator, Dr. James Cook (University of Wisconsin-Milwaukee), demonstrate 
that PWZ-029 binds selectively (i.e., ≈20- to 30-fold greater selectivity) to α5 subunit-
containing receptors compared to the other isoforms of the GABAA receptor complex, 
specifically the α1 subunit-containing receptors, which are associated with sedative side 
effects of non-selective BZ ligands (Figure 1B and 1C). Electrophysiology experiments in 
Xenopus oocytes demonstrated that PWZ-029, at a concentration of 1 μM, significantly 
reduced GABA initiated control currents, thereby indicating a partial inverse agonist 
effect of PWZ-029 on GABAA receptors possessing the α5 isoforms (Figure 1B). 
Additional experiments carried out by the NIMH Psychoactive Drug Screening Program 
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(PDSP) at the University of North Carolina Chapel Hill Medical School showed that 
PWZ-029 is a highly selective ligand of the BZ-binding site, confidently indicating that the 
observed cognitive enhancing effects elicited by this ligand are likely the result of binding 
at the GABAA receptor complex and not other receptor classes, such as cannabinoids, 
histamines, prostaglandins, glutamate, Ca+ channel, transporters, adrenergic, 
acetylcholine, dopamine, serotonin, and opiates (data not shown).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ligand MW α1 α2 α3 α4 α5 α6 
PWZ-029 291.7 362.4 180.3 328.2 ND 6.2 ND 
 
 
Figure 1. Structural, electrophysiological, and binding 
characterizations of PWZ-029 show the ligand is a partial 
inverse agonist with functional selectivity and in vitro 
efficacy at α5 subunit-containing GABAA receptors. Panel A. 
Chemical structure of PWZ-029 classifies the compound as a 
benzodiazepine, a class of compounds with a well-characterized 
safety profile. Panel B. Oocyte electrophysiology data 
demonstrating the selectivity of GABA attenuation by inverse 
activity with α5 isoforms. Panel C. Binding affinity (Ki, nM) and 
selectivity of PWZ-029 against the various α-containing GABAA 
receptors.   
A. 
B. 
 C. 
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Preliminary profiling of PWZ-029 pharmacokinetics, maximum tolerated dose, and 
oral bioavailability (data not shown). In our Phase I rat experiments, we showed that 
peak plasma concentrations were detected by LC/MS at 0.25 hours (h) post-dose when 
PWZ-029 was administered by intravenous (1 mg/kg, i.v.) and oral gavage (5 mg/kg, 
p.o.) routes. These preliminary data indicate a rapid absorption into the blood 
compartment via the oral route. The concentration-time curves for both i.v. and p.o. 
administrations indicated at least two separate phases of redistribution with significant 
amounts of compound in the plasma compartment at 4 h and remaining detectable for 
24 h post-dose. The bioavailability of PWZ-029 was found to be roughly 11% when 
calculated by the area under the curve method and when accounting for the larger 
concentration used for the p.o. dose. In addition, brain samples were taken from rats 2 h 
after dosing to determine the potential of PWZ-029 to traverse the blood brain barrier. 
PWZ-029 was detected in brain tissue at 2 h after oral dosing and represented 2.1% of 
peak plasma concentration. A brain/blood ratio of 0.7 was determined for PWZ-029, with 
a brain/blood ratio of greater than 0.3-0.5 serving as our reference for sufficient access 
to the target organ. This was the first report showing both the oral bioavailability and 
target organ accessibility of PWZ-029.  
Additionally, a dose escalation experiment investigated oral doses of PWZ-029 at 30, 
100, 300, and 1000 mg/kg. Doses were given in single administrations, animals were 
observed for toxicological effects for 48 h post-dose, and then the next escalating dose 
was administered with the same experimental design followed for all phases of the 
escalation paradigm. All experimental animals survived each arm of dosing, and body 
weight loss was not observed for the duration of the experiment. Although mild tremors 
and facial twitches were noted, specifically at 300 and 1000 mg/kg, there were no overt 
signs of toxicity observed.  
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Minimal side effects observed with PWZ-029 administrations in mice, rats, and 
non-human primates. Single-dose proconvulsant studies utilizing male Swiss mice 
(Crl:CFW(SW)) treated with pentylenetrazole (PTZ) were conducted at NINDS and at 
PsychoGenics (Tarrytown, NY). Results demonstrated that PWZ-029 is not 
proconvulsant at any dose (10, 20, or 40 mg/kg) in the PTZ mouse model (data not 
shown). Furthermore, Harris et al. [30] found that systemic dose administrations in mice 
of PWZ-029 at a dose of 30 mg/kg did not result in convulsions. 
Our Phase I experiments utilized a standard battery of behavioral and motor 
coordination tests to elucidate side effects that are common to the BZ class of 
compounds. The rotarod test was used to assess motor coordination effects of single 
oral doses of PWZ-029 at 5, 10, and 20 mg/kg versus saline- and diazepam-treated rats 
in the Dahl/SS rat strain. No signs of impaired motor coordination or sedation were 
observed at any of the three PWZ-029 doses (data not shown). The Dahl/SS rat strain 
was also utilized for the elevated plus maze and the open field test. Oral doses of PWZ-
029 at 5, 10, and 20 mg/kg were tested against saline-treated and DMCM-treated rats in 
both assays. The combined results of these experiments suggest that PWZ-029 activity 
does not elicit anxiogenic side effects relative to the DMCM- or diazepam-treated control 
rats (data not shown). We suspect that the overall data suggest a mild sedative effect of 
PWZ-029; however, a sedative effect was not observed in the rotarod studies. 
Targeted studies in monkeys were conducted in order to assess possible anxiolytic-like 
effects, abuse potential, and sedative-motor effects. In a rhesus monkey conflict model 
of the anxiolytic effects of drugs [40], PWZ-029 was ineffective over a 1000-fold dose 
range (up to 1.0 mg/kg, i.v.), suggesting that although this compound is a weak agonist 
at α1, α2, and α3 subunit-containing receptors, the efficacy at these subtypes is 
insufficient to induce anxiolysis-like behavior or alter operant responding. Similarly, 
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PWZ-029 lacked reinforcing effects over a 300-fold dose range in monkeys self-
administering the BZ, midazolam (i.v.), under a progressive-ratio procedure, suggesting 
that this compound has no abuse potential (data not shown). 
Figure 2 represents the results of sedation studies in rhesus monkeys treated with 3.0 
mg/kg PWZ-029 (i.v., panel A) or alprazolam (i.v., panel B) and then monitored for 120 
minutes (min) post-dose. PWZ-029 did not induce significant signs of sedation at doses 
200-300 times higher than the lowest dose shown to enhance performance in cognitive 
tasks (see below). Conversely, the non-selective BZ, alprazolam, induced significant 
rest/sleep posture and deep sedation, thus providing a positive comparator.   
 
 
 
 
 
 
 
 
 
Time after PWZ-029 Injection (min)
0 7.5 15 30 60 120
Fr
eq
ue
nc
y 
Sc
or
e
0
5
10
15
20
Rest/Sleep Posture
3.0 mg/kg
Deep Sedation
3.0 mg/kg
0 7.5 15 30 60 120
Time after Alprazolam Injection (min)
0 7.5 15 30 60 120
Fr
eq
ue
nc
y 
Sc
or
e
0
5
10
15
20
Rest/Sleep Posture
0.1 mg/kg
Deep Sedation
3.0 mg/kg
0 7.5 15 30 60 120
A.
B.
Figure 2. Sedation studies carried out with PWZ-029- (A) and alprazolam- (B) 
treated rhesus monkeys (n=5). Data were obtained as modified frequency scores 
by trained observers unaware of the treatments or purpose of the studies (inter-
rater reliability scores > 90%). “Rest/sleep posture” was defined as the monkey 
assuming a posture associated with rest or assumed sleep, with eyes closed for at 
least 3 sec, but responsive to an auditory cue. “Deep sedation” was recorded if the 
monkey assumed an atypical posture, with eyes closed for at least 3 sec, and non-
responsive to an auditory cue. These measures are adapted from the American 
Association for Anesthesiology standards for levels of sedation. All data presented 
as mean ± SEM.  
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PWZ-029 demonstrates efficacy in the attenuation of cognitive deficits in mice, 
rats, and NHP. Assessments of the contextual fear response (i.e., % freezing) to 
stimulus (Figure 3) in scopolamine-treated, male C57BL/6 mice demonstrated that PWZ-
029 attenuated the scopolamine-induced impairment of contextual memory (Harris, et al., 
2008). 
 
  
 
 
 
 
 
 
In a company-sponsored Morris Water Maze (MWM) experiment, we examined the 
effects of PWZ-029 in a novel rat model of Alzheimer’s disease (AD) - the FAB-
Samaritan rat (Taconic Farms, Inc., Hudson, NY). FAB-Samaritan rats were carried 
through the MWM task (1 day of visible acquistion followed by 2 days of hidden platform 
tests) in subsequent weeks following brain infusions of an AD-inducing solution [41]. 
Infusion pumps were installed in the animals, and rats received brain infusions of saline 
(positive model control) or a proprietary FAB solution (negative control and test groups). 
Animals (n=8/group) were dosed for ≈28 days via p.o. gavage with vehicle (positive 
model and negative controls), donepezil (positive drug control, 3 mg/kg), or PWZ-029 
Figure 3. Pavlovian fear conditioned contextual memory test 
in scopolamine-treated C57BL/6 mice.  Each mouse was 
injected via intraperitoneal injection with vehicle (white bar), 1.5 
mg/kg scopolamine (black bar), or 1.5 mg/kg scopolamine plus 10 
mg/kg PWZ-029 (gray bar). N=12 mice/group. *P<0.05 versus 
scopolamine-treated mice (Harris et al., 2008)  
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(10 mg/kg) at ≈30 minutes prior to entering the maze. In the second arm of testing for 
the animals, PWZ-029-treated rats performed significantly better on Day 2 of the hidden 
phase in both latency to platform and distance travelled when compared to the FAB-
Samaritan negative control animals (P<0.05 versus negative control, data not shown). 
As an additional part of our SBIR Phase I project, we conducted preliminary experiments 
to evaluate the extent to which PWZ-029 could alter memory processes in a 
translationally-relevant primate species. Figure 3 shows very promising results with 
PWZ-029 in the Object Retrieval with Detours (ORD) task in rhesus monkeys. The ORD 
task in monkeys is often described as providing a measure of executive functioning [42, 
43]. Impairments in executive functioning (i.e., decision making, planning, response 
inhibition, cognitive flexibility) often emerge after mild cognitive impairment in the 
progression to AD [44]. Importantly, Ballard et al. reported that an inverse agonist with 
selectivity for α5-containing receptors enhanced performance in the ORD task, providing 
initial proof-of-concept support for our studies [42]. 
The ORD task consists of a food-retrieval procedure in which a small food treat (e.g., 
banana slice) is placed in a transparent box with one open side, and the animal’s ability 
to retrieve the treat is measured (see Figure 4). Performance in the ORD task was not 
enhanced (mean percentage of successfully-completed trials in a daily session) by i.v. 
injections of PWZ-029 when the task included easy trials (i.e., open side directly in front 
of monkey, Figure 4A); however, performance was robustly enhanced when trials were 
difficult (i.e., open side on right or left, treat deep within the box, Figure 4B). When 
performance on the ORD task was attenuated by the cholinergic agent, scopolamine, 
PWZ-029 treatment effectively reversed this deficit (Figure 4C). Finally, the 
enhancement of ORD performance induced by PWZ-029 could be blocked by an 
antagonist selective for α5-containing GABAA receptors (Figure 4D). Together, these 
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findings provide strong support for PWZ-029 as a cognitive enhancer of executive 
functioning in a primate species with close genetic similarity to humans. 
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Figure 4. Effects of PWZ-029 in the 
Object Retrieval with Detour (ORD) 
task. Monkeys were trained to retrieve 
food from an opaque box with one open 
end (above right). Panel A. PWZ-029 was 
ineffective when tested with a 
combination of Easy and Difficult Trials. 
Panel B. PWZ-029 enhanced 
performance when only Difficult Trials 
were tested (*p<0.05 vs. vehicle, V). 
Panel C. Scopolamine (S, 0.01 mg/kg) 
inhibited ORD performance, which was 
reversed by PWZ-029 (**p<0.05 vs. S). 
Panel D. Enhanced performance with 
PWZ-029 in Difficult Trials was blocked 
by the antagonist XLi-093 (*p<0.05 vs. V; 
**p<0.05 vs. PWZ-029 alone, P). 
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C2. EXPERIMENTAL APPROACH 
Aim 1.  Define the exposure/safety relationship of PWZ-029 in rats to determine 
whether this compound exhibits a sufficient level of safety to support Phase I 
clinical trials. The safety and potential target-organ toxicity of a drug must be 
established to demonstrate a sufficient efficacy/safety margin prior to entering a 
compound into clinical trials [45]. Here, escalating-dose and 7-day repeat dosing studies 
will be carried out in rats with the goal of establishing the no observable adverse effects 
level (NOAEL), dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and the 
safety/exposure relationship of PWZ-029. We will use these data to support the definitive, 
IND-enabling GLP safety studies needed prior to initiating a Phase I clinical trial.   
Rationale: Determining the toxicology and safety of a compound prior to testing in 
humans is crucial to the process of drug development [45]. As multiple benzodiazepines 
are currently on the market, their general safety profile is well documented. To establish 
the specific safety profile of PWZ-029, a series of safety/toxicological experiments will be 
carried out to assess the MTD and NOAEL in acute and multiple dosing paradigms. The 
toxicology assessments will be carried out in Sprague Dawley (SD) rats.  We will 
determine the general safety profile of PWZ-029 and incorporate pharmacokinetic 
measurements to establish its safety/exposure relationship. Potential differences in 
toxicological responses between genders will also be evaluated. In parallel to the in vivo 
safety studies, standard in vitro assays for selectivity, mutagenicity, and 
clastogenicity/aneugenicity will be conducted to assess the potential for ‘off-target’ 
toxicity. 
Experimental Design: Information gained from the escalating-dose MTD studies will 
drive the doses of PWZ-029 to be used in subsequent 7-day toxicological studies, and 
the outcomes of these studies will then determine the ultimate design of the GLP-safety 
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studies. A preliminary dose-ranging study in rats (using doses up to 1000 mg/kg) has 
already been conducted as part of an initial safety evaluation of PWZ-029. Although no 
overt findings of toxicological significance were observed, increased facial movements 
(twitching) were noted, especially at 300 and 1000 mg/kg. Therefore, a second MTD 
study will be conducted in rats using doses up to 2000 mg/kg, paying particular attention 
to potential abnormal muscular activity (i.e., twitching/tremors). 
In addition to the Phase I single dose pharmacokinetic (PK) analysis that has already 
been conducted with PWZ-029 in rats, PK analysis will be carried out after a single dose 
and after 4 daily doses to assess the potential for drug accumulation or the potential for 
induction of liver metabolism that may affect drug exposure upon chronic dosing. Results 
from these rat safety studies will be used to seek funding from other sources for further 
study and to design PK, single-dose MTD, and sub-chronic safety studies in beagle dogs.   
Additionally, in vitro safety assessment will be conducted by an established contract 
research organization (Cerep Inc., Redmond, WA). The desired outcome of these 
studies is to further define the safety and selectivity profile of PWZ-029. 
PK analysis to establish safety/exposure ratio in rats. Three male SD rats (8-weeks old, 
250 g) will be dosed p.o. with 10 mg/kg of PWZ-029. Blood will be sampled after 0.08, 
0.25, 0.5, 1, 2, 4, 8, 18 and 24 h to assess PWZ-029 exposure and to determine single 
dose PK parameters. Subsequently, rats will be dosed at 24 h intervals, and after the 
fourth daily dose, blood will be sampled following the schedule utilized on Day 1 to 
determine whether multiple-day dosing affects any of the PK parameters. 
Escalating-dose MTD studies. Male SD rats (8-weeks old, 250 g) will be dosed via p.o. 
gavage with either vehicle (n = 5) or with escalating doses of PWZ-029 (100, 500 and 
2000 mg/kg; n = 5/group). On day 1 of the study, rats will be dosed with vehicle or the 
lowest dose of PWZ-029 (100 mg/kg) and then observed for behavioral effects. For the 
first 120 minutes, animals will be intensely monitored for signs of acute toxicity (i.e. 
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morbidity and mortality) with special attention being paid toward unusual muscular 
activity (i.e., twitching, tremors and/or convulsions). Animals will be subsequently 
monitored for an additional 46 h for overt signs of toxicity such as ataxia, greater than 
10% decrement in body weight, tremors, loss of righting response, morbidity, and 
mortality. Following the initial dose, rats will be dosed at 48 h intervals with either vehicle 
or the escalating doses of PWZ-029 and monitored as described for the 100-mg/kg dose. 
Forty-eight hours after the final vehicle or 2000 mg/kg dose of PWZ-029, animals will be 
terminated and gross pathological observations documented. Blood will be collected to 
assess clinical chemistries, and the adrenals, brain, heart, kidneys, liver, spleen, thyroid 
with parathyroid, skeletal muscle and thymus will be weighed, collected, and stored in 
formalin for histological analysis. 
In vivo safety assessment in rats (7-day repeat dose study). A low, mid, and high dose of 
PWZ-029 will be established based upon the findings from the dose-ranging 
experiments. A total of 32 SD rats will be distributed among 8 experimental groups. 
• 16 female SD rats will be distributed into 4 experimental groups (n=4/group): Control 
group, low dose group, mid dose group and high dose group.   
• 16 male SD rats will be distributed among 4 dose groups as with the females.  
All experimental animals will be dosed via p.o. gavage once a day for 7 consecutive 
days. Detailed clinical observations including unusual muscular activity (i.e., twitching, 
tremors and/or convulsions), body weights, and food consumption will be recorded daily. 
On day 7, blood will be collected 1 h after administering the final dose for drug exposure 
and clinical chemistries. Animals will be terminated, and the adrenals, brain, heart, 
kidneys, liver, spleen, thyroid with parathyroid, skeletal muscle, and thymus will be 
collected, weighed, and stored in formalin for histology. The 1 h post-dose timing was 
chosen based on the PK data obtained from Phase I experiments. 
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In vitro selectivity and gene safety assessment. The potential for off-target 
pharmacology/toxicology will be assessed using a broad panel of ~150 human receptors 
and enzymes The potential for genetic toxicity will be assessed using the Ames 
fluctuation assay and the in vitro micronucleus assays run in the presence and absence 
of S9 liver fractions (Cerep Inc., Redmond, WA). 
Benchmark for Success. Results from the PK study will refine the PK parameters 
estimated in the preliminary studies that indicated rapid oral absorption of PWZ-029 into 
the blood compartment with a bioavailability of about 11% and biphasic elimination 
kinetics. Success will be determined from the escalating-dose MTD studies if we 
observe of a sufficiently high MTD to proceed to a multiple-dose safety assessment in 
rats. Successful outcomes of the 7-day repeat dosing study will establish a relationship 
between chronic dosing and DLT, define a therapeutic index (TI) sufficient for continued 
development of PWZ-029, and demonstrate that PWZ-029 does not induce its own 
metabolism nor show drug accumulation upon multiple-day dosing. Successful 
outcomes will Finally, in vitro analyses will be successful will demonstrate that PWZ-029 
does not induce its own metabolism nor show drug accumulation upon multiple-day 
dosing. Finally, successful in vitro analyses will be defined as demonstration of an in 
vitro selectivity profile ≥50-fold and a lack of gene toxicity. 
Anticipated Problems and Solutions. The increased facial movements (i.e., twitching) 
that were observed in the preliminary dose-ranging study may be confirmed or another 
unanticipated DLT may be discovered. If increased facial twitching is confirmed, we will 
determine whether it decreases or stops in a multiple-day dosing study (i.e., toleration). 
Assessment of any toxicological observations will require their assessment in multiple-
day dosing studies and protocols will be designed to incorporate the necessary 
measurements. Identification of off-target activity in the selectivity panel would first 
require confirmation in secondary enzyme and/or cell-based assays. Confirmed off-
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target activity would require the evaluation of potential side effects and further toxicology 
studies would need to incorporate assessment of these in study designs. Positive results 
in the genetic toxicity assays would require the identification of a back-up compound 
devoid of this activity. 
Aim 2. Examine the potential of PWZ-029, an inverse agonist of α5GABAA 
receptors, to mitigate cognitive deficits in a transgenic mouse model of AD. 
Despite an ever-growing population of aged individuals, there are few, effective 
therapeutic options for individuals suffering from cognitive deficits associated with AD. 
To expand on our preliminary evidence that suggests inverse agonist action at α5-
subunit containing GABAA receptors can mitigate AD-associated cognitive decline, we 
will test the efficacy of PWZ-029 to improve performance in the contextual-fear 
conditioning assay with the APPswe Tg2576 mouse model of AD. All behavioral 
experiments will be controlled with age-matched, non-transgenic littermates, as well as 
positive and negative drug controls (n=10 mice/group). From these experiments, we 
expect to gain proof-of-concept data that supports inverse agonist action at α5GABAA 
receptors as a novel therapeutic option for improving cognition in those suffering from 
AD. 
Rationale: Research carried out to characterize the distribution of the various GABAA 
receptor subtypes in rodent brains shows that α5GABAA subunits are highly 
concentrated in the Ammon’s horn of the hippocampus, specifically in the CA1 dorsal 
region [13, 14, 16]; a region of the hippocampus that is specifically targeted in context-
dependent fear conditioning assays [46-50]. Furthermore, studies have shown that the 
α5GABAA subunits are spared in the hippocampus, even with the pathophysiological 
brain shrinkage and neuronal death that is commonly associated with AD [7, 29, 34-37]. 
To this end, we hypothesize that PWZ-029, an inverse agonist that has repeatedly 
demonstrated high selectivity for α5GABAA receptors, will improve performance in 
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context-dependent fear conditioning experiments, thereby establishing proof-of-concept 
for a novel therapeutic mechanism to mitigate AD-associated cognitive decline.  
Experimental Design: The following experiments will have oversight by Dr. Catherine 
Kaczorowski, a leading AD expert from the Medical College of Wisconsin. The evidence 
gained from these experiments will guide the direction in which impactful and successful 
commercialization of PWZ-029 is most likely. 
Formulation. Formulation of PWZ-029 will be carried out identically for all Aims. All 
compounds will be administered via p.o. gavage 30-60 minutes prior to entering the fear 
conditioning experiments. PWZ-029 will be synthesized by Cambridge Major 
Laboratories (Germantown, WI). PWZ-029 will be administered to the animals only on 
the day of training (see conditioning protocol below) at 10 mg/kg, a dose shown to 
improve performance on memory tasks in adult mice (Figure 3) and rats (refer to MWM 
data in the preliminary data section of this proposal), suggesting that a 10 mg/kg dose of 
PWZ-029 will enhance cognition in the APPswe model [30, 39]. Premeasured amounts 
of PWZ-029 will be dissolved in a widely used solvent that contains 85% distilled water, 
14% propylene glycol, and 1% Tween 80 [30, 38, 39]. Donepezil (catalog # D6821), 
which will serve as the positive drug control, will be purchased from Sigma-Aldrich (St. 
Louis, MO), formulated in vehicle, and administered daily at 0.3 mg/kg for 6 weeks prior 
to the fear-conditioning assay, including the training day of the behavioral assay [51, 52]. 
Triazolam, a non-selective BZ agonist that has been shown to inhibit performance in fear 
conditioning assays [53] will serve as the negative drug control, and will also be 
purchased from Sigma Aldrich (catalog # T9772), formulated in vehicle, and 
administered at 0.03 mg/kg prior to the training phase of the fear conditioning protocol. 
To acclimate all mice to the same handling/dosing exposure and to maintain blinded 
treatments, PWZ-029 and triazolam groups will be dosed with vehicle for the 6-week 
period that donepezil will be dosed prior to the conditioning assay. There will be no 
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doses administered on the testing day when freezing behaviors are scored. 
Research Model. Taconic Farms, Inc. (Hudson, NY) will provide male APPswe Tg2576 
mice (001349-T-RD1) along with the age-matched, non-transgenic, wild type littermates 
(001349-W-RD1). Prior to being shipped to the PhysioGenix Animal Facility, the mice 
will be screened for the RD1 mutation, which causes blindness. Any animal carrying the 
mutation will be excluded and replaced. Animals will be shipped from Taconic at ≈6 
months of age and housed at PhysioGenix until the animals are aged to 9-12 months, 
which is the age where Aβ deposition notably affects performance in memory tasks [54]. 
Body weights will be collected weekly for the entire duration that the animals are housed 
at PhysioGenix as a means of monitoring animal health and to calculate dosing volumes 
for each study animal. 
Contextual fear conditioning assay to assess associative learning and memory. 
Behavioral assays will be carried out in an isolated laboratory where traffic and sound 
inference is negligible. Experiments will be carried out during the light phase of a 12/12hr 
light/dark cycle, and all technicians will be blinded to the treatments of the animals. Fear 
chambers will be procured from Med Associates (St. Albans, VT). Study animals will be 
acclimated to the experimental room for 60-90 minutes before entering into the fear-
conditioning assay. After the period of acclimation, an animal will be placed into the fear 
chamber, which will serve as the novel context, i.e., conditioned stimulus. The animal will 
be allowed to explore the novel context for 148 s, at the end of which a foot shock 
(duration of 2 s at 0.4 mA) will be introduced [55, 56]. The animal will remain in the 
chamber for 30 s following the foot shock before returning to the home cage. Twenty-
four hours later, the animal will be returned to the experimental room, allowed to 
acclimate in the room, and placed back into the chamber. Freezing, which will be defined 
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as the complete absence of movement, except for respiratory actions, will be scored 
every 10 s for 4 min.  
Benchmark for Success. Success will be defined as a significant increase (P<0.05) in 
percent freezing at the 24-hour time point for APPswe transgenic and/or non-transgenic 
mice treated with PWZ-029 relative to the negative controls (vehicle and triazolam). 
Anticipated Problems and Solutions. If differences are not observed between the 
treatment groups, we will consult Dr. Kaczorowski for procedural amendments that may 
enhance the differentiating potential of the fear conditioning assay (e.g., condition mice 
to the context prior to administering unconditioned stimulus training). We may still find 
that PWZ-029 does not enhance performance in this mouse model and in this assay. If 
these results are encountered, in our next round of funding, we will test the ability of 
PWZ-029 to mitigate cognitive deficits in mouse models of ‘normal’ aging. 
Aim 3. Examine the potential of PWZ-029 to enhance executive function and 
memory in rhesus monkeys. Our research during the SBIR Phase I project showed 
that PWZ-029 enhanced performance on the ORD task of executive function in a 
manner consistent with a role for α5-containing GABAA receptors. We first will expand 
these findings to assess specific aspects of executive function, including set-shifting and 
response inhibition. In addition, we will introduce studies on working memory—a 
cognitive domain regulated by and influencing executive function [57]. Notably, deficits of 
this domain are considered a hallmark of AD [2, 44]. Finally, we will evaluate 
fundamental processes that may influence results from executive function and memory 
tasks, specifically attention and motivation.   
Rationale: In order to evaluate the extent to which PWZ-029 enhances executive 
function and memory, our proposal will utilize the Cambridge Neuropsychological Test 
Automated Battery (CANTAB). A clear strength of the CANTAB approach is that its tasks 
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are based on corresponding procedures developed for human patients, which will greatly 
facilitate our ultimate goal of translating findings from monkeys to humans. For executive 
function, we will use two tasks, including the intradimensional/extradimensional (ID/ED) 
set-shifting task, which evaluates the ability of a subject to acquire discriminations, 
attend to specific stimulus attributes, and shift attention to other attributes, thus providing 
an assessment of cognitive flexibility. To evaluate “impulsivity,” a behavior shown to be 
impaired in AD [58], we will use the delayed reinforcement choice (DRC) task, in which 
monkeys must choose between a delayed, large reward or an immediate, small reward. 
To assess memory, we will use the self-ordered spatial search (SOSS) task, which is a 
short-term spatial working memory task similar to the radial-arm maze procedure used in 
rodents [59]. Attention will be assessed with the serial-reaction time (SRT) task [60], and 
motivational processes will be assessed with a progressive-ratio (PR) procedure. 
Altogether, these tasks will provide a comprehensive evaluation of the ability of PWZ-
029 to enhance executive function and memory, as well as to assess the relative roles of 
attentional and motivational variables that potentially contribute to PWZ-029’s ability to 
enhance cognition. 
Experimental Design: Our overall approach will be similar to that described for our 
ORD results in the preliminary data section of this proposal (see Figure 4): (1) examine a 
range of doses of PWZ-029 (0.001-1.0 mg/kg) compared to a positive control (donepezil, 
0.01 or 0.03 mg/kg [61]); (2) assess the ability of PWZ-029 to reverse the performance-
attenuating effects of scopolamine (0.01 mg/kg, which will serve as a negative control; 
and (3) assess the ability of the preferential α5-containing receptor antagonist, XLi-093 
(0.1-1.0 mg/kg), to block enhanced performance, if present, of a maximally effective 
dose of PWZ-029.   
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Route of Administration. In order to compare our results with the results from the Phase I 
studies, we will initially administer all drugs via the i.v. route using indwelling chronic 
venous catheters (implanted using the methods described in detail by Platt et al., 2011) 
[62]. The use of the i.v. route will also help to minimize limitations of interpretation due to 
differences in pharmacokinetic variables. Oral dosing is a key consideration, however, 
and in the event that a positive effect of PWZ-029 emerges for a cognitive task, we will 
evaluate targeted doses using the intragastric (i.g.) route via a nasogastric tube in awake 
monkeys. Our co-PI, Dr. Rowlett, has extensive experience with this methodology [63-
69]. We will choose the maximally effective dose, assuming a decrease in potency when 
switching from i.v. to i.g. administration, and increase (or decrease) the dose by ½ log 
unit in order to adjust for potency differences across the two routes. 
Subjects. Experiments will be conducted with adult male and female rhesus monkeys 
(Macaca mulatta), born and reared at the New England Primate Research Center 
breeding facility and/or obtained from outside sources. Based on our research during the 
Phase I grant, as well as power analyses derived from the literature, we are proposing a 
sample size of at least N=6 monkeys. For cognitive testing, monkeys will be prepared 
with a non-allergenic nylon vest (Lomir Biomedical, Inc., Malone, NY) and seated in 
primate chairs (Crist Instruments, Hagerstown, MD) enclosed in ventilated, sound-
attenuating chambers (Med Associates). All animals will be monitored for food intake, 
and will undergo relatively mild food restriction, based on limiting caloric intake (for 
detailed methods, see Taffe, 2004 [70]). The monkeys will be weighed and assessed for 
body condition once per week. Weekly weighing of the conflict monkeys will occur 
throughout the studies to adjust feeding based on a combination of weight, performance, 
and overall health (assessed in consultation with the clinical veterinary staff).  
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CANTAB tasks for assessing executive function, memory, attention, and motivation. All 
monkeys to be used in this application will receive training to sit in the chair, with 
different stages of training for the individual tasks (most monkeys will be trained and 
ready by the project start date). During a given experimental session, the monkey will be 
placed into the chair and brought to a sound-attenuated chamber (Med Associates) with 
ventilation, white noise, and a CANTAB touch screen unit. Sessions typically last no 
more than 2 hours, and 1 or 2 tasks are conducted per session (usually a single 
session/day). During tests with PWZ-029 (administered 5-10 min before the session), 
only a single task will be scheduled.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Attentional set-shifting in 
monkeys. A. Diagram illustrating ID/ED task.  
B. Representative baseline performance in a 
rhesus monkey. 
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Intradimensional/Extradimensional Set Shifting (ID/ED). This task consists of a series of 
four discrimination learning stages, plus reversals, wherein touching only one of two 
stimuli presented on the screen results in food pellet delivery (for summary, see Figure 
5).  Within any given stage of the task, a pair of stimuli is presented and the same 
stimulus is associated with reinforcement (S+ stimulus) until the performance criteria are 
met (18 of 20 consecutive trials correct). Correct choices must be made within 30 s, and 
following a correct choice, the screen is blanked for 5 sec while an incorrect choice (S- 
stimulus) results in a 0.2 s tone and a 9-s period of blank screen. Four distinct stimulus 
sets will be used in 4 stages. In the first stimulus set (stage 1A), two distinctly shaped 
stimuli will be presented, with touches on one shape resulting in food pellet delivery.  
Stage 1B will consist of a stimulus reversal, in which the same two shapes are retained, 
but pressing the S+ stimulus now does not result in reinforcement, whereas touching the 
former S- stimulus will result in food pellet delivery. In Stage 2A, a compound 
discrimination is presented. For this discrimination, the two shapes from Stage 1B are 
present, but additional stimuli, consisting of lines, will be superimposed onto the existing 
shapes. Because the shape discrimination from the previous stage does not change, the 
lines are irrelevant to this discrimination. Stage 2B will consist of a shape reversal, 
similar to Stage 1B. 
Stage 3A will consist of the ID shift stage. For this discrimination, two new shapes with 
new lines will be presented. This is considered an ID shift due to the fact that despite 
new shapes and lines being introduced, the shape remains the relevant dimension for 
the discrimination. Stage 3B will consist of a reversal of the shape S+ and S- from Stage 
3A. In the final two stages, the ED shift will be introduced. Thus, in Stage 4A, new 
shapes and lines will be presented; however, the lines—not the shape—will be the 
relevant discriminative stimulus. Stage 4B will consist of a reversal of the line S+ and S- 
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contingencies. Performance is determined as the number of errors at each stage, and 
the data will be subjected to a square root transformation to achieve normal distributions 
[59]. Data will be analyzed with repeated measures ANOVA and Bonferroni t-tests for 
multiple comparisons. 
Delayed Reinforcement Choice (DRC). Our preliminary data with the ORD task 
suggested the possibility that PWZ-029 enhances the ability of the monkey to withhold or 
inhibit prepotent responding. The ID/ED task will allow recording of persistent incorrect 
responding, similar to barrier reaches in the ORD task. A prominent interpretation of this 
type of behavior is dysfunctional inhibitory control, or “impulsivity.” A more complex form 
of inhibitory control involves choice behavior, which can be investigated using the DRC 
task, also commonly referred to as “delayed discounting” task. 
The CANTAB “Impulsive Choice” task offers subjects a choice between two reinforcers, 
which can differ in magnitude, probability, and delay. We are focusing on delay of 
reinforcement in the DRC task, based on pharmacological studies [71, 72]. In this task, a  
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Figure 6. Delayed reinforcement choice task from the monkey CANTAB system.  
A. Schematic of the task.  
B. Prediction of the effects of a cognitive enhancer on data analyzed by discount 
functions. The k rate is the slope of discounting for the hyperbolic function—in this 
example, k is reduced by the cognitive enhancer, indicating a higher degree of choice for 
the larger, but delayed, reward. 
 
choice is offered between a relatively large reward (4 or more food pellets) and a small 
reward (1 food pellet). A trial will initiate by a touch of a single stimulus, which is 
replaced by two stimuli, referred to as the “delay” and “immediate” stimulus. Touching 
the delay stimulus results in a blank screen for a specified duration (e.g., 0-80 s), 
followed by a signaled delivery of the large reward. Touching the immediate stimulus will 
result in signaled delivery of the small reward with no delay. After reward, the screen will 
be blank for 10 s. Data will be analyzed initially by comparing the percentage of delay 
stimulus responding as a function of delay (typical delay sequence= 0, 10, 20, 40, 80 s, 
randomly presented). As the delay is increased, animals characteristically choose the 
large reward less [71] (for summary, see Figure 6A). An improvement in performance by 
PWZ-029 would be manifested as a significant increase in percentage of choices for the  
delayed, yet larger reward, relative to control conditions. Data also may be analyzed 
using a hyperbolic discounting function [73], which provides a rate (k) of discounting 
value (Figure 6B). Enhancement of performance by PWZ-029 would be reflected as a 
significant decrease in the k value. 
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Self-Ordered Spatial Search (SOSS). The SOSS task is a short-term spatial working 
memory task similar to the radial-arm maze procedure used in rodents (see Figure 7, 
[59]).  
 
 
 
 
 
 
 
 
 
 
 
 
 
In each trial, two, three or four small, colored, rectangular boxes are displayed on the 
screen in positions randomly allocated from 16 possible locations. The monkey must 
touch a box within 30 s of stimulus onset. After each successful touch, the color of the 
touched box is briefly (100 ms) changed and the screen is then blanked and a reinforcer 
delivered. After a 2-s delay, the boxes are re-displayed and the monkey must touch a 
box that was not previously touched in the trial in order to receive a food pellet. The trial 
is completed when the animal has either touched all boxes without a repetition (correct), 
touched a box that had previously been selected in that trial (error), or failed to touch a 
box within 30 s of stimulus presentation (omission). A tone and a 4-s screen blank will 
follow errors and omissions. After 5 s, another trial is presented with stimuli in new 
(randomly allocated) positions. A session will consist of 40 trials grouped into 6 blocks 
that differ according to the number of boxes presented. The different blocks, with 
 
Figure 7. Self-ordered spatial search (SOSS) task 
from the monkey CANTAB system. 
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number of trials in parentheses, will be: 2 boxes (5), 3 boxes (7), 4 boxes (7), 3 boxes 
(8), 4 boxes (8), and 2 boxes (5). Accuracy scores will be calculated for each trial type 
by dividing the number of correctly completed trials by the number of trials in which there 
was at least one response (omissions will be excluded from the calculation). Accuracy 
scores will be analyzed by repeated measures ANOVA and Bonferroni t-tests, with trial 
type and PWZ-029 dose as factors. 
Serial Reaction Time (SRT). This task is based on methods described in detail by Weed 
and Gold [60]. Briefly, the task consists of a discrete-trials procedure in which each trial 
begins with the presentation of a grid with 5 open circles (3 cm diameter) on the touch 
screen. The monkeys will be trained to press and hold a lever for a variable duration 
(between 0.75 to 2.5 s, randomly determined) and then to release the lever at the onset 
of a 2 cm yellow stimulus presented in one of the 5 circles. If the monkey touches this 
circle within 2 s, the screen will go blank and 2 food pellets will be delivered, and a 3 s 
inter-trial interval will begin. The yellow stimulus duration will consist of brief flashes of 
0.02, 0.1, and 1.0 s durations. If the monkey fails to press the lever or fails to respond to 
the screen within the allotted time, or touches an incorrect circle, then a tone will sound 
and the screen will go blank for 4 s until the next trial, with no food reward given (for 
summary, see Figure 8).  
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Each session will consist of 45 trials with the 3 flash durations presented randomly 3 
times in each of the 5 choice circles.   
Data that will be analyzed include latency to release the lever following stimulus onset 
and the time taken to move the hand from the lever to the screen. Failure to touch the 
screen after pressing the lever will be considered an omission error, which will be 
analyzed as the average number of errors per trial.  All data will be analyzed with 
repeated measures ANOVA with dose and stimulus duration as factors, as well as with 
Bonferroni t-tests for multiple comparisons. 
Progressive-Ratio (PR) schedule of reinforcement. PR procedures consist of response 
requirements that progressively increase across a session until responding ceases 
(Figure 9). The last response requirement completed, termed “break point,” provides a 
quantitative measure of the reinforcing effectiveness of a stimulus. For these studies, a 
colored box appearing in the middle of the screen will initiate a session. Touching the 
box once will result in food pellet delivery, and the response requirement will 
progressively increase following each reinforcer by an incremental value beginning at 1 
and doubling after 8 response requirements are completed successfully. Thus, the 
 
Figure 8.  Serial reaction time task from the monkey 
CANTAB system. 
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response requirement sequences will consist of: Increment=1, response requirements=1, 
2, 3, 4, 5, 6, 7, 8; Increment=2, response requirements=10, 12, 14, 16, 18, 20, 22, 24; 
Increment=4, response requirements=28, 32, 36, 40, 44, 48, 52, 56; and so on. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sessions will be a maximum of 20 min and will be terminated if 3 min elapses without a 
response. Performance will be measured as the break point and number of food pellets 
delivered per session. This procedure provides a measure of the ability of the animal to 
respond, as well as an assessment of “motivation” to perform. We do not anticipate that 
PWZ-029 will significantly alter the mean break points or number of food pellets 
delivered, which would rule out changes in motivational levels as an interpretation for 
changes in cognitive performance. 
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Benchmark for Success. Success will be defined as α5-containing receptor mediated 
enhancements in ID/ED, DRC, and SOSS performance, in the absence of robust 
changes in SRT and PR.  
Anticipated Problems and Solutions. SRT enhancements might suggest that broader 
cognitive processes are augmented simply due to an enhancement in attention, which in 
and of itself might be therapeutically useful. Change in PR performance, however, is a 
more significant issue, given that increases in motivation might explain increases in task 
performance by a non-cognitive mechanism (e.g., enhanced food palatability). We are 
unaware of any precedent in the literature for this type of effect.  
Recent evidence has suggested an age-dependency for cognitive-enhancing effects of 
inverse agonists at α5 subunit-containing GABAA receptors [15]. For our ORD studies, 
the monkeys generally were in the “middle-aged” category (≈15-20 years old), a time 
period documented to show mostly moderate cognitive impairments [57, 74] and a 
similar group of monkeys will be available for the present project. If warranted, future 
plans will involve targeted cognitive tests with PWZ-029 in aged monkeys (20+ years 
old) depending on availability of monkeys in this age range. 
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BINDING AFFINITY
Experiment Type of Test Model Figure Summary of Results
Functional 
and subtype 
selectivity 
of PWZ-029
Used to determine the 
subtype selectivity of 
PWZ-029 to the 
GABAA receptors, 
especially the α5 
subtype.
Xenpus oocytes 
electrophysiology
PWZ-029 concentrations 
of up to 1 μM 
demonstrated a 
significant 20% reduction 
of control GABA elicited 
current indicating a 
partial inverse agonist 
effect at GABAA 
receptors possessing the 
α5 subtype.  PWZ-029 
also exhibited agonistic 
selectivity for the α1 and 
α3 bearing GABAA 
receptors. P<0.01, 
Student's t-test.
Binding 
Affinity of 
PWZ-029
Used to determine the 
affinity of PWZ-029 
to the GABAA 
receptor subtype, α5.
Mouse fibroblast 
L(tk-) cells 
expressing 
recombinant 
human GABAA 
receptor subunits
PWZ-029 binding affinity 
for α5 sutypes are near 60-
fold times that of  α1 
subunits.
PWZ-029 Preliminary Data Compilation
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Experiment Type of Test Model Figure Summary of Results
Convulsant/    
Proconvulsant 
Effects
Used to determine the 
convulsant/proconvulsant 
drug side-effects.
Male Swiss mice 
(Crl:CFW(SW)) 
treated with 
pentylenetetrazole 
(PTZ)
N/A
PWZ-029 did not cause 
convulsions at any 
concentration (10, 20, or 40 
mg/kg) in the PTZ mouse 
model. 
Rotarod
Rotarod tests are used to 
assess motor coordination.  
The longer an animal 
stays on the rotating rod, 
the more coordination 
their motor skills.  The 
test further assesses drug 
side-effects, such as 
dizziness and muscle 
relaxation.  If these effects 
are present the subject is 
expected to spend less 
time on the rotating rod.
Dahl Salt-Sensitive 
(SS) rats 
(n=12/group) were 
treated per os with 
either vehicle, 
diazepam, or one of 
three concentrations 
of PWZ-029.  After 
a training period, the 
animals were 
subjected to the 
rotating rod test for 
a maximum of 300 
seconds.
No significant decrease in 
motor coordination was 
observed at any of the three 
PWZ-029 concentrations. 
However, the success rate of 
rats  increased with PWZ-
029 treatment.                        
SIDE-EFFECTS
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Experiment Type of Test Model Figure Summary of Results
Operant 
Responding
Very basically assesses 
the individual's 
response that is 
required to carry out 
cognitive tasks.  This 
experiment is highly 
sensitve to sedative-
motor effects of 
conventional 
benzodiazepines (e.g. 
alprazolam).
Rhesus monkeys 
treated with vehicle 
and then increasing 
concentrations of 
alprazolam or PWZ-
029. This Operant 
Responding task 
required the animal to 
press the lever 20 
times to receive a 
food pellet.
   C.      Operant Responding
PWZ-029 showed no 
evidence of inhibition 
in the baseline levels of 
operant responding 
maintained by food. 
Observational 
Studies
Based on defined 
behaviors observed in 
animals under baseline 
conditions, post-dose 
observations are 
indicative of drug side-
effects.
Rhesus monkeys were 
treated with vehicle, 
alprozolam, zolpidem, 
or PWZ-029. Post-
dose observations 
were documented as 
no change, increase, 
decrease or increase 
and decrease in 
respective behavior.
No increase or decrease 
in behavior were 
observed for PWZ-029.
SIDE-EFFECTS Continued
PWZ-029 Preliminary Data Compilation
Table 2.  Analysis of all behavioral categories following multiple doses of the three test compounds.  Significant effects were identified as 
at least one dose significantly different from vehicle (N=4-5 monkeys).  See Table 1 for definitions of abbreviations. 
Compounds No Change Increase Decrease Increase & Decrease 
Alprazolam Loc, Grm, Scr, Ste, For, 
Voc, Thr, Yaw, BSm, Pre, 
Dri, NRu, LSm, CSh, LDr 
RSP, MSe, DSe, Atx Pas, Tac   
Zolpidem Loc*, Grm, Scr, Ste, For, 
Voc, Thr, Yaw, BSm, Pre, 
Dri, NRu, LSm, RSP, MSe, 
CSh, LDr 
DSe, Atx Pas Tac 
PWZ-029 Pas, Loc, Grm, Tac, Scr, 
Ste, For, Voc, Thr, Yaw, 
BSm, Pre, Dri, NRu, Atx, 
LSm, RSP, CSh, MSe, DSe, 
LDr 
   
*Loc was associated with a significant overall main effect of dose (ANOVA) but none of the doses were significantly different from vehicle 
(Bonferroni t-tests, P>0.05). 
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Experiment Type of Test Model Figure Summary of Results
Sedation 
Measures
Based on defined 
sedative postures 
for primates, 
sedative side-effects 
can be measured 
with these 
experiments.
Rhesus monkeys 
were treated with 3.0 
mg/kg PWZ-029 
(i.v.) or one of two 
concentrations of 
alprazolam and then 
monitored for 120-
minutes post-dose.
PWZ-029 did not alter 
either species-specific 
behavior or induce 
significant signs of 
sedation at doses 200-
300 times higher than the 
lowest dose that 
enhanced ORD 
performance.  
Conversely, the non-
selective benzodiazepine 
alprazolam suppressed 
some aspects of normal, 
species-typical behavior 
and engendered 
rest/sleep posture, 
moderate and deep 
sedation; thus providing 
a positive control for the 
PWZ-029 data.
SIDE-EFFECTS Continued
PWZ-029 Preliminary Data Compilation
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Experiment Type of Test Model Figure Summary of Results
Pavlovian 
Fear 
Conditioned 
Contexual 
Memory
Assesses the 
contexual fear 
response (i.e. freezing) 
to stimulus.
Scopolamine-treated 
C57BL/6 mice 
(n=12/group) - Each 
mouse received i.p. 
injections with either 
vehicle (0.9% saline 
containing 2.5% 
encapsin), 1.5 mg/kg 
scopolamine, or 1.5 
mg/kg scopolamine 
plus 10 mg/kg PWZ-
029.
 PWZ-029 attenuated the 
scopolamine-induced 
impairment of  contextual 
memory [3]. ***p <0.05.
IMPAIRED BASELINE RECOVERY AND COMPLEX MEMORY
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Experiment Type of Test Model Figure Summary of Results
Object 
Retrieval 
with 
Detours 
(ORD)
ORD is a manual 
test sensitive to 
frontostriatal 
deficits that 
investigates 
executive 
function.
Rhesus monkeys were 
treated with vehicle or 
1 of 3 concentrations 
of PWZ-029 and then 
subjected to 15 mixed 
or difficult task 
configurations over 14-
21 experimental 
sessions.  The percent 
success rate of object 
retrieval was 
measured. 
PWZ-029 enhanced cognition 
under conditions in which 
baseline performance was 
impaired (i.e. difficult trials).  
*P<0.05 vs. vehicle (V)
IMPAIRED BASELINE RECOVERY AND COMPLEX MEMORY Continued
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Experiment Type of Test Model Figure Summary of Results
Object 
Retrieval with 
Detours 
(ORD)
ORD is a manual 
test sensitive to 
frontostriatal 
deficits that 
investigates 
executive 
function.
Rhesus monkeys were 
treated with vehicle, 
scopolamine, or 1 of 3 
concentrations of PWZ-
029 and then subjected 
to 15 mixed or difficult 
task configurations over 
14-21 experimental 
sessions.  The percent 
success rate of object 
retrieval was measured. 
Scopolamine-induced deficits 
in ORD performance were 
reduced with PWZ-029.  
*P<0.05 vs. Vehicle (V); 
**P<0.05 vs. scopolamine (S)
Delayed Non-
Match to 
Sample Task 
(DNMS)
Short-term 
recognition 
memory task
Rhesus monkeys treated 
with vehicle or 
increasing 
concentrations of PWZ-
029 (n=2-3), and 
subjected to DNMS 
tasks with and without 
delay.
Performance was not affected 
by PWZ-029 without delay.  
A 0.1 mg/kg dose of PWZ-
029 significantly enhanced 
performance when a 1-minute 
delay was introduced.  
*P<0.05                            
IMPAIRED BASELINE RECOVERY AND COMPLEX MEMORY Continued
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Experiment Type of Test Model Figure Summary of Results
DNMS
Short-term 
recognition memory 
task
Rhesus monkeys 
treated with vehicle or 
0.01 mg/kg of PWZ-
029 (n=4), and 
subjected to DNMS 
tasks  without delay, 
as well as with a 10-
minute delay and 
distractors.
At 0.01 mg/kg, PWZ-029 
significantly enhances 
recognition memory in the 
DNMS task when a 10-minute 
delay and distractors are 
introduced.  *P<0.05
Object 
Retrieval 
with 
Detours
Theorized to assess 
Executive Function
Rhesus Monkeys 
treated with and 
without scopolamine 
and/or PWZ-029 
(n=4).
PWZ-029 appeared to recover 
the scopolamine-induced deficit 
of retrieving the objects. 
*P<0.05 vs. no treatment (first 
bar)
IMPAIRED BASELINE RECOVERY AND COMPLEX MEMORY Continued
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474 
PWZ-029 Preliminary Data Compilation
Experiment Type of Test Model Figure Summary of Results
Acquisition 
Phase of 
MWM
Assess spatial 
learning and 
working memory
Male, Dahl SS, n=10, 
red bars = 10 mg/kg 
PWZ-029
PWZ-029 significantly improves 
the ability of SS rats to acquire 
the location of the hidden 
platform after four days of 
acquisition training.  
MWM
Assess spatial 
learning and 
working memory
Male, FAB-Samaritan 
rats; blue bars = 
positive control, red 
bars = negative control, 
green bars = donepezil, 
3 mg/kg; turquoise bars 
= PWZ-029, 10 mg/kg 
On the second week of the 
MWM protocol, PWZ-029 
significantly improved 
performance in the experiment 
compared to the Group 2 
(negative control).
MWM
Assess spatial 
learning and 
working memory
Male, FAB-Samaritan 
rats; blue bars = 
positive control, red 
bars = negative control, 
green bars = donepezil, 
3 mg/kg; turquoise bars 
= PWZ-029, 10 mg/kg 
On the second week of the 
MWM protocol, PWZ-029 
significantly improved 
performance in the experiment 
compared to the Group 2 
(negative control).
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